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ABSTRACT 
The immunologic and prognostic significance of tumor cell HLA class II 
expression and immune cell infiltration in invasive breast carcinoma is unclear. The 
studies described in this thesis involved investigating several hypotheses regarding the 
anti-tumor immune response in invasive breast carcinoma in an attempt to provide 
clarification. 
We postulated that the significance of tumor cell HLA-DR expressiOn 1s 
dependent on HLA-DRB allotypes. In a pilot study, HLA-DR+ tumor cells differentially 
expressed HLA-DR~ allotypes, with DR~ I *04 preferentially expressed. An expanded 
study with clinicopathological arid outcome data, confirmed these findings and 
demonstrated HLA-DR~l *04 and HLA-DR~l *13 expression by breast tumor cells, 
oppositely associate with survival. Evaluation of the intratumoral cytokine milieu 
suggested prognostic differences were attributable to variation in immune responsiveness, 
as HLA-DR~l *04+ tumors had elevated THl-type cytokines, while DR~ I *13 expressing 
tumors had elevated immunoregulatory markers. In non-DRBI *04 tumors, lack of 
expression of one or more HLA-DR~ allotypes by HLA-DR+ tumors independently 
predicted decreased survival time, suggesting it may function in immune evasion. 
Since in vitro studies demonstrated HLA-DR+ tumor cells function as antigen 
presenting cells, we evaluated the role of co-expression of the HLA class II co-
chaperones, Ii and HLA-DM. DR+Ii+DM+ breast tumor cells independently predicted 
improved survival while DR+Ii+DM- tumors predicted decreased survival. 
Determination of intratumoral cytokine levels indicated improved prognosis of patients 
iii 
with DR+Ii+DM+ tumors was attributable to enhanced THl-type immunity and elevated 
IFN-y associated with improved survival. 
As infiltrating inflammatory cells constitute the major source of immune-
modulating cytokines, we correlated infiltrating cell subsets with cytokine mRNA levels. 
We observed the prognostic significance of tumor infiltrating cells is dependent on the 
balance ofpro-inflammatory and immunoregulatory cytokines. A small exploratory study 
investigating whether genetic variation in cytokine genes partially regulate intratumoral 
cytokine responses demonstrated that allelic variation in cytokine gene regulatory 
sequences play a minor role controlling cytokine levels in breast tumors. 
This expanded characterization of the in situ immune response m breast 
carcinoma enhances the understanding of anti-tumor immunity. This study suggests that 
future attempts to design and implement immunotherapeutic strategies in breast 
carcinoma patients should consider HLA-DRB allotypes, and involve co-incident 
enhancement of cell mediated immunity and suppression of immunoregulatory 
mechanisms. 
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CHAPTER 1: INTRODUCTION AND OVERVIEW 
1.1 Preface 
The following literature review is divided into subsections that will provide the 
reader with a comprehensive summary of established prognostic indicators of breast 
carcinoma, Human Leukocyte Antigens (HLA) and anti-tumor immune responsiveness. 
The first part will describe the prognostic and predictive nature of clinicopathological 
parameters in breast carcinoma. HLA antigens will then be reviewed with a focus on the 
genetic complexity of HLA class II genes, control of HLA class II gene expression, the 
function of classical and non-classical HLA class II molecules and the related co-
chaperone invariant chain (li) in antigen presentation and the influence of HLA class II 
polymorphisms on immune responsiveness. The remaining sections will highlight 
literature that has attempted to elucidate the biological and prognostic significance of 
HLA class II antigens in breast carcinoma and provide an overview of immune 
responsiveness in breast carcinoma. 
1.2 Breast Carcinoma 
The mature adult breast is comprised of 15-25 lobes each associated with 
lactiferous ducts, which originate from the nipple. Each lobe of the breast consists of a 
system of branching ducts, embedded in hormone responsive stroma. At the onset of 
puberty, elevated levels of estrogen, progesterone, insulin and growth hormone are 
responsible for ductal outgrowth and lobuloalveolar differentiation. Lobules develop at 
the ends of the terminal ducts, resulting in the formation of terminal ductal-lobular units 
[1]. The majority of hyperplastic and neoplastic breast lesions develop following 
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epithelial transformation in the lining of the terminal ductolobular unit [2]. In situ 
carcinomas are non-invasive and contained within the basement membrane of either the 
duct (ductal carcinoma in situ, DCIS) or lobule (lobular carcinoma in situ, LCIS). Once 
the malignant cells have invaded the basement membrane tumors are classified as 
invasive [3]. 
1.3 Evaluation of Prognosis and Outcome in Invasive Breast Carcinoma 
Several clinicopathological factors have been defined for breast carcinoma, which 
function as predictive and/or prognostic indicators. Predictive factors determine response 
to a particular therapy and include the hormone receptors, estrogen receptor (ER) and 
progesterone receptor (PR), and human epidermal growth factor receptor-2 (Her-2/neu). 
These factors are also prognostic indicators as they are used to estimate the risk of 
disease recurrence or death, independent of adjuvant treatment. Other factors which 
estimate patient outcome are the histological type and grade of the breast tumor, tumor 
diameter, axillary lymph node involvement and the presence of metastasis to distant sites 
within the body. 
1.3.1 Histological Tumor Type 
Invasive breast carcinomas largely arise from transformation of epithelial cells 
lining the ducts and are termed invasive ductal carcinomas (IDC). Special subtypes of 
IDC are classified based on the architectural growth pattern of the malignant cells. For 
example, the malignant cells of tubular breast carcinomas display a tubular growth 
pattern, cribiform carcinomas are marked by islands o( invasive tumor cells forming 
arches outlining well-defined spaces, mucinous tumors contain malignant cells 
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surrounded by an extracellular matrix of mucin, and medullary carcinomas display a 
sheet-like growth pattern. IDC that do not satisfy the criteria for classification in other 
categories are defined as IDC no special type (IDC NST) and comprise 50-70% of all 
invasive breast cancers [3]. The second most common form of invasive breast carcinoma 
is invasive lobular carcinoma (ILC), which originates in the breast lobule [3]. Patients 
with ILC have improved survival as compared to those with IDC NST [3, 4]. Likewise, 
patients with the aforementioned subtypes of IDC have prolonged disease-free and 
overall survival as compared to IDC NST [3]. 
1.3.2 Histological Grade of Tumor Differentiation 
Most classification schemes for the grade of tumor differentiation are based on the 
scheme of Bloom and Richardson, which assigns qualitative scores of 1-3 for each of 
tubule formation, nuclear pleomorphism and mitotic rate. The three scores are combined 
to assign a tumor grade from 3-9, and tumors are further divided into either low (Grade I, 
scores 3-5), intermediate (Grade II, scores 6-7) or high (Grade III, scores 8-9) tumor 
grade. In this large scale study, patients with Grade I tumors show improved 5, 10- and 
15-year survival over patients with Grade II and III tumors [5]. The commonly used 
Nottingham modification of this grading system uses a semi quantitative assessment of 
each of these three factors (Table 1.1) to create a more objective scoring system for 
histological grade. Tumors are classified as well-differentiated (Grade I, scores 3-5), 
moderately differentiated (Grade II, scores 6-7) or poorly differentiated (Grade III, scores 
8-9). Similar to the results of Bloom and Richardson (1957), using this system, patients 
with grade I tumors show significantly improved disease-free and overall survival than 
those with grades II or III [6]. 
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Table 1.1: Nottingham/Tenovus Primary Breast Cancer Study semi quantitative method 
for assessment of histological grade in breast carcinoma* 
Mitotic 
Feature Classification 
Countt 
Score 
Majority of tumor (>75%) 1 
Tubule formation Moderate amount (10-75%) 2 
Little or none (<10%) 3 
Small, regular uniform cells 1 
Nuclear 
Moderate increase in size and variability 2 
pleomorphism 
Marked variation 3 
0-9 1 
Leitz Ortholux (250X; field area 0.274mm2) 10-19 2 
Mitotic counts >20 3 
(dependent on 0-5 1 
microscope field - Nikon Labophot (400X; field area 0.152mm2) 6-10 2 
representative >11 3 
examples shown) 0-11 1 
Leitz Diaplan (400X; field area 0.312rnm2) 12-22 2 
>23 3 
*Table modified from Elston and Ellis (1991) [6]. 
t# of mitotic cells per 10 microscope fields at the tumor periphery. 
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1.3.3 Tumor Size, Lymph Node Status and TNM Tumor Stage 
Two of the most important prognostic parameters for breast carcinoma are 
regional lymph node (LN) status and the diameter of the tumor. In a large scale study, 
stratification of tumors by tumor size ( < 2cm, between 2 and Scm and larger than 5 em) 
or lymph node involvement (negative, 1-3 involved nodes and 4 or more involved nodes) 
show 5-year survival rates are highest when the tumor is <2 em and there is no LN 
involvement. Furthermore, 5-year survival decreased with increasing tumor size or 
increasing LN involvement and these two parameters were shown to act as independent 
but additive prognostic indicators [7]. 
The American Joint Committee on Cancer (AJCC) has established an in depth 
pathological staging system which takes into account tumor size {T), the number of 
involved axillary lymph nodes (N), and presence or absence of distant metastasis (M) 
(Table 1.2) [8]. Using the revised AJCC classification system, a clear difference in 
survival is observed based on the number of involved axillary lymph nodes. The 5-year 
disease-free survival rates are 69.5% for the Nl group, 46.8% for the N2 group, and 
25.7% for the N3 group. Likewise, disease-free survival rates are progressively worse 
with increasing TNM stage [9]. 
Assessment of tumor size may be complicated by the occurrence of multiple 
tumor foci in the same breast, in such cases it is recommended that tumor size be 
recorded as the largest foci diameter [8]. However, tumor multifocality is prognostic as it 
predicts local cutaneous recurrences in patients with stage I or II tumors, treated with 
breast-conserving therapy [10]. 
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Table 1.2: AJCC Stage Groupings for breast carcinoma 
TNM Stage Classification Category 
Tumor Size * LN statust Metastasist 
Stage 0 Tis NO MO 
Stage I Tl NO MO 
Stage IIA TO Nl MO 
Tl Nl MO 
T2 NO MO 
Stage liB T2 Nl MO 
T3 NO MO 
Stage IliA TO N2 MO 
Tl N2 MO 
T2 N2 MO 
T3 Nl MO 
T3 N2 MO 
Stage IIIB T4 NO MO 
T4 Nl MO 
T4 N2 MO 
Stage IIIC AnyT N3 MO 
Stage IV AnyT AnyN Ml 
• Tis= Carcinoma in situ; TO= no evidence of primary tumor; T1 = ~2cm; T2 = 2.1-Scm; T3 =>Scm; T4 = 
any size with direct extension to the chest wall or skin or inflammatory cancer. 
t NO= No regional lymph node metastasis; N1 =Metastasis in 1-3 axillary lymph nodes; N2 =Metastasis 
in 4-9 axillary lymph nodes; N3 = Metastasis in ~ 10 axillary lymph nodes 
t MO =No distant metastasis; Ml =Distant metastasis 
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1.3.4 Hormones and Hormone Receptors 
A role for hormones in the development of breast cancer is suggested by the fact 
that breast cancer incidence begins to increase late in the third decade of life, whereas the 
incidence rates for other common cancers (e.g. colorectal) start to increase in the late 40s. 
This difference has been attributed to the responsiveness of breast epithelium to ovarian 
hormones, which are elevated from puberty to menopause [11]. It has long been 
recognized that early oophorectomy leads to decreased breast cancer risk [12] and serum 
estrogen levels are higher in breast carcinoma patients than controls [13]. Further indirect 
evidence for a role of prolonged hormone exposure in elevated breast cancer risk is 
provided by the fact that breast cancer incidence is increased in women who experience 
early menarche(:::; 12 years) [14], late menopause (>55 years as compared to <45 years) 
[12], later age of first pregnancy (>35 years as compared to <20 years) [15] and 
nulliparity [14]. Experimental evidence is provided by rodent studies where long term 
exposure to high doses of either 17P-estradiol or synthetic progesterone leads to the 
development of malignant mammary tumors [ 16, 17]. 
The hormone receptors, ER and PR, are members of the nuclear receptor 
subfamily of transcription factors [18]. Following hormone binding and dimerization they 
translocate to the nucleus where they activate or repress target gene transcription [18]. ER 
and PR are important for normal breast development as evidenced by lack of epithelial 
ductal outgrowth in ER knockout mice [19] and the lack of alveolar development in PR 
knockout mice [20]. The importance of ER and PR in breast tumorigenesis is illustrated 
by the decreased incidence of mammary tumors in PR and ER knockout mice 
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administered tumorigenic doses of the carcinogen 7, 12-dimethylbenz(a)anthracene 
(DMBA) [21, 22]. 
Presence of ER and PR predicts response to hormone treatment as tumors that 
express both hormone receptors show marked regression following endocrine therapy, 
with tamoxifen accounting for the majority of treatments [23]. Likewise, both function as 
prognostic indicators as illustrated by a recent population-based cohort study of over 
155,000 breast carcinoma patients with up to 11 years of follow-up. Hormone receptor 
status functioned as an independent prognostic factor after controlling for other 
prognostic variables and patients with ER+PR+ tumors had the best survival rates, while 
EKPK tumors associated with the lowest survival rates [24]. 
1.3.5 Her-2/neu 
The HER (human epidermal growth factor receptor) family of receptors includes 
epidermal growth factor receptor (EGFR or HER-I or erb-Bl), HER-2 (Her-2/neu or erb-
B2), HER-3 (or erb-B3) and HER-4 (or erb-B4). HER receptors exist as inactive 
monomers that form hetero- or homodimers upon ligand binding resulting in cross-
phosphorylation of their cytoplasmic tyrosine kinase domains, signal transduction to the 
nucleus, nuclear gene activation and cell growth [25]. 
Her-2/neu is a proto-oncogene located on Chromosome 17 q21 which encodes a 
185 kD transmembrane glycoprotein with extensive homology to EGFR [26]. Early 
studies using Southern blotting reported Her-2/neu is over expressed in up to 30% of 
breast tumors [27]. Her-2/neu expression has been evaluated using numerous techniques 
including Southern blotting, immunohistochemistry with specific monoclonal antibodies, 
enzyme-linked immunoabsorbent assay (ELISA), reverse transcriptase polymerase chain 
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reaction (RT-PCR) and in situ hybridization, and the proportion of breast tumors with 
over amplification ofthe Her-2/neu gene or over expression of the Her-2/neu protein has 
been reported between 10% to 34% [28]. The most common cause of over expression of 
Her-2/neu protein is gene amplification resulting in 2 to 100-fold amplification as 
assessed by Southern blotting and densitometry, normalized to collagen genes [29]. Her-
2/neu over-expression is associated with histological unfavorable micropapillary and 
apocrine breast carcinomas [30], apoptosis inhibition and increased cell proliferation, via 
phosphoinositide 3-kinase (PI3K) activation and suppression of p53 [31 ], increased 
mitogen-activated protein kinase (MAPK) activation [32], increased anchorage 
independent growth and metastatic potential [33], and increased vascular endothelial 
growth factor (VEGF) expression and angiogenesis (34]. The prognostic power of Her-
2/neu expression is evident as membrane over-expression of the Her-2/neu protein 
independently predicts poor relapse-free and overall survival, after controlling for the 
effects ofLN metastasis, tumor size, diagnosis age and hormone receptor status (27]. 
Expression of a rat neu proto-oncogene, with an activating mutation in the 
transmembrane region, under control of the murine mammary tumor virus (MMTV) 
promoter leads to spontaneous development of mammary tumors in mice [35]. A 
MMTV lneu trans gene without the activating mutation also resulted in Her-2/neu over 
expression, increased tyrosine kinase activity and mammary tumor development. The 
kinetics of tumor development were slower than that seen with the activated transgene 
but a high percentage of mice also developed metastatic lung tumors [36]. A later study 
revealed spontaneous somatic mutations in wild type neu in this model, leading to its 
over-expression [37]. 
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Her-2/neu was initially considered a predictive factor as its over-expresston 
resulted in poor response to tamoxifen treatment in a long-term (median follow-up 12 
years) randomized controlled clinical trial [38]. This was likely an indirect association, 
attributable to the negative correlation observed between Her-2/neu and ER expression. 
Certainly, Her-2/neu over-expression failed to predict poor response to tamoxifen therapy 
in ER positive breast cancer patients [39]. More recently, an anti-Her-2/neu humanized 
antibody, trastuzumab (Herceptin®), has been evaluated for beneficial efficacy in breast 
carcinoma. Slamon et al. (200 1) demonstrated improved response rate, prolonged time to 
progression and overall survival in metastatic breast carcinoma patients treated with 
chemotherapy and trastuzumab as compared to those administered chemotherapy alone 
[ 40]. The results of large multi-center trials revealed significantly decreased risk of 
recurrence in Her-2/neu-positive breast cancer patients treated with trastuzurnab 
combined with or following chemotherapy treatment [41, 42]. However, it is important to 
note that the results of these studies represent that of the interim efficacy analyses and 
further follow-up of patients may yield varying risks. 
1.3.6 Age at diagnosis 
Young women (<35/<40 years) diagnosed with breast cancer more frequently 
present with tumors that lack expression of ER and PR and are poorly differentiated [ 43, 
44]. The prognostic value of age at diagnosis remains unclear. Some studies reported no 
difference in survival between early onset and late onset breast carcinoma [ 45, 46], while 
others found improved survival in patients diagnosed at an early age [47]. However, after 
controlling for other prognostic factors and treatment, numerous studies identified early 
age at diagnosis as an independent risk factor for poor survival [4, 48-50]. Increased 
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levels of circulating hormones in young women may contribute to carcinogenesis by 
increasing cell proliferation, allowing for accumulation of genetic errors. 
The more aggressive tumor phenotype and decreased survival of young women 
with breast cancer may in part be due to increased incidence of germline mutations in 
these patients. Approximately 40% of women diagnosed before age 40 years have a 
family history ofbreast or ovarian cancer [51] and 10% of those carry germline mutations 
in the carcinoma predisposing genes, breast cancer (BRCA)-1 or BRCA-2 [51, 52]. In 
addition, germline BRCA-1 mutations are associated with high tumor grade, ER-
negativity and decreased survival of breast cancer patients [53]. Germline mutations in 
the tumor suppressor gene E-cadherin located on chromosome 16 are frequent in lobular 
breast carcinomas [54]. Increased risk for early-onset breast carcinoma is also associated 
with Li-Fraumeni syndrome, which is caused by a dominant mutation in the tumor 
suppressor gene TP53 (tumor protein p53) located on chromosome 17, and Cowden's 
syndrome, which is caused by a mutation in the tumor suppressor gene PTEN 
(phosphatase and tensin homolog) located on chromosome 10 [55]. 
A role for HLA genes, which are key regulators of immunity, in early onset breast 
carcinoma is suggested by the case-control study of Chaudhuri et al. (2000) who reported 
that HLA-DRBl *11 and HLA-DQBl *0303 were decreased in early onset breast 
carcinoma patients ( :::;40 years), as compared to age-matched healthy controls. Although 
these associations may be indirect and attributable to linkage of these HLA class II alleles 
with unidentified tumor suppressor genes, other HLA-DRBl alleles known to be carried 
with HLA-DQBl *0303 did not associate with disease protection. This suggests the 
association may reflect an influence of these alleles on anti-tumor immune surveillance, 
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as HLA class II alleles encode glycoproteins that present antigens to CD4+ T cells, which 
are the central players in immune responsiveness. 
1.4 The Major Histocompatibility Complex 
The Major Histocompatibility Complex (MHC) is a collection of genes contained 
within a long segment of DNA and referred to as the H-2 complex in mice and the HLA 
complex in humans. Both complexes are organized into groups of genes that code for 
three classes of molecules. Class I and Class II genes encode cell surface glycoproteins 
that bind and present peptides to CDS+ and CD4+ T cells, respectively. Class III genes 
encode molecules crucial for immunity but share no structural similarity to the MHC 
class I or II molecules. Due to their role in antigen presentation class I and class II 
molecules are termed classical MHC molecules. MHC class I molecules are encoded by 
the K and D loci in mice and A, B and C loci in humans, while MHC class II molecules 
are encoded by the I-A and I-E regions in mice and the DR, DP and DQ regions in 
humans [56]. 
1.4.1 Human Leukocyte Antigens 
The HLA complex is located on Chromosome 6p21.3 and is the human form of 
the MHC, which contains many genes, involved in innate and adaptive immunity. 
Recently, an extended human MHC map has been published which spans 7.6 mega base 
(Mb) pairs and includes 252 expressed genes and 139 pseudogenes [57]. The first gene 
map of the HLA complex, termed the classical human MHC was 3.6 Mb and contained 
224 loci [58]. As mentioned above, the classical human MHC is organized into three 
classes (Figure 1.1 ). The HLA designation is given only to those genes in the class I and 
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Figure 1.1: The HLA complex is located on the short arm of Chromosome 6 (6p21.3) 
and is organized into three regions based on Class. The HLA class II region spans 1000 
kB and encodes for the classical HLA class II (DP, DQ, DR) molecules and the non-
classical HLA-DM and HLA-DO molecules, as well as the TAP and LMP molecules 
involved in the HLA class I pathway. Figure adapted from Goldsby, Kindt and Osbourne 
(2000) [56]. 
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class II regions that encode class I and II glycoproteins (often referred to as allotypes) 
involved in antigen presentation and their related pseudogenes [59]. 
The classical HLA Class I genes (HLA-A, -B, -C) encode glycoproteins 
expressed by nearly all nucleated cells that form heterodimers with the monomorphic B2-
microgloblin protein and present endogenously derived peptides of 8-10 amino acids in 
length to CD8+ T cells for recognition [59]. The class I region also encodes the non-
classical HLA genes (HLA-E, -F, -G) [58], which function as natural killer (NK) cell 
inhibitory ligands [60, 61] and the MHC class !-related chain A (MICA) and MICB [58], 
which act as NK activating ligands [62]. 
The HLA class III region encodes a series of genes that are not involved in direct 
antigen presentation but still play a role in regulating immune responses, including tumor 
necrosis factor (TNF)-a, lymphotoxin and the complement factors C2 and C4 [58]. 
Classical HLA class II genes (HLA-DPA, -DPB, -DQA, DQB, -DRA and -DRB) 
encode class II a chain and p chain glycoproteins that form heterodimers and present 
exogenously-derived peptides, of 12-24 amino acid residues in length, to CD4+ T cells 
for recognition [59]. HLA class II antigens are constitutively expressed by thymic 
epithelial cells and the professional antigen presenting cells (APC), B cells, dendritic 
cells (DC), and macrophages but can be up-regulated in so called non-professional 
antigen presenting cells (e.g., keratinocytes, epithelial cells, endothelial cells and 
fibroblasts), most notably in response to interferon gamma (IFN-y) [63-65]. The class II 
region also encodes the non-classical HLA-DM and HLA-DO antigens [58], which act as 
co-chaperones facilitating peptide loading of HLA class II molecules [66, 67] and the 
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transporter associated with antigen processing (TAP) and low molecular weight protein 
(LMP) molecules [58], involved in the cytosolic HLA class I processing pathway [68]. 
Classical HLA class II molecules are highly polymorphic. HLA-DRA IS 
considered monomorphic, with minimal variation between the DRA alleles and the 
polymorphism of HLA-DR antigens is attributable to the HLA-DR~ chain. In contrast, 
both a and f3 chains contribute to the polymorphism of HLA-DP and HLA-DQ antigens 
and the non-classical HLA-DM and HLA-DO isoforms exhibit little polymorphism [59]. 
1.4.2 HLA class II antigens 
The IMGT/HLA database has identified 3 DRA, 430 DRB (354 DRB1, 1 DRB2, 
39 DRB3, 12 DRB4, 17 DRB5, 3 DRB6, 2 DRB7, 1 DRB8, and 1 DRB9), 25 DQAl, 56 
DQB1, 20 DPAl and 106 DPB1 alleles [69]. The genes that encode the HLA a and f3 
chains are designated as A and B, respectively. HLA-DQ is encoded by HLA-DQA1 and 
HLA-DQB1 and there are also HLA-DQA2, HLA-DQB2 and HLA-DQB3 pseudogenes. 
HLA-DP is encoded by HLA-DPA1 and HLA-DPB1 and there are also HLA-DPA2 and 
HLA-DPB2 pseudogenes. HLA-DM is encoded by HLA-DMA and HLA-DMB, HLA-
DO by HLA-DOA and HLA-DOB [59]. 
The HLA class II region that encodes HLA-DR molecules is far more complex 
due to the extraordinarily high number of allelic variants at the HLA-DRB 1 locus, most 
ofwhich are in linkage with additionalstructural HLA-DRB genes [70]. HLA-DRB1*15 
and 16 alleles are expressed in association with HLA-DRB5 alleles (DR51); HLA-
DRB1 *03, 11, 12, 13 and 14 with HLA-DRB3 alleles (DR52); HLA-DRB1 *04, 07 and 
09 with HLA-DRB4 (DR53); while HLA-DRBl *01, 10 and 08 are not in association 
with any other expressed HLA-DRB genes (Figure 1.2). Thus, resultant from the tight 
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Figure 1.2: HLA-DR alleles are grouped into 5 haplotype groups based on shared DR~ 
genes. Pseudogenes are indicated by grey boxes. Figure adapted from Campbell and 
Trowsdale (1993) [70]. 
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linkage of DRB genes and co-dominant expression of HLA loci, an individual can 
express up to four different HLA-DR allotypes. Furthermore, the tight linkage between 
HLA-DR and HLA-DQ genes results in a limited number ofhaplotypes (Table 1.3). 
1.4.3 HLA Class II Antigen Processing and Presentation Pathway 
HLA class II a and p chains are synthesized in the rough endoplasmic reticulum 
and exist briefly in high molecular weight aggregates containing immunoglobulin heavy 
chain binding protein (BiP) [71]. These aggregates then assemble into Ii containing 
oligomers associated with calnexin, a chaperone protein [72]. The association between Ii 
and class II molecules in the endoplasmic reticulum is important in stabilizing correctly 
folded class II molecules, through the formation of a nine-subunit ( ap)3Ih complex 
which is transported from the endoplasmic reticulum [73]. Binding of Ii also prevents 
premature binding of antigenic peptides while in the endoplasmic reticulum and during 
transport to the endosomes [74]. 
The release of calnexin corresponds with the formation of complete nonameric 
(ap)3Ih complexes [72, 75]. These nonameric complexes are transported through the 
Golgi apparatus and trans-Golgi network to endocytic compartments, including early 
endosomes, late en do somes and lysosomes. The greatest abundance of intracellular MHC 
class II is in late endosome/lysosome-like compartments, which are termed MHC class II 
loading compartments (MIIC} [76]. Within MIIC, Ii is degraded and a class II-associated 
Ii peptide (CLIP) remains bound to the peptide binding groove [77]. Peptide loading 
often occurs within MIICs and can also occur in multivesicular class II vesicles (CIIV), 
which more closely resemble late endosomes [78]. 
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Table 1.3: HLA-DRB1-DQB1 Haplotype Groups in European Americanst 
HLA-DRB Linked DRP1 HLA-DR Associated HLA-DQ 
Haplotype DRP Serological DQP1t Serological 
Grou,e S,eecificitiest S,eecificitiest 
0101 DR1 05 DQ5 
DRl/10 0102 DR1 05 DQ5 0103 DR103 05/0301 DQ5/DQ7 
1001 DR10 05 DQ5 
0801 DR8 04/03011/0302 DQ4/DQ7/DQ8 
DR8 0802 DRS 04 DQ4 0803 DR8 0301 DQ7 
0804 DR8 04 DQ4 
1501 DR15 (2) 06/05 DQ6/DQ5 
1502 DR15 (2) 06 DQ6 
DR51 DRP5 1503 DR15 (2) 06 DQ6 
1601 DR16 (2) 05 DQ5 
1602 DR16 {2) 05/0301 DQ5/DQ7 
0301 DR17 (3) 0210301/06 DQ2/DQ7 /DQ6 
1101 DR11 030110302106 DQ7/DQ8/DQ6 
1102 DR11 0301 DQ7 
1103 DR11 0301 DQ7 
1104 DRll 0301105/06 DQ7/DQ5/DQ6 
DR52 DRP3 
1201 DR12 0301 DQ7 
1301 DR13 (6) 06/05 DQ6/DQ5 
1302 DR13 (6) 06 DQ6 
1303 DR13 (6) 0301 DQ7 
1305 DR13 (6) 0301 DQ7 
1401 DR14 (6) 05/06 DQ5/DQ6 
1404 DR14 (6) 05 DQ5 
0401 DR4 030110302/04 DQ7/DQ8/DQ4 
0402 DR4 0302 DQ8 
0403 DR4 0302/0304/0305 DQ8/DQ7/DQ8 
0404 DR4 0302/02/04 DQ8/DQ2/DQ4 
DR53 DRP4 0405 DR4 0302/02 
DQ8/DQ2 
0406 DR4 04 DQ4 
0407 DR4 030110302 DQ7/DQ8 
0408 DR4 030110304 DQ7/DQ7 
0701 DR7 02/0303/0301 DQ2/DQ9/DQ7 
0901 DR9 0303/02 DQ9/DQ2 
tTable created from information in Klitz et al (2003) [79], European American defined as self-described as 
Caucasian, White or European origin. Infrequent haplotypes indicated by italics. A total of 1899 individuals 
with 3798 haplotypes were molecularly typed by PCR-SSP for HLA-DR and HLA-DQ alleles. 
+serological specificities obtained from Schreuder et al (2005) [80]. Numbers in parenthesis represent older 
serological designations. 
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In normal APC, CLIP is exchanged for an exogenously derived antigenic peptide 
that is loaded into the peptide-binding groove, via the action of the co-chaperone HLA-
DM. Cells lacking HLA-DM molecules do not undergo this exchange and CLIP remains 
bound within the groove [81]. HLA-DM enhances the rate ofremoval of CLIP indicating 
that it is a necessary molecule for active removal [66, 82]. However, HLA-DM negative 
cells can self-release CLIP enabling them to bind exogenous antigens [83]. HLA-DM 
may act as a selecting agent for epitope binding, removing kinetically unstable peptides, 
and allowing for binding of only high-stability peptides [84]. 
The HLA class II molecule HLA-DO forms stable complexes with HLA-DM in B 
cells, with HLA-DM being required for transport of HLA-DO from the endoplasmic 
reticulum to lysosomes, where both molecules are found [85]. HLA-DO preferentially 
promotes loading of HLA class II molecules that depend on HLA-DM, thereby acting as 
a co-chaperone of HLA-DM, controlling the binding of antigenic peptides that are to be 
presented at the cell surface. In this role, HLA-DO influences peptide editing in a positive 
way for some peptides and negatively for others. In particular, HLA-DO was found to 
enhance the efficiency of peptide loading of class II molecules such as HLA-DR~1 *04 
and DRBl *01 over HLA-DM alone, but had no effect on HLA-DRBl *03 molecules 
[67], while over expression of HLA-DO leads to the accumulation of HLA-DR-CLIP 
complexes at the cell surface of a HLA-DR+DM+ human T cell line [86]. 
HLA class II molecules classically present peptides derived from exogenous 
antigens, however, peptides generated from cytosolic antigens have also been eluted from 
the peptide-binding groove [87]. The source of HLA class II peptides is also influenced 
by cell type as epithelial cells transfected with HLA-DR~1 *04, Ii and HLA-DM have a 
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more diverse epitope repertoire and display more cytoplasmic-derived peptides than B 
lymphoblastoid cell lines [88]. The identification of tumor cell activation of tumor 
antigen specific HLA class II restricted CD4+ T cells [89] highlights the importance of 
endogenous antigen presentation by HLA class II molecules. Immune escape 
mechanisms employed by viruses that block this phenomenon further emphasize its 
importance. For example, the human cytomegalovirus (HCMV) carries two 
glycoproteins, which inhibit the HLA class II pathway preventing in vitro activation of 
CD4+ T cells. The glycoprotein US2 binds to and causes the degradation of DRa and 
DMa chains and the glycoprotein US3 binds newly-synthesized HLA class II af3 dimers 
inhibiting their interaction with Ii and causing decreased accumulation of HLA class II in 
peptide-loading compartments [90]. As these glycoproteins are only expressed in virally 
infected cells they likely evolved to block the presentation of endogenous viral antigens 
by HLA class II molecules to anti-HCMV CD4+ T cells. 
1.4.4 Regulation of HLA class II Expression 
HLA class II gene expression is tightly regulated, underlying the restricted 
expression of HLA class II antigens to professional APC and thymic epithelial cells. The 
induction of HLA class II expression in other cell types is also tightly regulated, 
occurring in response to exogenous signals, most notably IFN-y produced during 
infection and/or inflammation. 
I. 4. 4.1 HLA class II promoter elements and trans-acting transcription factors 
The promoters of all HLA class II, Ii, HLA-DM and HLA-DO genes contain a 
conserved SXY motif, which binds DNA transcription factors to promote gene 
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expression. Substantial information regarding MHC class II regulation was obtained from 
investigation of the mutations responsible for the MHC class II immunodeficiency, bare 
lymphocyte syndrome (BLS). Cell-fusion experiments performed with MHC class II-
negative cell lines derived from BLS patients revealed BLS patients could be grouped 
into one of 4 complementation groups (A-D), based on the ability to restore MHC class II 
expression in the hybrid cells [91]. Restoration ofHLA class II expression in B cell lines 
from BLS patients by transfection with eDNA libraries and DNA sequencing confirmed 
the identification of the four mutated genes. BLS complementation groups A-D, carry 
mutations in the MHC class II transactivator (CIITA) [92], regulatory factor X (RFX)-
associated ankyrin-containing protein (RFXANK) [93], RFX5 [94] and RFX associated 
protein (RFXAP) [95], respectively. 
The SXY region is bound by trans-acting factors, which mediate HLA class II 
transcription (Figure 1.3). In vitro assays have shown the S-box can bind RFX, however, 
the function of the S-box in recruiting CIITA to the enhanceosome is mediated by an 
unidentified DNA binding transcription factor [96]. The X-box is bound by RFX5 [94], 
RFXANK [93] and RFXAP [95] which form the trimeric RFX complex. The X2-box is 
bound by cyclic-AMP-responsive-element-binding factor (CREB) [97]. The Y-box is 
bound by the nuclear factor binding to the Y-box (NF-Y) protein [98]. This multiple 
protein HLA class II regulatory module formed by binding of trans-acting proteins to the 
SXY motif is termed the enhanceosome [99]. 
1.4.4.2 The MHC Class II Transactivator (CIITA) 
CIITA is non-DNA-binding but acts as a scaffold, binding RFX, CREB and NF-Y 
proteins within the enhanceosome [100] (Figure 1.3). CIITA then coordinates gene 
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transcription via the recruitment of proteins involved in histone acetylation (CREB-
binding protein (CBP), p300 and p300/CBP-associated factor (PCAF)), methylation (co-
activator-associated arginine methyltransferase 1 (CARMI), chromatin remodeling 
(brahma-related gene 1 (BRG 1 ), transcription initiation (transcription factor liD (TFIID) 
and TFIIB) and transcription elongation (positive transcription elongation factor b (P-
TEFb)) [101]. CIITA transcription is tightly controlled by three independent promoter 
units (CIITA-PI, -Pill and -PIV), each transcribing a different first exon and resulting in 
three CIITA isoforms with differing amino-termini. A fourth promoter (CIITA-PII) is 
also found in the human CIITA gene, but its function is not yet known [102]. 
The functions of the three CIIT A promoters were determined by assessing the 
phenotype of mice with targeted deletions of the CIIT A gene. A targeted deletion that 
excised CIITA-PIV and its associated first exon but left CIITA-PI and CIITA-PIII intact 
[103] revealed that CIITA-PIV was essential for IFN-y-induced MHC class II expression 
in non-hematopoietic cells (epithelial cells, endothelial cells, astrocytes and fibroblasts). 
However, constitutive MHC class II expression was not altered in B cells, DC or tissue 
macrophages and IFN-y induction ofMHC class II expression on peritoneal macrophages 
and migroglial cells was unaltered, indicating CIITA-PIV is not required for this process. 
These mice also have impaired positive selection of CD4+ T cells, owing to the lack of 
expression of MHC class II on cortical thymic epithelial cells. However, the role of 
CIITA-PIV in MHC class II expression by thymic epithelial cells is likely independent of 
IFN-y, as CD4+ T cell positive selection is not abolished in mice lacking IFN-y or the 
IFN-y receptor [104, 105]. A second strain of mice contains a deletion that excises 
CIITA-PIII and CIITA-PIV and their associated first exons but leaves CIITA-PI intact 
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CIITA 
Transcription co-factors 
Gene encoding HLA class II, 
Ii, HLA-DM, HLA-DO 
Figure 1.3: CIITA is the master regulator ofHLA class II gene transcription. The human 
CIITA gene has four promoters (PI-IV) that control the transcription of four different first 
exons connected to a common second ex on. PI, Pill and PIV control CIIT A transcription 
in myeloid DC and macrophages, B cells and plasmacytoid DC, and IFN-y induced 
CIITA, respectively. The function of PII is unknown. All HLA class II genes contain a 
SXY motif, comprised of S, X, X2 and Y boxes, which are bound cooperatively by the 
trimeric RFX, CREB, NFY and an unidentified S-box-binding protein. This four-protein 
complex forms the enhanceosome that binds CUT A, which drives the transcription HLA 
class II genes via recruitment of co-factors involved in histone acetylation, methylation, 
chromatin remodeling and transcription initiation and elongation. Figure adapted from 
Reith, LeibundGut-Landmann and Waldburger (2005) [99]. 
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[106]. These mice illustrate the importance of CIITA-PIII for B cell MHC class II 
expression as they completely lack expression of CIIT A and MHC class II in both B-1 
and B-2 B cell subsets and fail to produce antibodies to the T-cell-dependent antigen (4-
hydroxy-3-nitrophenyl)-acetyl-chicken gamma globulin. CIITA and MHC class II 
expression was also lacking in plasmacytoid DC, while expression was unaltered in 
myeloid DC and macrophages. In summary, constitutive CIITA expression is controlled 
by CIITA-PI in myeloid DC and macrophages and CIITA-PIII in B cells and 
plasmacytoid DC, while IFN-y inducible CIITA in non-hematopoeitic cells is controlled 
by CIITA-PIV. 
1.4.4.3 IFN-yinduction ofCIITA-PIV 
IFN-y induces CIITA-PIV activation via its effects on three regulatory elements 
located proximal to CIITA-PIV, an IFN-y-activated site (GAS), an E box and an IFN-
regulatory factor element (IRF-E) (Figure 1.4). IFN-y binding to the IFN-y receptor 
induces Janus kinase (JAK)-1 and JAK-2 activation, which phosphorylate signal 
transducer and activator of transcription (STAT)-1. STAT -1 then dimerizes and 
translocates to the nucleus where it binds the GAS element, in concert with upstream 
transcription factor (USF)-1, which binds theE-box [107]. STAT-1 also induces IRF-1 
activation, which then binds with IRF-2 to the IRF-E region ofCIITA-PIV [108]. STAT-
I, USF-1, IRF-1 and IRF-2 binding to regulatory elements in CIITA-PIV leads to 
transcription initiation and CIITA expression [99]. 
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Plasma Membrane 
Nuclear Membrane 
Transcription 
Figure 1.4: Induction of CIITA promoter IV (PIV) transcription via IFN-y. Binding of 
IFN-y to its receptor induces Janus kinase (JAK)-1 and JAK-2 cross-phosphorylation, 
which in tum phosphorylate signal transducer and activator of transcription (STAT)-1. 
Phosphorylated STAT -1 dimerizes, translocates to the nucleus and binds co-operatively 
with upstream transcription factor (USF)-1 to the IFN-y-activated site (GAS)-E-box motif 
of PIV. STAT-1 also activates IFN-regulatory factor 1 (IRF1), which binds co-
operatively with IRF2 to the IRF-element (IRF-E) of PIV. Figure adapted from Reith, 
LeibundGut-Landmann and Waldburger (2005) [99]. 
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1.4.4.4 HLA-DRB Promoter Polymorphisms 
Although HLA class II genes are generally coordinately regulated by CIIT A, 
discordant expression has also been reported. For example, the RJ2.2.5 B cell line, which 
is transfected with a dominant negative mutant of CIIT A, lacks expression of DRa, DRP 
and DQa, while DQp, DPa, DPp, DOa, DOP, DMa and DM~ are expressed in the 
absence of CIITA [109]. Furthermore, low levels of Ii and HLA-DM transcripts are 
found in the BLS-2 B cell line [110] and the CEM T lymphoblastoid cell line [111], 
which lack functional CIITA genes. Additional cis-acting elements have been identified 
in the promoters of Ii and HLA-DM which likely contribute to their expression in the 
absence ofCIITA [112, 113]. 
Mitchison and Roes (2003) proposed that polymorphisms in the coding and 
regulatory sequences of MHC genes co-evolved in response to infection, following their 
discovery of linkage disequilibrium between murine MHC class II promoter variants and 
exon 2 sequences, which encode the peptide binding site of MHC class II molecules 
[114]. Polymorphisms within the promoters of HLA class II genes cause transcription 
factors to bind with varying affinities. Sequencing studies of the DRB promoters of 
Epstein-Barr virus (EBV)-transformed B cell lines (BCL) revealed nucleotide variability 
in the X and Y boxes and the spacers between the two as well as sequences containing 
CCAAT and TATA boxes [115, 116]. 
The influence of these promoter polymorphisms on the transcriptional activity of 
HLA-DRB genes was shown by promoter-chloramphenicol acetyltransferase (CAT) 
reporter assays performed in BCL. Louis et al. (1994) compared DRB promoters from all 
HLA-DR haplotype groups and showed the hierarchy of transcriptional activity was in 
26 
the order DRBI and DRB3 alleles of the DR52 haplotype group> DRBI alleles ofDRl, 
DR8 and DR51 haplotype group > DRBI and DRB4 alleles of the DR53 haplotype 
group. DRB5 showed weaker transcriptional activity than its associated DRB 1 alleles. 
Nucleotide substitution studies showed X box polymorphism accounts for the observed 
transcriptional activity differences [117]. 
Vincent et a1 (1996) determined the steady state levels of DRB messenger 
ribonucleic acid (mRNA) in peripheral blood B cells using competitive RT-PCR and 
showed a similar hierarchy of transcriptional activity that correlated with the amount of 
transcribed mRNA for all except DRB 1 *04, which was over expressed as compared to 
the transcriptional activity of the DRB 1 *04 promoter, suggesting a post-transcriptional 
mechanism modulates HLA-DRBl *04 mRNA expression [118]. Further evidence for 
post-transcriptional control of HLA class II expression was provided by ribonuclease 
protection assay comparison of pre-mRNA and mRNA levels in a DRB 1 *07 
homozygous BCL. Although DRB1 *07 pre-mRNA was 3-4 times greater than DRB4 
pre-mRNA, DRB1 *07 mRNA was 7 times greater than DRB4 mRNA [119]. A similar 
assay, performed using PBMC from 7 healthy DRBI *07+ donors, confirmed this 
difference for two DRB4 alleles and showed that DRB4*0101 is expressed at higher 
levels than DRB4*0103, when normalized to DRB1*07 pre-mRNA or mRNA from the 
same individual [120]. 
1.4.5 Influence of MHC class II polymorphisms on CD4+ T cell responsiveness 
Following recognition of the MHC-peptide complex via the T cell receptor 
(TCR), CD4+ TH cells can become activated and differentiate into either THl cells 
characterized by the secretion of IL-2 and IFN-y or T H2 cells characterized by the 
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secretion of interleukin (IL)-4 and IL-10. THl cells are crucial for the development of 
cellular immunity and activation of CD8+ cytotoxic T lymphocytes. In contrast T H2 cells 
function to elicit humoral immune responses through B cell activation and induction of 
antibody production. T H cell differentiation is largely dependent on the influence of 
surrounding cytokines with IL-12 and IFN-y enhancing TH1 development, while IL-4 
promotes TH2 development, coincident with the interaction with MHC-peptide 
complexes [121]. 
The level of expression of MHC class II molecules influences T cell activation 
and ensuing cytokine production. For example, flow cytometry and bead quantification of 
CDllb+ bone marrow derived macrophages from mice of different H-2 haplotypes 
revealed l-Ab and I-EK molecules were expressed at higher levels and for a longer time 
period than l-Ad, I-Ak, and I-Aq. Immunization of mice with keyhole limpet hemocyanin 
(KLH) or chicken immunoglobulin, followed by in vitro re-stimulation ofT cells isolated 
from the draining lymph node showed l-Ab-restricted T cells were more frequently IFN-
y+ and IL-4-, while l-Ad restricted T cells were more frequently IL-4+ and IFN-y- [122]. 
Antigen dose also influences the TH1/TH2 polarization of naive CD4+ T cells, with low 
dose antigen favoring T H2 polarization with high IL-4 production and high dose antigen 
favoring THl polarization and IFN-y production [123]. 
Polymorphisms in HLA class II alleles that affect the affinity of HLA for peptide 
also influence the cytokine production and proliferation of CD4+ T cells. HLA-DR-
restricted CD4 + T cell lines specific for an immunodominant and promiscuously 
recognized peptide of the bacterium Mycobacterium tuberculosis all proliferated in a 
HLA-DR restricted manner in response to peptide pulsed autologous irradiated peripheral 
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blood mononuclear cells (PBMC). However, the greatest IFN-y production, proliferative 
response and cytotoxicity were directed against HLA-DR-matched EBV-transforrned 
homozygous BCL expressing either DRB 1 *0 101, * 1501 or *040 1, which bound the 
peptide with the highest affinity (IC50 < 10 ~-tM, as determined by competitive MHC 
binding assay). HLA-DR polymorphisms, located outside the peptide-binding groove in 
positions ~ 180-189, also influence interaction with the CD4 co-receptor of the T -cell 
receptor (TCR) and resultant IL-2 production [124]. Experimental studies have also 
demonstrated high levels of MHC class II/CLIP complexes, formed from exogenously 
added CLIP or endogenously expressed by APC, modulated antigen-specific effector T 
cells, inducing a shift from THl to TH2 responses [125, 126]. 
T cell activation and cytokine production are also affected by the affinity of the 
peptide for TCR. Studies using altered peptide ligands revealed that varying the sequence 
of the peptide bound to TCR shifts T H cell responses from IFN -y producing T H 1 cells to 
IL-4 producing T H2 cells. This skewing was attributed to decreased signal strength 
through the TCR by the altered peptide ligand, resulting in decreased zeta-chain-
associated protein kinase (ZAP)-70 phoshorylation and decreased calcium flux [127]. 
I. 5 HLA class II allele associations witlt breast carcinoma 
Studies of HLA class II associations with disease susceptibility and prognosis and 
outcome in cancer are complicated by the enormous genetic variation of the HLA system. 
As a consequence of this complexity, several contradictory reports have arisen from such 
studies. For example, early serological studies found HLA-DR4 was increased in Russian 
breast carcinoma patients (46.8%) as compared to the general Moscow population 
(16.3%). In addition, HLA-DR4 positive patients more frequently had EK tumors and 
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had a worse outcome (50% increase in the 5 year survival of the DR4 negatives 
compared with the DR4 positives) [128]. In contrast, the frequency of HLA-DR4 was 
decreased in Italian women with breast cancer (2/62, 3.2%) as compared to controls 
(29/242, 12%) [129]. Another serological study revealed HLA-DRw6 (DRB1 *13 and 
DRBl *14) was increased in Chinese breast cancer patients and associated with ER 
expression [130]. 
The first molecular-based investigation of HLA class II alleles and disease 
susceptibility in breast cancer was perfonned by Chaudhuri et al. (2000) [131]. Using 
PCR with sequence-specific primers (PCR-SSP) to DNA-type early-onset breast cancer 
patients for HLA-DR, -DP and -DQ alleles, they found DQB1 *03032 and DRBl *11 
were significantly decreased in patients. In contrast, Gourley et al (2003) did not reveal a 
protective effect of DRBl *11 [132]. These differences may reflect study design as 
Gourley et al. (2003) did not limit patient selection to early age of onset. Another small 
molecular typing study of 36 Iranian breast cancer patients revealed a significant 
association ofDRB1 *12 and disease susceptibility [133]. These molecular-typing studies 
have focused on disease association and were not designed to evaluate associations of 
HLA class II alleles with prognostic parameters and outcome in breast carcinoma 
patients. 
1. 6 Expression of HLA class II antigens in breast carcinoma 
1.6.1 Expression of HLA class II in breast cancer cell lines 
In contrast to HLA class I molecules, HLA class II expressiOn is typically 
restricted to APC, such as B-cells, macrophages and dendritic cells. However, HLA class 
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II can be induced on other cell types, including breast cancer cell lines, by IFN-y [134], 
IL-1a, IL-113 [135], TNF-a [136] and IL-4 [137]. Several groups have examined IFN-y 
up-regulation ofHLA-DR on breast cancer cell lines using immunofluorescence and flow 
cytometry [134, 136, 138]. These studies employed different anti-HLA-DR monoclonal 
antibodies (L243, Bra30, and D1-12) but all found that HLA-DR antigens were induced 
after IFN-y treatment. The same result was obtained for several of the cell lines using 
radioimmunoassay to detect HLA-DR expression [64, 139]. A more recent study, in our 
laboratory, found constitutive and IFN-y inducible expression ofHLA class II and the co-
chaperones Ii and HLA-DM in breast carcinoma cell lines (BCCL). HLA-DR, HLA-DP, 
Ii and HLA-DM were constitutively expressed in 4/11, 2/11, 4/11 and 2/11 BCCL and 
inducible in 7/11, 8/11, 7/11 and 5/11, respectively. None of the BCCL constitutively 
expressed HLA-DQ, but it was inducible in 5/11 BCCL. HLA-DRI3 allotypic expression 
was also examined in these cell lines and 5/11 showed selective up regulation of DRI3 
allotypes by IFN-y [140]. 
1.6.2 Expression of HLA class II in breast tissue 
1. 6.2.1 Classical HLA class II expression in breast carcinoma 
HLA class II molecules are not expressed by resting breast epithelial cells but are 
present de novo in the lactating breast [141, 142], likely up-regulated in response to 
prolactin [143]. As breast tumors are frequently infiltrated by immune cells [144], it is 
plausible that HLA class II molecules may be up-regulated on tumor cells in response to 
the cytokine milieu of the surrounding tumor microenvironment. Alternatively, HLA 
class II expression on breast tumor cells may be independent of cytokine modulation and 
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due to molecular changes induced during the progression to carcinoma as several groups 
have shown HLA class II expression in benign hyperplastic breast epithelium [141, 145-
148]. However, the presence of lymphocytic infiltrating cells adjacent to HLA-DR 
expressing non-neoplastic epithelial cells [146] suggests cytokines produced by stromal 
inflammatory cells may also modulate HLA class II expression in benign breast 
epithelium. 
To date, IHC staining of over 1000 surgically removed breast carcinoma lesions 
has shown that HLA class II antigens are often up-regulated on malignant tumors of 
mammary epithelial cells [141, 145-158]. The frequency of HLA class II antigen 
expression in breast carcinoma lesions has been reported to average around 30%, 
however, frequencies have varied between 13% (10/77) [152] and 89% [150]. The 
differences among the reported frequencies of HLA class II antigen expression in breast 
carcinoma lesions are likely to result from the effect of many variables including patient 
population characteristics, sample size, criteria utilized to score HLA class II antigen 
expression and methodological differences in fixation protocols and antibodies used. All 
studies investigated HLA-DR antigen expression while only five have examined HLA-
DP and HLA-DQ antigen expression. In all five studies, irrespective of the frequency of 
HLA class II antigen detection in the breast carcinoma lesions analyzed, HLA-DR 
antigens were more frequently expressed than HLA-DQ and DP antigens [146, 147, 151, 
156, 159]. 
1.6.2.2 Expression ofHLA class II co-chaperone molecules in breast carcinoma 
No studies have reported on the expression of HLA-DM in breast carcinoma 
while two studies examined Ii expression [146, 151]. Both reported Ii is expressed in a 
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greater subset of breast carcinomas than HLA-DR, followed by HLA-DP and HLA-DQ, 
yet the implications of this discordant expression of Ii and HLA-DR in breast carcinoma 
remain unclear. Ii is expressed at higher levels than HLA-DR in invasive colon 
carcinoma and while high Ii expression associated with poorly differentiated tumors, no 
relationship with tumor stage was observed [160]. In contrast, Ii expression by gastric 
tumor cells did not associate with tumor grade but was increased according to depth of 
invasion and also associated with decreased survival [161]. These studies did not address 
the discordant expression of Ii and HLA-DR but merely related both factors 
independently with prognostic factors. If not fortuitous, the association of Ii expression 
with disease progression may be due to the prevention of tumor antigen (TA)-derived 
peptide presentation to CD4+ T cells for recognition, since in vitro studies have shown 
that HLA class II-transfected tumor cells are unable to present TA-derived peptides to 
CD4+ T cells in the presence ofli [89, 138]. 
1. 7 The biological and prognostic significance of HLA class II antigen expression 
in breast carcinoma 
1. 7.1 Associations of tumor cell HLA class II expression with T cell infiltration in 
breast carcinoma 
Working on the hypothesis that the induction of HLA class II antigens on breast 
cancer cells is attributable to the cytokine milieu within the tumor, which is largely 
influenced by cytokine producing infiltrating T cells, one would expect to see a clear 
association between the two factors. Yet, previous studies have not identified a clear 
relationship between the two as some groups have reported a positive relationship [162], 
while others showed no association [145, 154]. Some of the discrepancies in these studies 
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may be dependent on the subjective and inconsistent scoring schemes for tumor cell HLA 
expression and infiltrating T cells. 
The lack of association of tumor cell HLA class II expression and infiltrating T 
cells may reflect the absence of co-stimulatory molecule expression by tumor cells, 
resulting in T cell anergy [163]. However, a study conducted in our laboratory revealed 
although BCCL lack expression of the co-stimulatory molecules CD80 and CD86, the co-
stimulatory molecule CD40 was expressed in 7/11 BCCL [140]. Thus, additional co-
stimulatory molecules expressed on breast tumor cells may provide the second signal 
necessary for T cell activation in the context of breast carcinoma. In particular, in the 
context of anti-tumor immunity, initial naive T cell activation is likely via DC, which 
present tumor antigen derived peptides in the draining lymph node and such antigen-
specific T cells have less stringent requirements for subsequent re-activation at the tumor 
site [164]. 
The association of HLA class II expression by tumor cells and infiltrating T cells 
is likely dependent on numerous factors including co-stimulatory molecule expression, 
the phenotype of infiltrating T cells (and subsequent cytokine production) and the 
intratumoral pattern of T cell distribution. However, there is substantial evidence to 
support a role for tumor cell expression of HLA class II antigens in the induction of anti-
tumor immunity (discussed in the following section). 
1.7.2 Experimental evidence to support a role for tumor cell HLA class II antigen 
expression in anti-tumor immunity in breast carcinoma 
While the importance of CDS+ T cells in the anti-tumor immune response has 
long been recognized, several articles have also highlighted the requirement for CD4+ T 
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cell-recognition of tumor peptides presented by HLA class II molecules (HLA-DR, DP, 
DQ) for optimal anti-tumor immunity [ 165-167]. While initial CD4+ T H cell activation 
occurs in the tumor draining lymph node via DCs that have obtained tumor associated 
antigens (T AA) at the tumor site, experimental evidence from murine studies has 
identified a role for HLA class II antigen expressing tumor cells in the generation of 
effective anti-tumor immunity. Ostrand-Rosenberg's group, have shown that the HLA 
class II-transfected murine SAl sarcoma cell line efficiently presents tumor peptides and 
transplantation of these tumor cells into syngeneic mice results in the generation of a 
CD4+ anti-tumor immune response and elimination of the tumor [89, 138]. Recently, the 
importance of HLA class II antigen expression in breast carcinoma was shown by 
transfecting a murine mammary adenocarcinoma cell line with CIITA. This resulted in 
expression of HLA class II antigens and rejection of the transplanted tumor in syngeneic 
mice in a CD4+ T cell dependent manner [168]. 
Human studies have identified HLA class II restricted tumor antigen-specific 
CD4+ T cells exist in the peripheral blood and tumor infiltrating lymphocytes (TIL) of 
breast cancer patients and have shown that breast tumor cells can function as APC. For 
example, Tuttle et al (1998) [169] showed that peripheral blood CD4+ T cells from 
primary breast cancer patients with HER-2/neu positive tumors proliferated in vitro in 
response to primary stimulation of PBMCs with HER-2/neu derived peptides. 
Furthermore, direct recognition of class II positive breast tumor cells was shown by 
Dadmarz et al (1995) [170] who found that cultured CD4+ TIL produced granulocyte-
macrophage stimulatory factor (GM-CSF) and TNF-a, in a HLA-DR-restricted manner, 
in response to stimulation with autologous tumor cells. Sotiriadou et al (200 1) [ 171] 
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showed that the HER-2/neu tumor antigen was a naturally processed and presented tumor 
antigen as CD4+ T cell clones, derived from a healthy volunteer, proliferated and 
produced IFN-y in response to the HER-2/neu+ breast cancer cell line SKBR3 induced to 
express HLA class II antigens by combined IFN-y and TNF-a treatment. Antibody 
blocking experiments showed that this recognition was HLA-DR restricted. Perez et al 
(2002) further showed that HER-2/neu was naturally processed and presented by HLA-
DR antigen expressing breast, colorectal and pancreatic tumor cells, which were directly 
recognized by Her-2/neu-specific CD4+ T cell clones derived from a healthy individual 
[172]. 
1.7.3 Associations of tumor cell HLA class II expression with prognosis and 
outcome in breast carcinoma 
The finding of HLA class II antigen expression in benign breast lesions and well-
differentiated tumor cells with apparent difference in inflammatory infiltrate between 
HLA-DR antigen positive and negative tumors, led some to hypothesize that HLA class 
II antigen expression is not influenced by cytokines but rather by the differentiation state 
of the tumor [147]. Two other studies observed a relationship between tumor cell 
expression of HLA-DR antigens and low tumor grade [153, 159]. However, four other 
studies have found no significant associations of HLA class II antigen expression and the 
differentiation state of the tumor [146, 150, 155, 162]. 
The histological type of the tumor may also affect HLA class II expression by 
tumor cells. One study comparing HLA-DR antigen expression in different tumor types 
found DR expression is much higher in medullary, than atypical medullary or invasive 
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ductal breast carcinomas [157]. However, others have found no difference in HLA class 
II antigen expression across tumor types [146]. 
A role for hormonal control of HLA class II antigen expression was suggested by 
Brunner et al. (1991) who found HLA-DR antigen expressiOn was significantly 
associated with estrogen and progesterone receptor expressiOn [159]. No such 
relationship was observed in three other studies [150, 152, 155]. HLA class II antigen 
expression in primary tumor lesions has not been found to associate with lymph node 
metastasis [154, 156] tumor stage [152, 159] or mitotic index [154, 155]. Likewise, HLA 
class II expression is not an independent predictor of either disease-free or overall 
survival [152, 155]. 
The discrepancies m the aforementioned studies may reflect methodological 
variability and are also likely to be influenced by the complexity of breast carcinoma, 
which is not a single disease entity, and is characterized by many different interacting 
factors. For example, women with the most common histological type of breast 
carcinoma, invasive ductal, are more likely to be diagnosed at an earlier age and with 
tumors that are poorly differentiated, hormone receptor negative and of smaller diameter, 
whereas women with the next most common type, invasive lobular breast carcinoma, are 
more frequently diagnosed at a later age and with tumors that are better differentiated, of 
larger diameter and more often hormone receptor positive [173]. Thus, the interplay of 
these factors combined with hormones and cytokines in the tumor microenvironment is 
likely to influence up-regulation ofHLA class II antigen expression by tumor cells. 
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1. 8 The immune response to breast carcinoma 
1.8.1 Inflammatory cell infiltration in breast carcinoma 
Mononuclear cell infiltration is markedly increased in invasive breast carcinoma 
as compared to non-malignant breast tissue [145, 162, 174]. Several studies in the 1980's 
and 1990's used immunohistochemistry or flow cytometry of collagenase disrupted 
tumors to characterize the immune cell infiltrate in breast carcinoma lesions at the time of 
surgery. T cells and macrophages were reported to be the major tumor infiltrating cell 
subsets with some studies reporting T cells exceed macrophages [162, 174-176] and 
others reporting the opposite [144, 177, 178]. Likewise, the CD4+/CD8+ T cell ratio has 
varied among studies with some groups finding the majority of tumors have greater 
numbers of CD4+ T cells [145, 162, 176, 178, 179] and others reporting the opposite 
[175, 180, 181]. Dendritic cells (DC) are also abundant in breast carcinoma, however, 
mature DC are located at the tumor periphery while intratumoral DC have an immature 
phenotype [182]. The number of B lymphocytes, as detected by antibodies to CD19 or 
CD20, is reduced in comparison to T cells and macrophages [144, 162, 175, 176, 181, 
183] and breast carcinomas contain a relative paucity of NK cells, determined using 
antibodies to CD16, CD56 and CD57 [174-176, 179, 183]. Tissue mast cells, plasma cells 
and eosinophils are also present in low numbers [178]. 
1.8.2 Central roles of CD4+ T cells in the anti-tumor immune response 
The importance of HLA class II molecules in the initiation of immunity is via the 
activation of CD4+ T H cells, which recognize peptides in the context of HLA class II 
molecules. Experimental models have demonstrated CD4+ T H cells are central to the 
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anti-tumor immune response as they function as 'helper' cells orchestrating multiple arms 
of the immune response through their activation of immune effector cytotoxic T 
lymphocytes (CTL) and B lymphocytes and their recruitment and activation of cells of 
the innate immune response such as macrophages, eosinophils and NK cells. Recent 
studies have identified a substantial proportion of CD4+ T cells infiltrating breast tumors 
are immunoregulatory, characterized by secretion of the immunosuppressive cytokines 
IL-10 and transforming growth factor (TGF)-~1 and capable of in vitro suppression of 
effector cell proliferation and cytokine secretion [184]. Such CD4+ Treg cells can 
suppress anti-tumor immunity via their actions on DC, na'ive CD4+ TH cells and effector 
CD4+ and CD8+ T cells (Figure 1.5). 
1.8.3 The prognostic significance of infiltrating CD4+ T cells in breast carcinoma 
While the importance of CD4+ T cells in orchestrating the anti-tumor immune 
response in murine models is well established, the clinical significance of CD4+ T cell 
infiltration in human breast carcinoma remains unclear. Many studies have attempted to 
correlate the degree of T cell infiltration with prognostic parameters. Infiltrating T cells 
negatively associate with LN metastasis is some studies [154, 185], while the opposite 
was reported in other studies [186, 187]. Contradictory reports regarding associations of 
infiltrating T cells and tumor stage have also arisen [181, 185]. Several groups have 
shown infiltrating T cells associate with the poor prognostic indicator of increased 
histological grade [162, 174, 187], while others found no association [179, 181]. 
Likewise, the majority have reported an inverse correlation between hormone receptor 
expression and T cell infiltration [174, 181, 187], yet others did not observe such an 
association [179, 186]. Despite published associations ofinfiltrating T cells with 
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Figure 1.5: Central roles of CD4+ TH cells in anti-tumor immunity. Tumor cells shed 
antigens, which are endocytosed by dendritic cells, processed and presented in the 
context of HLA class II to CD4+ TH cells and HLA class I to CDS+ T cells, following 
dendritic cell (DC) migration to the draining lymph node. Activated CD4+ T H cells then 
traffic to the tumor where they orchestrate multiple arms of the anti-tumor immune 
response. CD4+ THl cells secrete IL-2 and IFN-y and are crucial for the induction of 
cellular immunity. IL-2 secreted by CD4+ THl cells activates MHC class !-restricted 
CD8+ T cells, driving their differentiation to cytotoxic T lymphocytes (CTL) and NK 
cells, which directly lyse HLA class I+ tumor cells. IFN-y produced by THl cells 
activates immature DC enabling their efficient presentation of tumor associated antigens 
to CDS+ T cells and tumor associated macrophages (TAM), which lyse tumor cells via 
secretion ofTNF-a and reactive oxygen and nitrogen species. CD4+ TH2 cells secrete IL-
4, inducing B cell activation and differentiation into tumor-specific antibody secreting 
plasma cells and recruitment and activation of eosinophils, which degranulate. CD4+ T 
cells can also be directly activated by and lyse HLA class If tumor cells via secretion of 
tumoricidal cytokines. The anti-tumor immune response can be suppressed in the 
presence of immunoregulatory TAA-specific CD4+ Treg cells via suppression of naive 
CD4+ T H cell proliferation, inhibition of cytokine secretion by CD4+ and CDS+ effector 
T cells and suppression of DC maturation. Figure adapted from Goedegebuure and 
Eberlein (1995) [186], Pardoll and Topalian (1998) [164], Wang (2001) [187] and Wang 
and Wang (2005) [188]. 
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prognostic parameters, the degree of T cell infiltration fails to predict relapse-free or 
overall breast cancer survival [187, 191, 192]. A more recent study of ovarian carcinoma 
patients has outlined the importance of studying the distribution of T cells within the 
tumor as the presence of intratumoral T cells independently predicted improved disease-
free and overall survival in ovarian cancer patients [193]. 
The discrepancies in the above studies may in part be due to the presence of 
regulatory T cell subsets. Not all CD4+ T cells that infiltrate breast tumors function in an 
effector capacity. Breast cancer patients have increased numbers of functionally 
immunosuppressive CD4+CD25+ Treg cells within the tumor microenvironment and 
circulation [184, 194]. Thus, the balance of effector and regulatory cell subsets will have 
important consequences for the anti-tumor immune response and prognosis in breast 
carcinoma patients. Indeed, a high CD8+/CD25+FOX-P3+ Treg TIL ratio associates with 
improved survival in ovarian carcinoma [195]. 
1.8.4 The cytokine milieu in breast carcinoma 
1. 8.4.1 In situ cytokine production by tumor infiltrating immune cells 
While it is well documented both CD4+ and CDS+ isolated TIL are capable of 
cytokine secretion in response to stimulation with autologous or HLA-matched allogeneic 
tumor cells [170, 188, 196] or non-specific mitogen stimulation in vitro [197], few 
studies have evaluated in situ cytokine production in breast carcinoma. A small-scale, in 
situ hybridization study of 13 breast carcinomas, using cytokine specific probes for IL-2, 
TNF-a. and IFN-y mRNA, revealed for the majority of tumors (9/13), few mononuclear 
cells express these cytokines. However, mucinous breast carcinomas (N=4) contained a 
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much higher percentage of cytokine producing cells, and it was suggested tumor-
associated mucins may provide increased immunogenicity [198]. This study was limited 
in size and also failed to relate the number of cytokine producing cells with the degree of 
mononuclear cell infiltration. However, 7/9 tumors with low numbers of cytokine 
expressing cells had minimal mononuclear cell infiltration. Camp et al. (1996) used 
immunohistochemistry to assess protein expression of a much larger panel of cytokines in 
89 primary breast carcinomas and 14 benign breast lesions [191]. Significantly more 
tumors contain tumor infiltrating T cells that produce IL-2, IL-4, TGF-rH and TNF-a 
than IFN-y and GM-CSF, using a cutoff of 3% positive TIL. Furthermore, IL-4, IL-2 and 
TGF-.81 production was significantly higher in breast carcinoma as compared to benign 
breast tumors. However, this study did not dual stain infiltrating T cells but rather 
compared cytokine stained sections to CD3 stained sections to ascertain T cell specific 
cytokine production. 
The relationship of in situ cytokine production with prognostic parameters was 
investigated in a small study, of 19 breast carcinoma and 7 benign breast lesions, where 
cytokine mRNA was detected using RT-PCR and Southern hybridization of bulk tissue 
RNA [183]. The majority of tumors expressed TNF-a (12119), TGF-.81 (12/19) and IL-10 
(13/19). IL-4, IL-6, and IFN-y were not detected but a subset expressed IL-2 (7/19) and 
IL-8 (2/19) mRNA. Only IL-2 (2/7) and IL-10 (1/7) were detected in benign lesions. The 
presence of detectable TNF-a did not associate with prognostic parameters but detectable 
IL-10 associated with increased tumor size. Relative TGF-{J1 levels were semi-quantified 
using competitive PCR and were significantly decreased in tumors from patients of 
advanced stage as compared to those alive without residual disease. However, the true 
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significance of these results must be interpreted with caution due to the small sample 
size. Furthermore, despite knowledge of numbers of infiltrating cell subsets in 14119 
tumors, the authors failed to correlate cytokine mRNA with infiltrating cell subsets. 
Green et al. (1997) compared bulk tumor cytokine mRNA in a larger number of 
malignant breast tissues (N=77) to normal breast tissue (N=58). Relative amounts of 
mRNA were not determined but rather presence or absence of detectable mRNA was 
assessed. The proportion of tissues with detectable IL-la, IL-l~, IL-4, IL-6, TNF-a and 
TNF-~ did not significantly differ between the two groups, but IL-8 was more frequently 
detected in malignant tissues. IL-2, IL-3, IL-5, IL-7 and IFN-y were not detected in either 
tissue. The expression of individual cytokine mRNA did not correlate with tumor stage, 
tumor grade, LN metastasis or menopausal status [199]. However, this study assessed 
cytokine mRNA in the absence of information on tumor infiltration by inflammatory 
cells. 
1.8.4.2 Genetic polymorphisms that regulate cytokine production 
Although it is likely the T cell mediated cytokine response in breast carcinoma 
will be dependent on the type and dose of tumor-associated antigens and the HLA 
allotypes expressed within the tumor, genetic differences in cytokine genes that influence 
cytokine production may also affect anti-tumor immunity. Cytokine and cytokine 
receptor genes generally have highly conserved exon sequences but often contain 
polymorphisms in regulatory regions [200]. Studies of cell lines transfected with cytokine 
allele promoter reporter gene constructs have shown single nucleotide polymorphisms 
(SNPs) affect cytokine gene transcription [201, 202]. Such polymorphisms also associate 
with differential cytokine production following in vitro activation of peripheral blood 
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mononuclear cells with mitogen or aCD3/aCD28 [203-206], and in vivo plasma levels 
from healthy blood donors [207, 208] and in response to vaccination [209]. 
Weak associations of SNPs in cytokine genes have been linked to prognosis and 
outcome and susceptibility or protection from breast cancer [210-216]. Contradictory 
reports have arisen with respect to such associations. For example, in a large prospective 
cohort study of 3075 American Caucasian women, the TGF-,61 Codon10 C/C genotype 
associated with decreased risk ofbreast carcinoma [217], while a large case-control study 
of UK, German and Finnish individuals did not demonstrate such an association [201]. 
The authors suggest this discrepancy might be explained by the increased number of 
cases (3987 patients and 3867 age-matched controls), decreased age and lack of non-
invasive cases in their study. Discrepant reports also exist regarding associations of SNP 
genotypes with prognosis and outcome. For example, the IL-6 -174C allelic variant 
associated with LN metastasis, increased tumor grade and decreased overall survival of 
unselected breast carcinoma patients [218]. In contrast, in high-risk LN positive patients, 
the IL-6 -174C SNP associates with increased survival [219]. Importantly, studies 
of cytokine SNPs with prognosis and survival in breast carcinoma have not evaluated 
intratumoral cytokine production. Rather, such studies have grouped patients into high or 
low cytokine producing groups based on published reports of in vitro cytokine 
production. Yet, discrepant reports exist regarding associations of cytokine SNPs with in 
vitro cytokine production. It is important to note, studies aimed at investigating such 
associations have varied in their use of cell subsets, method and length of cell 
stimulation. For example, stimulation of PBMC from healthy individuals with 
Concanavalin A (ConA) or phytohemagglutinin (PHA) resulted in significantly increased 
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IFN-'}' secretion from individuals homozygous for the +874T allele [205], while anti-CD2 
stimulation of PBMC from healthy individuals did not demonstrate such an association 
[220]. Variation in the dose of stimulus can also influence associations as in vitro TNF-a 
secretion is significantly increased from individuals carrying the -308A allelic variant, 
following prolonged low dose lipopolysaccharide (LPS) stimulation (lng/ml for 24hours) 
of whole blood, but not short-term high dose (lOOng/ml for 3hr) treatment [221]. Kroeger 
et al. (2000) showed, using reporter gene assays, that the transcriptional activity of TNF-
a promoter variants was influenced by both cell type and type of stimulation, suggesting 
cell-type specific transcription factors likely influence cytokine gene transcriptional 
control [222]. Furthermore, associations of cytokine gene polymorphisms with in vitro 
cytokine production, observed in healthy individuals are not always shared by individuals 
in a diseased state [223]. Assumptions should not be made regarding in vivo cytokine 
levels based on carriage of particular cytokine gene polymorphisms, as levels are surely 
dependent on the pattern of immune cell infiltration and the stimulus. Also, the multiple 
facets of anti-tumor immunity suggest patient outcome will be dependent on the balance 
of pro-inflammatory and immunosuppressive cytokines. Thus, associations of individual 
cytokine allelic variants with susceptibility and prognosis in breast carcinoma will likely 
be influenced by the other cytokine alleles carried by the patient. 
1.9 OVERVIEW 
1.9.1 Rationale and Thesis Overview 
The preceding· literature review has highlighted the fact that studies aimed at 
investigating associations of tumor cell expression of HLA class II antigens and the 
immune response and prognosis in breast carcinoma have been fraught with controversy. 
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Such studies have not assessed individual HLA class II allotypic expression but rather 
have examined HLA-DR, -DP and -DQ antigen expression, utilizing locus specific 
monoclonal antibodies. This may in part be due to the lack of availability of allospecific 
mAb that recognize determinants expressed in formalin-fixed and paraffin-embedded 
tissue sections. As allelic differences in HLA class II antigens are known to influence T 
cell activation and cytokine production, knowledge of tumor cell HLA class II expression 
in the absence of information on the HLA class II alleles carried by the tumor may be 
uninformative. 
Based on the knowledge that allelic differences in HLA-DR molecules influence 
level of expression and T cell activation, we hypothesized that associations of tumor cell 
HLA-DR expression with T cell infiltration in breast carcinoma were influenced by the 
DRB alleles carried by the patient. Furthermore, as loss of expression of individual HLA 
class I allotypes was a common occurrence in breast carcinoma [224, 225] and 
experimental evidence suggests a role for T cell pressure in the generation of HLA loss 
variants [226, 227], we hypothesized that similar pressure from CD4+ T H cells might 
exist and that individual HLA-DRJ3 allotypes would be differentially expressed by breast 
carcinoma cells. Due to the published association of HLA-DRBl *04 with a poor 
prognosis in breast carcinoma [128], we selected an equal number of tumors from HLA-
DRBl *04+ and non-HLA-DRBl *04 patients to investigate these theories (Chapter 2). 
As the study described in Chapter 2 was not designed to assess the clinical 
significance of HLA-DR,6 allotypic expression in breast carcinoma (due to the biased 
selection for DRB 1 *04+ tumors, and the small sample size), we performed a larger study 
on a randomly selected set of breast carcinomas. We postulated that differential 
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expression of individual HLA-DR,B allotypes by breast tumor cells might represent an 
additional immune evasion strategy and thereby correlate with a poor prognosis. 
Furthermore, as HLA-DRB allelic variants influence immune responsiveness, we 
postulated that expression of particular HLA-DR,B allotypes might associate with a 
particular cytokine profile and with prognosis in breast carcinoma (Chapter 3). 
Although murine studies have illustrated HLA class II expressing tumors cells can 
act as antigen presenting cells leading to CD4+ T cell activation and tumor rejection, 
studies of human breast carcinoma have failed to investigate the in situ expression of the 
antigen processing machinery involved in the HLA class II pathway and their influence 
on immune responsiveness and patient outcome. Induction of HLA class II antigens and 
their related co-chaperones in breast carcinoma cells in situ is likely dependent on the 
cytokine milieu of the tumor microenvironment. We hypothesized that expression of 
components of the HLA class II antigen processing machinery by breast tumor cells 
would be influenced by the presence of infiltrating inflammatory cells and the in situ 
cytokine milieu. Furthermore, we anticipated expression of co-chaperone molecules 
would enable breast cancer cells to function as efficient APC and thereby correlate with 
improved patient outcome. To test these hypotheses, we evaluated tumor cell expression 
of HLA-DR and the co-chaperones Ii and HLA-DM and assessed the relationship of 
these factors to immune cell infiltrate and relative cytokine levels in a subset of breast 
carcinoma patients with prognostic and outcome information (Chapter 4). 
As immune cells mediate their functions through the release of cytokines, we 
hypothesized the cytokine milieu of the tumor microenvironment would be dependent on 
the pattern of inflammatory cell infiltration and that published disparities in the 
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prognostic significance of inflammatory cell infiltration in breast carcinoma might be 
explained by variability in the balance of immune promoting and immune suppressing 
cytokines. Using our subset of invasive breast carcinoma patients with prognostic and 
outcome information, we assessed the relationships of inflammatory cell subset 
infiltration, cytokine mRNA levels and prognosis and outcome (Chapter 5). 
Coincident with this, we further hypothesized some of the variability m 
intratumoral cytokine production might be dependent on genetic variability in cytokine 
genes, which have been documented to influence cytokine gene activity and secretion. To 
investigate this, we evaluated single nucleotide polymorphisms of a panel of cytokine 
genes and assessed the relationship to tumor derived cytokine levels, in a subgroup of our 
invasive breast carcinoma samples with prognostic and outcome information (Chapter 6). 
The aim of this research project was to provide a comprehensive study, which 
takes into account the interplay of immunologically relevant markers on breast carcinoma 
cells (i.e., HLA-DR and the co-chaperones Ii and HLA-DM) with infiltrating 
inflammatory cells and immunomodulatory cytokine mRNA levels, in the context of 
knowledge of the HLA-DRB genetic differences of the patients. Breast carcinoma 
samples were phenotyped for the aforementioned immunological markers and a thorough 
statistical analysis was performed to assess the strength of relationship of these factors 
and their prognostic significance in the clinical course of breast carcinoma. 
1.9.2 Co-authorship statement 
The thesis author and S.D. were responsible for study design. All experiments 
were conducted under the supervision of S.D. The thesis author solely conducted all 
research and development studies to establish optimal immunohistochemistry (IHC) 
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protocols (as described in Chapter 2, Material and Methods), performed all IHC 
experiments (Chapters 2-6) and cytokine SNP genotyping experiments (Chapter 6) and 
contributed to the HLA class II DNA-typing of breast carcinoma samples described in 
Chapter 3. The thesis author was solely responsible for database construction, all 
statistical analysis and manuscript preparation, with major editorial contributions by S.D. 
Additional co-authors include J.D.R. (Chapters 2 and 4) who served as a second reader 
for the interpretation of all IHC slides and offered expert pathological expertise; D.C. 
who contributed to HLA class II DNA typing (Chapter 3) and conducted RT-PCR 
experiments (Chapters 3-6); P.W. (Chapters 2 and 4) of the Manitoba Breast Tumor Bank 
(MBTB) who provided the breast tumors utilized in these studies; and V.G. (Chapters 3 
and 4) who provided statistical expertise. 
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2.1 ABSTRACT 
The biologic and prognostic significance ofHLA-DR expression and T-cell infiltration in 
breast carcinoma are presently controversial. To test the hypothesis that these factors are . 
influenced by particular HLA-DRB alleles, 52 breast tumor samples, composed of 26 
DRB1 *04 and 26 non-DRB1 *04 tumors, were assessed using immunohistochemistry for 
expression ofHLA-DR and its associated invariant chain (Ii) and for infiltrating CD3+ T 
cells. While HLA-DR expression by tumor cells was significantly associated with T-cell 
infiltration, DRB1 *04 tumors were more frequently HLA-DR+Ii+ and contained smaller 
CD3+ infiltrates than non-DRB1 *04 tumors. This difference was largely attributable to 
DRB1 *07 tumors, which were typically DR-Ii-, although they contained similar numbers 
of T cells to DR+Ii+ tumors. Further analysis of HLA-DR+ tumors using allotype 
discriminating antibodies revealed that DRB 1 *04 alleles were always expressed, while 
non-DRB 1 *04 alleles were inconsistently expressed. The results of this study provide the 
first reported evidence that HLA-DRB alleles influence HLA-DR expression and T-cell 
infiltration in breast carcinoma and suggest that multiple factors contribute to HLA-DR 
expression. Ongoing studies aimed at elucidating the molecular and immunologic 
mechanisms controlling differential HLA-DR expression and implications for prognosis 
and outcome should further our understanding of the antitumor immune response and 
evasion strategies employed by tumor cells 
2.2 INTRODUCTION 
A prerequisite for tumor eradication by CD8+ cytolytic T cells is recognition of 
tumor antigen presented by HLA class I molecules on the tumor cells and this is reflected 
by the numerous studies showing loss or down regulation of HLA class I on established 
52 
tumors [228, 229]. Optimal anti-tumor immunity also requires participation of CD4+ T 
cells, which recognize tumor peptides presented by HLA class II molecules (HLA-DR,-
DP, -DQ) [138, 166, 167]. However, the importance ofHLA class II expression on breast 
carcinoma cells and implications for anti-tumor immunity are currently unclear. Unlike 
HLA class I, HLA class II molecules are not normally present on resting epithelial cells, 
although they are detected de novo in the lactating breast and in a subset of breast 
carcinomas [141]. They can also be induced in vitro on many cell types, including breast 
cancer cell lines, by interferon-y (IFN-y) [134, 230] and other immunomodulators [136, 
143], suggesting that in situ expression on carcinoma cells may be regulated by cytokines 
and/or hormones. Antigen presentation by HLA class II positive breast cancer cells, 
which lack co-stimulatory molecules typically found on professional antigen presenting 
cells (APC), could potentially induce T cell anergy. However, reports of direct 
recognition of tumor cells by HLA class II-restricted CD4+ T cells [170, 172] suggest 
that HLA class II+ tumor cells play an important role in determining the outcome of an 
anti-tumor immune response. 
Studies investigating expression of HLA class II in breast carcinoma generally 
concur that HLA-DR and its co-chaperone Ii are more often and more strongly up 
regulated than HLA-DP or DQ [146, 151]. However, the significance of these findings is 
controversial as some studies suggested HLA-DR expression on breast tumor cells is 
associated with favorable prognostic indicators such as well differentiated tumors [147, 
148] and hormone receptor expression [159], while others found no effect [146, 152]. 
Similarly, tumor cell HLA-DR was positively associated with T cell infiltration in some 
studies [162, 177] and unrelated in others [145, 147]. 
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Interpretation of the above studies may have been hampered by the fact that 
generic and not allelic HLA-DR expression was examined. This was likely because of the 
paucity of allotype specific antibodies and the large number of HLA-DRB 1 alleles, most 
ofwhich are in linkage with additional structural HLA-DRB genes. These include HLA-
DRB1 *15 and 16, expressed in association with HLA-DRB5 (DR51); HLA-DRB1 *03, 
11, 12, 13 and 14 with HLA-DRB3 (DR52); HLA-DRB1 *04, 07 and 09 with HLA-
DRB4 (DR53); and HLA-DRB*01, 10 and 08 which are not in association with any other 
HLA-DRB expressed genes. As most individuals are heterozygous, expressing up to four 
HLA-DR allotypes and since carcinomas are known to selectively down regulate HLA 
class I alleles [228, 229], we hypothesized that HLA-DRB alleles would also be 
differentially expressed in HLA-DR+ tumors. 
To test this hypothesis we compared DRB1 *04 to non-DRB1 *04 tumors. 
DRB 1 *04 has been reported to confer a poor prognosis in different carcinomas including 
breast [128, 231], but a similar study in our laboratory has not confirmed the association 
of DRB 1 *04 per se with poor prognostic factors in breast carcinoma patients. However, 
DRB1 *04 allelic differences were noted as DRB1 *0401 was increased in Stage I invasive 
ductal breast carcinomas, while other DRB 1 *04 alleles were increased in stage III tumors 
(data not shown). As part of this investigation, we also examined whether DRB1 *04 
and/or its individual alleles, influenced expression of generic HLA-DR, its co-chaperone 
Ii and T cell infiltration in breast carcinoma. HLA-DR+ tumors were further evaluated 
for expression of individual HLA-DRB alleles. Since HLA class I is ubiquitously 
expressed, but frequently down regulated on tumor cells, its expression was also assessed 
partly as an intrinsic control but also as an indicator of MHC integrity on the tumor cells. 
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2.3 MATERIALANDMETHODS 
2.3.1 Patient Sample 
Fifty-two invasive breast carcinoma samples were obtained from the Manitoba 
Breast Tumor Bank (Winnipeg, Manitoba, Canada). The samples were comprised of 40 
ductal, 6 lobular and 6 ductal-lobular mixed. The age at diagnosis ranged from 31 to 92 
years (median 66 yrs). The tumors spanned a wide range of grade (grades 5-9), 
determined using the Nottingham grading system. Estrogen and progesterone receptor 
levels were determined by ligand binding assay and values ranged from 0 to 273 fmol/mg 
(median 21.5 fmol/mg) and 0 to 1088 fmol/mg (median 16.1 fmol/mg), respectively. 
Tumor size was available for 50 tumors and 36 had a diameter larger than 2 em. Lymph 
node status was available for 43 patients of which 20 were positive. 
The above cohort of 52 tumors were randomly selected from a larger sample that 
was DNA typed for HLA-DR by PCR-SSP using HLA class II typing kits (Bio-
Synthesis, Inc., Lewisville, TX, USA) as part of an ongoing study in our laboratory (data 
not shown). To determine whether DRB 1 *04 alleles influenced HLA-DR or Ii expression 
by carcinoma cells or T cell infiltration, we investigated 26 DRB1 *04 samples, which 
had been subtyped using DRB1 *04 subtyping kits (Bio-Synthesis), and 26 non-DRB1 *04 
samples. 
2.3.2 Monoclonal Antibodies 
Monoclonal antibodies (mAbs) (spent supernatants) were used to detect generic 
HLA-class I (W6/32, 1:150, ATCC, Manassas, VA, USA) and HLA-DR (L243, 
2.4J..Lg/ml, ATCC). Commercially available mAbs were used to detect Ii chain (clone 
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LN2, 2.5j..tg/ml, Pharmingen, Mississauga, ON, Canada) and CD3-positive infiltrating T 
cells (clone UCHT1, 2.5j..tg/ml, Pharmingen). Negative controls consisted of isotype 
matched non-specific mouse immunoglobulins (Southern Biotechnology Associates, Inc., 
Birmingham, AL, USA). Samples that contained HLA-DR+ tumor cells were further 
evaluated for expression of individual HLA-DRB alleles using a panel of monoclonal 
antibodies that distinguish HLA-DR polymorphisms (Table 2.1). These included local 
mAbs NFLD.D1 [232, 233], NFLD.D10 [232], and NFLD.D7 [232], and SFR16 [234] a 
kind gift from Susan Radka. UK8.1 [235], 7.3.19.1 [236], PL3 [237] and MAD88 were 
obtained through the 1oth International Histocompatibility Workshop (IHW). 
To determine optimal antibody concentrations and show that mAbs neither 
recognized cell type restricted epitopes nor cross-reacted with additional HLA-DRB 
allotypes, immunohistochemistry was performed on various cell types with known HLA-
DRB allotypes. These included, IFN-y treated ovarian and breast cancer cell lines, 
peripheral blood mononuclear cells (from local donors), B cell lines (101h IHW), mouse 
L-cell fibroblast lines transfected with HLA-DR molecules (11th IHW) and synovial 
tissue sections (data not shown). All mAbs showed reactivity in concordance with their 
published specificities. MAD88 was submitted to the lOth IHW as a HLA-DR~1 *08 
specific mAb but was found to cross react to alleles of the HLA-DR~3 (DR52) 
haplotype. However, additional alleles with which MAD88 reacts were not present in the 
DRB 1 *08 tumors in this study. 
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Table 2.1: HLA-DRP Allotype Specific mAbs used in this Study 
mAb Isotype Concentration/ Dilution HLA-DRJ3 Specificity 
--------------
NFLD.D1 lgG1 10j.lg/ml J31*04 
NFLD.D7 lgG1 11100 J31*04, 15, 16; J33 
NFLD.D10 IgG1 3j.!g/ml J31*01, 15,04\141,09, 10;J35*02 
SFR16 lgG2a 1/25 J31*07 
UK8.1 IgG2b 1/1000 J31 *03, 11, 13, 141 
7.3.19.1 IgG2b 111000 J31*03,J33 
PL3 IgG3 11400 J31*07,09;J34 
MAD882 IgG 11100 J31 *08, J33 
1Not all allelic products of this HLA-DR type carry the epitope recognized by this antibody. 
2This mAb was reported as DR~l *08 specific in the 101h IHW but shows cross reaction with HLA-DR~3 
alleles. 
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2.3.3 Immunohistochemistry 
Serial frozen sections (8 f..!m) were fixed in acetone for 10 minutes at -20°C, 
shipped from the NCIC Manitoba Breast Tumor Bank and stored at -70°C until 
immunohistochemical staining. After thawing, drying and rehydrating in phosphate 
buffered saline (PBS) (pH 7.4), sections were treated with 1.5% hydrogen peroxide in 
PBS for 30 minutes to remove endogenous peroxidases, and nonspecific binding was 
blocked with 15% goat serum in PBS for 1 hour. Sections were incubated for 1 hour with 
primary antibody followed by incubation for 30 minutes with goat anti-mouse DAKO 
En Vision horseradish peroxidase (HRP) labeled polymer (DAKO Diagnostics Canada 
Inc., Mississauga, ON, Canada). Antibody binding was visualized by incubating with 
diaminobenzidine + hydrogen peroxide (Sigma, Oakville, ON, Canada) for 5 minutes. 
The reaction was stopped with water and sections were counterstained in Mayer's 
haematoxylin. Infiltrating mononuclear cells served as intrinsic positive controls for the 
immunoreactivity of the monoclonal antibodies. 
2.3.4 Immunohistochemistry Interpretation 
All slides were coded and independently examined by three readers (J.D.R, S.O., 
and S.D.). Infiltrating T cells were coded based on estimated numbers: - (no or a few 
scattered cells); -/+ (small numbers of scattered cells or occasional small aggregates); + 
(moderate numbers of scattered cells, numerous small aggregates or occasional large 
aggregates); ++ (large numbers of scattered cells or several large aggregates). For 
analysis, sections were considered positive for an infiltrating T cell population if scored + 
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or ++. The distribution of infiltration (within tumor nests and/or throughout the 
intervening tumor stroma) was also determined. 
The percentage of tumor cells expressing HLA-DR, Ii and HLA class I was coded 
based on comparison to expression levels on inflammatory cells within the same tissue 
section: - (0-24% tumor cells positive); -/+ (25-49% tumor cells as strong as 
inflammatory cells or 25-74% tumor cells weaker than inflammatory cells);+ (50-100% 
tumor cells as strong as inflammatory cells or 75-100% tumor cells weaker than 
inflammatory cells). Since HLA-DR and Ii are not normally expressed on breast 
epithelial cells, for categorical analysis samples with HLA-DR or Ii up regulated in at 
least 25% of tumor cells were classified as positive. For HLA class I, only those coded+ 
were considered positive as samples coded - or -/+ were considered to have a substantial 
down regulation of HLA class I. Likewise, only the percentage of tumor cells strongly 
positive for HLA class I was used for continuous variable analysis while total percentage 
of tumor cells positive (weak or strong) was included for HLA-DR and Ii .. 
2.3.5 Statistical Analysis 
Analysis was performed usmg SPSS Version 10.0 statistical software. 
Contingency tables were analyzed using Pearson's chi-square analysis or Fisher's exact 
test for 2x2 tables with expected counts :::::;; 5. Non-parametric Mann-Whitney U or 
Kruskal-Wallis H tests were used when assessing statistical significance of the actual 
percentages of tumor cells positive for HLA-DR, Ii and HLA class I. All tests were two-
sided and differences between groups were considered significant ifp < 0.05. In the text, 
-
mean percentage of positive tumor cells ( x %) is reported as mean ± standard deviation. 
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1.4 RESULTS 
2.4.1 Tumor cell expression of HLA-DR, Ii and HLA class I molecules is positively 
associated with T cell infiltration 
Breast carcinoma samples were assessed for tumor cell expression ofHLA-DR, Ii 
and HLA class I and estimated numbers of infiltrating T -cells (Table 2.2). Based on 
-
categorical values, 20 were classified as HLA-DR+ (x% = 77% ± 22%), 32 were HLA-
- - -
DR- (x% = 3% ± 6%), 28 were Ii+ (x% = 80% ± 23%), 24 were Ii- (x% = 5% ± 7%), 36 
- -
were HLA class I+(x% = 72% ± 31%) and 14 were HLA class I- (x% = 4% ± 6%). 
As shown in Figure 2.1, the mean percent of tumor cells with strong HLA class I 
expression was significantly decreased in HLA-DR- compared to the HLA-DR+ tumors 
(Mann-Whitney U test, P=0.003), suggesting a negative effect on the HLA complex on 
chromosome 6. HLA class !-expression was also decreased in Ii- compared to Ii+ tumors 
but this difference was not significant. As expected, tumor cell HLA-DR and Ii were co-
coordinately regulated in the majority of tumors (Pearson's x2=27.857, P<O.OOOl) with 
20 co-expressing HLA-DR and Ii, 24 lacking expression of both and 8 expressing Ii in 
the absence ofHLA-DR. Representative examples ofDR+Ii+, DR-Ii-, and DR-Ii+ tumor 
cells are illustrated in Figures 2.2A, 2.2B and 2.2C, respectively. 
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Table 2.2: HLA-DRB alleles and immunohistochemistry results for breast carcinoma 
samples examined in this study. 
ID# HLA-DR Alleles * Expression by Tumor Cells t CD3+ 
Other infiltratet DRI31 HLA-DR Ii HLA class I 
DR 
7959 04, 12 134,133 +§ -/+§ +§ -I+ 
9914 0401, 03 134, 133 +§ +§ -/+ -I+ 
11023 0401,03 134,133 +§ +§ +§ ++§ 
9822 0401,09 134,134 +§ +§ +§ -I+ 
8192 0401, 15 134,135 +§ -/+§ +§ 
11093 0402, 16 134,135 +§ -/+§ +§ -I+ 
11702 0403, 13 134,133 +§ +§ +§ ++§ 
11999 0404,08 134 +§ +§ +§ ++§ 
10881 0404, 13 134,133 +§ +§ +§ ++§ 
8043 0407, 11 134,133 +§ +§ +§ +§ 
11214 0407, 15 134,135 +§ +§ +§ ++§ 
11710 0401,0404 134,134 -/+§ +§ +§ -I+ 
11838 0401, 08 134 -I+§ +§ +§ -I+ 
11696 04,04 134,134 -I+ 
11243 0401,0404 134,134 +§ +§ 
9112 0401,03 134,133 
8183 0401, 13 134,133 +§ -I+ 
11115 0401, 15 134,135 +§ -I+ 
12023 0401, 15 134,f35 +§ -I+ 
7952 0402,01 134 +§ +§ -I+ 
8824 0404, 13 134,133 +§ +§ 
11246 0405,01 134 +§ ++§ 
10960 0408,0408 134,134 -I+ -/+ 
11770 0408,0408 134,134 +§ +§ 
7963 0408, 11 134,133 -I+§ -I+ -I+ 
10871 0423,07 134,134 NR 
11644 01, 10 +§ +§ +§ +§ 
8196 03,03 133,133 +§ +§ +§ ++§ 
10970 07,08 134 +§ +§ +§ ++§ 
11353 08, 16 135 +§ +§ +§ ++§ 
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ID# HLA-DR Alleles * Expression by Tumor Cells t 
CD3+ 
Other infiltrate~ DR~1 HLA-DR Ii HLA class I 
DR 
10842 09, 11 f34,f33 +§ +§ +§ +§ 
11393 13, 14 f33,f33 +§ +§ +§ -I+ 
11603 13, 15 ~3,f35 +§ +§ +§ +§ 
9930 01, 15 ~5 -/+§ -I+ -I+ 
11740 03, 13 f33,f33 
7953 03,07 f33,f34 -I+ 
8795 07,07 f34, f34 NR ++§ 
9110 07, 13 04,03 +§ -I+ 
10666 07,07 ~4,f34 +§ +§ ++§ 
11000 07, 10 f34 +§ 
11148 07, 11 f34,f33 +§ -I+ 
11288 07,11 f34,f33 +§ 
11372 07,08 f34 +§ +§ 
12020 07, 16 f34,f35 +§ 
11982 09, 15 04,05 -I+§ +§ ++§ 
8740 11, 16 f33,f35 -/+§ -I+ +§ 
11778 11, 14 ~3,f33 +§ -I+ 
10528 12, 13 f33,f33 +§ -I+ -I+ 
11692 13, 13 f33,f33 +§ +§ 
8772 15, 16 ~5,f35 +§ +§ 
11084 15, 15 f35,f35 +§ 
11802 15, 16 @5,@5 +§ +§ 
32 (61.5) 24 (46) 14 (28) 25 (48) 
No. Samples(%) + 20 (38.5) 28 (54) 36 (72) 27 (52) 
Total 52 52 50 52 
• Since samples were DNA typed for HLA-DR by PCR-SSP using HLA class II typing kits, samples that 
typed for only one HLA-DR~l allele were considered homozygous. 
t Tumor cell expression was classified as- (<25% positive);-/+ (25-74% weak or 25-49% strong); or+ 
(75-100% weak or 50-100% strong) as defined in text. Samples considered positive by IHC are shaded in 
ray; nr =no result (due to loss of tissue section during staining procedure). 
CD3+ infiltrating cells were classified as- (no or very few); -/+(small numbers);+ (moderate numbers); 
or ++ (large numbers) as defined in text. 
§Samples categorically classified as positive by IHC, as defined in methods. 
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Figure 2.1: HLA class I expression is decreased in both HLA-DR- (Mann-Whitney U 
test P=0.003) and Ii- (Mann-Whitney U test, P=0.069) tumors. Data shown are the mean 
% of tumor cells with HLA class I expression as strong as inflammatory cells ± SEM. 
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Figure 2.2: HLA-DR and Ii expression by tumor cells in breast carcinoma samples 
detected by indirect immunohistochemistry showed different expression patterns. A: The 
most common phenotype was tumor cells negative for HLA-DR (A2) and Ii (A3). B: A 
minor subset of HLA-DR negative samples (B2) did express Ii (B3). C: Samples with 
HLA-DR expressing tumor cells (C2) also expressed Ii (C3). Further analysis of samples 
with HLA-DR positive tumor cells showed that carcinoma cells discordantly express 
HLA-DRB alleles. In this representative example, tumor cells did not express the 
DRP 1 *08 allotype (C4) although tumor cells showed homogeneous expression of the 
DRP 1 *04 (C5) and DRP4 (C6) allotypes. Hematoxylin and eosin stained sections from 
each sample are depicted (Al, Bl and Cl). Infiltrating inflammatory cells and stromal 
cells served as intrinsic positive controls for antibody binding (arrowheads). Original 
magnification, XlOO (Bl, Cl), X200 (Al) and X400 for remaining photos. 
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Infiltrating CD3-t- T cells were detected, both intratumorally and throughout the 
intervening tumor stroma, in 46 tumors of which 27 contained a moderate to large T cell 
infiltrate (Table 2.2). The location of infiltrating T cells was predominately stromal in 
those tumors with small to moderate CD3+ infiltrates but intratumoral for the majority of 
tumors with large CD3+ infiltrates (Figure 2.3A). Of the 46 tumors with infiltrating T 
cells, those with intratumoral T cells exceeding stromal T cells had a higher mean 
percentage of HLA-DR+ tumor cells ( x% = 48%±43 versus 25±37%; Mann-Whitney U 
test, P=0.161, not depicted) and intratumoral T cells were detected in all HLA-DR+ 
tumors (Fisher's exact test P=0.017). Overall, as shown in Figure 2.3B, CD3+ T cell 
infiltration was significantly associated with tumor cell expression of HLA-DR, Ii and 
HLA class I, independent of location. 
2.4.2 HLA-DRB alleles influence tumor cell expression of HLA-DR and Ii and 
infiltrating T cells 
To determine whether DRB 1 *04 and/or individual DRB 1 *04 alleles influenced 
tumor cell expression of HLA-DR and Ii, these factors were compared between the 
DRB1 *04 and non-DRB1 *04 tumors. As shown in Figure 2.4, 13/26 DRB1 *04 tumors 
were HLA-DR+, 16/26 were li+ and 11126 contained moderate to large T cell infiltrates. 
This trend was reversed in non-DRB1 *04 tumors as only 7/26 were HLA-DR+, 12/26 
were Ii+, but a greater number 16/26 contained a substantial T cell infiltrate. However, 
both DRB1 *04 and non-DRBI *04 tumors contained a higher percentage of HLA-DR+ 
tumor cells when intratumoral T cells exceeded stromal T cells (not depicted). 
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Figure 2.3: Infiltrating CD3+ T cells are contained within the tumor stroma and 
intratumorally and associate with tumor cell expression ofHLA-DR, Ii and HLA class I. 
A) Location of infiltrating CD3+ T cells in breast carcinoma samples. Tumors with large 
T cell infiltrates contain predominantly intratumoral T cells (Pearson's x2=10.937; 
P=0.004); I = intratumoral, S = stromal. B) Increased CD3+ T cell infiltrate was 
significantly associated with an increased percentage of tumor cells expressing HLA-DR 
(Kruskal-Wallis x2=12.0, P=0.007), Ii (Kruskal-Wallis x2=10.9, P=0.012) and HLA class 
I (Kruskal-Wallis x2=17.0, P=O.OOl). Data are shown± the standard error ofthe mean. 
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Figure 2.4: HLA-DR allotype influences tumor cell expression of HLA-DR. Indirect 
immunohistochemistry was used to detect tumor cell expression of HLA-DR, and Ii and 
T cell infiltration in breast carcinomas. HLA-DR and Ii expression was increased in 
DRB1 *04 tumors (HLA-DR: Pearson's x2=2.925; P=0.087; Ii: Pearson's x2=1.238; 
P=0.266). Decreased T cell infiltration in DRB 1 *04 tumors, was attributable to the 
DRB1 *0401 tumors (Pearson's x2=2.818, P=0.093). Decreased HLA-DR and Ii in non-
DRB 1 *04 tumors was largely influenced by the DRB 1 *07 allotype (Fisher's exact test 
P=0.190 for HLA-DR and P=0.051 for Ii). 
69 
Furthermore, while more DRB 1 *04 tumors were HLA-DR+ based on categorical data, 
within the HLA-DR+ tumors, the mean percentage of tumor cells expressing HLA-DR 
-
was lower in DRB 1 *04 compared to non-DRB 1 *04 tumors ( x% = 68±22% versus 
91±11 %, Mann-Whitney U test, P=0.030; not depicted), possibly reflecting the decreased 
numbers of infiltrating T cells. 
DRB 1 *04 samples were further analyzed for potential differences in HLA-DR-
expression and T -cell infiltration in tumors carrying the most common allele, 
DRB1 *0401, present in 11/24 samples that were subtyped. Surprisingly, only 3/11 
contained moderate to large T cell infiltrates compared to 8/13 of the remaining 
DRB1 *04 tumors (Figure 2.4 inset). However, decreased T-cell infiltration in 
DRB 1 *040 1 tumors was significant only if compared to that in non-B 1 *040 I tumors in 
the total set (Pearson's x2=4.056, P=0.044). Although categorical expression ofHLA-DR 
and Ii by DR~1 *0401 tumors was similar to that observed for all DRB1 *04 tumors 
(Figure 2.4), the mean percentage of HLA-DR+ tumor cells was decreased compared to 
-
other DRB1 *04 tumors (x% = 63±24% versus 77±21). Again, this likely reflects 
decreased numbers of infiltrating T cells. 
Within the non-DRB 1 *04 subset, we made the unexpected observation that only 
1/10 DRB1 *07 samples was HLA-DR+ and 2/10 were Ii+ compared to 6/16 and 9/16, 
respectively, of non-DRB1 *07 tumors (Figure 2.4 inset). Furthermore, the only 
DRB 1 *07 tumor within the DRB 1 *04 subset was also DR-Ii-. This poor expression of 
HLA-DR and Ii by DRB 1 *07 tumors was statistically significant when compared to non-
DRB 1 *07 tumors in the total sample (Fisher's exact two-sided test P=0.035 (HLA-DR); 
P=0.015 (Ii)). T-cell infiltration was somewhat decreased in DRB1 *07 tumors, but this 
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was not significant when compared to non-DRB1 *07 tumors within the non-DRB1 *04 
subset or within the total sample. 
Examination of the DR51, DR52 and DR53 haplotype groups revealed no 
significant associations with HLA expression by tumor cells or T cell infiltration (not 
depicted), suggesting that differences in HLA-DR expression were influenced by 
individual HLA-DRB1 alleles and not by groupings of haplotypes based on additional 
shared HLA-DRB alleles. 
2.4.3 HLA-DR+ tumor cells discordantly express HLA-DRB allelic products 
Additional tissue was available to evaluate 15 of the HLA-DR+ samples for 
expression of individual HLA-DRB alleles (Table 2.3). At least 6/15 tumors did not 
express all HLA-DRB alleles. A representative example of the discordant expression of 
HLA-DR allotypes is given in Figure 2.2C depicting sample 11999 which contained 
tumor cells negative for DR~1 *08 (Figure 2.2C4) while 100% of tumor cells expressed 
the DR~1 *04 (Figure 2.2C5) and DR~4 (Figure 2.2C6) alleles. Furthermore, in each 
tumor section analyzed, the relevant mAbs bound to infiltrating inflammatory cells 
(Figure 2.2C, arrows) suggesting that the relevant allele was not up regulated on the 
tumor cells. These 15 HLA-DR+ samples carried a total of 57 HLA-DRB alleles, of 
which expression could be determined for 43 (9 DR~1 *04, 15 other DR~1, 9 DR~3 
(DR52), 7 DR~4 (DR53) and 2 DR~5 (DR51) alleles). Interestingly, the DR~1 *04 
allotype was expressed in all nine DRBl *04 samples compared to 11/15 non-DR~l *04 
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Table 2.3: HLA-DR~ Alleles Detected on HLA-DR+Tumor Cells 
----~--~ ------·---------~ ---------*--··-·--Sample HLA-DRB alleles Expressed by HLA-DR+Tumor Cells 
~---~---------··-·--·--~~~--~-··------·-·-··-,--·-----·--·-·------~·---------------~~-·-------··-
ID Detected Undetected Undetermined 
-----------·- -·-- ··- --··-------·-·------------------·-----···---------------·----------------····--~---~------------~-- ·--------
11702 ~1 *0403, ~1 *13, DR52, DR53 0 0 
8043 ~1 *0407, ~1 *11, DR52, DR53 0 0 
8196 ~1 *03, DR52 0 ~1*03, DR52 
10881 ~ 1 *0404, ~ 1 * 13, DR52, DR53 0 0 
11353 ~1 *08, ~1 *16, DR51 0 0 
9822 ~1*0401 0 ~1 *09, DR53, DR53t 
11393 ~1 *14, DR52 0 ~1 *13, DR52 
11023 ~1 *0401, ~1 *03, DR53 0 DR52 
11603 ~1 *13, ~1 *15, DR52 0 DR51 
9914 ~1 *0401, DR52 ~1 *03, DR53 0 
10970 ~1*07 ~1*08 DR53+ 
11999 ~ 1 *0404, DR53 ~1*08 0 
7959 ~1*04 DR52 ~1 *12+, DR53§ 
11093 ~1*0402 DR51, DR53 ~1*16 
10842 ~1 *11, DR52 ~1 *09; DR53t 
-. Allel;·;~p;;i~;;,:;;s clas;i£i";d as desc;ilie'di; text: positive (~ 25% tumor cells positive); negative (0~-
24% tumor cells positive) or undetermined (expression could not be determined using available panel of 
antibodies). DRSI = DRpS; DR52 = DRp3; DR53 = DRp4. 
For samples that are homozygous for a particular allotypes, expression of only one of the alleles can be 
ascertained using the allotype specific mAbs. 
t Tumor cells stained positively with the PL3 antibody, however, this antibody cannot distinguish between 
the DRP I *09 and DRP4 allelic products. 
t Allele is likely expressed due to differences in % of tumor cells positive for other alleles and % positive 
for total HLA-DR. 
§ Tumor cell expression could not be accurately assessed as DR53 was not expressed by infiltrating 
inflammatory cells in this tumor (possible null allele). 
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alleles. The DR~3, DR~4 and DR~5 allotypes were expressed in 7/9, 517 and 1/2 tumors, 
respectively. Discordant allelic expression was unique to the individual tumor as each of 
the allotypes not expressed was detected within another tumor. Importantly, the HLA-
DR+ sample 10970 did express its DR~1 *07 allele, demonstrating that this allotype can 
be up regulated by tumor cells in breast carcinoma. 
2.5 DISCUSSION 
A major goal of this study was to determine if tumor cell expression ofHLA-DR 
and the presence of infiltrating T -cells in breast carcinoma are influenced by an 
individual's HLA-DRB alleles. Secondly, since most individuals are heterozygous for 
DRB 1 and associated structural DRB genes, we postulated selective expression of these 
alleles in the subset of tumors that were HLA-DR+. Using an equal number of randomly 
selected DRB1 *04 and non-DRB1 *04 samples and a panel of mAbs that distinguished 
polymorphic epitopes on HLA-DR allotypes, we made three novel findings: a) DRB1 *04 
tumors are more frequently HLA-DR+ but contain smaller numbers of infiltrating T-cells 
than non-DRB 1 *04 samples; b) within the non-DRB 1 *04 tumors, only 9% of tumors that 
carried DRB1 *07 express DR; c) at least 40% of tumors that were HLA-DR+ fail to 
express one or more of their HLA-DR allotypes. 
Since tumor cell expression of HLA-DR positively associated with infiltrating T-
cells in the whole sample, our finding that DRB 1 *04 tumors, especially those carrying 
the DRBl *0401 allele, were more frequently HLA-DR+ despite having reduced T-cell 
infiltration was unexpected. However, all DRBl *0401 HLA-DR+ tumors contained 
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some intratumoral T cells, whose presence may explain why categorical numbers of 
HLA-DR+ tumors were not decreased. On the other hand, reduced numbers ofT-cells 
were reflected by the decreased mean percentage of HLA-DR+ tumor cells in 
DRBl *0401 tumors. Thus, it seems that up-regulation of HLA-DR on tumor cells is 
related not only to numbers of infiltrating T cells but also to their location within the 
tumor. This may have important implications for disease outcome in breast carcinoma as 
the presence of intratumoral T cells independently predicted for improved disease-free 
and overall survival in late stage ovarian cancer patients [193]. 
The most novel finding from this study was the absence of HLA-DR-expression 
by 10/11 DRB 1 *07 tumors, despite possessing DRB alleles that were expressed in non-
DRB1 *07 tumors. Since HLA-DR was strongly expressed on stromal and inflammatory 
cells in all samples, we are confident that this phenomenon is not a technical artifact. An 
attractive explanation is loss of chromosome 6p, the most frequent mechanism 
contributing to HLA haplotype loss [238] combined with mutations/deletions of the 
remaining HLA genes resulting in the loss both haplotypes. However, we favor an, as yet, 
undefined epigenetic effect for two reasons: i) HLA class I was strongly expressed in at 
least 6/10 DRB1 *07 HLA-DR- tumors suggesting that in those tumors both HLA 
haplotypes were not lost; ii) Ii, which is not located on chromosome 6, and which is 
coordinately regulated with HLA class II genes, was scarcely expressed in DRB 1 *07 
tumor cells. Defects in one or more factors, such as the class II transactivator (CIITA), 
required for transcription of HLA class II and Ii, have been reported in various carcinoma 
cell lines that do not up regulate HLA class II expression [239, 240]. It would be 
surprising, however, if defective CIITA was more frequent in DRB I *07 tumors, but the 
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effect could be indirect since CIITA activation in tumor cells requires IFN-y whose 
effects are known to be inhibited by TGF-P [241]. Thus, if DRB1 *07 tumors 
preferentially stimulate immunosuppressive T -cells, it could explain poor tumor cell 
expression of all HLA-DR allotypes as well as Ii, despite the presence of infiltrating T-
cells. While we have not addressed the phenotype of the infiltrating T cells in this study, 
others have found that breast and pancreatic carcinoma patients have increased numbers 
of CD4+CD25+ regulatory T cells, which potentially serve as another mechanism for 
tumor immune escape [184]. 
Mechanisms responsible for discordant HLA-DR allelic expression in HLA-DR+ 
tumor cells are likely to be different from those responsible for complete absence of 
HLA-DR-expression. In the 15 HLA-DR+ tumors analyzed, all DRBI *04 alleles were 
expressed, but other alleles, whether present in DRB 1 *04 or non-DRB 1 *04 tumors were 
inconsistently expressed. In fact, the one DRBI *07 sample expressed its DRBI *07 allele 
but not its DRB 1 *08 allele, indicating that DRB 1 *07 can be up regulated on breast tumor 
cells. Loss of heterozygosity (LOH) at chromosome 6p21.3 is a common mechanism 
leading to HLA class I haplotype loss in several human cancers, including laryngeal 
[242] and colorectal carcinomas [243] and may represent one mechanism responsible for 
discordant allelic HLA-DR-expression in the tumors in which at least one HLA-DR allele 
was not expressed. For example, LOH may be responsible for the loss of the DRB 1 *08 
haplotype in samples 11970 and 11999. However, the pattern of allelic expression for 
sample 9914 suggests an alternative mechanism as one allele from each inferred 
haplotype is expressed. Differential expression of HLA-DR by tumor cells may also be 
modulated by polymorphisms in the X andY-boxes ofHLA-DRB promoters [244, 245]. 
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Comparing HLA-DRB promoter polymorphism related differences in transcriptional 
activity to levels of HLA-DRB mRNA suggest that differential HLA-DRB gene 
expression is regulated at both transcriptional and post-transcriptional levels [118, 119]. 
Thus, factors produced during tumorigenesis may contribute to HLA-DRB gene 
regulation. 
The implications of discordant expression of Ii and HLA-DR, in our and other 
studies of breast carcinoma [146, 151] remain unclear. Independent evaluation of Ii 
expression by tumor cells has revealed an association with a poor prognosis in colon 
carcinoma [160] and gastric carcinoma [161]. Others have reported that lack of HLA 
class II and Ii expression correlated with down regulation of tumor cell HLA class I 
[146], a finding supported in this study. Indeed, the degree of HLA class I loss is likely 
underestimated as most tumors classified as HLA class I+ using the W6/32 mAb do 
indeed contain altered HLA class I phenotypes [225]. 
The small sample size and biased selection for DRB 1 *04 in this study precludes a 
meaningful statistical analysis of tumor cell expression of HLA-DR and Ii and T-cell 
infiltration with prognostic indicators. However, there were some notable trends such as 
reduced ER levels in non-DRB1 *04 tumors that expressed HLA-DR and Ii compared to 
ER levels in DRBl *04 DR+ tumors, suggesting that ER may be implicated in regulating 
HLA-DR expression in these tumors. Furthermore there was a trend for lower tumor 
grade in those tumors that expressed HLA-DR in the absence of a substantial T cell 
infiltration, suggesting HLA-DR expression in the absence ofT cell-derived cytokines 
may result from molecular changes during malignant transformation. Overall, in 
concordance with earlier studies [162, 177], HLA-DR was significantly associated with T 
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cell infiltration, supporting the hypothesis that HLA-DR is induced on tumor cells in 
response to the cytokine milieu of the tumor microenvironment. 
In conclusion, expression of HLA-DR by breast carcinoma cells appears to be a 
complex phenomenon mediated by many interacting factors within and outside the tumor. 
These include polymorphisms within the non-coding and coding regions of HLA-DRB 
alleles that directly influence anti-tumor T cell responses and production of cytokines 
known to modulate tumor cell expression of HLA-DR. Other variables, likely to affect 
HLA-DR expression, include the differentiation state of the tumor, hormones and 
hormone receptors. Discordant expression of particular HLA-DRB alleles in HLA-DR+ 
tumors and the association ofDRBl *07 with HLA-DR- tumors illustrate the importance 
of examining specific expression of HLA-DRB alleles in future studies aimed at 
elucidating the biological and prognostic significance of HLA-DR expression m 
carcmoma. 
77 
CHAPTER 3: TUMOR CELL EXPRESSION OF HLA-DRBI ALLOTYPES HAS 
IMPORTANT IMPLICATIONS FOR ANTI-TUMOR IMMUNITY AND SURVIVAL 
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3.1 ABSTRACT 
There is strong experimental evidence to support a role for HLA-DR expression 
by tumor cells in the induction of an anti-tumor T cell response. However, studies 
attempting to relate the two have yielded conflicting results. To determine if allelic 
differences in HLA-DR antigens influence anti-tumor immunity and resultant patient 
outcome, 121 breast carcinoma lesions with prognostic information were DNA-typed for 
HLA-DRB alleles. Tumor cell HLA-DR expression and CD4+ tumor infiltrating 
lymphocytes (TIL) were examined using indirect immunohistochemistry. HLA-
DR+HLA-DRB1 *04+ tumors had decreased tumor size and independently predicted 
improved distant recurrence-free survival (dRFS) and disease-specific survival (DSS) 
while HLA-DRB3 and HLA-DRBl *13 tumors that express HLA-DR were larger, more 
frequently had lymph node metastasis and independently associated with decreased 
dRFS. Variability in intratumoral cytokine levels suggest HLA-DRB1 *04 expression 
may promote a favorable anti-tumor TH1-type response marked by IFN-y production 
while expression of HLA-DRB3 and HLA-DRBl *13 may promote an 
immunosuppressive immune response, marked by elevated TGF-p1, allowing tumor 
outgrowth. Immunohistochemical evaluation usmg HLA-DR~ allotype-discriminating 
antibodies confirmed our previous finding that the majority of HLA-DR+ tumors exhibit 
differential DR~ allotypic expression, with HLA-DR~1 *04 preferentially expressed. In 
non-DRB1 *04 tumors, differential DRf3 allotype expression associated with decreased 
dRFS and DSS, suggesting lack of expression of particular DRf3 allotypes may represent 
an immune evasion strategy employed by tumor cells, similar to that observed with HLA 
class I antigens. Ongoing studies aimed at elucidating the mechanisms that control HLA 
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class II expression in breast carcinoma will provide important insights into host-tumor 
interactions and immune evasion strategies employed by tumor cells. 
3.2 INTRODUCTION 
Immune-mediated eradication of solid tumors involves CD4+ tumor infiltrating 
lymphocytes (TIL) that recognize tumor peptides, presented in the context of HLA class 
II antigens (HLA-DR, -DP, -DQ) [166, 167]. Extensive polymorphism of HLA-class II 
molecules, localized to the peptide binding sites, determines peptide selection and CD4-
recognition while limited polymorphism in class II promoter regions influences 
expression levels on various cell types [118, 119]. Class II molecules are abundantly 
expressed on conventional antigen-presenting cells (APC) such as dendritic cells, 
activated macrophages and B-cells, but may be up regulated on various cell types, 
including breast cancer cells, in response to immunomodulating agents and cytokines 
[134-136]. Thus, the efficacy of a CD4+ T cell specific anti-tumor response is not only 
influenced by allelic differences in antigen-presenting molecules but also by the cells on 
which the HLA class II/peptide complexes are presented. 
Breast carcinomas are frequently infiltrated by HLA-DR expressing inflammatory 
cells and CD4+ TIL [186]. Furthermore, a subset of breast carcinomas express HLA-DR 
antigens on their tumor cells and accumulating experimental evidence supports a role for 
HLA class II expression by tumor cells in the induction of an anti-tumor T cell response 
[89, 138, 168, 170]. CD4+ TIL isolated from breast cancer patients have been shown to 
secrete THl-type cytokines in response to autologous tumor cells [170] and both TH1 and 
TH2-type cytokine producing TIL are detected in breast carcinomas [191]. In one study, 
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up to 20% of CD4+ TIL expressed an immunoregulatory (Treg) phenotype, and secreted 
TGF-j31 and IL-10 in response to non-specific stimulation and were capable of in vitro 
suppression of activated CD4+CD25- and CD8+CD25- T cells [184]. Since allelic 
differences in HLA-DR antigens influence CD4+ T cell activation and ensuing cytokine 
production [124, 246], in the context of carcinoma, the effectiveness of the anti-tumor 
immune response is surely dependent on the HLA-DRj3 allotypes expressed on tumor 
cells and/or infiltrating APC. 
Although several studies have shown that HLA-DR molecules are preferentially 
expressed on HLA class II-positive breast carcinomas, there is no clear consensus on the 
prognostic value of HLA-DR expression by breast tumor cells [146-148, 152, 155, 156, 
159, 247]. Discrepancies regarding associations of prognostic factors and survival with 
HLA-DR+ tumor cells may be methodological in that previous studies examined generic 
HLA-DR expression in the absence of information on carriage and expression of the 
patient's HLA-DRB alleles. Such studies are complicated by a large number of HLA-
DRB 1 alleles, which are further organized into haplotype groups based on their linkage 
with additional structural HLA-DRB genes and HLA-DRB pseudogenes. HLA-DRB1 *15 
and 16 alleles are expressed in association with HLA-DRB5 alleles (DR51); HLA-
DRB1 *03, 11, 12, 13 and 14 with HLA-DRB3 alleles (DR52); HLA-DRB1 *04, 07 and 
09 with HLA-DRB4 (DR53); while HLA-DRB1 *01, 10 and 08 are not in association 
with any other expressed HLA-DRB genes [70]. Since HLA antigens are co-dominantly 
expressed an individual can express up to four different DRj3 allotypes [70], and 
expression of only one of these will yield a positive result when tumor cells are analyzed 
for generic DR-expression. 
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We previously reported that most HLA-DR+ breast carcinoma cells differentially 
express their HLA-DRP allotypes with DRB1 *04 preferentially expressed [248]. 
Furthermore, we have recently identified that carriage of HLA-DRB allotypes belonging 
to the HLA-DR52 (DRB3) haplotype group, in particular HLA-DRB1 *13, associates 
with decreased survival in breast carcinoma (Drover et al., manuscript in preparation). 
This implies a role for HLA-DRP allotypes in tumor immune responses, and 
consequently outcome, in patients with breast carcinoma. To determine the implications 
of these findings, we investigated whether HLA-DRB allotypic differences influence 
tumor cell HLA-DR expression, immune responsiveness in terms of CD4+ T cell 
infiltration and cytokine production and levels of the immunoregulatory T cell marker 
FOX-P3, or have any implications for prognosis and outcome. 
3.3 MATERIALANDMETHODS 
3.3.1 Study subjects 
One-hundred and four primary and 17 recurrent breast tumor lesions were 
randomly selected, based on tissue availability, from a larger sample with prognostic and 
outcome information, obtained from the Manitoba Breast Tumor Bank (Winnipeg, 
Manitoba, Canada), with approval of the local Human Investigation Committees. Tissue 
samples were subjected to immunohistochemical evaluation and following exclusion of 
samples where tumor tissue comprised <I 0% of the section area, immunohistochemical 
information was available for 99 primary and 15 recurrent lesions. As several biological 
changes mark progression to metastatic disease, associations of immunological 
parameters with prognosis and survival were assessed for primary lesions only. To verify 
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that tumor samples selected for immunohistochemical analysis were representative of the 
entire set of primary tumors, for which prognostic information was available, associations 
of HLA-DRB alleles with prognostic parameters were assessed in both tumor sets 
(Appendix I). 
Primary treatment information was available for 97 patients, of which 21 were 
treated with surgery only and the remainder received adjuvant therapy. Information on 
tumor type was available for 96 samples of which 81 were infiltrating ductal (IDC), 13 
infiltrating lobular (ILC) and 2 mixed IDC+ILC. Tumor grade was available for 91 
tumors of which 12 were Grade I, 44 were Grade II and 35 were Grade III, determined 
using the Nottingham grading system [6]. Tumor size was available for 96 patients 
(mean±SD = 3.3±2.3), and was categorized as small (~2 em, n=24) or large (>2 em, 
n=72). Lymph node (LN) status was available for 98 patients and obtained using 
pathological determination for LN+ tumors and pathological and/or clinical 
determination for LN- tumors. Fifty-three patients were LN+ (1-3 nodes positive, N=38; 
>3 nodes positive, N=15). Ninety-five tumors were staged, according to AJCC guidelines 
[8], and there were 12 Stage I, 63 Stage II, 17 Stage III and 3 Stage IV tumors. The age at 
diagnosis ranged from 32 to 86 years (mean±SD = 58.8±14.4 years; median 60 years). 
Estrogen and progesterone receptor levels were determined by ligand binding assay and 
values ranged from 0 to 331 fmol/mg (mean±SD = 40.0±60.8 fmol/mg; median 13.1 
fmol/mg) and 0 to 1088 fmol/mg (mean±SD = 59.6±142.4; median 15.8 fmol/mg), 
respectively. Tumors were stratified based on a cutoff of 10 fmol/mg and there were 43 
tumors with ER<10 fmol/mg and 56 withER 2:: 10 fmol/mg and 34 with PR<10 fmol/mg 
and 65 with PR ~ 10 fmol/mg. Her-2/neu expression was assessed in 89 tumors, as 
described below, and 19 (21.3%) tumors over-expressed Her-2/neu (code 3+). Survival 
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data was available for all patients with a median follow-up time of 60 months (mean±SD 
= 57.8±30.3; range 2-127 months). During this follow-up period, 34 patients suffered a 
distant relapse (mean time to relapse±SD = 23.7±17.4 months; range 0-64 months) and 
30 patients died from breast cancer (mean time to death±SD = 31.2±20.6 months; range 
2-90 months). The prognostic significance of clinicopathological parameters is provided 
in Appendix II. 
3.3.2 DNA extraction and HLA class II typing by PCR-SSP 
DNA was isolated from thawed, fresh-frozen breast tumor tissues by 
homogenization in DNAzol (Gibco BRL, Rockville, MD). DNA was typed for generic 
HLA-DRB and HLA-DRB1 and HLA-DRB3 alleles by polymerase chain reaction with 
sequence-specific primers (PCR-SSP) using Micro SSP™ (One Lambda, Inc., Canoga 
Park, CA, USA) or Fastype™ System (Bio-Synthesis, Inc., Lewisville, TX, USA) typing 
kits. 
3.3.3 Immunohistochemistry 
Serial frozen sections (8 !lm) were fixed in acetone for 10 minutes at -20°C, 
shipped from the Manitoba Breast Tumor Bank (Winnipeg, Manitoba, Canada) and 
stored at -70°C until immunohistochemical staining. Hematoxylin and eosin staining was 
performed on one section for each breast carcinoma and samples where tumor cells 
comprised <10% of the section area were excluded from analysis. Indirect 
immunohistochemistry was performed and interpreted as previously described (Chapter 
2) [248]. In brief, tumors with at least 25% of tumor cells expressing HLA-DR were 
classified as HLA-DR+ and the percentage of tumor cells expressing HLA class I was 
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assessed as an indirect measure of integrity of HLA loci. Tumor cells were identified 
using anti-cytokeratin mAb (AE1/AE3, 5J..tg/ml, DakoCytomation, Mississauga, ON, 
Canada). Monoclonal antibodies in the form of spent supernatants were used to detect 
generic HLA-class I (W6/32, 1:150, ATCC, Manassas, VA, USA) and HLA-DR (L243, 
2.4J..tg/ml, ATCC). CD4+ TIL were detected using anti-CD4 mAb (clone RPA-T4, 
0.6J..tg/ml, Pharmingen) and semi quantitatively scored as none(-), small(-/+), moderate 
(+) or large numbers (++), based on numbers of scattered cells and/or size of focal 
aggregates, as previously described (Chapter 2) [248]. For analysis, those coded- or-/+ 
were classified as CD4+Lo and those coded+ or++ were classified as CD4+Hi. Negative 
controls consisted of isotype matched non-specific mouse immunoglobulins (Southern 
Biotechnology Associates, Inc., Birmingham, AL, USA). Tumor cell expression of Her-
2/neu was determined with specific mAb (clone CBll, 11100; clone N12, 2 J..tg/ml, 
Neomarkers, Quebec, Canada) in 89 primary tumors and coded as 0 (<10% with 
membrane staining), 1+ (210% with weak, incomplete membrane staining), 2+ (210% 
with weak to moderate complete membrane staining) or 3+ (210% with strong complete 
membrane staining). As some tumors coded 2+ by IHC will not show gene amplification 
by fluorescent in situ hybridization [249], only those tumors coded 3+ were considered 
clinically positive for analysis. 
Expression of individual HLA-DRP allotypes was determined using a panel of 
monoclonal antibodies that distinguish HLA-DR polymorphisms (Supplementary Table 
3S1). These included local mAbs NFLD.Dl [232, 233], NFLD.D10 [232], and NFLD.D7 
[232], and SFR16 [234], a kind gift from Susan Radka. UK8.1 [235], 7.3.19.1 [236], PL3 
[237], JS-1 [250] and MAD88 were obtained through the 101h International 
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Histocompatibility Workshop. Optimal antibody concentrations and confirmation of 
antibody specificity were determined as previously described (Chapter 2) [248]. Tumors 
were classified based on tumor cell HLA-DR expression as DRW1- (HLA-DR not 
expressed), DRf3-/+ (HLA-DRf3 allotypes differentially expressed) or DRf3+/+ (HLA-DRf3 
allotypes homogeneously expressed). 
3.3.4 RNA extraction, and semi quantitative RT-PCR 
Total RNA was isolated from breast tumor tissues by homogenization in Trizol 
reagent (Gibco BRL, Rockville, MD), followed by treatment with DNA-free reagent 
(Ambion, Austin, TX) to remove any contaminating DNA. Reverse transcription was 
performed on 1 J..lg RNA using the First Strand eDNA Synthesis Kit (Pharmacia Biotech, 
Quebec, Canada). PCR was performed using a Biometra T Gradient thermocyc1er 
(Montreal Biotech Inc., Quebec, Canada) to amplify eDNA using primers described in 
Supplementary Table 3S2. Primer pairs specific for f3-actin [251 ], IFN-y, IL-2, IL-4, IL-
6, IL-10, IL-12 p40, TNF-a [252], IL-1f3 [253], TGF-f31 [254] and FOX-P3 [255] were 
synthesized by Gibco BRL. Primers were used at concentrations of 20 pM for f3-actin, IL-
1f3, IL-6, TNF-a and FOX-P3 and 10 pM for all others. MgClz (Gibco BRL) 
concentration was 1.5 mM for f3-actin, IL-4 and FOX-P3 and 2mM for all other reactions. 
0.2 J.!L of Taq DNA polymerase (Gibco BRL) was used for f3-actin, IL-1f3, IL-6 and 
FOX-P3 reactions and all others used 0.25 J..lL per reaction. All PCR reactions were 
performed in a volume of 50 J..lL with 200 J..lM dNTPs (Gibco BRL) and 1 J..lL eDNA. 
PCR buffer contained 20 mM Tris-HCl buffer (pH 8.4) and 50 mM KCl. Samples 
containing water instead of test eDNA were included as contamination controls and 
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eDNA from the cell lines Jurkat E6-l (IL-2, IL-4, IL-10, TGF-~), ClO/MJ (IFN-y, IL-6, 
FOX-P3), U937 (TNF-a, IL-l~) and YAR (IL-12) were used as positive controls. 
Reaction mixtures were amplified for 35 cycles of denaturation at 94°C for 1 min, 
annealing for 1 min at 55°C (IFN-y and IL-2), 72°C (TNF-a) or 65°C (all others), and 
extension at 72°C for 1 min, followed by a separate 5 min extension step at 72°C for all 
but IL-1~, IL-6 and FOX-P3. The intensity of amplified products was semi-quantified 
and normalized as a percent of ~-actin using the Chemiimager 4000 with Alphaease 4.0 
Software. 
3.3.5 Statistical Analysis 
Contingency tables were analyzed using Pearson's chi-square test or Fisher's 
exact test for 2x2 tables when at least one expected count was ~ 5 (two-sided). Non-
parametric Mann-Whitney U test was used to assess statistical significance of all 
continuous variables except diagnosis age, which followed a normal distribution and was 
assessed by one-way analysis of variance (ANOVA). Variables were tested for normality 
using the Kolmogorov-Smimov test. To assess HLA-DR~ allotypic influences, tumors 
were stratified only by those HLA-DRB allotypes that occurred at a frequency of at least 
10%. 
Survival estimates were calculated using Kaplan-Meier method with log-rank 
statistic. Ninety-five percent confidence intervals (95% CI) around each estimate were 
calculated using the standard error (SE) of the cumulative survival probability (95%CI = 
cumulative survival probability ±1.96 x SE). Estimates were calculated as time to distant 
metastasis for distant recurrence-free survival (dRFS) and time to death from breast 
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cancer for disease-specific survival (DSS). For DSS, patients who died of other causes 
were censored at the time of death. Cox proportional hazards models were constructed for 
multivariate survival analyses, using backward stepwise method, using a probability of 
P<0.05 for stepwise entry and P>0.06 for removal. No patients were lost to follow-up 
and patients not experiencing the event were censored at the time of last follow-up or at 5 
years for 5-year survival. For multivariate analysis, correlation matrices were constructed 
to ensure lack of collinearity of covariates. All analysis was performed using SPSS 
Version 11.5 statistical software. All tests were two-sided and differences between 
groups were considered significant if P<0.05. 
3.4 RESULTS 
3.4.1 Characterization of tumor cell HLA-DR expression and associations with 
CD4+ TIL in breast carcinomas stratified by HLA-DRB allotypes 
To ascertain whether genetic variation in HLA-DRB influences tumor cell 
expression ofHLA-DR antigens and CD4+ TIL, primary tumors were stratified by HLA-
DRB alleles. HLA-DR was expressed by tumor cells in 36/99 (36.4%) primary lesions. 
CD4+ TIL were detected intratumorally and throughout the intervening stroma in 82/97 
(84.5%) breast tumors, with 46/97 (47.4%) containing moderate to large numbers of 
CD4+ TIL (CD4+Hi). HLA-DR+ tumors were more frequently CD4+Hi (Figure 3.1) and 
HLA-DR expression also associated with the pattern of CD4+ TIL infiltration. Of the 82 
primary tumors that contained CD4+ TIL, T cells were diffusely distributed in 22/33 
(66.7%) HLA-DR+ versus 21/49 (42.9%) HLA-DR- tumors (x2=4.5, P=0.034). 
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Figure 3.1: HLA-DRB allotypic variation in tumor cell HLA-DR expressiOn and 
associations with CD4+ TIL in breast carcinoma patients. HLA-DR expression was 
compared in primary tumors stratified by DRB allotypes. HLA-DRBl *04+ patients more 
frequently express HLA-DR antigens on their breast tumor cells (x.2=3.6, P=0.058; as 
compared to non-DRBl *04 tumors). In contrast, HLA-DR is poorly expressed in tumors 
that carry DRBl *01 (:x,2=6.0, P=0.014), DRBl *03 (x.2=2.6, P=O.llO) and DRB3*01 
(:x,2=5.4, P=0.020). Only HLA-DRB allotypes that occurred in at least 10% of patients 
are depicted. HLA-DR+ tumors more frequently contain CD4+ TIL (x.2=15.8, P<O.OOl). 
This was observed in all HLA-DRB allotype groups. The percentage of tumors, in each 
group, with moderate to large numbers of CD4+ TIL (CD4+ Hi) is indicated at the right. 
nr = no result. 
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In agreement with our previous study (Chapter 2) [248], tumors carrymg 
DRB1 *04 were more frequently HLA-DR+ than non-DRB1 *04 tumors, reflected by the 
DRB 1 *040 1 allele, although differences were not statistically significant. In contrast, 
HLA-DR expression was decreased in DRB1 *01+, DRB1 *03+ and DRB3*01+ tumors 
(Figure 3.1). Carriage of particular HLA-DRB alleles did not associate with the presence 
of CD4+ TIL (data not shown). However, tumors that expressed HLA-DR more 
frequently contained CD4+ TIL than HLA-DR- tumors, in all HLA-DRB allotype groups 
(Figure 3.1). The proportion ofCD4+Hi HLA-DR+ tumors was decreased in DRB1*0401 
tumors as compared to non-DRB1 *0401 tumors that expressed HLA-DR (Fisher's exact 
test P=0.081) and within the CD4+Lo tumor subset, DRB1 *0401+ tumors were more 
frequently HLA-DR+ [5/13 (38.5%) DRB1 *0401 + versus 4/38 (10.5%) DRB1 *0401-, 
Fisher's exact test P=0.036]. 
3.4.2 HLA-DRJ3 allelic variation affects associations of tumor cell HLA-DR 
expression with prognostic parameters in breast carcinoma patients 
We have recently demonstrated that tumor cell expression of generic HLA-DR 
and the co-chaperone invariant chain associates with earlier age at diagnosis and reduced 
ER expression in breast carcinoma (Chapter 4) [256]. To determine whether associations 
of tumor cell HLA-DR expression with clinicopathological parameters are affected by 
HLA-DR alleles, we assessed these relationships in HLA-DR allotype groups. As HLA-
DR was poorly expressed in DRBl *01+, DRBl *03+, and DRB3*01+ tumors, 
stratification was not warranted for these alleles. 
The most pronounced association of diagnosis age and ER with tumor cell HLA-
DR expression was observed in HLA-DRB1 *15+ and HLA-DRB1 *07+ individuals, 
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respectively. The age at diagnosis was decreased in all HLA-DRB allotype groups except 
DRB1 *04+, DRB1 *0401+ and DRB1 *11+ patients (Figure 3.2A). All HLA-DR+ tumors 
had decreased ER, regardless of HLA-DRB alleles (Figure 3.2B). PR levels were also 
decreased in HLA-DR+ tumors but differences were not statistically significant (Figure 
3.2C). As all individuals are heterozygous for HLA-DRB alleles, to ensure the 
relationships observed across all HLA-DRB allele groups were not attributable to 
dominant effects of these alleles, associations were compared in HLA-DRB1 genotype 
categories. All genotype categories displayed a negative relationship between HLA-DR 
expression and diagnosis age except DRB1 *04+DRB1 *15-, DRB1 *0401 +DRB1 *15- and 
DRB1 *ll+DRB1 *15- tumors and all genotype groups showed decreased ER in DR+ 
tumors (data not shown). 
Although generic HLA-DR expression did not associate with tumor size or LN 
status, DRB allelic differences were observed (Figure 3.2D-E). Tumor diameter was 
decreased in DR+DRB1 *04+ tumors (Figure 3.2D), reflected by the DRB1 *0401 
allotype group (P=0.065, data not shown). DR+DR~1 *13+ tumors had increased tumor 
diameter (Figure 3.2D) and were more frequently LN+ (Figure 3.2E), reflected by the 
associated DRB3 allotype group, which included DRB3 *0 1, 02 and 03 alleles, all of 
which were represented in DRB1 *13+ patients. The association was not significant for 
the DRB3*02 allele group, owing to the fact that both HLA-DR+ (10/11) and HLA-DR-
(8112) DRB3*02+ tumors are more frequently LN+ (x2=2.0, P=0.317). Tumor cell HLA-
DR expression did not associate with tumor type, histological grade, TNM stage or Her-
2/neu over-expression overall or within DRB allele groups. 
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Figure 3.2: Associations of tumor cell HLA-DR expression with prognostic parameters 
in breast carcinoma patients stratified by carriage of HLA-DRB allotypes. A) Diagnosis 
age is decreased in patients with HLA-DR+ tumors (F=8.0, P=0.006). This was most 
evident in DRB1 *15+ patients (F=11.2, P=0.003), which also carry the DRB5 allotype 
(F=11.5, P=0.002) but was not observed in DRBl *04+ or DRB1 *11 + individuals. B) 
ER levels are decreased in HLA-DR+ tumors (Mann-Whitney U test P=0.012). This was 
observed in all DRB allotype groups but was most evident in DRB 1 *07+ individuals 
(Mann-Whitney U test P=0.035), reflected by the linked DRB4 allotype (Mann-Whitney 
U test P=0.018). C) HLA-DR+ tumors also display a trend for decreased PR levels 
(Mann-Whitney U test P=0.071), although differences were not statistically significant 
within HLA-DRB allotype groups. D) HLA-DR expression associates with increased 
tumor diameter in DRBl *13+ patients (Mann Whitney U test P=0.012), which also carry 
the DRB3 allotype (Mann Whitney U test P=0.068), while DRB 1 *04+ patients have 
decreased tumor size when HLA-DR antigens are expressed (Mann Whitney U test 
P=0.065). E) HLA-DR expression associates with lymph node metastasis in DRBI *13+ 
(Fisher's exact test P=0.044) and DRB3+ (Pearson's x2=7.9, P=0.005) patients. *P<O.OS, 
**P<O.Ol. 
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3.4.3 HLA-DR~ allelic variation affects associations of tumor cell HLA-DR 
expression with survival in breast carcinoma patients 
Despite the associations of tumor cell HLA-DR expression with markers of a poor 
prognosis (Figure 3.2), univariate analysis did not reveal an influence on distant 
recurrence-free survival (dRFS; Log rank= 2.0, P=O.l61) or disease-specific survival 
(DSS; Log rank= 0.7, P=0.393). We recently demonstrated patient survival is influenced 
by the HLA-DRB allelic differences (Drover et al., manuscript in preparation). In this 
study, survival rates were compared in tumors stratified by tumor cell HLA-DR 
expression and HLA-DRB alleles that occurred at a frequency of at least 10%, to 
ascertain whether the HLA-DRB alleles carried by the patient influence associations of 
tumor cell HLA-DR expression with patient survival. Within HLA-DR+ tumors, those 
that carried the DRB 1 *04 allotype had significantly improved dRFS and DSS (Figure 
3.3A). In contrast, DR+DRB3+ tumors had decreased dRFS and DSS (Figure 3.3B). This 
was most evident in those patients that carried the HLA-DRBl *13 allele. DRBl *13+ 
tumors that did not express DR also displayed a trend for decreased dRFS but not DSS 
(Figure 3.3C). The stratification variables of the most frequent HLA-DRBl *04 allele, 
HLA-DRBl *0401 and of the HLA-DRB3 allele, HLA-DRB3*02, displayed similar 
patterns as DRB 1 *04 and DRB3 expression categories, respectively (data not shown). All 
other DRB stratification categories did not significantly associate with patient survival 
(data not shown). 
Cox proportional hazards models were constructed to determine if the influence 
ofHLA-DRB alleles on tumor cell HLA-DR expression independently predicted patient 
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Figure 3.3: The HLA-DRB allotypes carried by the patient influence associations of 
tumor cell expression of HLA-DR with distant recurrence-free survival (dRFS) and 
disease-specific survival (DSS) in breast carcinoma patients. A) Patients with DRB 1 *04+ 
tumors that express HLA-DR have improved dRFS and DSS as compared to patients 
with HLA-DR+ tumors that do not carry the DRB1 *04 allotype (DR+DRB1 *04-: 
#events/#cases = 11117, 5-year% survival (95% CI) = 35(13-58) versus DR+DRB1 *04+: 
5/19, 72(51-93) for dRFS; DR+DRB1 *04-: 11/17, 34(11-57) versus DR+DRB1 *04+: 
2/19, 89(75-100) for DSS). B) Patients with DRB3+ tumors that express HLA-DR have 
decreased dRFS and DSS as compared to patients with HLA-DR+ tumors that do not 
carry the DRB3 allotype (DR+DRB3-: 5/20, 74(54-94) versus DR+DRB3+: 11116, 30(7-
53) for dRFS; DR+DRB3-: 4/20, 80(63-98) versus DR+DRB3+: 9/16, 41(15-66) for 
DSS). C) Patients with DRB1 *13+ tumors that express HLA-DR have decreased dRFS 
and DSS as compared to patients with HLA-DR+ tumors that do not carry the DRB1 *13 
allotype (DR+DRB1 *13-: 9/28, 67(49-85) versus DR+DRB1 *13+: 7/8, 13(0-35) for 
dRFS; DR+DRB1 *13-: 7/28, 75(58-91) versus DR+DRB1 *13+: 6/8, 25(0-55) for DSS). 
All other HLA-DRB allotypes did not show significant differences with respect to patient 
survival. Survival rates were compared using Kaplan-Meier method with Log rank (LR) 
statistic. Overall significance between the four groups is provided in top right comer, 
levels of significance for comparison of 5-year survival for stratified variables are 
indicated on graphs. Censored observations indicated by symbols. 
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survival. HLA-DRB allele/HLA-DR expressiOn stratification variables were 
independently entered into Cox regression models that controlled for treatment, tumor 
type, TNM stage, estrogen receptor, progesterone receptor, and age at diagnosis. 
Histological grade and Her-2/neu status were not included in the models as their 
inclusion decreased sample size and did not alter the prognostic significance of the other 
covariates (data not shown). When controlling for the above prognostic factors, the 
DRB 1 *04/DR category was an independent predictor of dRFS and DSS, while DRB3/DR 
and DRB1 *13/DR categories independently predicted dRFS but not DSS (Table 3.1). In 
particular, DRB1 *04+ patients with HLA-DR+ tumors were only 0.24 times as likely to 
suffer a distant recurrence and 0.12 times as likely to die from breast cancer as compared 
to non-DRBl *04 patients with DR-expressing tumors. In contrast, DRB3+ patients with 
HLA-DR+ tumors were 4.47 times more likely to suffer a distant recurrence than non-
DRB3 patients with HLA-DR+ tumors. Likewise, DRB1 *13+ patients with HLA-DR+ 
tumors were 4.72 times more likely to suffer a distant recurrence than non-DRB1 *13 
patients with HLA-DR+ tumors. Similar results were obtained for 5-year survival. All 
other DRB allele stratification variables did not independently associate with patient 
outcome (data not shown). 
3.4.4 Decreased survival of patients with HLA-DR+ tumors that differentially 
express HLA-DR~ allotypes is dependent on the HLA-DRB alleles carried by the 
patient 
In a previous study we showed that most HLA-DR+ breast tumors differentially 
express individual HLA-DRP allotypes [248], but we did not address its implications for 
prognosis and survivial. As stratification of tumors based on HLA-DRB alleles and 
99 
Table 3.1: Multivariate Cox Proportional Hazards regression models using backward 
stepwise methodt to assess the significance of HLA-DRB alleles and tumor cell HLA-
DR expression on patient survival. 
dRFS DSS 
Model Total Total 
p HR (95%CI) p HR (95%CI) 
l)DRBl *04/DR 0.017 0.032 
DRB 1 *04-DR+ Reference Reference 
DRBl *04+DR+ 0.011 0.24 (0.08-0. 73) 0.006 0.12 (0.02-0.55) 
DRBl *04-DR- 0.023 0.37 (0.16-0.87) 0.067 0.41 (0.16-1.06) 
DRB 1 *04+DR- 0.010 0.21 (0.06-0.69) 0.393 0.62 (0.21-1.85) 
Model x.2 (P-value)t 20.1 (0.001) 20.8 (0.001) 
2} DRB3/DR 0.020 ns 
DRB3-DR+ Reference Reference 
DRB3-DR- 0.793 1.17 (0.36-3.85) ns 
DRB3+DR+ 0.008 4.47 (1.49-13.44) ns 
DRB3+DR- 0.211 1.97 (0.68-5.68) ns 
Model x.2 (P-value) 19.4 (0.002) 7.0 (0.008) 
3}DRB1 *13/DR 0.003 ns 
DRB1*13-DR+ Reference Reference 
DRBl *13-DR- 0.556 0.76 (0.31-1.89) ns 
DRB1 *13+DR+ 0.005 4.72 (1.59-14.02) ns 
DRB1 *13+DR- 0.133 2.25 (0.78-6.49) ns 
Model x.2 (P-value) 28.2 (<0.001) 7.0 (0.008) 
# events/# at risk 32/91 28/91 
tcox proportional hazards models were analyzed using backward stepwise method with entry at P<O.OS 
and removal at ?;:::0.06. All models controlled for treatment, tumor type, TNM stage, diagnosis age, ER, 
and PR. For model 1, TNM stage and ER status were also independent predictors of dRFS, while TNM 
stage and PR independently predicted DSS. For model 2, ER status independently predicted dRFS while 
PR status was an independent predictor of DSS. For Model 3, TNM stage and ER status were also 
independent predictors of dRFS, while PR independently predicted DSS. HR=hazards ratio; CI=confidence 
interval for HR. 
+ Model statistics 
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generic tumor cell HLA-DR expression does not address individual HLA-DR~ allotype 
expression by tumor cells, we further assessed HLA-DR~ allotypic expression in HLA-
DR+ primary tumors. A smaller numbers of recurrent breast carcinoma lesions were also 
examined to determine if differential HLA-DR~ allotype expression associates with 
disease progression. Using the available panel of allotype-discriminating antibodies, we 
determined at least 21135 primary and 4/4 recurrent HLA-DR+ tumors lacked expression 
of one or more HLA- DR~ allotypes (Supplementary Table 3S3), thus confirming our 
previous findings. Representative examples of tumors that homogeneously or 
differentially express their HLA-DR~ allotypes are provided in Supplementary Figures 
3S1 and 3S2, respectively. Discordant allelic expression was unique to the individual 
tumor as each of the allotypes not expressed was detected within another HLA-DR+ 
tumor (Supplementary Table 3S3). However, the DR~1 *04 allotype was expressed most 
frequently as 17/19 (89.5%) of DR~1 *04+ tumors expressed the DR~1 *04 allotype as 
compared to 27/42 (64.3%) of other DR~1 allotypes. Furthermore, in the subgroup of 
patients that carry HLA-DRB3, tumor cell expression of the HLA-DR~3 allotype could 
be determined in 14/16 HLA-DR+ tumors and notably 7114 did not express the DR~3 
allotype (Figure 3.4A). 
To ascertain whether DR~ allotypic expression by tumor cells has prognostic 
implications, prognostic parameters were assessed in tumors grouped based on 
expression of individual HLA-DRI3 allotypes (Supplementary Table 384). As no 
particular HLA-DR~ allotype showed preferential dysregulation, associations of HLA-
DR~ allotype expression categories with prognostic parameters paralleled that of generic 
HLA-DR expression, stratified by HLA-DRB alleles (Figure 3.2). Namely, diagnosis age 
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Figure 3.4: Differential expression of HLA-DRP allotypes associates with decreased 
survival in breast carcinoma patients. A) Expression of individual HLA-DRP allotypes in 
HLA-DR+ tumors was determined using indirect immunohistochemistry and a panel of 
allotype-specific monoclonal antibodies. B-C) Differential expression of HLA-DRP 
allotypes by breast tumor cells associates with decreased dRFS and DSS. Survival rates 
were compared using Kaplan-Meier method with Log rank (LR) statistic. Overall 
significance between the four groups is provided in top right comer, levels of significance 
for 5-year survival rates are indicated on graphs. D-E) In the subset ofHLA-DR+ tumors, 
expression of the HLA-DRPl *04 allotype by breast tumor cells associates with improved 
dRFS (LR=7.3, P=0.007) and DSS (LR=8.5, P=0.004), while expression of the HLA-
DRPl *13 allotype associates with decreased dRFS (LR=5.9, P=0.016) and DSS 
(LR=4.9, P=0.028). F) Within the subset of patients that carry the HLA-DRB3 allotype 
and have HLA-DR+ tumor cells, dysregulated expression of the HLA-DRP3 allotype 
associates with decreased dRFS (LR=l2.6, P<O.OOl) and DSS (LR=7.3, P<O.OOl). 
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was decreased in all HLA-DR~ allotype expressiOn categories except DR~1 *04, 
DR~1 *0401 and DR~1 *11 and ER was significantly decreased in all HLA-DR~ allotype 
expression categories as compared to DRp-'- tumors, but was most marked in tumors that 
express the DR~1 *07 allotype. PR was generally decreased in HLA-DR~ allotype 
expression categories, except in tumors that express the DR~1 *13 and/or DR~3 
allotypes. Tumors that express the DR~1 *0401 allotype have significantly decreased 
tumor diameter and all DRB 1 * 13 and DRB 1 * 11 patients with tumors that express the 
respective HLA-DR~ allotypes have LN metastasis. 
To determine if differential expression of DR~ allotypes by tumor cells has 
clinical implications, univariate survival analysis was performed in tumors stratified by 
HLA-DR~ expression categories. Patients with DR~-/+ tumors had markedly decreased 
dRFS and DSS (Figure 3.4B-C). Overall, differential DR~ allotype expression 
independently predicted dRFS and DSS by multivariate Cox proportional hazards 
regression analysis, controlling for standard prognostic indicators, as above. Using 
patients with DR~-/- tumors as a reference, tumors that differentially express HLA-DR~ 
allotypes (DRW/+) are 2.5 times more likely to suffer a distant recurrence and 2.3 times as 
likely to die from the disease within 5 years. Similar results were obtained when 
comparing overall survival rates (Supplementary Table 3S5). 
Since stratification by generic HLA-DR expression and HLA-DRB alleles 
demonstrated allelic differences and tumor cells differentially express HLA-DR~ 
allotypes, we assessed the specific influence of HLA-DR~ allotype expression by 
comparing tumors in which a particular HLA-DR~ allotype was expressed to tumors that 
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express other HLA-DR~ allotypes. Within HLA-DR+ tumors, those that express the 
DRJ31 *04 allotype have improved survival, as compared to tumors that express other 
DRJ3 allotypes, while those that express the DRJ31 * 13 allotype have decreased survival 
(Figure 3.4D-E). Importantly, within HLA-DR+ tumors 17119 DRB1 *04 tumors express 
the HLA-DRB1 *04 allotype and only 118 DRBl *13 tumors lack expression of the 
DRBI *13 allotype. Thus, similar results were obtained if only DRW1+ tumors were 
assessed, but with decreased numbers of samples (data not shown). Although the number 
ofHLA-DR+ tumors that lack expression ofHLA-DRJ31 *04 or HLA-DRf31 *13 was too 
few to permit comparison with tumors that express these allotypes, DRJ33 was 
dysregulated in enough tumors to warrant further evaluation. Within HLA-DRB3 
patients, lack of expression of the DRJ33 allotype by HLA-DR+ breast tumor cells 
associates with decreased dRFS and DSS (Figure 3.4F). 
3.4.5 DRBl *13DR+ tumors have decreased IFN-y and elevated IL-lf3 and IL-6 
mRNA 
To determine if the inverse association with patient survival of DRB 1 *04 and 
DRB3 and DRBl *13 tumors that express HLA-DR was attributable to variation in 
immune responsiveness, cytokine mRNA levels were compared in HLA-DRB allotype 
subgroups stratified on HLA-DR expression (Figure 3.5). Stratification by HLA-
DRB 1 *04 (Figure 3.5A) showed both HLA-DR+ subgroups have elevated IFN-y. In 
contrast, HLA-DR+DRB1 *04+ tumors have significantly lower IL-4 as compared to non-
DRB1 *04 tumors that express HLA-DR. HLA-DR+DRB1 *04+ tumors also have 
markedly decreased TGF-f31 as compared to non-DRB1 *04 HLA-DR+ tumors. This 
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Figure 3.5: Relative intratumoral cytokine and FOX-P3 mRNA levels in breast tumors 
stratified by tumor cell HLA-DR expression and carriage of HLA-DRB allotypes. A) 
Stratification by HLA-DRBl *04 shows both HLA-DR+ tumor subsets have elevated 
IFN-y mRNA (P=0.048), but non-HLA-DRBl *04 HLA-DR+ tumors have elevated IL-4 
(P=0.079). Although not statistically significant, non-DRBl *04 HLA-DR+ tumors also 
have elevated TGF-~1 (P=0.578), FOX-P3 (P=O.lOl), and IL-l~ (P=0.289). B) DRB3 
HLA-DR+ tumors have decreased IFN-y (P=0.033). IL-4 levels did not significantly 
differ (P=0.508) but relative levels ofTGF-~1 (P=0.067), FOX-P3 (P=O.lOl), and IL-l~ 
(P=0.126) were increased. C) DRBl *13 HLA-DR+ tumors have decreased IFN-y 
(P=0.033). Relative levels of IL-4 did not significantly differ (P=0.409) but TGF-~ 1 
(P=O.l65), FOX-P3 (P=O.lOl), and IL-l~ (P=0.022) were increased. Differences 
between the four groups were compared using Kruskal-Wallis H test. Asterisks indicate 
significant differences in HLA-DRB allotype groups within HLA-DR+ tumors, as 
determined by Mann-Whitney U test. *P<0.05. 
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Figure 3.5 continued 
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trend was enhanced in the most frequent HLA-DRBl *04 allele, DRBl *0401 (Kruska1 
Wallis H test, P=0.052, data not shown), which also demonstrate a similar relationship as 
DRBl *04 with IFN-y (Kruskal-Wallis H test, P=0.077) (data not shown). Non-DRBl *04 
HLA-DR+ tumors also show a trend for increased FOX-P3 and IL-l~. These 
relationships were largely influenced by the DRB3 haplotype group, in particular 
DRBI *13+ tumors. Both DRB3 HLA-DR+ and DRBl *13 HLA-DR+ tumors contain 
decreased IFN-y and elevated TGF-~1, FOX-P3 and IL-l~ (Figure 3.5B-C). HLA-DR+ 
tumors that carry DRB3 and DRBl *13 also contain elevated levels of IL-6 [Kruskal-
Wallis H test, P=O.Ol6 (DRB3), P=0.049 (DRBl *13), data not shown]. Other cytokine 
mRNA levels did not significantly differ in DRB allotype categories (data not shown). 
3.5 DISCUSSION 
The results of this study suggest that the course of disease in breast carcinoma is 
influenced by allelic variation in HLA class II antigens, likely via effects on the anti-
tumor immune response. Carriage of the HLA-DRB3 allele, associates with advanced 
disease and decreased survival in breast carcinoma patients (Drover et al., manuscript in 
preparation). This may in part be attributable to increased levels of the pro-inflammatory 
cytokines IL-l~ and IL-6 in these patients. IL-l~ and IL-6 can facilitate neoplastic 
progression via stimulation of cancer cell growth and production of pro-angiogenic 
factors, such as VEGF [257]. Levels of IL-l~ were highest in DRB3 and DRB 1 * 13 
patients with HLA-DR expressing tumor cells. This likely reflects the ability ofiL-1~ to 
induce HLA-DR expression in breast carcinoma cells [135]. Furthermore, HLA-DRB3 
patients with HLA-DR+ tumors, particularly those that carry the DRB1 *13 allele, 
associate with the poor prognostic indicators of increased tumor diameter and lymph 
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node metastasis and independently predicted poor distant recurrence-free survival. 
Although the infiltrating CD4+ T cells were not phenotyped in this study, breast 
carcinomas do contain elevated numbers of CD4+ T regulatory cells [184]. Thus, HLA-
DR expression by DRB1 *13+ tumors may result in inefficient anti-tumor immunity via 
the activation of immunoregulatory CD4+ cells or T H2 CD4+ T cells, as opposed to 
effector CD4+ THl cells, as suggested by the decreased levels of IFN-y mRNA and 
elevated TGF-131 and FOX-P3 mRNA in DRB1 *13 tumors that express HLA-DR. Recent 
studies have demonstrated HLA-DRBI *13 restricted TAA-specific Treg can be generated 
from TIL of cancer patients following limiting dilution [258]. In addition, the ligands that 
preferentially stimulate TAA-specific CD4+ Treg are antigens that are processed and 
presented by tumor cells but not pAPC pulsed with the same tumor celllysates [259]. 
In support of our previous study [248], DRj31 *04 is expressed more frequently by 
tumor cells than other DR~ allotypes. HLA-DR expressing DRB1 *04+ tumors displayed 
elevated IFN-y and decreased TGF-~1. As TGF-~1 can suppress IFN-y induction of 
HLA-DR via Smad3 dependent inhibition of CIITA promoter IV activity [260], 
decreased TGF-~1 in this subset of DRB1 *04 tumors may allow IFN-y mediated 
induction of HLA-DR antigens. However, although all 10 DR+DRB1 *0401+ tumors 
expressed the DRj31 *040 1 allotype, only 50% contained moderate to large numbers of 
infiltrating CD4+ T cells and it was these tumors that had elevated IFN-y (data not 
shown). Furthermore, HLA-DR expression in DRBl *0401 tumors did not associate with 
decreased age at diagnosis, suggesting factors other than T -cell derived cytokines and 
hormones may induce HLA-DR~1 *0401 expression in DRB1 *0401+ tumor cells. Using 
competitive RT-PCR, Vincent et al. (1996) [118] demonstrated that levels of DR~1 *04 
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mRNA in peripheral blood B cells were increased over predicted based on DRB 1 *04 
promoter activity [117], suggesting a post-transcriptional modification. Reasons for 
enhanced expression of DRj31 *040 1 are unknown but may involve differential targeting 
of HLA-DRj31 *0401 molecules through the endocytic pathway and differential peptide 
loading of DRI3l *0401 molecules, via heat shock protein interactions [261]. HLA-DR 
expression by DRB 1 *04+ tumors was an independent predictor of improved DSS. 
DRB1 *0401 transfected neuroendocrine epithelial cells are known to express a wide pool 
of self-protein derived peptides from the plasma membrane and cytoplasm, as compared 
to DRB1 *0401 homozygous B cell line [88]. Thus, DRBl *04+ patients may display an 
enhanced propensity for presentation of endogenous tumor antigen derived peptides by 
tumor cells and promote the activation of tumor-specific CD4+ T H 1 cells. In support of 
this, at the time of surgery, DRB1 *04+DR+ tumors had a smaller tumor diameter and 
DRB 1 *04+ tumors that express HLA-DR in the presence of a CD4+ infiltrate have 
elevated IFN-y mRNA levels. In contrast, DRB1 *04+DR+ tumors have significantly 
decreased intratumorallevels of the TH2 cytokine, IL-4 as compared to non-DRB1 *04 
HLA-DR+ tumors. 
This study did not confirm the poor expression ofHLA-DR in DRI31 *07+ tumors 
that we previously observed [248]. However, all DRj31 *07+ tumors that expressed DR 
had ER levels <lOfmol/mg and in our previous study all DR-DRI3l *07+ tumors were 
ER+ (unpublished observations). The negative association of DR with ER expression 
supports the finding that 17-13 estradiol down-modulates IFN-y-induced MHC class II 
expression in a variety of cell types [262], and involves ER binding to MHC class II 
promoters [263]. Furthermore, 17-13 estradiol also inhibits IL-l a and IL-l 13 induction of 
113 
HLA-DR in ER+ human endometrial and breast carcinoma cell lines in a dose dependent 
manner [135]. In this larger study, poor expression of DR by tumor cells was observed in 
tumors carrying the DRBI *01, DRBI *03 and DRB3*01 allotypes, despite the presence 
of CD4+ TIL. These tumor subgroups have later age at diagnosis and decreased ER 
levels, possibly explaining poor DR-expression (data not shown). However, the highest 
expression of HLA-DR antigens was observed in young women withER- tumors (data 
not shown), suggesting in the absence of ER expression on tumor cells, the suppressive 
effects of E2-ER complexes on HLA-DR induction may be overcome. The association 
with earlier age at diagnosis further suggests a role for circulating hormones in the 
induction of HLA-DR. These effects may be indirect as 17~-estradiol is known to 
enhance the expansion of antigen-specific CD4+ THl cells and the production ofiFN-y in 
vivo [264]. Circulating estradiol also promotes the in vivo expansion ofregulatory CD4+ 
T cells [265]. As such, in the absence of competing ER on breast tumor cells, estradiol 
may promote the expansion of tumor infiltrating CD4+ T cells, whose phenotype is 
dependent on the HLA-DRB alleles carried by the patient. 
Loss of expression of individual HLA class I allospecificities occurs in breast 
carcinoma [224, 225] and experimental evidence suggests a role for T cell pressure in the 
generation of HLA loss variants [226, 227, 266]. We recently demonstrated this 
phenomenon also occurs for HLA-class II allotypes through the discovery of selective 
HLA-DRP allospecificity expression in a small number of breast carcinoma lesions [248] 
and have confirmed this finding in this study. The proportion of DRp-1+ tumors was 
increased in this subset of patients, possibly reflecting the biased selection and increased 
frequency ofDRBl *04+ tumors in the previous study [248]. As differential DRP allotype 
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expression is unique to an individual tumor, it supports the hypothesis that immune 
selective pressure will be dependent on both the HLA-DR genotype of the patient and the 
array of tumor-associated antigens expressed in that particular tumor allowing outgrowth 
ofsubpopulations of tumor cells that have lost the relevant HLA-DR antigens. In support 
of this, patients with primary tumors that differentially express DR~ allotypes have 
decreased dRFS and DSS and all metastatic lesions examined in this study were DR- or 
showed differential DR~ expression. Indeed, within individual patients, lymph node 
metastases are more frequently HLA class I and HLA class II negative than primary 
breast lesions [247]. 
As stratification of tumors based on HLA-DRB allele and generic tumor cell 
HLA-DR expression takes into account expression on pAPC and/or tumor cells but does 
not address individual HLA-DR~ allotype expression by tumor cells, we further assessed 
HLA-DR~ allotypic expression in HLA-DR+ primary tumors. Of the DR~ allotypes 
examined, DR~3 most frequently demonstrated selective expression. Thus, in this subset 
of tumors, DRJ33 may represent a restricting element for TAA-specific effector CD4+ 
TIL and its expression may be downregulated in response to selective immune pressure. 
Although the number of samples analyzed is too few to warrant definitive conclusions, in 
support of this hypothesis, all DRB3 patients with HLA-DR+ tumors that fail to express 
the DR~3 allotype suffered a distant recurrence within 2 years. In addition, since DRB3 
is in linkage with HLA-DRBl *13, the poor survival in HLA-DRBl *13 patients with 
HLA-DR+ tumors, may in part be influenced by down-regulation of the DR~3 allotype. 
Indeed 3/6 DR~l *13 expressing tumors lack expression of the DR~3 allotype 
(Supplementary Table 3S3). 
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The mechanisms responsible for differential DR~ allotypic expression have not 
yet been elucidated. One potential mechanism that may contribute to this phenomenon is 
loss of heterozygosity (LOH) at the HLA locus, as this mechanism causes HLA 
haplotype loss in a high percentage of tumors [238]. The pattern of allotypic expression 
in HLA-DR+ tumors, suggests LOH at chromosome 6p21.3 may contribute to selective 
HLA-DR~ expression in a subset of HLA-DR+ tumors, based on expression of DR~1 
allotypes and linked DR~3, DR~4 or DR~5 allotypes (Supplementary Table 3S3). The 
pattern of allotypic expression in the HLA-DR+ tumors that differentially express HLA-
DR~ allotypes, suggests that LOH may be responsible for differential DR~ allotype 
expression in 13/21 primary tumors and 4/4 recurrent tumors. Although HLA-DRW'-
tumors were more frequently HLA class I-, the percentage ofHLA class I- tumors did not 
significantly differ between DRjr1+ and DRp+l+ tumors [mean±SEM = 13.6±5.1% (DRW 
!+); 5.0±5.0 (DR~+/+); P=0.695], nor did the percentage of tumor cells with weak HLA 
class I expression [mean±SEM = 15.2±6.3 (DRW/+); 10.0±10.0% (DRP+/+); P=0.915], 
suggesting differential DR~ expression was not attributable to a dominant effect on the 
HLA locus, for the majority ofHLA-DR+ tumors. Selective HLA class I antigen loss can 
occur due to mutations in the relevant HLA class I a chain, including large deletions and 
single base pair deletions or substitutions [229]. Similar defects in HLA-DRB alleles may 
contribute to the selective expression ofHLA-DR~ allotypes in HLA-DR+ tumor cells. 
The common occurrence of tumor cells with altered HLA expression and the 
influence of HLA genetics on tumor cell expression of HLA-DR antigens highlight the 
complexity of host-tumor interactions. Future studies aimed at thoroughly characterizing 
the immune response in breast carcinoma patients and correlating this with patterns of 
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HLA antigen expression and the genetics of the patient should provide valuable advances 
in the knowledge of which patients might benefit from immunotherapeutic intervention. 
Successful cancer immunotherapy will likely require the preferential activation of CD4+ 
TH cells as opposed to Treg cells. Such strategies will likely be unique to the patient and 
dependent on both the HLA-DRB alleles carried by the patient and the array of TAA 
expressed by the tumor cells. 
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Supplementary Table 3Sl: DRB Allotype Specific mAbs used in this Study 
mAb I so type Concentration! Dilution DRI3 Specificity 
NFLD.D1 IgG1 10!-lg/ml 131*04 
NFLD.D7 lgG1 1/100 131*04, 15, 16; 133 
NFLD.DIO IgG1 3!J.g/ml 131*01, 15,04~ 14t,o9, 10;135*02 
SFR16 IgG2a 1/25 131*07 
UK8.1 IgG2b 1/1000 131 *03, 11, 13, 14t 
7.3.19.1 IgG2b 111000 131*03,133 
PL3 IgG3 1/400 131*07,09;134 
JS-1 IgG2a 1/1000 131 *01 t, 03, 04t, 1402, 133 
MAD88t IgG 1/100 131*08, 133 
t =Not all allelic products of this HLA-DR type carry the epitope recognized by this antibody 
t = This mAb was reported as DR~ 1 *08 specific in the 1 01h IHW but shows cross reaction with additional 
DR~3 allotypes. 
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Supplementary Table 3S2: Primer sequences for detection of mRNA m breast 
carcinoma lesions. 
GenBank 
Size 
Sense Primer (5'-3') Anti-sense Primer (5'-3') Accession 
(bp) 
Number· 
ATC TGG CAC CAC ACC CGT CAT ACT CCT GCT TGC 
~-Actin 840 NM 005159 
TTC TAC AAT GAG CTG CG TGA TCC ACA TCT GC 
AGT TAT ATC TTG GCT TTT ACC GAA TAA TTA GTC 
IFN-y 356 J00219 
CA AGCTT 
ACT CAC CAG GAT GCT AGG TAA TCC ATC TGT 
IL-2 269 HSU25676 
CACAT TCAGA 
CCA AGA ACT TGC AGC TGG GTC TAT TCC GTT GTG 
IL-12 p40 355 NM 002187 
TGAAG TC 
CCT CTG TTC TTC CTG CTA CCA ACG TAC TCT GGT 
IL-4 371 M23442 
GCA TGTGCC TGG CTT CCT TCA 
ATG CCC CAA GCT GAG TCT CAA GGG GCT GGG 
IL-10 352 NM 000572 
AAC CAA GAC CCA TCA GCT ATC CCA 
GCC CTG GAC ACC AAC AGG CTC CAA ATG TAG 
TGF-~ 165 X02812.1 
TATTGC GGGCAGG 
CAG CTG CCC ACA CTG CAT TTG CCA GCA GTG 
FOX-P3 384 AF277993 
CCCCTAG GGTAG 
ACA GAT GAA GTG CTC GTC GGA GAT TCG TAG 
IL-l~ 75 BT007213 
CTTCCA CTGGAT 
AGC TCA GCT ATG AAC GTC TCC TCA TTG AAT 
IL-6 340 NM 000600 
TCCTTCTC CCAGATTGG 
CGG GAC GTG GAG CTG CAC CAG CTG GTT ATC 
TNF-a. 354 NM 000594 
GCCGAGGAG TCTCAGCTC 
* All primer sequences were validated using published GenBank mRNA sequences. 
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Supplementary Table 383: 
and recurrent breast tumors t 
HLA-DR~ allotype expression and CD4+ TIL in primary 
Sample HLA- HLA-DRI3 Allotype Expression by Tumor Cells CD4+ Distribution 
ID DR Expressed Not Expressed Undetermine TIL 
d 
11353p + 131 *08, 131 * 16, - ++ D 
135 
11452p + 131 *0403, 131 *11, - ++ D 
133*02,134 
12450p + 131 *0406, 131 *13, - + FD 
133*03,134 
12817p + 131 *0401, 131 *07, - -I+ F 
134,134 
10810p + 131 *0401, 134,134 -I+ F 
131 *040(1: 
10881p + 131 *0404, 131 *13, - 134 + FD 
133*01 
11070p + 131*0407 131 *15, 134, ++ FD 
135 
11937p + 131*07,131*07 134,134 + F 
12291p + 131*0405,131*07 - 134,134 ++ FD 
12483p + 131 *07, 131 *15, - 135 ++ FD 
134 
12513p + 131*0401 131 *09, 134, + D 
134 
12816p + 131*0407 131 *16, 134, + FD 
135 
13058p + 131 *15, 131 *15 j35,j35 + D 
13412p + 131 *0401, 134,134 
131*0404 
10867p + 131 *1302, 133*01,133*03 ++ FD 
131 *1303 
11432p + 131*16 131 *1305, 133*02, - + FD 
135 
13091p + 131 *0401, 134 -I+ F 
131 *1101, 133*02 
13123p + 131 * 1302, 133 *02, 131*1401 + FD 
133*03 
10903p + 131 *1301 131*15,133*01 135 ++ D 
10970p + 131*07 131*08 134 ++ FD 
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Sample HLA- HLA-DRI3 Allotype Expression by Tumor Cells CD4+ Distribution 
ID DR Expressed Not Expressed Undetermine TIL 
d 
11008p + 131 *1305 133*02 131*10 -I+ F 
11129p + 131*0401 134 131*15,135 + D 
11352p + 131*03 133*01, 133*01 131 *1301 + D 
11673p + 131 *07, 131 *1101 133*02 134 + FD 
11889p + 131*0407,133*02 131*03 134 + F 
12273p + 131*1104 131*08 133*02 + FD 
12716p + 131*07,134 131*15 135 -I+ F 
13088p + 131*0401,133*02 131*03 134 
13118p + 131*1104,134 131*07 133*02 -I+ FD 
13282p + 131*0401 131*07 134.134 ++ FD 
13336p + 131*0401 134 131*10 + F 
13337p + 131*0401 131*07 134,134 + F 
11225p + 131 *0405, 131 *15, j35§ + F 
134 
12418p + 131*08,131*15 135§ -I+ F 
11644p + 131 *01, 131 *1011 nr 
13067p + 131 *0404, 131 *1101, - + D 
133*02, 134~ 
9571p 131 *0401, 131 *11, - -I+ F 
133,134 
9772p 131*01,131*08 
10796p - 131*07, 131*07, 134, - -I+ FD 
134 
10814p - 131 *01, 131 *0401, -
j34 
10832p - 131 *03, 131 *15, - -I+ F 
133*01,135 
10850p - 131 *1102, 131 *13, -
133*01,133*02 
10902p - 131 *07, 131 *15, 134, - -I+ F 
135 
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Sample HLA- HLA-DR~ Allotype Expression by Tumor Cells CD4+ Distribution 
ID DR Expressed Not Expressed Undetermine TIL 
d 
10958p - 131*01,131*07,134 -I+ FD 
10960p - ~1 *0404, ~1 *0404, - -I+ D 
~4.~4 
llOSlp - ~1*01,~1*07,~4 + D 
11084p - ~1*15, pl*IS, ps, - + FD 
ps 
11089p 
- ~1 *03, ~1 *07, - -I+ F 
p3*0l,p4 
11090p 
- PI *1101, PI *1301, - -I+ F 
P3*0l,P3*02 
11108p - ~1*04,~1*08,~4 + FD 
11125p - 131 *0407, 131 *15, - -I+ F 
~4,ps 
11170p 
- Pl *07, PI*1104, -
P3*02,P4 
11208p - 131 *0402, 131 *15, -
p4,p5 
1I216p - PI *1301, PI *1303, -
p3*01,133*02 
11332p - PI *0401, PI *15, - -I+ F 
p4,p5 
11372p - PI*07,Pl*08,p4 nr 
11378p - ~1 *03, ~1 *03, - + D 
~3*01,~3*01 
11418p - 131 *01, 131 *03, - -I+ F 
~3*01 
11555p - ~1 *0407, ~1 *08, - + FD 
134 
11556p - ~1 *1104, ~1 *16, - ++ FD 
~3*02,ps 
11565p - ~1 *0407, ~1 *11, - ++ FD 
P3*02,~4 
11740p - ~1*03, ~1*13, ~3, -
P3 
11757p 
- PI *01, PI *1302, - + F 
~3*03 
11799p 
- ~1 *03, ~1 *1301, - -I+ F 
~3*01,133*02 
11806p - 131 *0401, ~1 *0405, - -I+ F 
~4.~4 
11818p - ~1 *03, ~1 *0404, - + D 
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Sample HLA- HLA-DRP Allotype Expression by Tumor Cells CD4+ Distribution 
ID DR Expressed Not Expressed Undetermine TIL 
d 
P3*0I,P4 
11894p - p1 *1201, p1 *1301, - -I+ F 
p3,p3 
Il911p - PI *0404, PI *07, - ++ FD 
p4,p4 
Il915p - PI*I5, PI*I5, ps, - -I+ F 
ps 
12049p - PI *07, PI *07, p4, - -I+ FD 
P4 
12078p - PI *01, p1 *Itoi, - + FD 
P3*02 
I2094p 
- pi *03, p1 *0402, - -I+ FD 
p3,p4 
I2159p - pi *1I01, pt *1104, -
p3*02,p3*02 
I23I1p - p1 *0401, p1 *08, - -I+ F 
P4 
12375p 
- p1 *0103, pi *03, - + FD 
p3*0I 
I2495p - pt*07, pt*ts, p4, - + D 
ps 
1251Ip - PI*01,pi*07,p4 -I+ F 
12694p - pt *07, PI *130I, -
P3*01,P4 
12748p - pt *130I, PI *I5, - -I+ F 
f33*0I, ps 
I2750p - PI *07, PI *1402, - -I+ F 
p3*0I,p4 
I2782p - PI *I10I, PI *1303, - -I+ F 
P3*0I,p3*02 
I283I p - PI *03, pi *040I, - + F 
P3*01,p4 
I2858p - p1 *040I, p1 *15, - -I+ F 
p4,p5 
I2926p - p1 *03, p1 *07, -
P3*0I,p4 
12937p 
- PI*07, PI*15, p4, - + F 
ps 
I3054p - PI *01, PI *I302, -
P3*03 
13089p - PI *03, pt *0404, - + FD 
P3*0t,p4 
I31I3p - PI *IIOI, PI *I4, - -I+ D 
P3*02,P3*02 
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Sample HLA- HLA-DR~ Allotype Expression by Tumor Cells CD4+ Distribution 
ID DR Expressed Not Expressed Undetermine TIL 
d 
13269p - PI *09, PI *IIOI, - -I+ F 
P3*02,p4 
13287p - PI *040I, PI *I5, - + FD 
p4,p5 
13360p 
- PI *0408, PI *1303, - -I+ F 
P3*0I,p4 
13369p 
- pi *OI, pi *I5, p5 + F 
13373p - PI *03, P1 *03, -
P3*0I,p3*01 
13378p - P1 *130I, P1 *15, - + F 
P3*03,p5 
13390p - P1 *0401, P1 *15, - -I+ F 
p4,p5 
13415p - P1 *07, P1 *15, p4, - -I+ F 
P5 
13451p - p1 *01, p1 *15, p5 
14331p 
- P1*07, P1*15, p4, - + D 
ps 
14377p - P1 *01, P1 *0401, - -I+ F 
4 
11462r + P1*07 p1 *16, ps p4 ++ FD 
12433r + P3 P1 *03, PI *I401 P3 
13389r + P3*02 p1 *1101, p1 *15 ps + FD 
10842r + p1 *1103, P3 p1 *09, p4§ + FD 
12951r + P1 *01, PI *01~ -I+ FD 
10898r - p1 *03, p1 *07, - + D 
P3*01,p4 
11115r - p1 *0401, p1 *15, -
p4,p5 
11273r - p1 *0401, p1 *07, - -I+ F 
p4,p4 
11387r - 131 *03, 131 *16, -
133*01,135 
11751r - 131*0401, p1 *08, - -I+ F 
134 
11982r - 131*09, 131*15, p4, - ++ D 
135 
12023r - 131 *0401, 131 *15, - nr 
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Sample HLA- HLA-DRPAIIotype Expression by Tumor Cells CD4+ 
ID DR _E_x_p_r_e-ss_e_,_d __ _,_,__N_o_t!_E_x_p-re-s-se-d"----U-n_d_e-te-rrn-in_e_ TIL 
12987r 
13149r 
13283r 
p4,p5 
Pl*07,Pl*08,p4 
d 
p1 *09, p1 *09, p4, -
P4 
131 *03, 131 *10, -
p3*01 
+ 
-I+ 
Distribution 
FD 
F 
tp =primary tumor; r =recurrent tumor; CD4+ TIL scored as defined in methods; nr=no result anti-CD4 
IHC was not performed on these breast carcinoma samples due to limited tissue availablity, F=focal 
aggregates of CD4+ TIL, D=diffusely distributed CD4+ TIL. 
tin the case of HLA-DRj3 allotype homozygosity, if expression levels were comparable to infiltrating 
inflammatory cells both allotypes were considered expressed. 
§Allotype is likely expressed due to differences in % of tumor cells positive for other alleles and % positive 
for total DR (L243+), however an allotype distinguishing mAb was not available to ascertain expression. 
11100% of tumor cells were HLA-DR+ by L243 mAb, however, allotype specific mAbs were not utilized 
due to lack of tissue availability. 
~Although;?: 25% of tumor cells were positive for generic HLA-DR (L243+), individual allotype specific 
mAbs stained <25% of cells. 
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Supplementary Table 3S4: Association of tumor cell HLA-DRJ3 allotype expression with prognostic parameters in breast carcinoma 
patients. 
HLA-DRP expressiont Diagnosis Age (Yrs) ER (fmol/mg) PR (fmol/mg) Tumor Size (em) LN+(%) 
N Mean±SEM pt N Mean±SEM p N Mean±SEM p N Mean±SEM p N % p 
(Median) (Median) (Median) (Median) 
HLA-DR- 63 61.7±1.8 63 49.8±8.8 63 74.0±21.7 60 3.3±0.3 63 49.2 
(65.0) (16.3) (17.9) (2.7) 
DR(31 *04 expressed 17 59.2±2.4 0.001 17 28.2±10.3 0.006 17 45.3±16.6 0.063 17 2.8±0.6 0.053 17 64.7 0.420 
(56.0) (13.9) (14.5) (2.5) 
DRPX expressed 19 48.4±3.1 19 7.7±2.5 19 24.8±9.0 19 3.6±0.4 18 61.1 
-
(46.0) (3.2) (6.3) (3.2) N 
0'1 
DRP 1 *040 1 expressed 10 60.6±3.8 0.004 10 17.0±4.2 0.012 10 32.2±9.8 0.018 10 2.1±0.3 0.032 10 50 0.270 
(57.0) (15 .5) (21.6) (1.9) 
DRPX expressed 26 50.8±2.5 26 17.5±7.1 26 35.3±12.3 26 3.7±0.5 25 68 
(50.5) (3.7) (6.3) (3.1) 
DRP 1 *07 expressed 7 50.1±3.8 0.018 7 3.8±2.3 0.006 7 9.6±3.4 0.076 7 3.2±0.7 0.963 7 71.4 0.378 
(53.0) (1.2) (6.3) (3.6) 
DRI3X expressed 29 54.3±2.5 29 20.7±6.3 29 40.5±11.2 29 3.3±0.4 28 60.7 
(52.0) (9.1) (13.0) (2.7) 
DRB1 *11 expressed 5 63.0±6.4 0.006 5 10.1±5.4 0.041 5 14.3±4.4 0.194 5 3.3±0.9 0.997 5 100 0.085 
(60.0) (3.8) (11.1) (3.0) 
DRPX expressed 31 52.0±2.2 31 18.5±6.0 31 37.7±10.6 31 3.2±0.4 30 56.7 
HLA-DRI3 expressiont Diagnosis Age (Yrs) ER (fmol/mg) PR (fmol!mg) Tumor Size (em) LN+(%} 
N Mean±SEM pt N Mean±SEM p N Mean±SEM p N Mean±SEM p N % p 
(Median) (Median) (Median) (Median) 
(51.0) (4.8) (12.4) (2.7) 
D Rl31 * 13 expressed 6 46.7±3.9 0.008 6 28.7±22.1 0.059 6 87.7±41.6 0.174 6 4.8±1.3 0.118 6 100 0.058 
(47.5) (4.5) (45.0) (3.3) 
DRI3X expressed 29 54.6±2.5 29 15.6±4.8 29 24.5±6.5 29 2.9±0.4 29 55 
(53.0) (4.8) (12.4) (2.5) 
DRI33 expressed 7 52.7±4.3 0.008 7 29.7±18.4 0.019 7 82.3±36.8 0.118 7 4.0±1.3 0.892 7 85.7 0.185 
(53.0) (13.2) (29.0) (2.7) 
DRI3X expressed 27 52.3±2.4 27 14.2±5.2 27 23.5±6.5 27 3.0±0.3 26 53.8 
(51.0) (4.6) (12.0) (2.5) 
DRI33*02 expressed 5 52.2±5.9 0.007 5 9.6±4.3 0.034 5 30.0±21.1 0.202 5 2.8±0.9 0.702 5 80 0.426 
- (53.0) (4.1) (4.6) (2.6) N 
-....) 
DRI3X expressed 29 52.4±2.3 29 18.8±6.4 29 36.6±10.9 29 3.3±0.4 28 57.1 
(51.0) (4.8) (12.4) (2.8) 
Total 99 58.8±1.4 99 40.0±6.1 99 59.6±14.3 96 3.3±0.2 98 54.2 
(60.0) (13.1) (2.7) 
tonly those allotypes that were expressd in at least 10% ofHLA-DR+ tumors are depicted; DRB4 was excluded as DRB4 expression could not be determined 
using the available panel ofmAbs for a substantial proportion of tumors. HLA-DR+ tumors were stratified based on whether a particular HLA-DRI3 allotype was 
expressed (e.g., DRI3l *04 expressed) or if other HLA-DRI3 allotypes were expressed (DRI3X expressed). 
tP-values calculated by comparison of HLA-DR- and both HLA-DRB allotype expression categories using one-way analysis of variance for diagnosis age, 
Pearson's chi-square analysis for LN status and Kruskal-Wallis H test for ER, PR and tumor size. 
-N 
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Supplementary Table 385: Multivariate Cox Proportional Hazards regression models using backward stepwise methodt to test the 
effect of differential HLA-DR~ expression by breast tumor cells patient survival. 
dRFS DSS 
Variables remaining at 
Total 5yr Total 5yr 
last step 
p HR (95%CI) p HR (95%CI) p HR (95%CI) p HR (95%CI) 
HLA-DR ex:gression 0.005 0.006 0.003 0.004 
DRfl'· (N=56) Reference Reference Reference Reference 
DRfl1+ (N=20) 0.027 2.42 (1.17-5.23) 0.023 2.50 (1.14-5.51) 0.074 2.07 (0.93-4.57) 0.041 2.34 (1.04-5.31) 
DRj3+t+ (N=4) 0.976 0.00 0.977 0.00 0.981 0.00 0.983 0.00 
DRj3UD (N=ll) 0.704 0.79 (0.23-2.74) 0.753 0.82 (0.23-2.87) 0.124 0.20 (0.03-1.55) 0.156 0.23 (0.03-1.76) 
TNM Stage III/IV (vs IIII) 0.002 3.21 (1.53-6.77) 0.006 2.91 (1.36-6.25) ns ns 
PR<10fmol/mg 0.019 2.46 (1.16-5.23) 0.017 2.52 (1.18-5 .38) 0.004 3.05 (1.42-6.56) 0.008 2.90 (1.31-6.41) 
Model x} (p-value )t 24.0 (<0.001) 23.0 (<0.001) 19.8 (0.001) 19.3 (0.001) 
# events/# at risk 32/91 31191 28/91 26/91 
tcox proportional hazards models were analyzed using backward stepwise method with entry at P<0.05 and removal at ??.0.06. All models controlled for 
treatment, tumor type, TNM stage, Diagnosis age, ER, and PR. 
t Model statistics 
Supplementary Figure 3Sl: Representative immunohistochemistry example of breast 
tumor cells that homogenously express HLA-DRP allotypes. (A) Hematoxylin and eosin 
staining illustrating invasive ductal morphology. (B-H) Indirect immunohistochemistry 
using monoclonal antibodies (mAb) was performed on acetone-fixed breast carcinoma 
tissue sections. (B) Staining with IgG isotype control antibodies served as a negative 
control. (C) Infiltrating CD4+ (mAb RPA-T4) cells were detected in and around tumor 
nests. In this representative example (Tumor ID# 12450), total tumor DNA was HLA-DR 
typed as HLA-DRBl *0406, DRBl *1302, DRB3*03 and DRB4. (D) Tumor cells 
expressed generic HLA-DR (mAb L243) and expressed the (E) HLA-DRP 1 *04 (mAb 
NFLD.Dl), (F) HLA-DRP1*13 (mAb UK8.1), (G) HLA-DR~4 (mAb PL3) and (H) 
HLA-DR~3*03 (mAb 7.3.19.1) allotypes. Infiltrating inflammatory and stromal cells 
served as positive controls for the immunoreactivity of mAb (closed arrowheads). 
Representative tumor cells are depicted by open arrowheads. Original magnifications of 
200X (A) and 400X (B-H). 

Supplementary Figure 382: Representative immunohistochemistry example of breast 
tumor cells that differentially express HLA-DR~ allotypes. (A) Hematoxylin and eosin 
staining illustrating invasive lobular morphology. (B-H) Indirect immunohistochemistry 
using monoclonal antibodies (mAb) was performed on acetone-fixed breast carcinoma 
tissue sections. (B) Staining with IgG isotype control antibodies served as a negative 
control. (C) Infiltrating CD4+ (mAb RPA-T4) cells were detected mainly as focal 
aggregates within the tumor. In this representative example (Tumor ID# 13091), total 
tumor DNA was HLA-DR typed as HLA-DRB1 *0401, DRB1 *1101, DRB3*0202 and 
DRB4. (D) Tumor cells expressed generic HLA-DR (mAb 1243) and expressed the (E) 
HLA-DR~1 *04 (mAb NFLD.D1), (F) HLA-DR~1 *11 (mAb UK8.1) and (G) HLA-
DR~3*03 (mAb 7.3.19.1) allotypes but failed to express the (H) HLA-DRf34 (mAb PL3) 
allotype. Infiltrating inflammatory and stromal cells served as positive controls for the 
immunoreactivity of mAb (closed arrowheads). Representative tumor cells are depicted 
by open arrowheads. Original magnifications of200X (A) and 400X (B-H). 
"' /' J : ~~,.~- ·' .. < , ~~ 1ia' 
t 2 ~·· . ..... .... f "" J 
• J:.r .,. 
.,, , ,. I~~~ 
. .. j> .,.,. . ~
---r F ._ 
,e .s -· 
~ ~ . ~, . ., ~-• r -
' 
Jb- F tt...• ,_ • p 
• • , 
- -
.- ~ 
-
• 
/ ~. ~ ' • ,. 
l "~ .. - 7 ·-;; / ( <'-
r 
G H 
.~ 
'\, . 
• 
•• 
.. 
l 
132 
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4.1 ABSTRACT 
Studies aimed at elucidating the immunological and prognostic significance of 
HLA-DR expression on breast carcinoma cells have yielded contradictory results. To 
expand on previous studies, we have investigated the associations of tumor cell 
expression of HLA-DR and its related co-chaperones, invariant chain (Ii) and HLA-DM 
with infiltrating inflammatory cells, in situ cytokine mRNA levels and prognosis and 
outcome in 112 breast carcinoma patients with a median follow-up of 59 months. While 
the majority of HLA-DR+ tumors co-express Ii, only a minority express HLA-DM. 
Tumor cell expression of HLA-DR and co-chaperones positively associated with both 
infiltrating CD4+ and CD8+ T cell subsets (P<O.Ol). Expression of HLA-DR and Ii 
associated with decreased estrogen receptor alpha levels and younger age at diagnosis, 
suggesting a role for hormones in the control of HLA class II expression in breast 
carcinoma. Patients with DR+Ii+DM- tumors had markedly decreased recurrence-free 
and disease-specific survival as compared to patients with DR+Ii+DM+ tumors (P<0.05) 
and HLA-DR/co-chaperone expression was an independent predictor of survival by 
multivariate Cox regression analysis, controlling for standard prognostic indicators. 
Tumors that co-express HLA-DR, Ii and HLA-DM have increased levels of IFN-y, IL-2 
and IL-12 mRNA, suggesting improved survival of patients with DR+Ii+DM+ tumors 
may be attributable to THI dominated immunity. We conclude that expression of 
determinants of the immune response by tumor cells may influence breast tumor 
progression and patient outcome. 
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4.1 INTRODUCTION 
Successful anti-tumor immunity is dependent on CD4+ T cells, which recognize 
tumor peptides, presented by HLA class II antigens (HLA-DR, -DP, -DQ) [166, 167]. 
HLA class II antigen expression is generally restricted to professional antigen presenting 
cells (dendritic cells, macrophages, and B cells) and thymic epithelial cells, but HLA 
class II antigens are also expressed in a subset of benign and malignant breast tumors 
[146]. As HLA class II antigens are not normally present on resting breast epithelial cells, 
in the context of breast carcinoma HLA class II expression is likely dependent on the 
hormonal or cytokine milieu [134-136, 143, 230]. Several groups have demonstrated that 
HLA class II-positive tumor cells can induce an anti-tumor T cell response [138, 168, 
170]. Thus, one would expect to see a clear association between the two factors within 
breast carcinoma lesions, however, immunohistochemical studies attempting to relate the 
two have yielded discrepant results [145, 147, 162, 177]. 
Similarly, the prognostic implications of HLA class II expresswn on breast 
carcinoma cells remain unclear as some studies have reported HLA-DR expression on 
breast tumor cells associates with the favorable prognostic indicators of well 
differentiated tumors [147, 148] and hormone receptor expression [159], while others 
found no such relationships [146, 152]. The impact of HLA-DR expression on relapse-
free and disease-specific survival has also not been elucidated. Although HLA-DR 
expression associated with improved survival in a small subset of lymph node negative 
patients [155], most have reported no association [152, 156, 247]. 
These conflicting findings may be resolved by addressing other parameters of the 
anti-tumor immune response. The aforementioned studies investigated associations of 
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tumor cell HLA-DR expression with clinicopathological parameters, but did not address 
co-expression of the HLA class II co-chaperones invariant chain (Ii) and HLA-DM. Since 
Ii plays a critical role in HLA-DR trafficking [73], and HLA-DM facilitates peptide 
loading of HLA-DR molecules [66], discordant expression could have a detrimental 
effect on antigen-presentation of tumor peptides by HLA-DR+ tumor cells. To date, there 
are no published reports ofHLA-DM expression in breast carcinoma and two studies that 
examined co-expression of Ii and HLA class II found a greater subset of breast 
carcinomas expressed Ii than HLA-DR, followed by HLA-DP and HLA-DQ [146, 151]. 
In other carcinomas, high Ii expression is associated with poor prognosis and disease 
progression [160, 161], suggesting that Ii interferes with CD4+ T-cell recognition of 
endogenously-derived tumor peptides. This is supported by in vitro experiments in 
which HLA class 11-transfected tumor cells are unable to present tumor antigens to CD4+ 
T cells in the presence ofli [89, 138]. 
Previously, we showed an association between HLA-DR and Ii expression on 
breast carcinoma cells with CD3+ T-cell infiltration [248]. The effects of these factors on 
prognosis and outcome in breast carcinoma are expected to depend on the subsets of 
infiltrating inflammatory cells and the in situ cytokine milieu, which in tum influence 
class II expression on tumor cells and their ability to act as surrogate antigen presenting 
cells. Thus, in this study, we focused on the interrelationships of tumor cell expression of 
HLA-DR, Ii and HLA-DM with infiltrating cell subsets and prototypical THl (IFN-y, IL-
2, IL-12) and TH2/TH3 (IL-4, IL-10, TGF-f3) cytokine mRNA levels. These factors have 
been further evaluated for their associations with clinicopathological parameters and 
survival in invasive breast carcinoma patients. 
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4.3 MATERIALANDMETHODS 
4.3.1 Patient Sample 
One-hundred and twelve primary breast carcinoma lesions were obtained from the 
Manitoba Breast Tumor Bank (Winnipeg, Manitoba, Canada), with approval of the local 
Human Investigation Committees. Tumor type was known for 108 tumors, comprised 
mostly of infiltrating ductal (IDC, n=85), with 20 infiltrating lobular (ILC) and 3 mixed 
IDC+ILC. Tumors spanned a wide range of grade (grades 5-9), determined for 103 
tumors, using the Nottingham grading system [6] and were classified as I (score 5, n=15), 
II (scores 6-7, n=51) and III (scores 8-9, n=37). Tumor size was available for 109 tumors, 
categorized as small (<2 em, n=28) or large (>2 em, n=81). Clinical lymph node (LN) 
status was available for all but one patient, and 56 were LN+. One-hundred and eight 
tumors were staged according to AJCC guidelines [8], ofwhich 16 were Stage I, 71 were 
Stage II, 18 were Stage III and 3 were Stage IV. The age at diagnosis was available for all 
patients and ranged from 32 to 86 years (median 60 years; mean±SD = 59.3±14.5 years). 
Estrogen receptor (ER) and progesterone receptor (PR) levels were determined for all 
tumors by ligand binding assay and values ranged from 0 to 331 fmollmg (median 13.3 
fmol/mg; mean±SD = 35.4±57.7 fmol/mg) and 0 to 1088 fmol/mg (median 14.7 
fmol/mg; mean±SD = 59.6±138.0 fmol/mg), respectively. Using a cutoff for negativity of 
less than lOfmol/mg, 48 were ER- and 73 were PR-. Her-2/neu expression was assessed 
in 89 tumors, as described below, and 19 (21.3%) tumors over-expressed Her-2/neu. The 
median follow-up time was 59 months (mean±SD = 57±30 months; range 2-127 months), 
during which 34 patients died of breast cancer. The median time to recurrence was 51 
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months (mean±SD = 49.2±32.1 months), during which 45 patients experienced 
recurrences (32 distant, 8 regional and 5 distant+regional). 
Tumor samples were assessed by immunohistochemistry for HLA and co-
chaperone expression and infiltrating cells and RT-PCR for cytokine mRNA levels. In 
total, 77 tumors were examined by immunohistochemistry and RT-PCR, 27 were 
assessed by IHC only and 8 had only cytokine information. 
4.3.2 Monoclonal Antibodies 
Monoclonal antibodies (rnAbs) (spent supernatants) were used to detect generic 
HLA-class I (W6/32, 1:150, ATCC, Manassas, VA, USA) and HLA-DR (L243, 
2.4J..Lg/ml, ATCC). Commercially available rnAb (BD Biosciences Pharmingen, 
Mississauga, ON, Canada) were used to detect Ii chain (clone LN2, 2.5J.tg/ml), HLA-DM 
(clone MaP.DM1, 2.5J.tg/ml), Her-2/neu (clone CBll, 1/100; clone N12, 2J.tg/ml, 
Neomarkers, Quebec, Canada) and infiltrating CD3+ (clone UCHT1, 2.5J.tg/ml, 
Pharmingen), CD4+ (clone RPA-T4, 0.625J.tg/ml, Pharmingen), CDS+ (clone HIT8a, 
0.625J.tg/ml, Pharmingen), CD20+ (clone HI(FB1), 2.5J.tg/ml, Pharmingen), and CD68+ 
(clone EBMll, 2.15J.tg/ml, DakoCytomation, Mississauga, ON, Canada) cells. Tumor 
cells were identified using anti-cytokeratin mAb (clone AE1/AE3, SJ.tg/ml, 
DakoCytomation). Negative controls consisted of isotype matched non-specific mouse 
immunoglobulins (Southern Biotechnology Associates, Inc., Birmingham, AL, USA). 
4.3.3 Immunohistochemistry 
Serial frozen sections (8 J..Lm) were fixed in acetone for 10 minutes at -20°C, 
shipped from the Manitoba Breast Tumor Bank and stored at -70°C until 
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immunohistochemical staining. After thawing, drying and rehydrating in phosphate 
buffered saline (PBS) (pH 7.4), sections were treated with 1.5% hydrogen peroxide in 
PBS for 30 minutes to remove endogenous peroxidases, and nonspecific binding was 
blocked with 15% goat serum in PBS for 1 hour. Sections were incubated for 1 hour with 
primary antibody followed by incubation for 30 minutes with goat anti-mouse DAKO 
EnVision horseradish peroxidase labeled polymer (DAKO Diagnostics Canada Inc., 
Mississauga, ON, Canada). Antibody binding was visualized by incubating with 
diaminobenzidine + hydrogen peroxide (Sigma, Oakville, ON, Canada) for 5 minutes. 
The reaction was stopped with water and sections were counterstained in Mayer's 
hematoxylin. Infiltrating mononuclear cells served as intrinsic positive controls for the 
immunoreactivity of the monoclonal antibodies. Hematoxylin and eosin staining was 
performed on one section for each breast carcinoma and samples where tumor cells 
comprised <10% ofthe section area were excluded from analysis. 
4.3.4 Immunohistochemistry Interpretation 
All slides were coded and independently examined by two readers, in the absence 
of information on prognostic parameters and HLA class II alleles. The percentage of 
tumor cells expressing HLA-DR, Ii and HLA class I was coded based on comparison to 
expression levels on inflammatory cells within the same tissue section: - (0-24% tumor 
cells positive);-/+ (25-49% tumor cells as strong as inflammatory cells or 25-74% tumor 
cells weaker than inflammatory cells);+ (50-100% tumor cells as strong as inflammatory 
cells or 75-100% tumor cells weaker than inflammatory cells). Since DR and Ii are not 
normally expressed on breast epithelial cells, for categorical analysis samples with DR or 
Ii up regulated in at least 25% of tumor cells (Codes -/+ and +) were classified as 
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positive. As HLA-DM was expressed at much lower levels than HLA-DR or Ii on 
infiltrating inflammatory cells and tumor cells, we used a cutoff value of 10% for HLA-
DM expression. For HLA class I, only those coded+ were considered positive as samples 
coded - or -/+ were considered to have a substantial down regulation of HLA class I. 
Likewise, only the percentage of tumor cells strongly positive for HLA class I was used 
for continuous variable analysis while total percentage of tumor cells positive (weak or 
strong) was included for HLA-DR, Ii and HLA-DM. 
Infiltrating CD3+, CD4+, and CDS+, CD20+, and CD68+ cells were coded based 
on examination of the entire section and estimation of relative numbers: - (no or a few 
scattered cells); -/+ (small numbers of scattered cells or occasional small aggregates); + 
(moderate numbers of scattered cells, numerous small aggregates or occasional large 
aggregates); ++ (large numbers of scattered cells or several large aggregates). 
Tumor cell expression of Her-2/neu was determined in 89 tumors and coded as 0 
(<10% with membrane staining), 1+ (~ 10% with weak, incomplete membrane staining), 
2+ (~ 10% with weak to moderate complete membrane staining) or 3+ (~ 10% with 
strong complete membrane staining). As some tumors coded 2+ by IHC will not show 
gene amplification by fluorescent in situ hybridization [249], only those tumors coded 3+ 
were considered clinically positive for statistical analysis. 
4.3.5 RNA extraction, and semi quantitative RT-PCR 
Total RNA was isolated from breast tumor tissues by homogenization using 
Trizol reagent (Gibco BRL, Rockville, MD), followed by treatment with DNA-free 
reagent (Ambion, Austin, TX) to remove any contaminating DNA. Reverse transcription 
was performed on 1 J...tg RNA using the First Strand eDNA Synthesis Kit (Pharmacia 
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Biotech, Quebec, Canada). PCR was performed usmg a Biometra T Gradient 
thennocycler (Montreal Biotech Inc., Quebec, Canada) to amplify eDNA using primer 
pairs synthesized by Gibco BRL. Primer sequences and product sizes are described in 
Table 4.1 and included P-actin [251], IFN-y, IL-2, IL-4, IL-10, IL-12 [252] and TGF-Pl 
[254]. All PCR reactions were performed in a volume of 50J..lL with 200J..lM dNTPs 
(Gibco BRL) and lj.tL eDNA. PCR buffer contained 20mM Tris-HCl (pH 8.4) and 
50mM KCI. Samples containing water instead of test eDNA were included as 
contamination controls and eDNA from the cell lines Jurkat E6-1 (IL-2, IL-4, IL-10, 
TGF-p), C10/MJ (IFN-y) and YAR (IL-12) were used as positive controls. Primers were 
used at concentrations of20pM for P-actin and lOpM for all others. MgCh (Gibco BRL) 
concentration was 1.5mM for P-actin and IL-4 and 2mM for all other reactions. 0.2J..lL of 
Taq DNA polymerase (Gibco BRL) was used for P-actin reactions, all others used 
0.25J..lL. Reaction mixtures were amplified for 35 cycles of denaturation at 94°C for 1 
min, annealing for 1 min at 55°C (IFN-y and IL-2) or 65°C (all others), and extension at 
72°C for 1 min, followed by a separate 5 min extension step at 72°C. The intensity of 
amplified products was semi-quantified and normalized as a percent of P-actin using the 
Chemilmager 4000 with Alphaease 4.0 Software (Alpha Innotech Corporation, San 
Leandro, CA). 
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Table 4.1: Primer sequences for detection of cytokine mRNA in breast carcinoma 
lesions. 
Product GenBank 
Sense Primer (5'-3') Anti-·sense Primer (5'-3') Size Accession 
(bQ} Number* 
ATC TGG CAC CAC CGT CAT ACT CCT 
{3-Actin ACC TTC TAC AAT GCT TGC TGA TCC 840 NM 005159 
GAGCTGCG ACATCTGC 
IFN-y AGT TAT ATC TTG ACC GAA TAA TTA 356 J00219 GCTTTTCA GTCAGCTT 
IL-2 ACT CAC CAG GAT AGG TAA TCC ATC 269 HSU25676 GCTCACAT TGTTCAGA 
IL-12 CCA AGA ACT TGC TGG GTC TAT TCC 355 NM 002187 AGCTGAAG GTTGTGTC 
CCT CTG TTC TTC CCA ACG TAC TCT 
IL-4 CTG CTA GCA TGT GGT TGG CTT CCT 371 M23442 
GCC TCA 
ATG CCC CAA GCT TCT CAA GGG GCT 
IL-10 GAG AAC CAA GAC GGG TCA GCT ATC 352 NM 000572 
CCA CCA 
TGF-{3 GCC CTG GAC ACC AGG CTC CAA ATG 165 X02812.1 AACTATTGC TAGGGGCAGG 
*All primer sequences were validated using published GenBank mRNA sequences. 
4.3.6 Statistical Analysis 
Contingency tables were analyzed using Pearson's chi-square test or Fisher's 
exact test for 2x2 tables when at least one expected count was :$; 5 (two-sided). Non-
parametric Mann-Whitney (2 category variables) and Kruskal-Wallis ( ~ category 
variables) tests were used when assessing statistical significance of continuous variables, 
which were not normally distributed by Kolmogorov-Smirnov test. One-way analysis of 
variance and Fisher's least significant difference post hoc test were used to assess 
diagnosis age, which was normally distributed. 
142 
Survival estimates were calculated using Kaplan-Meier method with log-rank 
statistic. Ninety-five percent confidence intervals (95% CI) around 5-year percent 
survival estimates were calculated using the standard error (SE) of the cumulative 
survival probability (95%CI = cumulative survival probability ±1.96 X SE). Estimates 
were calculated as time to regional or distant metastasis for recurrence-free survival 
(RFS), time to distant metastasis for distant recurrence-free survival (dRFS) and time to 
death from breast cancer for disease specific survival (DSS). For DSS, patients who died 
of other causes were censored from analysis at time of death. Cox proportional hazards 
models were constructed for multivariate survival analyses using backward stepwise 
method. No patients were lost to follow-up and patients not experiencing the event were 
censored at the time of last follow-up or at 5 years for 5-year survival. For survival 
analysis, normalized cytokine units were stratified into high and low categories by 
comparing the 4th quartile to the 1 st_3rd quartiles. For multivariate analysis, correlation 
matrices were constructed to ensure lack of collinearity of covariates. All analysis was 
performed using SPSS Version 11.5 statistical software. 
4.4 RESULTS 
4.4.1 Tumor cells discordantly express HLA-DR and co-chaperones in breast 
carcinoma samples 
HLA-DR and Ii were assessed in 104/112 tumors and HLA-DM was assessed in 
102/112. Following exclusion of samples containing <10% tumor cells, information on 
HLA-DR/Ii and HLA-DM expression was available for 99 and 97 tumors, respectively. 
Using categorical classification, there were 36 HLA-DR+ (mean ± standard deviation 
- - -(x%) = 75±23.4%), 63 HLA-DR- (x% = 1.3±4.1%), 51 Ii+ (x% = 78.6±24.3%), 48 Ii-
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- - -(x% = 2±5.3%), 9 HLA-DM+ (x% = 28.9±14.5%), and 88 HLA-DM- (x% = 0±0%) 
tumors. Positive associations were observed between tumor cell expression of HLA-DR 
and Ii (x2=47.3, P<O.OOl), HLA-DM and HLA-DR (Fisher's exact test, P<O.OOl) and 
HLA-DM and Ii (Fisher's exact test, P=0.003) (not depicted). In total, 46 were DR-Ii-
DM-, 9 co-expressed all three antigens and discordant expression was observed in 42 
tumors with 25 DR+Ii+DM-, 1 DR+Ii-DM-, and 16 DR-Ii+DM-. Representative 
examples of breast tumor cells with the aforementioned HLNco-chaperone phenotypes 
are depicted in Figures 4.1A-D. As an indirect measure of integrity of the HLA loci, 
tumor cell expression of generic HLA class I antigens was determined. Comparison of 
the percentage of tumor cells with strong HLA class I expression within HLA-DR/co-
chaperone expression categories revealed decreased HLA class I in both HLA-DR-
categories (Figure 4.2A), suggesting a negative effect on the HLA complex in HLA-DR-
tumors. 
4.4.2 HLA-DR and co-chaperone expression associates with a THl cytokine profile 
in breast carcinomas 
Tumor cell expression of HLA-DR, Ii and HLA-DM positively associated with 
infiltrating CD3+, CD4+ and CD8+ T cells (Figure 4.2B-D) but did not significantly 
differ with respect to infiltrating CD20+ and CD68+ cell numbers (Figure 4.2E-F). All 
tumors that co-express HLA-DR and co-chaperones contain infiltrating CD3+ T cells 
comprised of both CD4+ and CD8+ T cell subsets (Figure 4.3A and representative 
example depicted in Figure 4.1B). Tumor infiltrating T cell populations associate with 
both TH1 and TH2 cytokine mRNAs in invasive breast carcinoma (Oldford et al., 
manuscript in preparation, Chapter 5). Thus, relative amounts of T H 1 and T H2/T H3 
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Figure 4.1: Representative immunohistochemistry examples of breast tumor cell 
expression patterns of HLA-DR, Ii and HLA-DM and tumor infiltration by CD4+ and 
CD8+ TIL. Indirect immunohistochemistry using monoclonal antibodies (mAb) against 
HLA class I (mAb W6/32), HLA-DR (mAb L243), Ii (mAb LN2), HLA-DM (mAb 
MaP.DMl), CD4+ TIL (mAb RPA-T4) and CD8+ TIL (mAb HIT8a) was performed on 
acetone-fixed breast carcinoma tissue sections. Staining with IgG isotype control 
antibodies served as a negative control. Hematoxylin and eosin (H&E) staining illustrates 
invasive ductal morphology. Infiltrating inflammatory and stromal cells served as 
positive controls for the immunoreactivity of mAb. (closed arrowheads). Representative 
tumor cells are depicted by open arrowheads. A) Breast tumor cells lack expression of 
HLA-DR, Ii and HLA-DM and the tumor contains a paucity ofCD4+ and CDS+ TIL. B) 
Breast tumor cells co-express HLA-DR, Ii and HLA-DM and CD4+ and CDS+ cells were 
detected in and around tumor nests. C) Breast tumor cells co-express HLA-DR and Ii but 
lack expression of HLA-DM and CD4+ and CDS+ cells were detected in and around 
tumor nests. D) Breast tumor cells express the co-chaperone Ii but fail to express HLA-
DR and HLA-DM and CD4+ and CDS+ cells were detected in and around tumor nests. 
Original magnifications of lOOX (H&E) and 200X (all others). 
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Figure 4.2: Associations of tumor cell HLA-DR and co-chaperones with HLA class I 
expression and infiltrating cells. A) HLA-class I expression is decreased in HLA-DR 
negative tumors. Chi-square and P-value in upper right comer corresponds to comparison 
of all groups using Kruskal-Wallis H test. Asterisks indicate significance in comparison 
to DR+Ii+DM+ tumors determined using Mann-Whitney U test (*P<0.05, ** P<O.Ol). 
B-F) Associations of infiltrating inflammatory cells with tumor cell expression ofHLA-
DR and co-chaperones in breast carcinoma were assessed using Kruskal-Wallis H test. B) 
Infiltrating CD3+ cells associated with tumor cell expression of HLA-DR (P=0.0003), Ii 
(P=0.0008) and HLA-DM (P<O.OOOl). (C) Infiltrating CD4+ cells associated with tumor 
cell expression of HLA-DR (P=0.0012), Ii (P=0.0005) and HLA-DM (P=O.Ol). (D) 
Infiltrating CD8+ cells associated with tumor cell expression ofHLA-DR (P=0.0024), Ii 
(P=0.0018) and HLA-DM (P=0.007). (E) Infiltrating CD20+ did not significantly 
associate with tumor cell HLA-DR (P=0.391), Ii (P=O.l59) or HLA-DM (P=O.l79) 
expression. Only one tumor contained large numbers of CD20+ cells so moderate and 
large numbers were grouped for comparison. (F) Infiltrating CD68+ cells did not 
significantly associate with tumor cell HLA-DR (P=O.l68), Ii (P=0.056) or HLA-DM 
(P=0.384) expression. 
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cytokine mRNAs were compared in tumors stratified by HLA-DR/co-chaperone 
expression. All DR+Ii+DM+ tumors had detectable IFN-y, IL-2 and IL-12 mRNA 
(Figure 4.3B) and levels of these THl cytokines were significantly increased in 
DR+Ii+DM+ tumors as compared to tumors that lack expression of one or more 
molecules (Figure 4.3C). The prototypical TH2/TH3 cytokines, IL-4, IL-10 and TGF-J3, 
did not significantly differ between expression categories (data not shown). 
4.4.3 Associations of tumor cell HLA class II and co-chaperone expression with 
prognostic indicators in breast carcinoma patients 
The clinical significance of tumor cell expression of HLA-DR and co-chaperones 
was assessed by examining associations with prognostic parameters. The age at diagnosis 
was decreased in patients with HLA-DR+ tumors, as compared HLA-DR- tumors (Figure 
4.4A). Tumors that express HLA-DR and Ii in the absence ofHLA-DM had significantly 
lower ER expression as compared to DR-Ii-DM- (Figure 4.4B). Likewise, ER-negative 
- -
tumors had increased HLA-DR (ER-: x% = 37.4±39.8% vs ER+: x% = 20.9±36.1%; 
- -
P=0.021) and Ii (ER-: x% = 54.5±43.0% vs ER+: x% = 31.4±39.4%; P=0.003) 
expression (not depicted). Expression categories did not significantly associate with PR, 
tumor grade, tumor stage, tumor size, LN status or Her-2/neu over-expression (Figure 
4.4C-F and data not shown). Although HLA-DR/co-chaperone expression categories did 
not associate with tumor differentiation, the percentage of tumor cells expressing Ii 
- -
positively associated with tumor grade (Grade 1: x% = 25.4±38.8%; Grade II: x% = 
39.7±42.2%; Grade III: ~% = 53.3±42.9%; Kruskal Wallis x2=6.6 P=0.036, not 
depicted). 
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Figure 4.3: Association of tumor cell HLA-DR/co-chaperone expression categories with 
infiltrating T cells and cytokines in invasive breast carcinoma. (A) Co-expression of 
HLA-DR, Ii and HLA-DM by tumor cells associates with increased numbers of CD3+ 
(x2=37.9, P<0.0001), CD4+ (x2=25.4, P=0.003), and CDS+ (x2=23.1, P=0.006) 
infiltrating cells. (B) All DR+Ii+DM+ breast tumors have detectable IFN-y, IL-2 and IL-
12 mRNA. RT-PCR was carried out using total RNA (1 )lg) prepared from fresh-frozen 
breast carcinoma tissue. ~-actin was amplified to confirm the integrity of the eDNA. 
Bands are representative of 1-3 RT-PCR reactions. Cell lines were used as positive 
controls for all RT-PCR reactions. (C) Tumors that co-express HLA-DR, Ii and HLA-
DM have increased IFN-y (x2=11.0, P=0.012), IL-2 (x2=7.4, P=0.060) and IL-12 (x2=9.1, 
P=0.028). Relative amounts of cytokine mRNA were normalized to ~-actin and averaged 
for each breast carcinoma sample. Chi-square and P-value in upper right comer 
corresponds to comparison of all three groups using Kruskal-Wallis H test. Asterisks 
indicate significance in comparison to DR+Ii+DM+ tumors determined using Mann-
Whitney U test (*P<0.05, **P<0.01). 
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Figure 4.4: Association oftumor cell HLA-DR/co-chaperone expression categories with 
prognostic parameters. A) Diagnosis age is decreased in patients with DR+Ii+DM+ and 
DR+Ii+DM- tumors. B) DR+Ii+DM- tumors have significantly decreased ER levels as 
compared to DR-Ii-DM- tumors. Tumor cell HLA-DR/co-chaperone expression 
categories did not significantly associate with PR levels (C), tumor differentiation (D), 
tumor stage (E) or Her-2/neu over-expression (F). F statistic or Chi-square and P-value in 
upper right comer correspond to comparison of all four groups using Kruskal-Wallis H 
test (:x,2) or one way analysis of variance (F-statistic). Asterisks and P-values indicate 
significance in comparison to DR-Ii-DM- tumors determined using Mann-Whitney U test 
for ER and Her-2/neu, and Fisher's least significant difference test for diagnosis age 
(*P<O.OS, **P<O.Ol). 
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4.4.4 Tumor cell co-expression of HLA-DR and HLA-DM predicts improved 
patient survival 
Kaplan-Meier survival analysis was performed to assess whether expression of 
HLA-DR or HLA class II co-chaperones associated with recurrence-free survival (RFS), 
distant RFS (dRFS) or disease-specific survival (DSS). As there was no significant 
difference in survival between Ii+ or Ii- tumors that did not express HLA-DR (DR-Ii-
DM- vs DR-Ii+DM-: LR=0.7, P=0.393 (RFS); LR=0.4, P=0.552 (dRFS); LR=0.5, 
P=0.461(DSS)), the two subsets were grouped for analysis. Patients with DR+DM+ 
tumors had prolonged RFS (Figure 4.5A), dRFS (Overall: LR=9.3, P=0.009; 5yr: 
LR=9.8, P=0.007, not depicted) and DSS (Figure 4.5B), while those with DR+DM-
tumors had the shortest time to recurrence or breast cancer specific death. Infiltrating cell 
populations did not associate with breast carcinoma patient survival (data not shown). 
However, significant differences in patient survival were observed when tumors were 
stratified using quartile cut points for cytokine mRNA levels. Patients with tumors 
containing high amounts of IFN-y mRNA had prolonged RFS (Figure 4.5C) and dRFS 
(Overall: LR=4.2, P=0.041; 5yr: LR=4.2, P=0.041, not depicted). Patients with high 
IFN-y mRNA levels also had improved DSS although the difference was not statistically 
significant (Figure 4.5D). Patient survival did not differ in patients stratified by levels of 
IL-2, IL-12, IL-4, IL-10, or TGF-~ mRNA (data not shown). 
Cox proportional hazards models were constructed to determine if co-expression 
of HLA-DR and HLA-DM was an independent predictor of improved survival (Table 
4.2). Cox regression models also contained treatment, tumor type, TNM stage, estrogen 
receptor, progesterone receptor, age at diagnosis and Her-2/neu status. Although 
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Figure 4.5: Association of tumor cell HLA-DR/co-chaperone expression and IFN-y 
rnRNA levels with patient survival. A) Patients with tumors that co-express HLA-DR, Ii 
and HLA-DM have improved recurrence-free survival as compared to patients with 
tumors that express HLA-DR and Ii in the absence of HLA-DM (5-yr % survival 
(95%CI) = 89% (68%-100%) for patients with DR+Ii+DM+ tumors, 39% (20%-59%) for 
patients with DR+Ii+DM- tumors and 58% (44%-71%) for patients with HLA-DR-
tumors). B) Patients with tumors that co-express HLA-DR, Ii and HLA-DM have 
improved disease-specific survival as compared to patients with tumors that express 
HLA-DR and Ii in the absence of HLA-DM (5-yr % survival (95%CI) = 89% (68%-
100%) for patients with DR+Ii+DM+ tumors, 51% (31%-71%) for patients with 
DR+Ii+DM- tumors and 72% (60%-84%) for patients with HLA-DR- tumors). (C) 
Patients with tumors containing high IFN-y mRNA levels have improved RFS (5-yr % 
survival (95%CI) = 71% (49%-93%) for patients with high IFN-y, 48% (35%-61 %) for 
patients with low IFN-y). (D) Patients with tumors containing high IFN-y rnRNA levels 
display a trend for increased DSS (5-yr % survival (95%CI) = 82% (63%-100%) for 
patients with high IFN-y, 60% (48%-73%) for patients with low IFN-y). Log rank (LR) 
statistic and P-value in upper right comers correspond to overall comparison, LR and P-
value for 5-year survival rates are indicated on graph. 
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histological tumor grade significantly associated with tumor type, LN, ER, PR and 
diagnosis age, it was not associated with overall or 5-year RFS, dRFS or DSS (Appendix 
II). Therefore, grade was not included in the multivariate models as the dependence 
among the covariates made the parameter estimates indeterminate resulting in a lack of 
coefficient convergence. When controlling for the above prognostic factors, tumor cell 
HLA-DR/DM expression was an independent predictor of RFS (P=0.001), dRFS 
(P=0.001) and DSS (P=0.031). Tumor stage, PR and Her-2/neu status were also 
independent predictors for RFS and dRFS, while PR expression independently predicted 
DSS. Similar results were obtained for 5-year survival models (data not shown). 
As fewer samples had information on cytokine mRNA, separate multivariate 
models were constructed to test the ability of IFN-y to independently predict patient 
survival. When controlling for the aforementioned clinicopathological parameters, high 
IFN-y displayed only a trend for improved RFS (at step 1: HR(95%CI)=0.38(0.12-1.21), 
P=0.101) and dRFS (at step 1: HR(95%CI)=0.33(0.09-1.23), P=0.099) and did not 
associate with DSS (at step 1: HR(95%CI)=0.32(0.06-1.74), P=0.188) (data not shown). 
4.5 DISCUSSION 
This study was aimed at investigating relationships of tumor cell expression of 
HLA-DR and the co-chaperones, Ii and HLA-DM with immune cell infiltration, the 
intratumoral cytokine profile and prognosis and outcome in breast carcinoma patients. 
HLA-DR, Ii and HLA-DM are typically coordinately regulated by the HLA class II 
transactivator (CIITA) [99], however, discordant expression by tumor cells was observed. 
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Table 4.2: Multivariate Cox Proportional Hazards regression models using backward 
stepwise method 
Variables RFS dRFS DSS 
remaining at last HR HR HR 
p p p 
stept (95%CI) t (95% CI) (95%CI) 
PR <10 fmol/mg 2.29 2.63 3.86 
0.037 0.025 0.003 
(vs ~10fmol/mg) ( 1.05-4.97) (1.13-6.15) (1.57-9.51) 
TNM Stage III/IV 3.03 3.02 2.47 
0.005 0.013 0.070 
(vs Stage 1111) (1.41-6.52) (1.26-7.23) (0.93-6.53) 
Her-2/neu Code 3 2.49 2.71 
0.017 0.020 ns 
(vs Codes 0-2) (1.18-5.25) ( 1.17 -6.25) 
DR/DM category 
0.001 0.001 0.031 
DR+DM- Reference Reference Reference 
0.07 0.07 0.12 
DR+DM+ 0.010 0.014 0.045 
(0.0 1-0.52) (0.01-0.58) (0.01-0.95) 
0.37 0.31 0.53 
DK 0.010 0.005 0.143 
(0.18-0. 79) (0.14-0.69) (0.23-1.24) 
Model x2 at last 22.6 21.8 15.8 
step (P-value) (<0.001) (0.001) (0.003) 
# events/# at risk 35/82 28/82 25/82 
t All regression models controlled for treatment, tumor type, ER, PR, diagnosis age, TNM stage and Her-
2/neu expression status. 
t Hazards ratio (95% confidence interval for hazards ratio) 
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Within HLA-DR+ tumors, 97% co-expressed Ii but only 26% were HLA-DM+. 
The underlying mechanisms responsible for discordant expression of HLA-DR and co-
chaperones are currently unclear. Ii expression in the absence ofHLA-DR and HLA-DM 
is likely attributable to CUT A independent transcription of Ii, owing to unique cis acting 
elements found within the Ii promoter [ 113]. Thus, trans-acting factors produced during 
tumorigenesis may facilitate Ii expression, possibly explaining the positive association of 
tumor cell Ii expression with increased histological grade of differentiation. Tumor cell 
expression ofHLA-DM did not occur independently ofHLA-DR or Ii and was observed 
only in those tumors with high levels of the THl cytokines IFN-y, IL-2, and IL-12. 
Discordant HLA-DM expression in HLA-DR+ tumors may be due to regulatory defects 
in HLA-DM since its promoters contain additional cis acting elements not shared by 
HLA class II or Ii promoters [112]. As such, additional trans-acting regulatory factors 
may be necessary for HLA-DM transcription. In support of this, the kinetics ofHLA-DM 
induction on synovial fibroblast lines is much slower than that of HLA-DR or Ii, in 
response to IFN-y treatment [267]. 
Discordant HLA-DM expression in the majority of HLA-DR+ tumors may also 
reflect a tumor escape mechanism similar to that reported for regulatory defects in HLA 
class I antigen processing machinery in breast carcinoma cell lines (BCCL). Down-
regulated immunoproteasome subunits LMP-2, LMP-7, LMP-10 and transporter 
associated with antigen processing (TAP)-1 and TAP-2 molecules were documented in 
BCCL, and these defects could be restored via IFN-y treatment [229]. Thus, if regulatory 
mutations are present and cause negative HLA-DM expression, they may be overcome in 
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the presence of high levels of intratumoral IFN-y. In support of this all DR+Ii+DM+ 
tumors had detectable IFN-')' and relative levels were significantly higher than in tumors 
that lack expression of HLA-DM. We have observed, high dose IFN-y treatment 
(500U/ml for 96hr) up-regulates HLA-DM protein expression in a majority of breast 
carcinoma cell lines (7/11 tested), and HLA-DM induction by IFN-y is clearly dose-
dependent (Oldford, Edgecombe and Drover, unpublished observations). 
The negative association of HLA-DR and Ii expression with ER suggests that ER 
may negatively modulate HLA class II expression in breast carcinoma. Furthermore, the 
decreased age at diagnosis of patients with HLA class II expressing tumors implies a role 
for circulating estradiol levels. This finding was intriguing as 17 {j-estradiol is known to 
negatively modulate HLA-DR expression. In particular, 17-13 estradiol inhibits IL-Ia and 
IL-lj3 induction ofHLA-DR in ER+ human endometrial and breast carcinoma cell lines 
in a dose dependent manner [135] and 17-13 estradiol can down-modulate constitutive and 
IFN-y induced MHC class II expression in a variety of murine and human cell types 
[262]. Its effects are independent of CIITA and involve ER binding to MHC class II 
promoters and activation of the c-Jun N-terminal kinase (JNK) pathway, leading to 
histone hypoacetylation and decreased association of CREB-binding protein (CBP) with 
the class II promoter [263]. Based on our findings we suggest that the down-modulatory 
effect of estradiol on HLA-DR expression may be overcome in ER- breast carcinoma 
cells. 
The association of tumor cell expression of Ii with a poor prognosis in this study 
and in other types of carcinoma [160, 161], is hypothesized to be due to inefficient 
presentation of endogenous tumor antigen derived peptides by HLA class II molecules. It 
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is plausible that induction of HLA-DM expression by tumor cells allows for efficient 
exchange of Ii for endogenous tumor antigen derived peptides that have transected the 
endocytic pathway. HLA-DM is important for the exchange of the class II associated Ii 
peptide (CLIP) for exogenous antigenic peptides [66, 82] and high levels of HLA-
DR/CLIP complexes are expressed by mutant B cells deficient in HLA-DM [81]. 
Similarly, we have observed increased surface HLA-DR/CLIP expression in a HLA-DM 
deficient breast carcinoma cell line as compared to HLA-DM expressing breast 
carcinoma cell lines (Oldford, Edgecombe and Drover, unpublished observations). Thus, 
improved survival of patients with DR+Ii+DM+ tumors over patients with DR+Ii+DM-
tumors may reflect differences in antigen presentation and the resulting T cell response. 
Indeed, experimental studies showed high levels of CLIP, whether exogenously added or 
endogenously expressed by antigen presenting cells (APC), modulated antigen-specific 
effector T cells, inducing a shift from TH1 to TH2 responses [125, 126]. Interestingly, 
other self-peptides did not have a polarizing effect on the effector CD4+ T H cell response. 
Meazza et al. (2003), showed CIITA transfected TS/A mammary adenocarcinoma 
cells strongly up-regulated MHC class II antigens and Ii and were rejected in syngeneic 
mice in a CD4+ T cell dependent manner [168]. Recently, Thompson et al. (2006) 
demonstrated human breast carcinoma cells transduced with CIITA are able to present 
endogenous Her-2/neu peptides and activate human CD4+ T cells to secrete high levels 
of IFN-'}', with or without siRNA suppression of Ii [268]. Although not investigated in 
either study, the improved immunogenicity of these tumor cells may be due to up 
regulation of DM, which is also transcriptionally controlled by CIITA [99], thereby 
allowing for efficient exchange of CLIP for endogenous tumor antigen peptides. Indeed, 
164 
high levels of CLIP on myeloid leukemia blast cells predicted poor patient survival and 
associated with decreased HLA-DM expression [269]. 
We can only speculate about the mechanism for HLA-DM expression association 
with improved patient survival. Possibly this association represents a bystander effect of 
high IFN-y produced by THl CD4+, CD8+ and/or NKT cells activated by tumor 
infiltrating antigen presenting cells (APC). Once HLA-DR and HLA-DM are up-
regulated on breast tumor cells, they may serve as efficient APC, driving the activation 
and cytokine production of THl CD4+ T cells, resulting in improved anti-tumor 
immunity and improved patient survival. In support of this, high levels of IFN-y 
associated with decreased time to recurrence by univariate analysis (Figure 4.4). Relative 
IFN--y mRNA levels did not independently predict patient survival in this study, possibly 
owing to the small sample size, but IFN--y is an independent predictor of survival in other 
solid tumors [270]. 
The intermediate survival of patients with HLA-DR- tumors may in part reflect 
the increased loss of HLA class I in HLA-DR- tumors (Figure 4.2). In a large study of 
439 breast carcinoma lesions, total loss ofHLA class I independently predicted improved 
patient survival [271], although not investigated, this may reflect enhanced NK cell 
recognition or increased susceptibility to apoptosis [247]. Decreased HLA class I 
expression in DR-Ii-DM- and DR-Ii+DM- tumors suggests a negative effect on 
chromosome 6p. Loss of heterozygosity (LOH) of chromosome 6p is likely to play a 
major role in the lack of HLA class II antigen expression, since this mechanism causes 
HLA class I haplotype loss in a high percentage of tumors and is frequently attributable 
to loss of an entire chromosome, as indicated by LOH at both 6p and 6q markers [238]. 
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This coupled with epigenetic mutations such as DNA methylation or histone 
deacetylation [229] likely explains the total loss ofHLA observed in these tumors. 
The results of this study suggest that coordinate expression of HLA-DR, Ii and 
HLA-DM by tumor cells is an indicator of improved prognosis in breast carcinoma. 
Furthermore, tumor cells that coordinately express HLA-DR and components of the HLA 
class II antigen processing machinery may function as effective antigen presenting cells, 
facilitating the induction of effective THl anti-tumor immunity. Investigations such as 
this provide improved understanding of the immune response to carcinomas and suggest 
targeting antigen processing aberrations may aid in the successful generation of specific 
immunotherapeutic approaches to cancer treatment. 
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5.1 ABSTRACT 
Breast carcinomas are frequently infiltrated by tumor infiltrating lymphocytes (TIL), 
which constitute the major source of immune-modulating cytokines. However, the 
prognostic significance of this infiltration remains unclear and is likely dependent on the 
balance of immunoregulatory and pro-inflammatory cytokines. To obtain a 
comprehensive evaluation of the in situ immune response we utilized 
immunohistochemistry to characterize the pattern of inflammatory cell infiltration and 
RT-PCR to determine the relative levels of intratumoral cytokine mRNA levels. As an 
indirect measure of immunoregulatory TIL, the Treg specific marker FOX-P3 was also 
assessed. The presence of TIL associated with decreased hormone receptor levels and 
earlier age at diagnosis, suggesting a role for circulating hormones in their recruitment 
and/or expansion. Invasive breast tumors with large TIL numbers contained elevated 
levels of THl, TH2, pro-inflammatory and immunoregulatory cytokines, demonstrating 
the existence of an integrated immune response within the tumor microenvironment. 
Patients with minor CDS+ TIL infiltration, exhibited low level THl cytokine production, 
elevated FOX-P3 mRNA and had decreased time to distant recurrence. In contrast, 
patients with large numbers of TIL had improved survival and demonstrated elevated 
levels of THl-type cytokines, which associated with decreased tumor diameter. Elevated 
TNF-a independently predicted patient survival, strengthened by an elevated TNF-
a:TGF-f31 ratio, demonstrating the prognostic significance of intratumoral TIL is 
dependent on the balance of pro-inflammatory and immunoregulatory cytokines. Future 
studies aimed at understanding the mechanisms of regulation of the anti-tumor immune 
response will aid in the development of immunotherapeutic regimes in breast carcinoma. 
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5.2 INTRODUCTION 
The majority of breast tumors contain an inflammatory infiltrate comprised 
mainly of macrophages and CD4+ and CDS+ T cells, with smaller numbers of B cells 
and a relative paucity of natural killer (NK) cells [174, 175]. Large numbers of CD68+ 
tumor associated macrophages (TAM) are generally associated with poor prognostic 
indicators such as high tumor grade and decreased hormone receptor expression [272, 
273]; however the prognostic significance of tumor infiltrating lymphocytes (TIL) in 
breast carcinoma is presently unclear. Several studies have failed to demonstrate an 
association of TIL with patient survival [187, 191, 192] and contradictory reports have 
been published with respect to associations of TIL with lymph node (LN) metastasis 
[154, 186], tumor stage [181, 185], histological grade [162, 181], and hormone receptor 
expression [ 181, 186]. 
Although discrepant reports on associations of immune cell infiltration in breast 
carcinoma with prognosis may in part be attributable to methodological variability, the 
location of infiltrating cell subsets within the tumor, the relative numbers of 
inflammatory cell subsets and their ensuing cytokine production, likely determine patient 
outcome. Indeed, the presence of intratumoral CD3+ TIL in ovarian carcinoma 
independently predicts progression-free and overall survival [193]. Likewise, the 
presence of CD8+ TIL at the invasive border of endometrial carcinoma independently 
predicts improved overall patient survival [274]. 
The effectiveness of the anti-tumor immune response is also dependent on the 
balance of effector and regulatory T cell (Treg) subsets as a high CD8+/CD25+FOX-P3+ 
Treg TIL ratio associates with improved survival in ovarian carcinoma patients [195]. 
169 
CD4+CD25+FOX-P3+ Treg, capable of in vitro and in vivo suppression of tumor antigen 
specific T -cell immunity are specifically recruited to ovarian tumors via CCL22 and high 
Treg numbers associate with decreased survival [275]. Recently, Wolf et al. (2005) 
demonstrated high bulk tumor FOX-P3 mRNA levels independently predicted poor 
progression-free and overall survival in ovarian cancer patients [276]. In breast 
carcinomas, a substantial proportion of CD4+ TIL exhibit a Treg phenotype 
(CD4+CD25+CTLA-4+CD45RO+) [184]. These T cells are elevated intratumorally and 
in the draining lymph nodes and peripheral blood and secrete interleukin (IL)-10 and 
transforming growth factor (TGF)-!3 but not interferon (IFN)-y in response to non-
specific stimulation, and suppress the proliferation and IFN-y secretion of non-
specifically activated CD4+CD25- and CDS+ in vitro [184]. 
Associations of TIL with prognosis in breast carcinoma have generally been 
investigated in the absence of information on intratumoral cytokine levels. The cytokine 
milieu of the tumor microenvironment is comprised of cytokines produced by tumor 
cells, stromal cells and infiltrating inflammatory cells. Tumor associated T cells are 
known to produce immune-modulating cytokines, in response to ex vivo stimulation and 
in situ in breast tumors [170, 188, 191, 196, 197], yet the clinical significance of cytokine 
production in breast carcinoma lesions and its relationship to immune cell infiltration 
have not been clearly elucidated [183, 199]. In this study we have characterized the 
pattern of immune cell infiltration in breast carcinomas and obtained immune profiles by 
assessing relative bulk tumor mRNA levels of the TH1-type cytokines (IL-2, IL-12 and 
IFN-y), TH2-type cytokine (IL-4), immunoregulatory cytokines (IL-10 and TGF-(31) and 
pro-inflammatory cytokines (IL-1(3, IL-6, and tumor necrosis factor (TNF)-a). The 
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presence of immunoregulatory T cells was indirectly determined by assessing FOX-P3 
mRNA levels. The interrelationships and clinical implications of these variables were 
determined to obtain a comprehensive evaluation of the in situ immune response m 
invasive breast carcinoma. 
5.3 MATERIALANDMETHODS 
5.3.1 Tumor samples and Study subjects 
One-hundred and twelve primary and 16 recurrent breast tumor lesions were 
randomly selected, based on tissue availability, from a larger sample with prognostic and 
outcome information, obtained from the Manitoba Breast Tumor Bank (MBTB) 
(Winnipeg, Manitoba, Canada), with approval of the local Human Investigation 
Committees. Tumor samples were assessed by immunohistochemistry (IHC) for immune 
cell infiltration and reverse-transcriptase polymerase chain reaction (RT-PCR) for 
cytokine and FOX-P3 mRNA levels. In total, 77 primary and 8 recurrent tumors were 
examined by immunohistochemistry and RT-PCR, 27 primary and 7 recurrent tumors 
were assessed by IHC only and 8 primary and one recurrent tumor had only RT-PCR 
information. A section of each tissue sample was stained with hematoxylin and eosin and 
following exclusion of samples where tumor tissue comprised < 10% of the section area, 
immunohistochemical information was available for 99 primary and 15 recurrent lesions. 
As several biological changes mark progression to metastatic disease, associations 
of immune cell infiltrate and relative mRNA levels with prognosis and survival were 
assessed for primary lesions only. Within the primary tumors, information on histological 
type was available for 108 tumors, of which most were infiltrating ductal (IDC, n=85), 
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with 20 infiltrating lobular (ILC) and 3 mixed IDC+ILC. Tumors spanned a wide range 
of grade (grades 5-9), determined for 103 tumors, using the Nottingham grading system 
[6] and were classified as I (score 5, n=l5), II (scores 6-7, n=51) and III (scores 8-9, 
n=37). Tumor size was available for 109 tumors, categorized as small (<2 em, n=28) or 
large (>2 em, n=81). Clinical lymph node (LN) status was available for all but one patient 
and 56 were LN+, with an average of 15 LN assessed per case (Mean± SEM = 14.9 ± 
1.5). One-hundred and eight tumors were staged according to AJCC guidelines [8], of 
which 16 were Stage I, 71 were Stage II, 18 were Stage III and 3 were Stage IV. The age 
at diagnosis was available for all patients and ranged from 32 to 86 years (median= 60 
years; mean±sd = 59.3±14.5 years). Estrogen receptor (ER) and progesterone receptor 
(PR) levels were determined by ligand binding assay for all primary tumors and values 
ranged from 0 to 331 fmol/mg (median= 13.3 fmol/mg; mean±sd = 35.4±57.7 fmol/mg) 
and 0 to 1088 fmol/mg (median = 14.7 fmol/mg; mean±sd = 59.6±138.0 fmol/mg), 
respectively. Using a cutoff for negativity of less than lOfmol/mg, 48 were ER- and 73 
were PR-. Her-2/neu expression was assessed in 89 tumors, as described below, and 19 
(21.3%) tumors over-expressed Her-2/neu. The median follow-up time was 59 months 
(mean±sd = 57±30 months; range 2-127 months), during which 34 patients died of breast 
cancer. The median time to recurrence was 51 months (mean±sd = 49.2±32.1 months; 
range 0-127 months), during which 45 patients experienced recurrences (32 distant, 8 
regional and 5 distant+regional). 
5.3.2 Monoclonal Antibodies 
Commercially available mAb (BD Biosciences Pharmingen, Mississauga, ON, 
Canada) were used to assess tumor cell expression of Her-2/neu (clone CBll, 1/100; 
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clone N12, 2!-lg/ml, Neomarkers, Quebec, Canada) and infiltrating CD3+ TIL (clone 
UCHT1, 2.5J,tg/ml, Pharmingen), CD4+ TIL (clone RPA-T4, 0.625!-lg/ml, Pharmingen), 
CD8+ TIL (clone HIT8a, 0.625J,tg/ml, Pharmingen), CD20+ B lymphocytes (clone 
HI(FB1), 2.5J,tg/ml, Pharmingen), CD56+ NK cells (clone Bl59, 2.5J.tg/ml, Pharmingen) 
and CD68+ TAM (clone EBMll, 2.15J,tg/ml, DakoCytomation, Mississauga, ON, 
Canada) cells. Tumor cells were identified using anti-cytokeratin mAb (clone AE1/AE3, 
5J..tg/ml, DakoCytomation). Negative controls consisted of isotype matched non-specific 
mouse immunoglobulins (Southern Biotechnology Associates, Inc., Birmingham, AL, 
USA). 
5.3.3 Immunohistochemistry 
Serial frozen sections (8 J.tm) were fixed in acetone for 10 minutes at -20°C, 
shipped from the MBTB and stored at -70°C until immunohistochemical staining. After 
thawing, drying and rehydrating in phosphate buffered saline (PBS) (pH 7.4), sections 
were treated with 1.5% hydrogen peroxide in PBS for 30 minutes to remove endogenous 
peroxidases, and nonspecific binding was blocked with 15% goat serum in PBS for 1 
hour. Sections were incubated for 1 hour with primary antibody followed by incubation 
for 30 minutes with goat anti-mouse DAKO EnVision horseradish peroxidase labeled 
polymer (DAKO Diagnostics Canada Inc., Mississauga, ON, Canada). Antibody binding 
was visualized by incubating with diaminobenzidine and hydrogen peroxide (Sigma, 
Oakville, ON, Canada) for 5 minutes. The reaction was stopped with water and sections 
were counterstained in Mayer's hematoxylin. Hematoxylin and eosin staining was 
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performed on one section for each breast carcinoma and samples where tumor cells 
comprised <10% of the section area were excluded from analysis. 
5.3.4 Immunohistochemistry Interpretation 
All slides were coded and independently examined by two readers, in the absence 
of information on prognostic parameters. Infiltrating CD3+, CD4+, CDS+, CD20+, 
CD56+ and CD68+ cells were coded based on estimated numbers: - (no or a few 
scattered cells); -/+ (small numbers of scattered cells or occasional small aggregates); + 
(moderate numbers of scattered cells, numerous small aggregates or occasional large 
aggregates); ++ (large numbers of scattered cells or several large aggregates). As the 
CD4 antigen is also expressed at lower levels on macrophages, to ensure CD4+ TIL 
specific coding, sections stained with anti-CD4 were compared to anti-CD3 and anti-
CD68 stained sections. The patterns of immune cell infiltrate were recorded as focal (F) 
and/or diffuse (D) and the relative proportion of infiltrating CD3+ TIL and CD68+ TAM 
located intratumorally within tumor nests or within tumor stroma was also assessed. 
Tumor cell expression of Her-2/neu was determined in 89 primary and 13 
recurrent tumors and coded as 0 (<10% with membrane staining), 1+ (;;::: 10% with weak, 
incomplete membrane staining), 2+ (;;::: 10% with weak to moderate complete membrane 
staining) or 3+ (;;::: 10% with strong complete membrane staining). As some tumors coded 
2+ by IHC will not show gene amplification by fluorescent in situ hybridization [249], 
only those tumors coded 3+ were considered clinically positive for analysis. 
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5.3.5 RNA extraction, and semi quantitative RT -PCR 
Total RNA was isolated from breast tumor tissues by homogenization using 
Trizol reagent (Gibco BRL, Rockville, MD), followed by treatment with DNA-free 
reagent (Ambion, Austin, TX) to remove any contaminating DNA. Reverse transcription 
was performed on 1 ).lg RNA using the First Strand eDNA Synthesis Kit (Pharmacia 
Biotech, Quebec, Canada). PCR was performed using a Biometra T Gradient 
thermocycler (Montreal Biotech Inc., Quebec, Canada) to amplify eDNA using primers 
described in Supplementary Table 5S1. All PCR reactions were performed in a volume of 
50 J.lL with 200).lM dNTPs (Gibco BRL) and 1 J.lL eDNA. PCR buffer contained 20mM 
Tris-HCl (pH 8.4) and 50 mM KCI. Samples containing water instead of test eDNA were 
included as contamination controls and eDNA from the cell lines Jurkat E6-1 (CD3, IL-2, 
IL-4, IL-10, TGF-J3), C10/MJ (IFN-y, IL-6, FOX-P3), U937 (TNF-a, IL-1J3) andY AR 
(IL-12) were used as positive controls. Primers were synthesized by Gibco BRL and 
included J3-actin [251], CD3, IFN-y, IL-2, IL-4, IL-6, IL-10, IL-12, TNF-a [252], IL-1J3 
[253], TGF-J31 [254] and FOX-P3 [255]. Primers were used at concentrations of 20 pM 
for J3-actin, IL-1J3, IL-6, TNF-a and FOX-P3 and 10 pM for all others. MgClz (Gibco 
BRL) concentration was 1.5 mM for J3-actin, IL-4 and FOX-P3 and 2 mM for all other 
reactions. 0.2 J.lL ofTaq DNA polymerase (Gibco BRL) was used for J3-actin, IL-1J3, IL-6 
and FOX-P3 reactions and all other reactions used 0.25 ).lL. Reaction mixtures were 
amplified for 35 cycles of denaturation at 94°C for 1 min, annealing for 1 min at 55°C 
(IFN-y and IL-2), 72°C (TNF-a) or 65°C (all others), and extension at 72°C for 1 min, 
followed by a separate 5 min extension step at 72°C for all but IL-1J3, IL-6 and FOX-P3. 
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The intensity of amplified products was semi-quantified and normalized as a percent of 
13-actin using the Chemilmager 4000 with Alphaease 4.0 Software. 
5.3.6 Statistical Analysis 
Contingency tables were analyzed using Pearson's chi-square analysis or Fisher's 
exact two-sided t-test for 2x2 tables with expected counts ::::;: 5. Non-parametric Mann-
Whitney (2 category variables) and Kruskal-Wallis ( ;:::2 category variables) were used 
when assessing statistical significance of continuous variables. Infiltrating inflammatory 
cell categories and relative amounts of CD3, cytokine and FOX-P3 mRNA were 
compared using Spearman's rank order correlation. 
Survival estimates were calculated using Kaplan-Meier method with log-rank 
statistic. Ninety-five percent confidence intervals (95% CI) around 5-year percent 
survival estimates were calculated using the standard error (SE) of the cumulative 
survival probability (95%CI = cumulative survival probability ±1.96 X SE). Estimates 
were calculated as time to regional or distant metastasis for recurrence-free survival 
(RFS), time to distant metastasis for distant recurrence-free survival (dRFS) and time to 
death from breast cancer for disease-specific survival (DSS). For disease-free survival, 
patients who died of other causes or who were alive with other malignancy were censored 
from analysis. 
Backward stepwise Cox proportional hazards models were constructed for 
multivariate survival analyses, using a probability of P<0.05 for stepwise entry and 
P>0.06 for removal. No patients were lost to follow-up and patients not experiencing the 
event were censored at the time of last follow-up or at 5 years for 5-year survival. For 
survival analysis, normalized cytokine and FOX-P3 units were stratified into high and 
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low categories by comparing the 4th quartile to the 1 st_3rd quartiles. Relative mRNA levels 
were also entered into univariate Cox regression analysis as continuous covariates to 
ensure no loss of data attributable to the categorization. To determine if the balance of 
relative mRNA levels influence patient survival, mRNA levels were ranked and ratios of 
ranked mRNA were computed. Again, tumors were stratified into high and low ratio 
categories using the 75th percentile of each rank ratio. For multivariate analysis, 
correlation matrices were constructed to ensure lack of collinearity of covariates. For all 
statistical tests, differences between groups were considered significant if P<0.05. All 
analysis was performed using SPSS Version 11.5 statistical software. 
5.4 RESULTS: 
5.4.1 Characterization of the immune cell infiltrate and cytokine milieu in invasive 
breast carcinoma lesions 
Infiltrating inflammatory cell subsets were assessed in 99 pnmary and 15 
recurrent breast carcinoma lesions, via indirect immunohistochemistry. Information on 
infiltrating CD3+ TIL and CD68+ TAM were available for all tumors. Both subsets were 
detected intratumorally and in surrounding stroma and representative staining patterns are 
depicted in Figure 5.1. Due to lack of tissue availability or tissue loss during staining 
procedure, infiltrating CD20+ cells were assessed in 98 primary tumors and all recurrent 
lesions and CD4+ and CDS+ TIL were evaluated in 97 primary and 14 recurrent lesions. 
All tumors had CD68+ infiltrating cells and the majority contained infiltrating CD3+, 
CD4+ and CDS+ cells. In contrast, CD20+ cells occurred in smaller numbers. Infiltrating 
CD56+ cells were evaluated in a subset of tumors (43 primary and 8 recurrent) and were 
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infrequent. An increased proportion of recurrent lesions lacked CDS+ TIL as compared 
to primary breast tumors (P=0.040) (Supplementary Table 5S2). Within primary tumors, 
positive correlations were observed between infiltrating CD3+, CD4+, CDS+, CD20+ 
and CD6S+ cell populations (Table 5.1). 
Tumors with large numbers of TIL and TAM had elevated proportions of CD3+ 
TIL and CD6S+ TAM located intratumorally (Supplementary Figure 5Sl). The 
distribution of TIL and TAM was also dependent on relative numbers of infiltrating cells. 
Infiltrating immune cells were distributed focally and/or diffuse throughout the tumor 
mass (Supplementary Figure 5S2). Small numbers of CD3+, CD4+ and CDS+ TIL were 
primarily focally aggregated in the tumor mass, while large numbers were distributed 
throughout the tumor. CD20+ B cells were relatively infrequent and were predominantly 
focally distributed. In contrast, CD6S+ TAM were diffusely distributed throughout the 
tumor mass (Supplementary Figure 5S3). CD56+ NK cells were detected in only 2/43 
tumors examined and in both cases were focally distributed (data not shown). 
Relative cytokine, CD3 and FOX-P3 mRNA levels were assessed in primary and 
recurrent lesions using RT-PCR (Supplementary Table 5S3). All tumors had detectable 
TGF-~1 and the majority contained CD3, IFN-y, IL-2, IL-12, IL-10, FOX-P3, IL-l~ and 
IL-6 transcripts. Relative levels of IL-4 and TNF-a mRNA were decreased in 
comparison. IL-12 was decreased in recurrent tumors as compared to primary tumors 
(P=0.030). Other cytokines and FOX-P3 did not significantly differ between primary and 
recurrent lesions. In total, 60 primary tumors had information on CD3, all cytokines and 
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Figure 5.1: Representative immunohistochemistry examples of infiltrating CD3+ and 
CD68+ cells in primary breast tumors. Indirect immunohistochemistry was used to assess 
infiltrating CD3+ TIL (mAb UCHTl) and CD68+ TAM (mAb EBMll) in invasive 
breast carcinoma lesions. Hematoxylin and eosin staining illustrates invasive ductal 
morphology (Al-Dl). Isotype control antibodies were included as a negative control (A2-
D2) and tumor cells were identified with anti-cytokeratin (mAb AE1/AE3) (A3-D3). 
These representative examples depict tumors that were coded for infiltrating CD3+ cells 
as none (A4}, small numbers (B4), moderate numbers (C4), and large numbers (D4). 
These tumor samples were infiltrated by small (A5), moderate (C5) and large (B5, D5) 
numbers of CD68+ cells, respectively. 
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Table 5.1: Spearman's correlation coefficientst for infiltrating inflammatory cell subsets 
in primary invasive breast carcinoma. 
Infiltrate 
Infiltrate 
CD3+ CD4+ CDS+ CD20+ 
CD3+ 1 
CD4+ o.88** 1 
CD8+ 0.87** 0.76** 1 
CD20+ 0.48** o.5o** 0.46** 1 
CD68+ 0.53** 0.57** 0.46** 0.37** 
tListwise comparison of primary breast tumors (N=96). 
** Correlation is significant at the 0.01 level (2-tailed). 
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FOX-P3 (Table 5.2). Levels of CD3 positively correlated with the THl cytokines, FOX-
P3 and IL-6. Positive correlations were observed between the THl cytokines, IFN-y, IL-2 
and IL-12; the TH2/TH3 cytokines, IL-4 and IL-10 and the pro-inflammatory cytokines 
IL-l~ and IL-6. Positive correlations were also observed between IL-10 and IL-12, IL-1~ 
and TGF-~, while IL-6 positively correlated with IL-2 and IL-12. FOX-P3 mRNA also 
positively correlated with levels of T H 1 cytokines and with the pro-inflammatory 
cytokines, IL-l~ and IL-6. 
5.4.2 Infiltrating inflammatory cells associate with the in situ cytokine milieu and 
CD3 and FOX-P3 mRNA in primary breast tumors 
As differences were observed between primary and recurrent lesions, to discount 
any immunological changes that coincide with metastasis development, associations of 
infiltrating cell subsets and relative cytokine mRNA levels were compared within 
primary tumors. Since TIL were sometimes focally distributed throughout the tumor, 
relative levels of CD3 mRNA were also assessed to ensure the bulk tumor RNA was 
derived from an area representative of the region of tumor assessed for TIL by IHC. By 
Spearman's correlation, relative levels of CD3 mRNA correlated with increasing 
numbers ofCD3+ TIL (p=0.37, P=0.008), CD4+ TIL (p=0.41, P=0.003), and CD8+ TIL 
(p=0.37, P=0.020), but not CD20+ (p=O.l7, P=0.242) or CD68+ (p=-0.09, P=0.529) 
infiltrating cell populations. 
Relative levels of cytokine and FOX-P3 mRNA were compared in tumors 
stratified by numbers of infiltrating inflammatory cells. To obtain a comprehensive view 
of the immune profile in these breast carcinoma lesions, analysis was performed on only 
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Table 5.2: Spearman's correlation coefficients for relative in situ CD3, cytokine and 
FOX-P3 mRNA amountst in breast carcinoma. 
T HI/ cellular immunity TH2/TH3/Treg 
CD3 IFN-y IL-2 IL-12 IL-4 IL-10 
CD3 1 - - - - -
IFN-y 0.74** 1 - - - -
IL-2 0.73** 0.75** 1 - - -
IL-12 o.55** 0.56** o.65** 1 - -
IL-4 -0.04 0.02 0.06 0.15 1 
-
IL-10 0.21 0.20 0.22 o.55** 0.27* 1 
TGF-~ 0.06 -0.20 -0.06 0.01 -0.01 0.15 
FOX-P3 o.Js·· o.4o·· 0.35** o.4o·· 0.16 0.11 
IL-113 0.23 0.001 0.16 0.22 0.13 0.07 
IL-6 0.39** 0.24 0.30* 0.30* 0.01 0.15 
TNF-a 0.10 0.19 0.17 0.24 0.02 0.06 
tustwise comparison of primary breast tumors (N=60). 
** Correlation is significant at the 0.01 level (2-tailed). 
* Correlation is significant at the 0.05 level (2-tailed). 
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Pro-inflammatory 
TGF-~ FOX-P3 IL-l~ IL-6 TNF-a 
- - - - -
- - - -
-
- - - - -
- - - -
-
- - - - -
- - - - -
1 - - - -
-0.04 1 - - -
0.33** 0.39** 1 - -
0.18 0.43** 0.59** 1 -
-0.01 0.20 0.02 0.05 1 
those tumors with complete mRNA profiles. For CD3+, CD4+ and CD8+ TIL, relative 
mRNA levels did not differ between those with small and moderate numbers (data not 
shown), thus both groups were grouped for comparison. For CD20+ B cells, only one 
tumor contained large numbers, thus moderate and large numbers were grouped for 
comparison. As shown in Figure 5.2 tumors with large numbers of CD3+ TIL had 
significantly increased levels of the TH1-type cytokines IFN-y, IL-2 and IL-12 mRNA, 
reflected by both CD4+ and CD8+ cell populations. IL-4 was also increased in tumors 
with large numbers of CD4+ cells or CDS+ cells as compared to those with small to 
moderate numbers and tumors with CD3+, CD4+ and CDS+ TIL had significantly higher 
FOX-P3 mRNA levels. Relative levels of TNF-a mRNA were increased in tumors with 
large numbers of CD3+ TIL, reflected mainly by the CD4+ subset. Tumors with 
moderate to large numbers of CD20+ cells had increased levels of both TH1-type 
cytokines, IFN-y, IL-2 and IL-12 and the TH2-type cytokines IL-4 and IL-10. Tumors 
with large numbers of CD68+ TAM had significantly higher IL-l 0 levels as compared to 
those with small numbers. Relative amounts of TGF-p, IL-lp, and IL-6 did not 
significantly associate with infiltrating inflammatory cell subsets (data not shown). 
Performing the above analysis on all informative samples yielded similar results (not 
depicted). Reflecting the associations with large numbers of infiltrating cells, those 
tumors in which the relative proportion of intratumoral TIL was equivalent to or 
exceeded stromal TIL had significantly higher levels of THI-type cytokines (IL-2, IL-12 
and IFN-y), IL-10, FOX-P3 and IL-6. Likewise, levels of IL-10 were significantly 
elevated in tumors where the proportion of intra tumoral TAM was greater than or 
equivalent to that of stromal TAM (data not shown). 
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Figure 5.2: Associations of tumor infiltrating inflammatory cells with relative in situ 
cytokine and FOX-P3 mRNA levels. Levels of intratumoral mRNA were compared in 
breast tumors categorized by infiltrating cell populations. Relative numbers of infiltrating 
cell subsets were determined using indirect immunohistochemistry as defined in 
Methods. RT-PCR was carried out using total RNA (1 J.Lg) prepared from fresh-frozen 
breast carcinoma tissue. Relative amounts of cytokine mRNA were normalized to ~-actin 
and averaged (1-3 RT-PCR reactions) for each breast carcinoma sample. Bars represent 
average of all breast tumors in each infiltrate subgroup ± standard error of the mean. 
Associations of infiltrating cell subsets with relative mRNA levels were determined using 
Kruskal-Wallis H test and P-values for 3 category comparisons are provided in the table. 
Asterisks indicate statistically significant differences in comparison to large numbers of 
infiltrating cells assessed using Mann-WhitneyU test (*P<0.05, **P<O.Ol, ***P<O.OOl). 
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5.4.3 Associations of infiltrating cells, and relative cytokine and FOX-P3 mRNA 
levels with prognostic indicators in breast carcinoma 
Associations of infiltrating cell subsets with clinicopathological parameters were 
assessed within primary tumors. Infiltrating CD3+ TIL associated with decreased ER, PR 
and diagnosis age and increased tumor grade, reflected by both CD4+ and CD8+ 
populations (Figure 5.3A-C). CD20+ infiltrating cells did not significantly associate with 
ER, PR or age at diagnosis, but positively associated with tumor grade (Figure 5.3D). 
Infiltrating CD68+ cells did not associate with ER, PR or diagnosis age but CD68+ 
infiltrate associated with increased histological grade (Figure 5.3D) and lymph node 
metastasis (Figure 5.3E). Infiltrating cell subsets did not significantly associate with 
tumor diameter (Figure 5.3F), TNM stage, tumor type or Her-2/neu over-expression (data 
not shown). 
Relative cytokine and FOX-P3 mRNA levels were compared in tumors stratified 
by categorical prognostic parameters (Table 5.3). IDC tumors had elevated levels of 
IFN-y and decreased IL-l~ and TGF-~1. Large numbers of TIL display only a trend for 
decreased tumor size, however, tumors with a small diameter (:5:2 em) had elevated levels 
of the elevated levels ofCD3 mRNA and the THl cytokines, IFN-y and IL-2 and display 
a trend for elevated IL-12. Paralleling the association of inflammatory infiltrate with 
tumor grade, levels of the pro-inflammatory cytokines IFN-y and TNF-a were increased 
in poorly differentiated Grade III tumors. Over-expression of Her-2/neu did not associate 
with immune cell infiltration or T cell specific cytokine production but negatively 
associated with TGF-~1 (P=0.018) and IL-l~ (P=0.029). Relative mRNA levels did not 
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Figure 5.3: Association of infiltrating T cell subsets with prognostic parameters in breast 
carcinoma patients. A) ER negatively associates with infiltrating CD3+ (P=0.054), CD4+ 
(P=0.003), and CD8+ (P=0.056) cells, but not CD20+ (P=0.267) or CD68+ (P=0.089) 
cells. B) PR negatively associates with infiltrating CD3+ (P=O.Ol5), CD4+ (P=0.003), 
and CD8+ (P=0.024) cells, but not CD20+ (P=O.l53) or CD68+ (P=0.474) cells. C) 
Diagnosis age is lower in patients with tumor infiltrating CD3+ (P=0.036), CD4+ 
(P=0.062), and CD8+ (P=O.l22) cells, but not CD20+ (P=0.564) or CD68+ (P=0.414) 
cells. D) All tumor infiltrating cell populations associate with histological grade III 
(CD3+ (P=O.OOl), CD4+ (P=0.003), CD8+ (P=0.004), CD20+ (P=0.009), CD68+ 
(P=0.017). E) Infiltrating CD68+ cells associate with LN metastasis (P=0.024), but other 
infiltrating cell populations do not associate with LN metastasis (CD3+ (P=0.906), CD4+ 
(P=0.299), CD8+ (P=0.470), CD20+ (P=O.l85)). F) Tumor diameter did not associate 
with infiltrating cell populations (CD3+ (P=0.339), CD4+ (P=O.l42), CD8+ (P=O.l42), 
CD20+ (P=0.537), CD68+ (P=0.224)). Numbers at end of bars represent N values for 
each category. Variables were analyzed using one-way ANOVA for diagnosis age, 
Kruskal-Wallis H test for ER and PR and Pearson's Chi-square test for categorical 
variables. 
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Figure 5.3 continued. 
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associate with categorical LN status, TNM stage, and ER, PR or diagnosis age. 
Spearman's correlation analysis of continuous prognostic variables with relative rnRNA 
levels identified negative associations between diagnosis age and CD3 mRNA (p=-0.241, 
P=0.030; N=81), ER and FOX-P3 (p=-0.248, P=0.029; N=77) and tumor diameter 
negatively correlated with IFN-y (p=-0.229, P=0.041; N=80) and IL-2 (p=-0.232, 
P=0.040; N=79). 
5.4.4 Relative numbers of CD3+ and CDS+ TIL predict patient survival 
Despite the association of infiltrating cell subsets with poor prognostic indicators 
(Figure 5.3), univariate testing did not demonstrate significant associations of infiltrating 
cell subsets, or their distribution and location within the tumor, with recurrence-free 
survival (RFS), distant RFS (dRFS), or disease-specific survival (DSS) (data not shown). 
However, a trend was observed for decreased dRFS of patients with tumors containing 
small to moderate numbers of CD3+ TIL. This was reflected by the CD8+ TIL subset but 
not the CD4+ TIL subset (Figure 5.4). Cox proportional hazards models were constructed 
and analyzed using the backward stepwise method, to test the ability of inflammatory cell 
subsets to independently predict patient survival, when controlling for standard 
prognostic indicators. In addition to advanced TNM stage and PR-negative tumors, the 
presence of small to moderate numbers of both CD3+ TIL and CDS+ TIL but not CD4+ 
TIL independently predicted earlier time to distant recurrence (Table 5.4). Infiltrating 
TIL subsets did not independently predict RFS or DSS and CD20+ B cell and CD68+ 
TAM categories did not associate with RFS, dRFS or DSS (data not shown). Neither Her-
2/neu expression status nor tumor grade were included in the above models as inclusion 
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Table 5.3: Associations of relative intratumoral cytokine and FOX-P3 mRNA levels with prognostic parameters in breast carcinoma 
Mean Relative mRNA ± SEM (N) 
Tul T u2ff u3/T re" Pro-inflammatory 
CD3 IL-2 IL-12 IFN-y IL-4 IL-10 TGF-1} FOX-P3 IL-l!} IL-6 TNF-a 
IDC 34.7±2.6 12.2±1.5 7.4±1.0 11.2±1.8 1.3±0.4 22.9±1.6 53.0±3.2 14.3±4.0 30.0±4.9 30.2±3.0 1.9±0.3 (63) (62) (58) (64) (59) (58) (54) (59) (59) (59) (53) 
ILCormixed 30.1±5.0 10.7±2.1 6.8±1.5 4.9±1.9 1.1±0.4 17.3±4.0 60.1±4.6 28.3±12.3 42.6±7.8 48.4±9.5 1.8±0.8 (16) (17) (15) (16) (15) (15) (13) (16) (16) (16) (16) 
P-va1ue 0.495 0.981 0.946 0.045 0.649 0.112 0.067 0.476 0.047 0.095 0.209 
Grade I+ II 31.1±2.9 10.4±1.2 6.2±0.9 7.5±1.4 1.2±0.4 20.6±1.9 53.6±3.6 16.5±4.8 31.2±3.5 36.6±4.4 1.4±0.3 (51) (52) (48) (52) (49) (48) (43) (49) (49) (49) (49) 
Grade Ill 38.3±4.3 13.7±2.7 9.5±1.9 15.2±3.6 1.5±0.6 23.2±2.5 55.7±5.0 14.4±6.8 35.8±11.6 28.7±3.6 3.3±0.6 (25) (24) (22) (25) (22) (22) (21) (23) (23) (23) (17) 
P-va1ue 0.143 0.554 0.137 0.081 0.744 0.379 0.864 0.235 0.695 0.651 0.001 
LN- 33.7±3.7 10.6±1.5 6.0±0.8 9.3±1.9 1.0±0.3 20.9±2.3 52.6±4.0 15.6±5.4 37.4±7.6 30.0±4.4 2.0±0.4 (40) (41) (38) (41) (38) (38) (34) (39) (39) (39) (36) 
LN+ 33.8±2.8 12.9±2.0 8.2±1.4 10.6±2.3 1.4±0.5 23.1±2.0 56.4±3.8 19.4±6.2 28.0±3.0 38.7±4.4 1.7±0.4 (40) (39) (36) (40) (37) (36) (34) (37) (37) (37) (34) 
P-va1ue 0.704 0.791 0.570 0.642 0.873 0.424 0.477 0.368 0.799 0.105 0.636 
T~cm 42.9±4.6 16.6±2.4 9.8±2.0 17.6±4.3 1.9±0.6 24.3±3.4 52.1±4.3 14.8±5.8 23.7±4.4 26.5±4.9 2.7±0.7 (20) (19) (20) (20) (20) (20) (18) (19) (19) (19) (18) 
T>2cm 31.1±2.6 10.3±1.4 6.1±0.9 7.5±1.2 1.0±0.4 21.4±1.7 56.1±3.4 18.7±5.2 36.3±5.4 37.4±3.9 1.5±0.3 (59) (60) (53) (60) (54) (53) (49) (56) (56) (56) (51) 
P-va1ue 0.026 0.008 0.067 0.028 0.062 0.439 0.921 0.562 0.057 0.115 0.104 
TNM Stage I-II 35.3±2.8 12.4±1.4 6.9±0.9 11.0±1.8 1.4±0.4 21.8±1.8 55.1±3.3 18.6±5.0 35.1±5.3 33.7±3.7 1.9±0.3 (63) (64) (58) (64) (58) (58) (53) (58) (58) (58) (56) 
Mean Relative mRNA ± SEM (N) 
THl TH2/TH3/Tre• Pro-inflammatory 
CD3 IL-2 IL-12 IFN-y IL-4 IL-10 TGF-~ FOX-P3 IL-l~ IL-6 TNF-a 
TNM Stage III-IV 28.5±3.3 8.6±2.3 7.1±2.2 5.7±1.3 0.3±0.1 23.0:1:3.3 54.7±4.4 14.7±6.9 27.0±3.8 38.8±6.2 1.2±0.3 (15) (14) (14) (15) (15) (14) (13) (16) (16) (16) (12) 
P-value 0.421 0.246 0.836 0.555 0.110 0.787 0.519 0.324 0.953 0.348 0.561 
ER<10 fmollmg 32.4±3.5 9.8±1.9 7.8±1.7 9.7±2.7 1.6±0.5 20.9±2.4 57.1±4.7 15.9±5.6 37.5±9.5 35.7±5.2 2.0±0.4 (32) (31) (27) (32) (27) (27) (23) (28) (28) (28) (27) 
E~10 fmol/mg 34.7±3.0 13.1±1.6 6.8±0.9 10.2±1.7 1.0±0.4 22.7±1.9 53.2±3.3 18.2±5.5 29.9±3.5 33.2±3.9 1.8±0.4 (49) (50) (48) (50) (49) (48) (46) (49) (49) (49) (44) 
P-value 0.757 0.099 0.947 0.404 0.700 0.581 0.441 0.165 0.427 0.649 0.462 
PR<10 fmol!mg 38.0±4.0 13.8±2.4 8.0±1.7 11.6±3.0 1.1±0.5 20.1±2.6 51.7±4.2 18.8±7.5 38.8±11.1 39.5±6.3 1.8±0.5 (28) (28) (23) (28) (23) (23) (20) (24) (24) (24) (23) 
P~10 fmol/mg 31.7±2.8 10.9±1.4 6.8±0.9 9.2±1.6 1.2±0.4 22.9±1.9 55.7±3.4 16.8±4.8 29.8±3.3 31.6±3.5 1.9±0.3 
(53) (53) (52) (54) (53) (52) (49) (53) (53) (53) (48) 
P-value 0.160 0.525 0.687 0.883 0.618 0.395 0.731 0.447 0.516 0.250 0.395 
Dx Age<50 years 35.2±4.1 11.1±2.3 7.7±1.7 9.5±2.5 0.8±0.3 22.5±2.4 58.8±7.3 14.0±6.6 41.5±11.7 34.8±6.2 2.0±0.6 (24) (24) (23) (24) (23) (23) (20) (23) (23) (23) (19) 
Dx Age~50 years 33.3±2.8 12.2±1.4 6.9±0.9 10.2±1.8 1.4±0.4 21.9±1.9 52.8±2.4 18.8±5.0 28.8±3.1 33.8±3.6 1.8±0.3 (57) (57) (52) (58) (53) (52) (49) (54) (54) (54) (52) 
P-value 0.552 0.518 0.931 0.967 0.846 0.756 0.926 0.482 0.322 0.929 0.833 
Her-2/neu (Codes 0-2) 36.0±3.2 11.7±1.5 7.1±1.0 10.4±1.8 1.0:1:0.4 21.7±1.8 56.3±4.0 17.8±5.3 32.8±6.2 35.4±3.6 1.8±0.3 (48) (49) (43) (49) (44) (43) (41) (45) (45) (45) (39) 
Her-2/neu (Code 3) 29.9±5.5 15.6±3.7 7.7±2.4 13.5±5.0 1.5±0.6 21.3±3.9 39.4±4.7 17.1±11.1 20.1±5.2 23.1±6.0 1.7±0.4 (15) (15) (15) (15) (15) (15) (13) (13) (13) (13) (15) 
P-value 0.290 0.375 0.790 0.943 0.418 0.716 0.018 0.695 0.029 0.058 0.829 
decreased sample stze and did not alter the prognostic significance of the other 
co variates. 
5.4.5 Elevated TNF -a. within breast tumors predicts improved survival of breast 
carcinoma patients 
We have recently reported that patients with tumors containing high relative 
levels of IFN-y have improved RFS, and dRFS, by univariate survival analysis, while 
levels of IL-2, IL-12, IL-4, IL-10 and TGF-~ did not associate with patient survival 
(Chapter 4) [256]. Here we have also analyzed relative mRNA levels of the pro-
inflammatory cytokines IL-l~, IL-6 and TNF-a and the Treg marker FOX-P3. Tumors 
were stratified into high and low groups using the 75th percentile cut-point. In addition, as 
recommended by Altman et al. (1994) [277], to ensure there was no loss of information 
due to relative mRNA level categorization, all cytokine and FOX-P3 mRNA levels were 
entered separately as a continuous covariate into an univariate Cox regression analysis. 
Categories of IL-l~. IL-6 and FOX-P3 mRNA levels did not significantly associate with 
RFS, dRFS or DSS (data not shown). Furthermore, analysis of these and the previously 
studied cytokines (Chapter 4) as continuous covariates did not yield significant 
differences (data not shown). 
With respect to TNF -a mRNA levels, although RFS did not differ in patients 
stratified by TNF-a levels (Overall: LR=l.l, P=0.290; 5-year LR=0.8, P=0.370, data not 
shown), a trend was observed for increased time to distant recurrence in patients with 
high tumor levels ofTNF-a (Figure 5.5A) and high TNF-a associated with significantly 
improved disease-specific survival (DSS) (Figure 5.5B). When relative mRNA levels 
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Figure 5.4: Patients with minimal TIL infiltrate have decreased time to distant 
recurrence. A) Patients with tumors containing small to moderate numbers of CD3+ TIL 
display a trend for decreased dRFS (LR=4.4, P=O.lll). This was reflected by (B) the 
CD8+ TIL subset (LR=5.5, P=0.063) but not (C) the CD4+ TIL subset (LR=2.1, 
P=0.345). 
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Table 5.4: Multivariate Cox proportional hazards modelst to assess contribution of infiltrating CD3+ and CDS+ TIL to dRFS in breast 
carcinoma patients 
CD3+TIL CDS+ TIL 
Variable P-value HR(95%HR} P-value HR(95%HR) 
TIL category: 0.031 0.044 
None 0.334 2.5(0.4-15.3) 0.473 2.1 (0.3-15 .8) 
Sm-Mod# 0.012 5.0(1.4-17.4) 0.027 5.3(1.2-23 .1) 
Lg# Reference Reference 
TNM Stage III/IV (vs IIII) 0.005 2.9(1.4-6.0) 0.005 2.9(1.4-6.1) 
PR<10fmol/mg 0.001 3.5(1.6-7.4) 0.006 2.9(1.4-6.1) 
ER< 10fmol/mg ns ns 
Surgery+ Adjuvant vs Surgery ns ns 
Diagnosis Age (years) ns ns 
IDC (vs ILC or mixed) ns ns 
#events/#cases 32/91 32/89 
Model y} (P) 20.7 (P<0.001) 18.9 (P=0.001) 
t Models employed backward stepwise method with entry at P<0.05 and removal at P>0.06. 
*P<0.05, variable eliminated from the Model during backward stepwise method. 
CD4+TIL 
P-value HR(95%HR) 
* ns 
Reference 
0.006 2.8(1.3-5. 7) 
0.031 2.2(1.1-4.5) 
ns 
ns 
ns 
ns 
32/89 
11.1 (P=0.004) 
were assessed as continuous covariates in univariate Cox regression analysis, only TNF-
a showed significant associations with patient survival. Similar to categorical 
designations, increasing TNF-a levels associated with improved DSS (P=0.041, 
HR(95%CI)=0.75(0.57-0.99)) and displayed a trend for improved dRFS (P=0.068, 
HR(95%CI)=0.82(0.66-1.02)). In multivariate survival analysis, controlling for the 
aforementioned prognostic parameters, high TNF a did not associate with RFS or dRFS 
but was an independent predictor of DSS (P=0.026, HR = 0.19; 95%CI for HR = 0.04-
0.82; Model x2=19.4, P<0.001). Tumor stage and ER were independent predictors for 
RFS and dRFS, while ER expression independently predicted DSS. Similar results for 
DSS were obtained when TNF-a was entered as a continuous covariate (P=0.014, 
HR(95%CI)=0.64(0.45-0.92); Model x2=19.0, P<0.001)) and for 5-year survival models 
(data not shown). 
In this sample of breast carcinoma patients we have shown that high levels of 
intratumoral IFN-y (Chapter 4) [256] and TNF-a (Fig. 5.5B) associate with improved 
patient survival. To determine if the influence of these cytokines on patient survival is 
dependent on their balance with TH2/immunoregulatory markers, ratios of ranked IFN-y 
and TNF-a mRNA to IL-4, IL-10, TGF-f31 and FOX-P3 mRNA were computed, as 
described in Methods. Patients with a high TNF-a/TGF-f31 ratio displayed a trend for 
improved dRFS (Fig. 5.5C) but had significantly improved DSS (Fig. 5.5D). Survival did 
not significantly differ in patients stratified by other ranked mRNA ratios (data not 
shown). In Cox proportional hazards models controlling for the aforementioned 
prognostic parameters, patients with tumors in which the rank of relative TNF-a 
exceeded that of TGF-f31 had improved dRFS (P=0.034, HR(95%CI)=0.37(0.15-0.93); 
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Model x2=19.6, P<O.OOI)) and DSS (P=O.OOI, HR(95%CI)=0.14(0.05-0.46); Model 
x2=18.7, P<O.OOI)). 
5.5 DISCUSSION: 
In support of previous immunohistochemical studies on invasive breast 
carcinoma, the inflammatory infiltrate was comprised predominately of CD6S+ TAM and 
CD3+ TIL, comprised of both CD4+ and CD8+ subsets, with relatively few B 
lymphocytes and NK cells [144, 17S]. The majority of invasive breast tumors contained 
an inflammatory infiltrate and a cytokine milieu comprised of both immunoregulatory 
and pro-inflammatory cytokines. As anticipated, positive correlations were observed 
between the THI-type cytokines IFN-y, IL-2 and IL-12, the TH2-type cytokines IL-4 and 
IL-10, and the pro-inflammatory cytokines IL-113 and IL-6. Although the findings of 
decreased CDS+ TIL and decreased IL-12 in recurrent lesions as compared to primary 
lesions are intriguing, as they may suggest decreased cellular immunity with disease 
progression, definitive conclusions cannot be drawn as comparative primary lesions from 
the same patients were not available for study. However, a small study of ovarian 
carcinoma patients demonstrated relative numbers of CDS+ TIL were decreased in 
recurrences as compared to matched primary tumors in ovarian cancer patients [278]. 
Variability in cytokine levels with tumor type likely reflects the distinct genetic 
profiles of IDC and ILC tumors as both exhibit unique differences with respect to genes 
involved in cell/cycle, apoptosis, angiogenesis and hormone responsiveness [279, 280]. 
The degree and pattern of infiltration in these tumor subtypes may also contribute to 
relative intratumoral cytokine mRNA levels. IDC tumors more frequently contain 
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Figure 5.5: Intratumoral TNF-a. mRNA levels associate with improved survival in breast 
carcinoma patients. A) Patients with tumors containing high TNF-a. mRNA levels 
display a trend for improved dRFS (5-yr% survival(95%CI) = TNF-a. high: 73%(49%-
96%); TNF-a. low: 50%(36%-65%)). (B) Patients with tumors containing high TNF-a. 
mRNA levels have improved DSS (TNF-a. high: 89%(74%-100%); TNF-a. low: 
56%(41%-70%)).(C) Patients with a high intratumoral TNF-a.:TGF-~1 mRNA ranked 
ratios have improved dRFS (TNF-a.>TGF-131: 67%(49%-84%); TNF-a.§GF-f31: 49(29-
70)) and (D) DSS (TNF-a.>TGF-~1: 83%(69%-97%); TNF-a.§GF-~1: 51(31-71)). Log 
rank (LR) statistic and P-value in upper right comers correspond to overall and 5-year 
comparison. 
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diffusely distributed inflammatory infiltrates while ILC infiltrates are often perilobular 
[144]. We observed a similar trend as CD3+ TIL were often diffuse in IDC tumors 
(49/73) as compared to ILC (5/8) (Fisher's exact 2-sided test, P=0.064). Her-2/neu 
overexpressing tumors had significantly decreased intratumoral TGF-~1 and IL-l~. 
Microarray analysis of mammary tumors from MMTV-Neu transgenic mice and wild 
type normal mammary tissue revealed downregulation of several genes involved in the 
Smad-dependent TGF-~ signaling cascade in Her-2/neu over-expressing tumors [281]. 
The negative association of Her-2/neu and IL-l~ may be indirect as IL-l~ positively 
correlated with TGF-~1 (Table 5.2) and IL-l~ is known to enhance TGF-~1 production 
in an autocrine manner [282]. 
The negative associations of TIL with decreased ER levels support previous 
studies [174, 181, 187]. Furthermore, the association with decreased age suggests a role 
for circulating hormones in T cell infiltration of the tumor. Thus, in the absence of 
competing ligand expression on breast tumor cells, circulating estrogens may promote the 
recruitment and expansion of TAA-specific T cells. The hormone 17~-estradiol can 
modulate T cell expression of chemokine receptors and in vitro T cell migration [283]. 
Estradiol enhances the proliferation and IFN-y production of antigen-specific CD4+ THI 
cells in vivo [264] and circulating estradiol also promotes the in vivo expansion of 
CD4+CD25+FOX-P3+ regulatory CD4+ T cells [265]. 
Large numbers of TIL are more frequently located intratumorally and are 
distributed in a diffuse manner throughout the tumor mass. Large numbers of infiltrating 
CD4+ and CD8+ TIL associated with relative levels ofTHl cytokines as well as the TH2 
cytokine, IL-4. Likewise, the presence of moderate to large numbers of CD20+ B cells 
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associated with both THl and TH2 cytokines. Indeed CD20+ B cell infiltration correlated 
with both CD4+ and CDS+ TIL subsets, suggesting an integration of humoral and cell 
mediated immunity. Following injection of murine TS/A adenocarcinoma cells into 
BALB/c mice, Reome et al. (2004), identified a progressive increase in CD3+ TIL with 
time, with substantially lower B cell infiltration which remained constant. Assessing the 
kinetics of infiltrating TIL subsets revealed IL-4 producing T H2 cells emerge at the tumor 
at earlier time points than IFN-y producing THl cells during progressive tumor growth 
[284]. The failure of this integrated immune response to facilitate tumor rejection may 
reflect the kinetics ofT cell subset infiltration but will also be dependent on the balance 
of anti-tumor immunity with immunoregulatory mechanisms and immune evasion 
strategies employed by the tumor. 
The presence of Treg cells within the tumor will likely suppress effector T cell 
responses. CD4+CD25+FOX-P3+ Treg cells, capable of suppression of TAA-specific T 
cell immunity, are present in close proximity to CDS+ TIL in ovarian cancer and 
associate with advanced stage of disease and decreased survival [275]. Large numbers of 
CD4+CD25+ T cells with in vitro regulatory capacity have been isolated intratumorally 
and from the draining lymph nodes and peripheral blood of breast cancer patients [184]. 
Although Treg cells were not specifically quantified in this study, we observed elevated 
levels of FOX-P3 mRNA in tumors that contained TIL. The positive correlation of the 
immunoregulatory T cell marker FOX-P3 with both THl and pro-inflammatory cytokines 
may reflect the recruitment of Treg cells to the site of inflammation. Those tumors in 
which the relative proportion of intratumoral TIL parallel or exceed stromal TIL 
contained elevated levels of THl-type cytokines, IL-6, IL-10 and FOX-P3, suggesting 
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intratumoral recruitment ofTreg cells. High levels ofiL-6 in these tumors might represent 
the host response to T reg mediated suppression as IL-6 induced during infection has been 
demonstrated to allow effector T cells to surmount Treg-induced suppression [285]. 
Studies in ovarian carcinoma patients have also demonstrated bulk tumor FOX-P3 
mRNA levels positively correlate with CD3 and IFN-y mRNA levels [276]. Using a 
murine model of ovarian carcinoma, Curiel et al. (2003) showed that Treg cells are 
recruited to the tumor in response to secretion of the chemokine CCL22 by tumor cells 
and intratumoral macrophages [275]. Thus the balance of effector and regulatory cell 
subsets will have important consequences for the induction of anti-tumor immunity and 
prognosis in breast carcinoma patients. Indeed, a high intratumoral CD8+/CD25+FOX-
P3+ Treg TIL ratio associates with improved survival in ovarian carcinoma [195]. 
Although we did not directly phenotypically quantify TIL subsets, the subset of patients 
with moderate inflammatory infiltration of their tumors showed decreased time to distant 
recurrence (Table 4). Tumors from these patients exhibit elevated FOX-P3 mRNA and 
decreased T H 1-type cytokines (Figure 2). In contrast, tumors with large numbers of TIL 
exhibit comparable FOX-P3 mRNA levels but showed a marked increase in levels of 
THl-type cytokines. Thus the improved survival of this subset of patients, despite the 
association with poor prognostic indicators, may reflect increased accumulation of 
effector THl cells and enhanced cell-mediated immunity. In support of this, at the time of 
surgery, THl-type cytokines are elevated in tumors of small diameter (Table 3) and 
tumors with large numbers of CD8+ TIL have improved dRFS (Table 4). The lack of 
association of CD4+ TIL with patient outcome likely reflects the presence of both 
effector T H cells as well as T reg· 
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Elevated levels of the pro-inflammatory cytokines IFN-y and TNF-a in 
histological grade III tumors reflect the relationship with inflammatory infiltration. 
Despite the association with more aggressive breast carcinoma, elevated CD8+ TIL 
(Table 4), TNF-a (Figure 5.5) and IFN-y (Chapter 4) [256] associate with improved 
patient survival. A small study of 25 breast carcinoma patients with histological grade III 
tumors, demonstrated patients that experienced recurrence and metastasis (N= 15) 
contained decreased numbers of TNF-a expressing inflammatory cells, which associated 
with lower numbers of apoptotic cancer cells, and higher tumor proliferation rates as 
compared to histopathologically matched patients who remained recurrence-free for 5-
years [286]. In a murine model of breast carcinoma, microsphere delivery of IL-12 and 
TNF-a into established tumors associated with increased CD4+ and CD8+ TIL 
infiltration, production of IFN-y and tumor regression and provided immunological 
memory capable of tumor rejection upon rechallenge [287]. 
TNF-a is a pleiotropic growth factor secreted mainly by T cells and macrophages 
that has a paradoxical role in carcinoma. Experimental models of carcinogenesis have 
demonstrated low level TNF -a production may foster a chronic inflammatory milieu, 
leading to increased angiogenesis, production of matrix degrading enzymes and tumor 
metastasis, while high intratumoral levels of TNF-a lead to cancer destruction via direct 
growth inhibitory effects on tumors cells and/or indirect action on tumor infiltrating cells, 
leading to tumor necrosis and apoptosis [288]. An additional role for high concentrations 
of TNF-a may be via its activity on immunosuppressive Treg cells in the tumor 
microenvironment. Recently, high concentrations of TNF-a were found to inhibit the in 
vitro immunoregulatory effects of both naturally occurring and TGF-~1 induced 
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CD4+CD25+ Treg of healthy individuals, via signaling through TNFRII expressed on Treg, 
which correlated with downregulated FOX-P3 expression [289]. In support of this 
hypothesis, survival was markedly increased in patients whose tumors display elevated 
ranked TNF-a/TGF-JH ratios (Figure 5.5D). 
The ability of high levels of tumoral TNF -a to independently predict improved 
disease specific survival may also reflect the enhanced delivery of chemotherapeutic 
regimens, to areas of residual disease, via TNF-a mediated induction of increased 
vascular permeability [290]. In support of this, high TNF-a associated with improved 
survival (LR=5.7, P=0.017) in the subset of patients treated with adjuvant chemotherapy 
(N=33, data not shown). 
In conclusion, the results of this study provide further insight into the complexity 
of the immune cell infiltrate in breast carcinoma. Much work remains to be done to 
understand the unique properties of tumor infiltrating inflammatory cells and how their 
cytokine responses are regulated in the context of the tumor microenvironment. A 
thorough understanding of the anti-tumor immune response will aid in the development 
of immunotherapeutic regimes in breast carcinoma. 
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Supplementary Table 5Sl: Primer sequences for detection of mRNA m breast 
carcinoma lesions. 
Sense Primer (5'-3') Anti-sense Primer (5'-3') 
ATC TGG CAC CAC ACC CGTCAT ACTCCTGCTTGC 
~-Actin 
TTC TAC AAT GAG CTG CG TGA TCC ACA TCT GC 
CTG GAC CTG GGA AAA GTA CTG AGC ATC ATC 
CD38 
CGCATC TCGATC 
AGT TAT ATC TTG GCT TTT ACC GAA TAA TTA GTC 
IFN-y 
CA AGCTT 
ACT CAC CAG GAT GCT AGG TAA TCC ATC TGT 
IL-2 
CACAT TCAGA 
CCA AGA ACT TGC AGC TGG GTC TAT TCC GTT GTG 
IL-12 p40 
TGAAG TC 
CCT CTG TTC TTC CTG CTA CCA ACG TAC TCT GGT 
IL-4 
GCA TGT GCC TGG CTT CCT TCA 
ATG CCC CAA GCT GAG TCT CAA GGG GCT GGG 
IL-10 
AAC CAA GAC CCA TCA GCT ATC CCA 
GCC CTG GAC ACC AAC AGG CTC CAA ATG TAG 
TGF-~ 
TATTGC GGGCAGG 
CAG CTG CCC ACA CTG CAT TTG CCA GCA GTG 
FOX-P3 
CCC CTA G GGT AG 
ACA GAT GAA GTG CTC GTC GGA GAT TCG TAG 
IL-l j3 
CTTCCA CTGGAT 
AGC TCA GCT ATG AAC GTC TCC TCA TTG AAT 
IL-6 
TCC TTC TC CCA GAT TGG 
CGG GAC GTG GAG CTG CAC CAG CTG GTT ATC 
TNF-a 
GCC GAG GAG TCT CAG CTC 
* All primer sequences were validated using published GenBank mRNA sequences. 
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Size 
(bp) 
GenBank 
Accession 
Number· 
840 NM 005159 
311 NM 000732 
356 J00219 
269 HSU25676 
355 NM 002187 
371 M23442 
352 NM 000572 
165 X02812.1 
384 AF277993 
75 BT007213 
340 NM 000600 
354 NM 000594 
Supplementary Table 5S2: Infiltrating cell subsetst in primary and recurrent breast 
tumors 
Primary Tumors Recurrent Tumors 
* P-va1ue 
N (%) N (%) 
None 11 (11.1) 4 (26.7) 0.352 
Sm# 30 (30.3) 5 (33.3) 
CD3+ 
Mod# 41 (41.4) 4 (26.7) 
Lg# 17 (17.2) 2 (13.3) 
None 15 (15.5) 4 (28.6) 0.646 
Sm# 36 (37.1) 4 (28.6) 
CD4+ 
Mod# 34 (35.1) 4 (28.6) 
Lg# 12 (12.4) 2 (14.3) 
None 14 (14.4) 6 (42.9) 0.040 
Sm# 41 (42.3) 2 (14.3) 
CD8+ 
Mod# 30 (30.9) 5 (35.7) 
Lg# 12 (12.4) 1 (7.1) 
None 77 (78.6) 12 (80.0) 0.982 
Sm# 14 (14.3) 2 (13.3) 
CD20+ 
Mod# 6 (6.1) 1 (6.7) 
Lg# 1 (1.0) 0 (0) 
None 41 (95.3) 7 (87.5) 0.366 
Sm# 1 (2.3) 1 (12.5) 
CD 56+ 
Mod# 1 (2.3) 0 (0) 
Lg# 0 (0) 0 (0) 
None 0 (0) 0 (0) 0.165 
Sm# 8 (8.1) 3 (20.0) 
CD68+ 
Mod# 32 (32.3) 2 (13.3) 
Lg# 59 (59.6) 10 (66.7) 
t Of the 99 primary and 15 recurrent tumors evaluated for immune cell infiltration, all had information on 
CD3+ and CD68+ cells. Due to lack of tissue availability or tissue loss during staining procedure, 
information on infiltrating CD20+, CD4+, CDS+ and CD56+ cells was available for 98, 97, 97, and 43 
primary tumors and 15, 14, 14 and 8 recurrent tumors, respectively. 
*P-value calculated using Pearson's Chi-square test. 
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Supplementary Table 583: Relative cytokine and FOX-P3 mRNA levels in primary and recurrent breast tumors 
Primary Tumors Recurrent Tumors 
P-value * 
mRNA (N) Mean±SEM Min-Max % negativef (N) Mean±SEM Min-Max %negative'~' 
Tcell CD3 (81) 33.8±2.3 0-82.3 1.2 (9) 29.9±7.6 1.9-67.0 0 0.619 
IFN-y (82) 10±1.5 0-71.3 18.3 (9) 11.0±4.0 0-32.0 22.2 0.779 
THllcellular 
IL-2 (81) 11.9±1.2 0-46.5 3.7 (9) 8.8±3.6 0-35.3 11.1 0.404 
immunity 
IL-12 (75) 7.2±0.8 0-35.7 8.0 (8) 2.6±1.2 0-9.8 37.5 0.030 
TH2!fH3/Treg IL-4 (76) 1.2±0.3 0-17.4 51.3 (8) 0.3±0.3 0-2.1 75.0 0.174 
IL-10 (75) 
N 
22.1±1.5 0-48.4 1.3 (7) 17.6±4.6 3.5-41.3 0 0.374 
0 
\0 
TGF-J3 (69) 54.5±2.7 9-148.2 0 (8) 58.8±10.1 33.7-107.3 0 0.815 
FOX-P3 (77) 17.4±4.0 0-157.3 15.6 (9) 2.7±0.9 0-7.6 33.3 0.188 
IL-1(3 (77) 32.6±4.1 3-280 0 (9) 14.9±2.7 0-24.1 11.1 0.073 
Pro-
IL-6 (77) 34.1±3.1 0-125.3 2.6 (9) 19.9±4.9 0-44.1 11.1 0.164 
inflammatory 
TNF-a (71) 1.8±0.3 0-12.8 32.4 (9) 0.7±0.3 0-2.3 55.6 0.137 
• P-value calculated using Mann-Whitney U test. 
tPercentage of tumors with undetectable mRNA (Relative mRNA spot density ratio to ~-actin=O). 
Small # Moderate # Large # 
CD3+ infiltrate 
GilT>= S 
• S>IT 
c 
:I 
0 
u 
Sm# Mod# Lg# 
CD68+ infiltrate 
GilT>= S 
.S>IT 
Supplementary Figure SSl: Large numbers of CD3+ TIL and CD68+ TAM associate 
with intratumoral location (CD3: x2=9.9, P=0.007; CD68: x2=5.0, P=0.082). 
IT=intratumoral, S=stromal, TIL=tumor infiltrating lymphocytes, TAM = tumor 
associated macrophages. 
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Supplementary Figure 5S2: Representative immunohistochemistry example illustrating 
focal and diffuse distribution of infiltrating CD3+ cells in breast carcinoma. (A) In this 
representative example, moderate numbers of infiltrating CD3+ cells (mAb UCHTl) 
were detected both diffusely distributed (D) throughout tumor stroma (B) and in focal 
(F) aggregates (C). Original magnifications of 40X (A) and 200X (B-C). 
• 
t 
.! (D) 
(D) 
• 
• 
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Supplementary Figure 5S3: Distribution of infiltrating cell populations in primary 
breast carcinoma lesions. Small numbers of CD3+, CD4+ and CDS+ TIL were primarily 
focally aggregated in the tumor mass, while large numbers were more frequently 
diffusely distributed throughout the tumor. CD20+ B cells were relatively infrequent and 
showed a predominantly focal distribution. CD68+ TAM were diffusely distributed 
throughout the tumor mass. F=focal aggregation of infiltrating cells, D=diffuse 
distribution of infiltrating cells, F+D=focal aggregates and diffusely distributed cells. 
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CHAPTER 6: RELATIONSHIP OF SINGLE NUCLEOTIDE POL YMORPHISMS IN 
CYTOKINE GENES WITH INTRATUMORAL CYTOKINE LEVELS AND 
PROGNOSIS IN BREAST CARCINOMA t 
Sharon A. Oldford, Dianne Codner, and Sheila Drover 
Division of Basic Medical Sciences, Faculty of Medicine, Memorial University of 
Newfoundland, St. John 's, Newfoundland, Canada 
t Manuscript in preparation. 
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6.1 ABSTRACT 
The anti-tumor immune response is dependent on the intratumoral cytokine milieu, which 
regulates the function of tumor infiltrating immune effector cells. Cytokine genes display 
a high degree of polymorphism and allelic variation associates with variability in 
cytokine levels. Studies investigating associations of cytokine gene polymorphisms with 
disease susceptibility and prognosis in breast carcinoma have yielded conflicting results. 
To determine if associations of cytokine gene single nucleotide polymorphisms (SNPs) 
with prognostic parameters are attributable to variation in the levels of intratumoral 
cytokine production, we assessed the relationships of cytokine SNPs with prognostic 
parameters and relative intratumoral cytokine mRNA levels in a pilot study of 60 
invasive breast carcinoma patients. Significant associations were observed between the 
IL-l j3 -511 + 3962 TC haplotype and tumor grade and decreased patient survival, the IL-6 
-174nt565 CA haplotype and elevated tumor ER levels and the IL-10 -1082-819-592 
GCC haplotype with decreased ER and PR. These associations were independent of 
variability in their respective cytokine mRNA levels, suggesting the prognostic influence 
of these allelic variants is attributable to unidentified linked genetic variants and/or 
additional factors that control cytokine production in the tumor microenvironment. 
Relative levels of IL-2, and IFN-y demonstrated significant positive associations with the 
IL-2 -330+166 TG haplotype and the IFN-y +874 T allele, respectively. However, 
assessment of these relationships in tumors subgrouped by proportions of CD3+ TIL 
suggest genetic variation in cytokine genes play a minor role in intratumoral cytokine 
production in the presence of large numbers of TIL. The results of this exploratory study 
suggest the true prognostic significance of genetic variation in cytokine genes in breast 
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carcinoma is presently unclear and will require extensive study of large numbers of 
patients with extended haplotype analysis. Furthermore, the interpretation of such studies 
will require a thorough knowledge of the full contribution of extended SNP haplotypes 
on cytokine production in response to various stimuli and in different cell types. 
6.2 INTRODUCTION 
Cytokine genes are highly conserved in terms of their exon sequences, however, 
polymorphisms within the regulatory region of cytokine genes can influence transcription 
via alteration of transcription factor binding, while intronic polymorphisms may 
influence mRNA splicing or the structure of gene enhancer or silencer regions [291]. 
Breast carcinoma lesions frequently contain an inflammatory cell infiltrate and there is 
substantial evidence to support a role for immune responsiveness in disease development 
and progression. The anti-tumor immune response is controlled by the balance of 
cytokines secreted by infiltrating immune cells and/or tumor cells. This regulation is 
accomplished by the ability of different cytokines to act synergistically or 
antagonistically. For example, IFN-y enhances TNF-a. mediated tumor cell growth 
inhibition and apoptosis, but acts antagonistically with IL-4 in the production of lgG 
subclasses by B lymphocytes [292]. 
Family and twin studies have demonstrated a strong genetic influence on cytokine 
secretion from in vitro stimulated human peripheral blood mononuclear cells (PBMC) 
[293], suggesting a genetic basis for control of cytokine production. As single nucleotide 
polymorphisms (SNPs) of cytokine genes can influence cytokine gene promoter activity 
[201, 204] and associate. with variable levels of cytokine production, following in vitro 
cell stimulation or in vivo in the plasma ofhealthy donors [204, 205], several studies have 
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attempted to correlate the carriage of such allelic variants with disease susceptibility and 
prognosis in breast carcinoma. However, in both instances discrepant reports have arisen 
[214, 218, 219]. 
The discrepancies of such reports may in part reflect ethnic differences in allele 
distribution; however, such studies have failed to examine the associations of SNPs with 
prognosis in the context of intratumoral cytokine levels. In an attempt to investigate 
whether the associations of SNPs of cytokine genes with prognostic parameters are 
attributable to an influence on immune responsiveness, we have molecularly typed 60 
invasive breast carcinoma patients for SNPs of cytokine genes and evaluated their 
relationship to prognostic parameters and relative intratumoral cytokine mRNA levels. 
6.3 MATERIALANDMETHODS 
6.3.1 Tumor samples and patient characteristics 
Tumors were randomly selected, based on tissue availability, from a larger sample 
with prognostic and outcome information, obtained from the Manitoba Breast Tumor 
Bank (MBTB) (Winnipeg, Manitoba, Canada), with approval of the local Human 
Investigation Committees. The median age of initial diagnosis was 61 years (mean±sd = 
59.4±14.0 years). The median follow-up time was 61 months (mean±sd = 70.9±56.2 
months; range 2-215 months), during which 19 patients died of breast cancer. The 
median time to recurrence was 46 months (mean±sd = 53.3±44.3 months; range 2-328), 
during which 31 patients experienced recurrences (20 distant, 7 regional and 4 
distant+regional). Breast tumor samples were comprised of 52 primary tumor lesions and 
8 recurrent tumors. Primary tumor prognostic information was available for 59 patients 
for tumor type (infiltrating ductal carcinoma (IDC): n=52, infiltrating lobular carcinoma 
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(ILC): n=7) and lymph node status (LN-: n=26; LN+: n=33). Primary tumor size was 
available for 57 patients (s2 em: n=13; >2cm: n=44). Fifty-five patients were staged 
according to AJCC guidelines [8] for TNM stage (Stage IIII: n=43; Stage III/IV: n=12). 
Primary tumor estrogen receptor (ER) and progesterone receptor (PR) levels were 
determined by ligand binding assay and available for 52 patients (ER: median = 16.5 
fmol/mg, mean±sd = 47.9±68.3 fmol/mg; PR: median = 16.6 fmol/mg, mean±sd = 
71.3±163.9 fmol/mg). Primary tumors were graded for 49 patients (Grade I: n=3; Grade 
II: n=28; Grade III: n=18), determined using the Nottingham grading system [6] 
6.3.2 DNA extraction and cytokine SNP genotyping 
DNA was isolated from thawed, fresh-frozen breast tumor tissues by 
homogenization using the DNAzol reagent (Gibco BRL, Rockville, MD). Single 
nucleotide polymorphisms (SNPs) in cytokine genes were detected by PCR with 
sequence-specific primers, using Pel-Freez Cytokine genotyping kits (Pel-Freez Clinical 
Systems, LLC®, Brown Deer; WI, USA). DNA from breast tumors was typed for SNPs 
in IL-l~ (-511C>T, +3962T>C), IL-lR (pstl 1970C>T), IL-lRN (mspal lllOOT>C), 
IL-2 (-330T>G, +166G>T), IL-4 (-1098T>G, -590T>C, -33T>C), IL-6 (-174G>C, 
nt565G>A), IL-10 (-1082G>A, -819C>T, -592C>A), IL-12 (-1188C>A), IFN-y 
(+874A>T), TGF-~1 (CodonlOC>T, Codon25G>C), TNF-a (-308G>A, -238G>A). 
PCR reactions were carried out using a Biometra T Gradient thermocycler (Montreal 
Biotech Inc., Quebec, Canada) following manufacturer's instructions (Pel-Freez Clinical 
Systems) with the addition of a final 5-minute extension step at 72°C at the end of 
thermal cycling. 
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6.3.3 RNA extraction and semi-quantitative RT-PCR 
Total RNA was isolated from breast tumor tissues by homogenization using the 
Trizol reagent (Gibco BRL, Rockville, MD), followed by treatment with DNA-free 
reagent (Ambion, Austin, TX) to remove any contaminating DNA. Reverse transcription 
was performed on 1 J..Lg RNA using the First Strand eDNA Synthesis Kit (Pharmacia 
Biotech, Quebec, Canada). PCR was performed using a Biometra T Gradient 
thermocycler (Montreal Biotech Inc., Quebec, Canada) to amplify eDNA using primers 
described in Table 6.1. All PCR reactions were performed in a volume of 50 J..LL with 200 
J..LM dNTPs (Gibco BRL) and 1 J..LL eDNA. PCR buffer contained 20 mM Tris-HCl (pH 
8.4) and 50 mM KCI. Samples containing water instead of test eDNA were included as 
contamination controls and eDNA from the cell lines Jurkat E6-1 (IL-2, IL-4, IL-10, 
TGF-f3), C10/MJ (IFN-y, IL-6), U937 (TNF-a, IL-1f3) andY AR (IL-12) were used as 
positive controls. Primers were synthesized by Gibco BRL and included f3-actin [251], 
IFN-y, IL-2, IL-4, IL-6, IL-10, IL-12 p40, TNF-a [252], IL-1f3 [253], and TGF-f31 [254]. 
Primers were used at concentrations of 20 pM for f3-actin, IL-1f3, IL-6, and TNF-a and 
lOpM for all others. MgC12 (Gibco BRL) concentration was 1.5 mM for f3-actin, and IL-
4 and 2 mM for all other reactions. 0.2 J..LL of Taq DNA polymerase (Gibco BRL) was 
used for ~-actin, IL-l~. and IL-6 reactions and all other reactions used 0.25 J.lL. Reaction 
mixtures were amplified for 35 cycles of denaturation at 94°C for 1 min, annealing for 1 
min at 55°C (IFN-y and IL-2), 72°C (TNF-a) or 65°C (all others), and extension at 72°C 
for 1 min, followed by a separate 5 min extension step at 72°C for all but IL-1f3, and IL-
6. The intensity of amplified products was semi-quantified and normalized as a percent of 
f3-actin using the Chemilmager 4000 with Alphaease 4.0 Software. 
220 
Table 6.1: Primer sequences for detection of cytokine mRNA in breast carcinoma 
lesions. 
GenBank 
Size 
Sense Primer (5'-3') Anti-sense Primer ( 5 '-3 ') Accession 
(bp) 
Number· 
ATC TGG CAC CAC ACC CGT CAT ACT CCT GCT TGC 
13-Actin 840 N11 005159 
TTC TAC AAT GAG CTG CG TGA TCC ACA TCT GC 
AGT TAT ATC TTG GCT TTT ACC GAA TAA TTA GTC 
IFN-y 356 100219 
CA AGCTT 
ACT CAC CAG GAT GCT AGG TAA TCC ATC TGT 
IL-2 269 HSU25676 
CACAT TCAGA 
CCA AGA ACT TGC AGC TGG GTC TAT TCC GTT GTG 
IL-12 p40 355 N11 002187 
TGAAG TC 
CCT CTG TTC TTC CTG CTA CCA ACG TAC TCT GGT 
IL-4 371 M23442 
GCA TGT GCC TGG CTT CCT TCA 
ATG CCC CAA GCT GAG TCT CAA GGG GCT GGG 
IL-10 352 NM_000572 
AAC CAA GAC CCA TCA GCT ATC CCA 
GCC CTG GAC ACC AAC AGG CTC CAA ATG TAG 
TGF-13 165 X02812.1 
TAT TGC GGG CAG G 
ACA GAT GAA GTG CTC GTC GGA GAT TCG TAG 
IL-113 75 BT007213 
CTTCCA CTGGAT 
AGC TCA GCT ATG AAC GTC TCC TCA TTG AAT 
IL-6 340 N11 000600 
TCC TTC TC CCA GAT TGG 
CGG GAC GTG GAG CTG CAC CAG CTG GTT ATC 
TNF-a. 354 N11 000594 
GCCGAGGAG TCTCAGCTC 
* All primer sequences were validated using published GenBank mRNA sequences. 
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6.3.4 Immunohistochemistry 
Commercially available monoclonal antibodies (mAb) (BD Biosciences 
Pharmingen, Mississauga, ON, Canada) were used to assess infiltrating CD3+ TIL (clone 
UCHTl, 2.5 J..Lg/ml, Pharmingen) and identify tumor cells (anti-cytokeratin mAb clone 
AE1/AE3, 5 j..Lg/ml, DakoCytomation) Isotype matched non-specific mouse 
immunoglobulins (Southern Biotechnology Associates, Inc., Birmingham, AL, USA) 
served as negative controls. Serial frozen sections (8!J.m) were fixed in acetone for 10 
minutes at -20°C, shipped from the MBTB and stored at -70°C until 
immunohistochemical staining. After thawing, drying and rehydrating in phosphate 
buffered saline (PBS) (pH 7.4), sections were treated with 1.5% hydrogen peroxide in 
PBS for 30 minutes to remove endogenous peroxidases, and nonspecific binding was 
blocked with 15% goat serum in PBS for 1 hour. Sections were incubated for 1 hour with 
primary antibody followed by incubation for 30 minutes with goat anti-mouse DAKO 
En Vision horseradish peroxidase labeled polymer (DAKO Diagnostics Canada Inc., 
Mississauga, ON, Canada). Antibody binding was visualized by incubating with 
diaminobenzidine + hydrogen peroxide (Sigma, Oakville, ON, Canada) for 5 minutes. 
The reaction was stopped with water and sections were counterstained in Mayer's 
hematoxylin. Hematoxylin and eosin staining was performed on one section for each 
breast carcinoma and samples where tumor cells comprised <10% of the section area 
were excluded from analysis. All slides were coded and independently examined by two 
readers, in the absence of information on prognostic parameters. 
Infiltrating CD3+ TIL were coded based on estimated numbers: - (no or a few 
scattered cells); -/+ (small numbers of scattered cells or occasional small aggregates); + 
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(moderate numbers of scattered cells, numerous small aggregates or occasional large 
aggregates); ++ (large numbers of scattered cells or several large aggregates). 
6.3.5 Statistical Analysis 
Contingency tables were analyzed using Pearson's chi-square analysis or Fisher's 
exact two-sided t-test for 2x2 tables with expected counts :::; 5. Non-parametric Mann-
Whitney (2 category variables) and Kruskal-Wallis (:::2 category variables) were used 
when assessing statistical significance of continuous variables. All cytokine SNP 
genotypes were tested to ensure their frequencies were in agreement with those expected 
from allele frequencies using the Hardy-Weinberg equation ( 1 =p2+2pq+q2), with 
deviations from expected assessed using x2-tests. P-values were corrected (Pc) for 
multiple comparisons using the Bonferroni method according to the formula Pc = 1 - (1 -
Pt, where Pc is the corrected value, Pis the uncorrected value, and n is the number of 
comparison groups. 
Survival estimates were calculated using Kaplan-Meier method with log-rank 
statistic. Ninety-five percent confidence intervals (95% CI) around 5-year percent 
survival estimates were calculated using the standard error (SE) of the cumulative 
survival probability (95%CI = cumulative survival probability ±1.96 X SE). Estimates 
were calculated as time to regional or distant metastasis for recurrence-free survival 
(RFS), time to distant metastasis for distant recurrence-free survival ( dRFS) and time to 
death from breast cancer for disease-specific survival (DSS). For disease-free survival, 
patients who died of other causes or who were alive with other malignancy were censored 
from analysis. Backward stepwise Cox proportional hazards models were constructed for 
multivariate survival analyses, using a probability of P<0.05 for stepwise entry and 
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P>0.06 for removal. No patients were lost to follow-up and patients not experiencing the 
event were censored at the time of last follow-up or at 5 years for 5-year survival. For 
multivariate analysis, correlation matrices were constructed to ensure lack of collinearity 
of covariates. For all statistical tests, differences between groups were considered 
significant if P<0.05. All analysis was performed using SPSS Version 11.5 statistical 
software. 
6.4 RESULTS AND DISCUSSION 
To determine if levels of intratumoral cytokine mRNA relate to associations of 
genetic polymorphisms of cytokine genes and prognostic parameters in breast carcinoma, 
60 invasive breast tumors were DNA-typed for single nucleotide polymorphisms (SNPs) 
of their cytokine genes and evaluated for relative intratumoral mRNA levels using RT-
PCR. All SNP genotypes followed Hardy Weinberg equilibrium (see Appendix III), 
except the IL-4 -1098 genotype (x2=7.6, P=0.023), which was excluded from analysis. 
With the exception of the TNF-a -308-238 AG haplotype, which was increased in 
recurrent tumors (6/8 (75%) recurrent versus 16/52 (30.8%) primary tumors, Fisher's 
exact test P=0.042), cytokine SNPs did not differ between primary and recurrent tumors. 
Furthermore, associations of cytokine SNP alleles/genotypes with relative cytokine 
mRNA levels were similar in the 52 primary tumors and in the combined primary and 
recurrent tumor set (see Appendix III). Therefore significant associations are depicted for 
the combined tumor set. Allelic variation in IL-4, IL-10, IL-12 and TNF-a genes did not 
associate with prognostic parameters, patient survival or intratumoral cytokine mRNA 
levels. In contrast SNPs in IL-l~, IL-6, IL-10, TGF-~1, IL-2 and IFN-y showed 
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associations with clinicopathological parameters and/or intratumoral cytokine mRNA 
levels, as discussed in the following sections. 
6.4.1 IL-l~ 
Members of the IL-l family of cytokines and receptors are expressed in tumor 
and stromal cells of breast carcinoma tissue and correlate with poor prognostic indicators 
and pro-angiogenic markers [294 ]. IL-113 represents a prototypical pleiotropic pro-
inflammatory cytokine and within the tumor environment, elevated IL-113 can promote 
tumor growth, invasion and metastasis [257]. We examined two polymorphisms of the 
IL-l~ gene; the -511 C->T transition of the IL-l~ promoter and the + 3962 T>C transition 
located in exon 5 of the coding sequence. 
Stratification of breast carcinoma patients by clinicopathological parameters 
revealed the IL-113 -511 T allelic variant associated with lower tumor grade, especially in 
individuals that carry the -511+3962 TC haplotype (Figure 6.1A). Despite the association 
with well-differentiated tumors, the IL-113 -511 T allelic variant associates with decreased 
recurrence-free survival (RFS: LR=8.4, P=0.004, data not shown), distant recurrence-free 
survival (Figure 6.1B) and disease-specific survival (Figure 6.1B). This was particularly 
evident for individuals that carry the IL-113 -511+3962 TC haplotype (RFS: LR=5.8, 
P=O.Ol7, data not shown; dRFS, DSS: Figure lC). The IL-113 -511+3962 TC haplotype 
remained an independent predictor of poor DSS in multivariate Cox regression 
proportional hazards analysis, controlling for tumor stage, tumor grade, diagnosis age and 
ER expression (P=0.016, HR (95%CI)=4.52(1.32-15.47); Model x,2=8.9, P=0.012). The 
observed associations of the IL-113 -511 T allele or -511 + 3962 TC haplotype with 
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Figure 6.1: Associations of IL-113 SNPs with prognostic factors and survival in invasive 
breast carcinoma. A) The IL-l p -511 T allelic variant associates with decreased tumor 
grade (Pearson's x2=8.6, P=0.003). This was particularly evident for individuals that 
carry the IL-113 -511 +3962 TC haplotype (Pearson's x2=9.1, P=0.003). B) The IL-113 -
511T allelic variant associates with decreased distant recurrence-free survival (dRFS: 
LR=10.2, P=0.001) and disease-specific survival (DSS: LR=7.3, P=0.007). This was 
particularly evident for individuals that carry the IL-113 -511+3962 TC haplotype (dRFS: 
LR=6.6, P=0.010; DSS: LR=4.8, P=0.028). 
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prognosis and survival were not attributable to variability in relative intra tumoral IL-l~ 
mRNA levels (Table 6.2). 
The association of the IL-l~ -511 + 3 962TC haplotype with decreased tumor grade 
supports the finding of Smith et al. (2004) who observed a trend for decreased tumor 
grade in IL-l~ -511T/C individuals as compared to C/C homozygotes, from a study of 
144 European breast carcinoma patients [210]. This study did not examine other SNPs 
within the IL-l P gene sequence and it is likely that the influence of IL-l gene 
polymorphism on disease progression will be dependent on the combination of alleles 
carried by the patient. Thus, it is unclear whether the association of IL-l P with prognosis 
and survival is via alterations in IL-l 13 production or linkage with an unidentified gene. 
We did not observe an association of IL-l p SNPs with IL-l~ mRNA levels 
(Table 6.2), however, the IL-1~ -SliT associates with enhanced LPS-induced IL-l~ 
secretion of ex vivo stimulated whole blood cells [295] and the IL-l~ exon 5 T allele 
associates with increased IL-l~ secretion . from LPS-stimulated peripheral blood 
monocytes [296]. The IL-l p -511 SNP is likely to play a minimal role in the control of 
IL-l~ production and any associations observed are likely attributable to the tight linkage 
of the -511 SNP with an upstream -31 polymorphism which influences the TATA box 
[297]. Others have demonstrated the IL-113 -511 allele has minimal effects on IL-113 
secretion. Instead, levels of constitutive and LPS-stimulated IL-l~ are dependent on the 
IL-lR antagonist, which is influenced by allelic variation in the IL-lRN gene and 
modulates IL-l~ via interception of the IL-l auto amplification loop through IL-lR 
[298]. We did not observe associations of either IL-lRN or IL-lR SNPs with relative 
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Table 6.2: Associations ofcytokine SNPs with relative intratumoral cytokine mRNA 
levels in invasive breast carcinoma 
Cytokine SNP 
IL-l~ -511T-
IL-l~ -511T+ 
IL-l~ -511+3962 TC-
IL-1~ -511+3962 TC+ 
IL-l~ -511 + 3 962 TC/TC 
IL-l~ -511+3962 TC/x 
IL-l~ -511+3962 x/x 
IL-6 -174nt565 CA-
IL-6 -174nt565 CA+ 
IL-6 -174nt565 CA/CA 
IL-6 -174nt565 CAlx 
IL-6 -174nt565 x/x 
IL-10 -1082-819-592 GCC-
IL-10 -1082-819-592 GCC+ 
IL-10 -1082-819-592 GCC/GCC 
IL-10 -1082-819-592 GCC/x 
IL-10 -1082-819-592 x/x 
TGF-13 Codon10Codon25 TG-
TGF-13 Codon10Codon25 TG+ 
TGF-~ Codon10Codon25 TG/TG 
Relative cytokine mRNA levels 
N 
Mean±SEM 
32 21.3±2.4 
23 18.6±1.8 
32 21.3±2.4 
15 19.3±2.6 
6 17.9±3.7 
9 20.2±3.8 
32 21.3±2.4 
19 32.3±5.3 
37 26.9±2.9 
4 40.1±5.2 
33 25.3±3.1 
19 32.3±5.3 
17 21.6±3.2 
37 22.0±2.0 
8 23.9±4.4 
29 21.5±2.2 
17 21.6±3.2 
5 76.1±16.0 
47 52.2±3.4 
19 54.4±7.3 
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Median 
17.8 
18.1 
17.8 
18.9 
16.3 
19.4 
17.8 
27.3 
23.2 
37.5 
22.3 
27.3 
22.7 
21.1 
21.9 
21.1 
22.7 
65.4 
52.0 
50.5 
p 
0.765 
0.991 
0.759 
0.467 
0.211 
0.918 
0.918 
0.052 
0.152 
Cytokine SNP 
TGF-13 Codon10Codon25 TG/x 
TGF-13 Codon10Codon25 x/x 
IL-2 -330+166 TG-
IL-2 -330+166 TG+ 
IL-2 -330+166 TG/TG 
IL-2 -330+166 TG/x 
IL-2 -330+ 166 x/x 
IL-2 -330+ 166 TT-
IL-2 -330+ 166 TT+ 
IL-2 -330+ 166 TT/TT 
IL-2 -330+166 TT/x 
IL-2 -330+ 166 x/x 
IFN-y +874 T-
IFN-y +874 T+ 
IFN-y +874 AlA 
IFN-y +874 A/T 
IFN-y +874 TIT 
Relative cytokine mRNA levels 
N 
Mean±SEM 
28 50.7±2.8 
5 76.1±16.0 
25 8.6±2.5 
35 14.7±1.9 
12 15.8±3.1 
23 14.2±2.4 
25 8.6±2.5 
28 14.0±2.2 
32 10.5±2.2 
5 6.2±3.0 
27 11.4±2.5 
28 14.0±2.2 
16 4.6±1.5 
43 13.9±2.4 
16 4.6±1.5 
31 16.9±3.1 
12 6.4±1.3 
231 
Median 
52.2 
65.4 
4.5 
12.6 
14.1 
11.1 
4.5 
10.8 
5.4 
4.1 
6.3 
10.8 
2.2 
6.9 
6.1 
17.2 
4.6 
p 
0.006 
0.020 
0.106 
0.206 
0.007 
0.010 
IL-l~ mRNA levels (Table 6.2). Furthennore, as the +3962 SNP is located in exon 5 of 
the coding sequence, it may influence protein structure. Thus, it is possible that such 
polymorphisms may still play a role in influencing levels of IL-113 and detection of 
mRNA levels may not be truly representative of protein levels. 
6.4.2 IL-6 
IL-6 represents another pleiotropic pro-inflammatory cytokine that can stimulate 
breast tumor cell growth [299] and enhance IL-l induced breast cancer cell motility 
[300]. The prognostic significance of IL-6 in breast carcinoma is variable depending on 
the stage of disease. Expression of IL-6 by breast tumor cells associates with decreased 
tumor grade and estrogen receptor expression [30 1] and improved survival in early stage 
breast carcinoma [302], while increased serum levels of IL-6 correlate with angiogenic 
factors and decreased patient survival in metastatic breast carcinoma patients [303, 304]. 
In this study, we assessed two polymorphisms located in the 5' untranslated region of the 
IL-6 gene; the -174 G->C transition and the nt565 G->A transition. 
Comparison of IL-6 SNP allelic variants with prognostic parameters revealed the 
IL-6 -17 4nt565 CA haplotype associated with increased ER levels (Figure 6.2). Likewise, 
fewer IL-6 -174nt565 CA+ individuals had ER- tumors as assigned by categorical 
designation (Pearson's x2=8.2, P=0.004, data not shown). The IL-6 -174C and IL-6 
nt565A alleles showed the same associations with ER as the -174nt565 CA haplotype 
(data not shown), as there was complete concordance between the two alleles (x2=60.0, 
P<O.OOOl). There were too few CNCA homozygous tumors withER information (N=3) 
to warrant genotype comparison. IL-6 SNPs did not associate with patient survival (data 
not shown) or intratumoral IL-6 mRNA levels (Appendix III and Table 6.2). 
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Figure 6.2: The IL-6 -174nt565 CA haplotype associates with increased ER levels in 
invasive breast tumors (Mann Whitney U test, P=0.003). 
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Our finding of increased ER levels in tumors carrying the IL-6 -174nt565 CA 
haplotype is in contrast to that of Iacopetta et al. (2004), who reported individuals of 
European Caucasian descent that were homozygous for the -174C allele had significantly 
decreased overall survival and had tumors that were more frequently of high histological 
grade and displayed a trend for lowER content [218]. However, the cut-off value for ER 
was not specificed in this study and they did not examine ER as a continuous variable. 
Two other studies of European Caucasians [214] and mixed ethnicity Americans [216] 
failed to demonstrate an association of the IL-6 SNP with ER, or other prognostic 
indicators. In contrast to Iacopetta et al. (2004 ), a study of LN positive breast carcinoma 
patients found IL-6 -174G/G homozygotes had significantly decreased disease-free and 
overall survival, that was more pronounced in the ER negative group of patients [219]. 
While not addressed in their study, individuals that carry the -174C allele were more 
frequently ER+ (32/51 (63%)) than -174G/G homozygotes (15/29 (52%)), using a cut-off 
value of 10% positive cells although this difference was not statistically significant 
(Pearson's :x,2=0.9, P=0.335). 
Associations of IL-6 promoter polymorphisms with ER levels are intriguing as 
estradiol downregulates IL-6 production via interactions of ER with NF-IL6 and NF-KB 
that prevent their binding to the IL-6 promoter [305]. This modulation is likely influenced 
by allelic variation in the IL-6 promoter as 17-13-estradiol mediates differential effects on 
the activity of IL-6 -174 allelic variants [306]. Using reporter gene assays in an ER+ cell 
line the -174C allele had higher phorbol-myristate acetate (PMA)-induced, but not 
constitutive, transcriptional activity in the absence of 17-13-estradiol than the -174G 
allele. Addition of 17 -13-estradiol corrected the inability of PMA to stimulate IL-6 -17 4G 
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allele transcription. Thus, associations of IL-6 SNPs with intratumoral IL-6 production 
will likely be dependent on estradiol levels, which were not assessed in this study. 
These aforementioned studies assessed only the IL-6 -174 SNP, which was 
previously identified to influence in vitro and in vivo IL-6 levels. Fishman et al. (2000) 
demonstrated, using reporter gene transfected He La cells, that the IL-6 -17 4 C promoter 
had lower constitutive, IL-l and LPS induced activity than the IL-6 -174G promoter. 
Furthermore, comparison of plasma IL-6 levels revealed IL-6 -17 4G/G homozygotes 
(n=35) had significantly increased plasma IL-6 as compared to C/C homozygotes (n=22). 
However Terry et al (2000) demonstrated, using transient transfection assays of IL-6 
haplotype constructs, that the genetic control of constitutive and IL-l-induced IL-6 
production was controlled by the combined effects ofthe -174G>C, -373AnTn, -572G>C 
and -597G>A (equivalent to nucleotide 565 of the gene sequence) polymorphisms and 
identified cell-type specific differences in this control [202]. Thus, in the context of 
breast carcinoma, the control of intra tumoral IL-6 levels is complex and likely influenced 
by the cell types present in the immune infiltrate as well as tumor cell ER expression and 
estradiol levels. 
6.4.3 IL-10 
IL-l 0 represents an important immunomodulatory cytokine and is present at high 
levels in breast carcinoma [307]. Although IL-10 can suppress anti-tumor immune 
responses via suppression of the pro-inflammatory effects of antigen presenting cells and 
inhibition ofT cell activation, experimentally IL-10 can also inhibit tumor growth via NK 
cell activation, blockade of angiogenesis and induction of metalloproteinase inhibitors 
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[308]. We evaluated three SNPs of the IL-l 0 promoter; the -1082 G-> A transition, the -
819 C->T transition and the -592 C->A transition. 
Comparison with prognostic parameters revealed the IL-10 -1082-819-592 GCC 
haplotype associated with decreased levels of ER and PR (Figure 6.3A). Likewise, by 
categorical assignment, individuals that carry the IL-10 -1082-819-592 GCC haplotype 
were more frequently ER- (x.2=6.0, P=O.Ol5, data not shown). ER levels were decreased 
in both GCC homozygotes and GCC heterozygotes (Figure 6.3B). The IL-10 -1082-819-
592 GCC haplotype also associates with infiltrating ductal tumors (Figure 6.3C), which 
contain lower levels of hormone receptors [Mann Whitney U test, P=0.012 (ER), 
P=0.040 (PR); data not shown]. IL-10 SNPs did not associate with patient survival (data 
not shown), or with intratumorallevels of IL-10 rnRNA (Appendix III and Table 6.2). 
This finding was not unexpected as intratumoral IL-l 0 rnRNA levels did not associate 
with hormone receptor expression or tumor type in the larger group of breast carcinoma 
patients from which this subset were selected (Chapter 5). 
Few studies have examined IL-10 SNP associations with prognosis in breast 
carcinoma. Although the IL-l 0 -592A allele associated with increased risk of breast 
cancer development in a study of 500 Austrian Caucasian breast carcinoma patients and 
500 age matched females, it did not associate with tumor size, LN status, tumor grade, 
ER, PR or diagnosis age [215]. Another study of mixed ethnicity American women 
assessed the IL-10 -1082, -819 and -592 SNPs and did not find an association of either 
SNP with risk of disease or prognosis [216]. The lack of consistent associations of IL-l 0 
SNPs with disease susceptibility and prognosis is hypothesized to be attributable to the 
dichotomy ofiL-10 in the immune response to carcinoma, functioning as both an anti-
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Figure 6.3: Associations of IL-l 0 SNPs with prognostic parameters in invasive breast 
carcinoma. A) The IL-l 0 -1082-819-592 GCC haplotype associates with decreased ER 
(Mann Whitney U test, P=0.004) and PR levels in invasive breast tumors (Mann Whitney 
U test, P=0.041). B) Both IL-10 -1082-819-592 GCC homozygotes and heterozygotes 
have decreased ER (Kruskal Wallis H test x2=8.7, P=0.013, Pc=0.038). While PR levels 
do not significantly associate with IL-10 genotype (P=0.118, Pc=0.3l4). Genotype 
groups were compared by Mann-Whitney U test, significant differences are indicated by 
asterisks. *P<0.05, **P<O.Ol. C) IL-10 -1082-819-592 GCC tumors are more frequently 
of the infiltrating ductal carcinoma (IDC) subtype (Fisher's exact 2-sided test, P=O.Ol9). 
All GCC/GCC homozygous tumors are IDC (Kruskal Wallis H test x.2=7.1, P=0.029, 
Pc=0.085). 
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inflammatory and angiogenesis promoting cytokine [309]. 
The IL-10 -1082-819-592 GCC haplotype has been demonstrated to associate 
with increased IL-l 0 transcriptional activity by reporter gene transfection assay [31 0] and 
significantly higher IL-l 0 secretion following in vitro stimulation of PBMC from healthy 
IL-l 0 -1082 GIG homozygotes [311 ], specifically IL-l 0-1082-819-592 GCCIGCC 
individuals [206]. Furthermore, plasma levels of IL-l 0 are increased in healthy GIG 
homozygotes, however, diseased individuals do not demonstrate such an association 
(312]. In contrast, Warle et al. (2003) observed IL-10 -1082-819-592 GCCIGCC 
homozygous PBMC produced significantly lower IL-l 0 production following in vitro 
stimulation in both healthy individuals and liver transplant patients, using a similar 
mitogen stimulation protocol as Turner et al. (1997) (311]. The reasons for this 
discrepancy are unclear; however, they may in part reflect the influence of other upstream 
IL-10 genetic variants. Extended promoter haplotype analysis revealed the GCC 
haplotype exhibits variability in its linkage to distal promoter gene variations, which were 
shown to influence IL-10 production by PBMC and EBV-transformed B cells [313]. This 
study also identified differential effects of cell stimulus (LPS, dibutyryl-cAMP and EBV) 
on associations of allelic variants with IL-l 0 production. Thus, genetic control of IL-l 0 
production likely involves the interaction of multiple allelic variants and will be cell-type 
and stimulus dependent. 
6.4.4 TGF -f31 
TGF-JH represents another immunomodulatory cytokine expressed at high levels 
in breast carcinoma that exhibits both tumor suppressing and tumor promoting effects. 
TGF -f31 inhibits tumor growth at the early stages of tumor development, but later, 
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autocrine TGF-f3 signaling in tumor cells can promote tumor growth, invasion and 
metastasis [314]. Indeed, breast carcinoma patients with advanced disease have elevated 
plasma TGF-131 [315] and intratumoral TGF-131 protein expression [316] associates with 
decreased survival in breast carcinoma patients. We evaluated two SNPs of the TGF-~1 
signal sequence. The Codon 10 T->C transition results in a leucine/proline substitution at 
amino acid 10, while the Codon 25 G->C transition results in an arginine/proline 
substitution at amino acid 25. 
In the breast carcinoma patients assessed in this study, TGF-~1 SNPs did not 
associate with prognostic parameters or survival (data not shown). However, tumors that 
carry the TGF-131 Codon 10 Codon 25 TG haplotype display a trend for decreased 
intratumoral TGF-IH mRNA (Table 6.2). This finding supports previous studies that 
found the TGF-(31 Codon 10 T allelic variant associates with decreased TGF-(31 
production. HeLa cells transfected with a TGF-131 eDNA CMV construct containing the 
T allele had a 2.8-fold decrease in secretion of TGF-131 than those transfected with the 
TGF-131 Codon 10 C allele CMV construct [201]. Furthermore, serum levels ofTGF-131 
are lower for Codon 10 TIT homozygotes as compared to C/C homozygotes [317]. 
Other groups have also observed a lack of association of TGF-~1 Codon 10 or 
Codon 25 SNPs with prognostic parameters in breast carcinoma patients [216, 217, 318], 
although the TGF-~1 Codon 10 C/C homozygous individuals have increased incidence of 
metastasis and decreased survival, as compared to individuals that carry at least one T 
allele at Codon 10 [216, 318, 319]. These findings would support the in vitro and in vivo 
associations of the TGF-131 Codon 10 T allele with decreased TGF-~1 and the role of 
high levels ofTGF-131 in disease progression [314]. 
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6.4.5 IL-2 
IL-2 is a prototypical T cell cytokine and substantial experimental and clinical 
evidence suggests IL-2 is crucial in the regulation of anti-tumor immunity, via its 
stimulatory actions on TAA-specific CTLs, NK cells, B cells and macrophages [320]. 
IL-2 mRNA and protein are also detected at low levels in breast carcinoma cells [321] 
and its expression may function as an autocrine growth factor [322]. We evaluated two 
SNPs of the IL-2 gene; the -330 T-> G transition of the 5' untranslated region and the 
+ 166 G->T transition of the leader peptide. 
We observed an association of the IL-2 -330+ 166TT haplotype with large tumors, 
when assessed as a categorical variable (Figure 6.4A), and IL-2 -330+ 166TT individuals 
displayed a trend for increased tumor size when tumor diameter was assessed as a 
continuous variable (Mann Whitney U test P=0.076, data not shown). This statistically 
significant difference was not observed when IL-2 -330+ 166 TT genotype categories 
were compared (Figure 6.4A). Other IL-2 SNP alleles/haplotypes did not associate with 
prognostic parameters (data not shown). Furthermore, there were no observed differences 
in patient survival with respect to IL-2 SNPs (data not shown). Despite the observed 
association with tumor size, the IL-2 -330+ 166TT haplotype did not associate with 
intratumoral IL-2 mRNA levels. This was somewhat unexpected as IL-2 mRNA levels 
negatively correlated with tumor size in the larger group of breast carcinoma patients 
from which this subset were selected (Chapter 5). However, patients that carried the IL-2 
-300+ 166 TG haplotype had significantly higher IL-2 levels (Table 6.2), reflected by both 
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Figure 6.4: Associations of IL-2 SNPs with prognostic parameters in invasive breast 
carcinoma. A) The IL-2 -330+ 166 TT haplotype associates with large tumors (x,2=4.4, 
P=0.036) and a trend of association was observed with -330+ 166 TT genotype groups 
(x,2=4.6, P=O.IOI, Pc=0.273). B) Median and Mean ± SEM of IL-2 mRNA levels in 
tumors stratified by relative numbers of infiltrating CD3+ TIL. The IL-2 -330+166 TG 
haplotype associates with increased intratumoral IL-2 mRNA in tumors with no CD3+ 
TIL (Mann-Whitney U test, P=0.024), small to moderate numbers of CD3+ TIL (Mann-
Whitney U test, P=0.030), but not in tumors with large numbers of infiltrating CD3+ TIL 
(Mann-Whitney U test, P=0.755), as detected by indirect immunohistochemistry. 
A 
-c 
:I 
0 1 
u 
IL-2 TI- (N=25) IL-2 TI+ (N=32) 
IL-2 -330T +166T 
nm (N=5) TI/x (N=27) x/x (N=25) 
IL-2 -330+166 Genotype 
245 
[] <=2cm 
• >2cm 
[5] <=2cm 
• >2cm 
8 
<( 
z 
a::: 
E 
~ 
..J 
c 
.! 
"C 
Cl) 
:E 5. 
IL-2 -330T +166G 
• IL-2 TG- (N=25) 
@J IL-2 TG+ (N=32) 
n=7 
None Sm-Mod # Lg # 
CD3+ Infiltrating Cells 
IL·2 ·330T +166G 
• IL-2 TG- (N=25) 
lli\"11L-2 TG+ (N=32) 
40.0 .....-------~============: 
-:E 
w 
en i- 30.0 
-<( 
z 
a::: E 20.0 
N 
I 
..J 
Cl) 
.~ 10.0 
..... 
cu 
& 
Figure 6.4 continued. 
None Sm-Mod # Lg # 
CD3+ Infiltrating Cells 
246 
TG/TG homozygotes and TG/x heterozygotes and 9/13 (69%) small tumors carried the 
IL-2 -330+166 TG haplotype as compared to 23/44 (52%) large tumors, although not 
statistically significant (x2=1.2, P=0.279). 
There have been no published reports examining IL-2 SNPs and disease 
susceptibility or prognosis in breast carcinoma. However, the effect of the IL-2 -330 
SNP on cytokine production has been investigated. Hoffinann et al. (2003) observed 
PBMC from healthy individuals homozygous for the IL-2 -330 G allele produce 
increased IL-2 protein following ex vivo stimulation via TCR engagement [206]. Using 
reporter gene constructs, Matesanz et al. (2004) [323] found that the Jurkat T cell line, 
transfected with the IL-2 -330G containing construct, produced twofold higher levels of 
gene expression than the -330T construct transfected cells, following PMA activation. 
However, they observed opposite contradictory observations when examining IL-2 
mRNA as IL-2 levels were increased in IL-2 -330 TIT and T/G stimulated peripheral 
blood lymphocytes, from healthy controls and multiple sclerosis patients, suggesting 
additional factors influence the in vivo situation. Indeed, we observed increased 
intratumoral IL-2 mRNA levels in individuals carrying the -330+ 166 TG haplotype but 
not the -300+ 166 TT haplotype, suggesting an influencing effect of allelic variation at 
position + 166, or an unidentified linked factor. 
As we have previously demonstrated high relative intratumoral levels of IL-2 
mRNA associate with increased numbers of infiltrating CD3+ TIL (Chapter 5), we 
further examined the influence of IL-2 SNPs within tumors subgrouped by CD3+ TIL. 
Stratification of primary tumors by relative numbers of CD3+ TIL revealed relative IL-2 
mRNA levels were increased in individuals carrying the IL-2 -330+ 166TG haplotype 
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with no or small to moderate numbers of CD3+ TIL. However, in the subgroup of 
patients with large numbers of CD3+ TIL, relative intratumoral IL-2 mRNA levels were 
independent of SNPs as both TG- and TG+ individuals had elevated IL-2 mRNA (Figure 
6.4B). This suggests the genetic control of IL-2 production in breast carcinoma is 
minimal in the presence of large numbers of infiltrating TIL. In the absence of substantial 
TIL, IL-2 production is attributable to other cell types; including breast tumor cells [321 ], 
which may exhibit cell type specific variability in regulatory elements that influence. the 
effects of genetic variation on IL-2 production. 
6.4.6 IFN-y 
IFN-y is produced mainly by THl cells, CTLs and NK cells and is a potent anti-
cancer agent via enhancement of the anti-tumor activity of host's immune cells. Elevated 
intratumoral IFN-y associates with decreased tumor size and improved patient survival in 
breast (Chapter 4) [256] and ovarian carcinoma [270]. Experimentally, IFN-y is critical in 
mediating the anti-tumor immune response to metastatic breast carcinoma [324]. We 
have investigated the IFN-y +874 T->A transistion, which correlates with a CA-repeat in 
intron 1 ofthe IFN-y gene [325]. 
In our subset of breast carcinoma patients, the IFN-y +874T allele associated with 
decreased tumor diameter and this was observed with both +874T/T homozygotes and 
A/T heterozygotes (Figure 6.5A). The IFN-y +874T allele also associated with 
histological grade III tumors (Figure 6.5B). Patients that carry the IFN-y +874T allele 
associated with increased intratumoral IFN-y (Table 6.2), but this was largely attributable 
to AfT heterozygotes (Table 6.2). These associations support our finding that increased 
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Figure 6.5: Associations of IFN-y SNPs with prognostic parameters in invasive breast 
carcinoma. A) The IFN-y +874T allele associates with decreased tumor size (Fisher's 
exact 2-sided test, P=0.012), and is most pronounced in A/T heterozygotes (x.2=8.3, 
P=0.015, Pc=0.044). B) The IFN-y + 874T allele associates with increased tumor grade 
(x.2=5.4, P=0.020), observed in both TIT homozygotes and A/T heterozygotes (x.2=5.7, 
P=0.058, Pc=0.164). C) Median and Mean ± SEM of IFN-y mRNA levels in tumors 
stratified by relative numbers of infiltrating CD3+ TIL. The IFN-y +874T allele 
associates with increased intratumoral IFN-y mRNA in tumors with small to moderate 
numbers of CD3+ TIL (Mann-Whitney U test, P=0.040), but not in tumors with no CD3+ 
TIL (Mann-Whitney U test, P=0.886), which have low levels of IFN-y or in tumors with 
large numbers of infiltrating CD3+ TIL as all but one tumor with large numbers of CD3+ 
TIL carry the IFN- y +874T allele (Mann-WhitneyU test, P=0.500). 
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intratumoral IFN-y mRNA levels associate with small tumor diameter and increased 
tumor grade (Chapter 5). 
The IFN-y +874 TIT genotype associated with increased breast cancer risk, in two 
small scale studies of Iranian [326] and Indian women [327], but did not predict 
increased risk of disease in a small study of American women of mixed ethnicity [216]. 
Previous studies did not demonstrate an association of the IFN-y +874 SNP with 
prognostic parameters [216, 326]. However, in contrast to our study, neither tumor size 
nor tumor grade were examined in these patients. 
The association of the IFN-y +874T allele with increased intratumoral IFN-y 
supports that of Pravica et al. (1999) who demonstrated in healthy individuals that IFN-y 
+874TIT homozygotes produce more IFN-y, following in vitro stimulation ofPBMC with 
mitogen [205]. Hoffmann et al. also demonstrated increased IFN-y secretion from PBMC 
of healthy individuals in both TIT homozygotes and NT heterozygotes following 
mitogen stimulation and significantly higher IFN-y secretion from TIT homozygotes 
compared to NT or NA individuals following anti-CD31CD28 stimulation of PBMC 
[206]. However, contradictory reports exist as Warle et al. (2003) did not demonstrate an 
association of the IFN-y +874 SNP with in vitro production of IFN-y in liver transplant 
recipients [223] and reporter gene assays demonstrated higher activity of the IFN-y -
874A promoter as compared to the -874 T variant HepG2 hepatoma and unstimulated and 
PMA treated Jurkat T cells [327]. Saha et al. (2005) suggest discrepancies in reports of 
transcriptional activity and protein levels in relation to IFN-y +874 SNPs may reflect the 
association with an unidentified variation apart from the CA repeat, which is in complete 
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linkage with position +874 [325] and shown to assocate with in vitro IFN-y production 
[205] or alternatively may reflect posttranscriptional differences attributable to the CA 
repeat length of the IFN-y intron region [327]. These studies suggest genetic control of 
IFN-y production is far more complex than the single polymorphism at position +874 and 
factors produced in diseased individuals may modulate IFN-y production in variable ways 
to that seen in healthy individuals. 
As relative intratumoral IFN-y mRNA also associates with numbers of CD3+ TIL 
(Chapter 5), IFN-y +874 SNP associations with IFN-y mRNA levels were assessed in 
tumors stratified by relative CD3+ TIL numbers. Relative intratumoral IFN-y was slightly 
increased in individuals carrying the IFN-y +874T allele with small or moderate numbers 
of CD3+ TIL. However, levels did not associate with the IFN-y +874T allele in tumors 
with no CD3+ TIL, reflecting the decreased IFN-y in these tumors, nor with tumors 
containing large numbers of CD3+ TIL, as all but one carried the IFN-y +874T allele 
(Figure 6.5C). This suggests infiltrating TIL play the predominant role in determining 
relative intratumoral IFN-y levels. 
6.5 CONCLUSION 
The small number of breast tumors examined and the semi quantitative 
determination of intratumoral cytokine mRNA levels limit interpretation of our findings. 
However, the results of this small study suggest reports of cytokine SNP associations 
with breast cancer susceptibility or prognosis must be interpreted with caution in the 
absence of information on the cytokine levels. Indeed, individuals in a diseased state do 
not always share the associations of cytokine gene polymorphisms with in vitro cytokine 
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production following cell stimulation or plasma levels, observed in healthy individuals 
[223, 312]. Few studies have evaluated the influence of genetic polymorphisms on in vivo 
cytokine production. However, establishing a link with cytokine production in the context 
of carcinoma and other diseased states will likely prove difficult as carcinomas are 
marked by inflammatory infiltrates and the interplay of other cytokines and growth 
factors likely override this genetic control. 
Although the number of samples was too few to warrant a meaningful statistical 
analysis, stratification of tumors based on relative numbers of CD3+ TIL and IFN-y or 
IL-2 SNPs revealed that although intratumoral cytokine mRNA levels may in part be 
influenced by promoter polymorphisms they are largely dependent on the relative number 
of infiltrating inflammatory cells. Furthermore, associations of some cytokine SNPs with 
prognostic parameters occurred in the absence of intratumoral cytokine variation. Thus, 
until the complexity of genetic control of cytokine production is elucidated rather than 
interpreting results based on published results of in vitro cytokine production studies on 
SNP associations with disease susceptibility and/or prognosis should be interpreted with 
respect to gene loci. Such associations may be independent of variation in immune 
responsiveness and attributable to linkage with additional cytokine gene allelic variants 
or an unidentified tumor suppressing or tumor-promoting gene. 
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CHAPTER 7: SUMMARY AND FUTURE DIRECTIONS 
The studies described in this thesis have made many novel and important findings 
which increase the understanding of the in situ immune response to invasive breast 
carcinoma. Early studies of anti-tumor immunity focused largely on TAA-specfic CDS+ 
CTL and tumor cell HLA class I antigen expression. However, substantial evidence 
supports a role for tumor cell HLA class II expression in the anti-tumor immune response 
(see Section 1.7.2). To further understand this role in the context of invasive breast 
carcinoma, we evaluated components of the anti-tumor immune response within the 
tumor microenvironment. The major findings of this research project, limitations of 
experimental design and possibilities for future investigative study are discussed in the 
following sections. 
7.1 Summary of major findings 
In a small comparison study of an equal number of HLA-DRBl *04+ and non-
HLA-DRBl *04 patients, we observed the DRI3l *04 allotype was expressed more 
frequently than other HLA-DRI3 allotypes and the majority of HLA-DR+ tumors lack 
expression of one or more HLA-DRI3 allotypes (Chapter 2). This study is the first to 
document differential HLA-DRI3 allotype expression in situ in carcinoma lesions. Several 
factors have impeded the investigation ofHLA-DRI3 allospecificities in carcinoma tissue, 
most notably, the lack of HLA class II allotype specific antibodies at the time of earlier 
studies of HLA class II expression in breast carcinoma. IHC represents an effective and 
necessary means for evaluating HLA antigen expression in tumor tissues as studies have 
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shown mutations in genes that encode HLA class I antigens that inhibit their translation 
but not their transcription [229]. Similar mutations are likely to occur in HLA class II 
genes as studies conducted in our laboratory revealed the lack of protein expression of 
particular HLA class II specificities despite the presence of mRNA using a panel of 
breast carcinoma cell lines and cultured fibroblast-like synoviocytes [140, 267]. 
The discovery of differential HLA-DRI3 allotype expression by breast tumor cells 
(Chapter 2) led to a larger study of unselected invasive breast carcinoma patients, with 
prognostic and outcome information, which allowed the investigation of the biological 
and prognostic implications of HLA-DRI3 allotype expression by breast tumor cells 
(Chapter 3). Again, HLA-DRI31 *04 was expressed more frequently by breast tumor cells. 
Furthermore, HLA-DRP1 *04 expression by tumor cells associated with elevated IFN-y 
mRNA levels, decreased tumor size and improved patient survival, while HLA-DRI31 * 13 
patients with DR-expressing tumor cells had decreased IFN-y, elevated IL-113, TGF-131 
and FOX-P3, LN metastasis and decreased survival. While these findings indirectly 
suggest the opposing influence of the DRB1 *04 and DRB1 *13 allotypes on patient 
outcome may be attributable to variability in immune responsiveness, this assumption is 
made based on relative intratumoral mRNA levels. Intratumoral mRNA levels provide 
an indication of the pattern of immune reactivity in breast carcinoma lesions, however the 
cellular source of cytokine mRNA was not identified in this study. Furthermore, the 
presence of mRNA is not necessarily indicative of protein production. Indeed cytokine 
mRNA and protein expression are not always perfectly correlated [183]. The lack of 
protein expression despite mRNA may reflect the improved sensitivity of RT-PCR, 
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problems with protein detection or, alternatively, post-translational modifications that 
prevent protein expression. 
As discussed in Chapter 3, it is plausible to speculate that DRBl *04+ patients 
display an enhanced propensity for presentation of endogenous tumor antigen derived 
peptides by tumor cells, to activate TAA-specific CD4+ THl cells. In support of this, at 
the time of surgery, DRBl *04+DR+ tumors had a smaller tumor diameter. This is in 
contrast to a Russian study which reported DRBl *04 associated with markers of a poor 
prognosis [128]. However, they only assessed carriage of HLA-DRB alleles and tumor 
cell expression of HLA-DRB 1 *04 protein was not examined. Furthermore, this 
discrepancy may be due to varying DRB1 *04 allele distribution between the two 
populations. The majority of DRBl *04+ patients in this study carried the DRBl *0401 
allele and in the larger subset of patients from which these samples were selected 
DRB 1 *040 1 was increased in small tumors. In contrast, no difference was observed for 
DRB I* 0404 and although DRB 1 *0407 occurred at a frequency <5%, 10111 
DRB1 *0407+ tumors had a tumor diameter> 2cm (data not shown). Allelic differences 
in DRB 1 *04 alleles may also influence their ability present peptides from endogenous 
tumor antigens due to differences in their relative affinity for CLIP, which is known to 
block the peptide binding groove preventing presentation of endogenously derived 
peptides. Certainly, DR~ I *0401 and DR~1 *0404 form less stable complexes with CLIP 
than DR~ 1 *0402 [328]. 
The idea that CLIP expression might repress effective anti-tumor immunity is 
suggested by our observation that co-expression of the peptide immunoeditor HLA-DM 
in HLA-DR expressing tumor cells associated with a TH1 immune profile and improved 
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survival (Chapter 4). Although limited tissue availability precluded the examination of 
CLIP by breast tumor cells in this study, as discussed in Chapter 4, in vitro studies using 
BCCL demonstrated elevated surface CLIP in HLA-DM deficient BCCL as compared to 
HLA-DM+ BCCL. Importantly, increased survival and enhanced THl-type immunity in 
patients with HLA-DM expressing tumors and HLA-DRJ31 *04-expressing tumors was 
not attributable to an association between the two factors (Fisher's exact 2-sided test, 
P=0.491; data not shown). This further suggests presentation of TAA-derived peptides 
by DRB1 *0401 may not require HLA-DM-mediated exchange of CLIP, for the effective 
activation ofT H 1 cells. This reduced affinity of alleles such as DRB 1 *040 1 for CLIP will 
likely enhance the presentation of antigenic peptides, including TAA derived peptides, 
even in HLA-DM- cells. 
Elevated intratumorallevels of the TH1-type cytokine IFN-y (Chapter 4) and the 
proinflammatory cytokine TNF-a (Chapter 5) associate with improved survival in 
invasive breast carcinoma patients. Although the cellular sources of cytokine production 
were not assessed in this study, IFN-y is secreted in high amounts by activated THl, Tel, 
NK and NKT cells and TNF-a can be secreted from macrophages, TH1 and TH2 CD4+ T 
cells, Tel and Tc2 CDS+ T cells as well as NK cells [121]. The association with large 
numbers of CD3+ TIL suggests a substantial contribution from TIL, most reflected by 
CD4+ TIL. Indeed, in an experimental model of invasive breast carcinoma, CD4+ TIL 
were the predominant producers of TIL-derived TNF-a [284] and TAA-specific CD4+ 
THl cells that secrete both IFN-y and TNF-a can be readily expanded ex vivo from breast 
carcinoma patients (329]. Since ovarian cancer patient survival was reported to be 
dependent on the balance of effector and regulatory cell subsets [195], survival was 
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assessed in patients categorized based on T Hl :T H2/Treg mRNA profiles (Chapter 5). There 
was no difference in survival when patients were stratified based on the ratio of IFN-y to 
IL-4, IL-10, TGF-Pl or FOX-P3. However, a marked increased in DSS was observed 
when ranked intratumoral TNF-a levels exceeded TGF-Bl. This suggests the balance of 
pro-inflammatory and immunoregulatory cytokines predict patient outcome. 
As intratumoral cytokine mRNA levels associated with prognosis and survival in 
breast carcinoma patients (Chapter 5) and published reports suggested cytokine 
production was in part controlled by genetic variation, a small scale exploratory study 
was conducted to assess the relationship of cytokine gene polymorphisms with relative 
intratumoral cytokine mRNA and prognosis (Chapter 6). As discussed in Chapter 6, the 
results presented in this study must be interpreted with caution owing to the small scale 
of the investigation. However, they suggest SNPs of cytokine genes play a minor role in 
the control of cytokine production in breast carcinoma patients. The true significance of 
genetic variation in cytokine genes in the context of carcinoma is at present unclear as the 
full contribution of extended SNP haplotypes on cytokine production in response to 
various stimuli and in different cell types remains to be fully characterized. More 
extensive in vitro and in vivo studies are required to understand the combined effects of 
these factors on the genetic control of cytokine production. Until such factors are 
elucidated it will remain difficult to assess the biologic and prognositic significance of 
genetic variation in cytokine genes in the context of complex disease. 
Intriguingly, expression of HLA class II and co-chaperones and the presence of 
TIL subsets associated with decreased age at diagnosis and lack of hormone receptor 
expression (Chapters 3-5). As discussed in these Chapters, this suggests a role for 
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hormonal control of expression of HLA class II antigens in breast carcinoma cells and/or 
the recruitment and activation ofT cell subsets and enhancement of cytokine production. 
Additional roles for estradiol-ER interactions with the anti-tumor immune response are 
suggested by the discoveries that in vitro culture with 17 -~-estradiol modulates cytokine 
and chemokine production by immature human DC and enhances the ability of mature 
DC to stimulate allogeneic T cell responses [330]. While these factors were not addressed 
in this study, they are important avenues for future investigation, to aid in unraveling the 
interplay ofhormones and cytokines in breast carcinoma. 
7.2 Study limitations 
Utilizing IHC to assess HLA antigen expression in tumor tissue is not without 
pitfalls. In particular it relies on the subjective determination of the degree of tumor cell 
staining. However, in our experience, reading of immunohistochemistry slides by three 
independent readers showed a high level of concordance with the estimated percentages 
of positive tumor cells never differing by more than 10%. While it is acknowledged that 
the morphology of acetone-fixed tissue sections is inferior to formalin-fixed paraffin 
embedded tissue (FF-PET), such methods are required for the investigation of HLA 
antigen expression as many of the determinants recognized by HLA antigen-specific 
mAbs are lost in FF-PET due to the denaturing conditions of the fixation protocol. It is 
important to note, that detection ofHLA-DR~ allotype and HLA co-chaperone molecule 
expression by immunohistochemistry does not exclude that they are non-functional or 
malfunctional because of mutations and/or changes in their conformation. Furthermore, 
as certain mAbs may be cell-type restricted and/or alternatively display extra reactions 
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depending on cell type and/or assay conditions, preliminary research and development 
studies investigated several fixation protocols and all antibodies were titrated for optimal 
detection of HLA allospecificities on breast cancer cell lines, at levels comparable to 
homozygous B cell lines (data not shown), using the same IHC procedure employed for 
breast carcinoma tissue sections. To further compensate for affinity differences in HLA-
DRS allotype specific mAbs, infiltrating inflammatory cells and stromal cells served as 
intrinsic controls. The possibility of cell-type specific reactivity was eliminated by testing 
antibodies on a panel of cell types that had been molecularly typed for HLA-DRB alleles 
(Chapter 2). Antibodies that did not conform to these guidelines were eliminated from the 
study. To decrease any discrepancy in detection of expression of HLA antigens and HLA 
co-chaperones that might be attributable to antibody affinity differences, antibodies 
directed against generic HLA-DR, HLA class I, Ii and HLA-DM were titrated for optimal 
reactivity against acetone-fixed cytocentrifuge preparations of B cell lines and IFN-y 
treated BCCL. In addition, all antibodies directed against cellular differentiation antigens 
were titrated using acetone-fixed PBMC cytocentrifuge preparations (data not shown). 
Limited tissue availability precluded immunohistochemical cytokine 
determination. Thus, semi-quantitative RT-PCR was utilized to determine the cytokine 
mRNA profile of the breast tumor lesions. RT-PCR allows for more sensitive 
determination of cytokine production in situ than immunohistochemistry and preliminary 
experiments demonstrated RT-PCR was much more efficient than ribonuclease 
protection assays which required greater amounts of RNA and were more time 
consuming. To control for variation in 13-actin levels in tumor cells, all PCR reactions 
included a control cell line and breast carcinoma samples giving a 13-actin level <25% 
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that of control cell line were eliminated from analysis. Furthermore, glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) control was also run with all IL-l~, IL-6 and FOX-
P3 reactions and natural log-transformed ratios were positively associated by Pearson's 
correlation (IL-l~: r = 0.72 , P<O.OOOl; IL-6: r = 0.90 , P<O.OOOl; FOX-P3: r = 0.95 , 
P<O.OOOl, data not shown). 
It is important to acknowledge, the breast carcinoma samples assessed by IHC 
and/or RT-PCR represent only a portion of the total breast tumor, which can have 
variability in clonal distributon of tumor cells. This study was also limited by its 
retrospective nature and restricted tissue availability. As previously discussed, 
associations of HLA class II expression and infiltrating T cells with earlier age at 
diagnosis and lack of estrogen receptor expression on tumor cells imply a role for 
hormonal regulation. However, levels of intratumoral or circulating estradiol were not 
determined in the patients utilized in this study and information on patient menopausal 
status was not available from the MBTB. In addition to standard hormone production, 
intratumoral enzymes such as aromatase, 17-~-hydroxysteroid dehydrogenase and 
estrone sulfatase regulate the production and metabolism of estrogens [331]. The use of 
the charcoal-dextran ligand binding assay to determine tumor cell hormone receptor 
expression of different histological subtypes of breast carcinoma can be problematic as 
lobular carcinomas can be falsely considered hormone receptor negative by biochemical 
assay as there are often fewer tumor cells dispersed in the sample [332]. However, in the 
subset of patients described in this thesis, primary tumors of ILC type had mean levels of 
63 fmollmg for ER and 117 fmol/mg for PR as compared to 35 fmol/mg and 47 fmollmg, 
respectively, for IDC tumors. In addition, using a cutoff of 10 fmol/mg, only 2/13 
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(15.4%) ILC tumors were ER- and 3/13 (23.1%) PR- compared to 39/81 (48.1%) ER-
and 29/81 (35.8%) PR- IDC tumors. 
Furthermore, information on patient ethnicity was not available from the MBTB. 
While the majority of patients are likely of European Caucasian descent, a proportion of 
patients are also likely to be of North American Indian and Asian descent. Ethnic groups 
display differences in their distribution of HLA alleles [333] as well as cytokine SNPs 
[334]. Ethnic differences can affect patient outcome and may have introduced bias in the 
results of this study. However, multivariate analysis was employed in this study to 
control for clinicopathological parameters, which may have varied by ethnicity. 
7.3 Future Directions 
The work described in this thesis has provided insight into the complexity of the 
immune response to carcinoma. Although the studies described are largely descriptive, 
owing to the nature of the sample material, they have allowed for the generation of 
several hypotheses that can be further investigated: 
1) Multiple mechanisms underlie the lack of HLA-DR and/or co-chaperone 
expression in breast carcinoma. 
As discussed in Chapters 2 and 3, the mechanisms responsible for differential 
HLA-DRP allotypic expression have not yet been elucidated. They are likely to include 
defects in CIITA or other transcription factors, epigenetic modifications, LOH, point 
mutations and variability in expression of cytokine receptors. Isolation of tumor cells 
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from breast carcinoma lesions will allow investigation of the mechanisms responsible for 
lack of expression of HLA class II and/or co-chaperones in breast carcinoma lesions. 
Enzyme disruption of tumors, followed by flow cytometry is a potential means to isolate 
tumor cells for further evaluation; however, due to advances in breast cancer diagnosis 
the size of available fresh breast carcinoma tumors available for such studies is minimal. 
Therefore, optimizing techniques such as laser capture micro-dissection, for isolation of 
tumor cells from archival FF-PET would allow further investigation of such mechanisms 
in a large series ofbreast carcinoma lesions. 
2) Differential expression of HLA-DRJ3 allotypes represents an immune evasion 
strategy 
As discussed in Chapter 3, lack of expression of a particular HLA-DR~ allotype 
by HLA-DR+ tumor cells may be reflective of immune-mediated selective pressure and 
the outgrowth of immune escape variants that have down-regulated the relevant HLA-DR 
allele. The finding that differential HLA-DRB allotype expression is a frequent 
phenomenon in HLA-DR+ breast carcinomas infiltrated by CD4+ T cells suggests it may 
be in response to immune selective pressure. In support of this, all secondary lesions 
show differential DR~ allotypic expression. However, the primary and secondary lesions 
examined in this study were not from the same patient. The recent advances in tumor 
bank sample and data collection make the comparison of primary and recurrent tumors 
from the same patient a realistic possibility. Future immunohistochemical studies aimed 
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at investigating expression of HLA-DR~ allotypes in primary and secondary lesions 
obtained from the same patient may provide insight into whether allotype loss correlates 
with disease progression. 
Contentious to this hypothesis is the finding that HLA-DR~l *04 expression by 
tumor cells associates with improved prognosis and the existence of T H !-dominated 
immunity. Reasons for enhanced expression of DR~ I *0401 are unknown and are 
unlikely to be explainable by differences in antibody affinity (Section 7.2). As discussed 
in Chapter 3, increased DRBl *0401 expression may involve differential targeting of 
HLA-DR~l *0401 molecules through the endocytic pathway and differential peptide 
loading of DR~ I *0401 molecules, via heat shock protein interactions [261]. Co-
localization experiments in HLA-DRB typed BCCL that express HLA-DR~ allotypes 
with heat shock proteins and markers of the endocytic pathway would offer insight into 
whether such differences exist in breast epithelial cells. Elucidating the mechanisms 
responsible for elevated HLA-DR~ 1 *04 expression may provide further insight into the 
control of differential HLA-DR,B allotype expression in carcinoma lesions. 
3) 17-~-estradiol and intratumoral cytokines modulate HLA class II expression by 
tumor cells 
The negative association of HLA-DR expression and diagnosis age and ER levels 
suggest a role for hormonal regulation of HLA-DR and mechanisms for such control 
have been discussed (Chapter 3-4). However, this hypothesis is speculative as 
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information on menopausal status and relative hormone levels were not available for the 
study subjects. Studies conducted in our laboratory, demonstrated both constitutive and 
IFN--y-induced HLA-DR expression by BCCL are modulated in a cell line specific 
manner by steroidal and non-steroidal estrogens [335]. As cell line specific differences 
were observed that extended beyond ER status, it suggested additional factors are 
responsible for the hormone mediated control of HLA-DR expression by tumor cells. 
Future studies employing the same cell line with or without transfected ER will provide 
further insight into the specific control of HLA-DR expression via 17-~-estradiol-ER 
complexes. As Ii and HLA-DM also associated with decreased diagnosis age and ER 
levels were lowest in tumors that co-express HLA-DR and Ii, elucidating the effects of 
17-J3-estradiol on HLA co-chaperone expression are also warranted. Furthermore, the 
association of HLA-DR expression with diagnosis age was somewhat variable based on 
the HLA-DRJ3 alleles carried by the patient. Thus it will be useful to investigate whether 
there are HLA-DRB allelic differences in the molecular control of HLA-DR expression 
via estradiol-ER complexes. 
The association of tumor cell expression of HLA-DR and the co-chaperones Ii 
and HLA-DM with elevated levels of THl cytokines (Chapter 4), likely reflects their 
upregulation in response to elevated intratumoral IFN-y, which is a potent inducer of 
HLA class II antigens on BCCL [134]. Furthermore, as discussed in Chapter 3, the 
increased expression ofHLA-DRBI *04 may in part reflect elevated IFN-y and decreased 
TGF-J31, which can suppress IFN-y induction of HLA-DR via Smad3 dependent 
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inhibition of CIITA promoter IV activity [260]. However, in vitro studies conducted in 
our laboratory have demonstrated that although TGF-~1 suppresses IFN-y-induced HLA-
DR expression in some BCCL, it is augmented in others, possibly via a Smad-
independent signaling pathway [335]. The association of HLA-DR~ 1 * 13 expression with 
elevated IL-l~ in the absence ofhigh intratumoral IFN-y levels, suggests a role for IL-l~ 
in the induction of HLA-DR expression in invasive breast carcinomas. As previously 
discussed, in vitro studies have demonstrated IL-l~ can induce HLA-DR expression in 
breast carcinoma cells [135]. Whether this induction is modulated by other cytokines is 
not known and could be examined in future studies. This modulatory effect is likely 
dependent on the hormone milieu as 17-13-estradiol can inhibit IL-l induced HLA-DR 
expression in a BCCL [135], although the mode of inhibition is unknown. Elucidating the 
mechanisms responsible for hormonal and cytokine mediated control of HLA-DR and 
HLA class II co-chaperones using BCCL will provide further insight into the crosstalk 
between steroid receptor and cytokine signaling in breast carcinoma. 
Cytokine induced expression of HLA-DR and co-chaperone molecules is also 
likely to be dependent on the relative expression levels of cytokine receptors on breast 
tumor cells. As discussed in Chapter 4, induction of HLA-DM on BCCL demonstrates a 
dose dependency in response to IFN-)'. Furthermore, not all tumors with elevated IFN-y 
expressed HLA class II antigens. In addition to the mechanisms discussed above, this 
lack of expression may reflect altered expression of IFN-y receptors on breast tumor 
cells. Further investigation of tumor cell expression levels of IFN-y, TGF-131 and IL-113 
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cytokine receptors in HLA class II negative breast tumors would address this as a 
possible mechanism. 
4) 17-(3-estradiol modulates TAA-specific T cell activation and cytokine production 
As discussed in Chapter 4, the negative association of HLA-DR with diagnosis 
age and ER may be indirect and attributable to their association with infiltrating T cells 
which show similar negative relationships (Chapter 5). Thus, in the absence of competing 
ER on tumor cells, circulating estradiol may bind ER on T AA-specific effector T cells 
and Treg cells driving their activation and cytokine secretion, as demonstrated in murine 
studies [264, 265]. To investigate whether 17-~-estradiol mediates similar effects in the 
context ofbreast carcinoma, it would be useful to examine the influence of 17-J3-estradiol 
on proliferative and cytokine responses of TAA-specific T cell lines (TCL) or ex vivo 
isolated TIL or PBMC from breast carcinoma patients. 
5) HLA-DRJ3 allotypes influence immune responsiveness 
The results of Chapter 3 suggest that variability in survival ofHLA-DRBl *04 and 
HLA-DRBl *13 patients may be explained by variation in immune responsiveness. 
However, as previously discussed, this speculation is made based on relative levels of 
whole tumor lysate cytokine mRNA. In vitro studies assessing the activation and 
cytokine production of CD4+ TIL in response to TAA-expressing tumor cells and APC 
expressing the relevant HLA-DRJ3 allotype could be employed to test this hypothesis. 
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Furthermore, phenotyping of the CD4+ TIL in DRB 1 *04 and DRB 1 * 13 expressing 
tumors to determine if they are producing TH1, TH2 or TH3/Treg type cytokines, may 
provide further in vivo evidence to support this hypothesis. 
6) Breast tumor cells that co-express HLA-DR, Ii and HLA-DM can function as 
efficient APC 
The association ofDR+Ii+DM+ tumors with large numbers of infiltrating T cells, 
high levels of T H 1 cytokines and improved survival warrants further investigation. It is 
plausible that the association is merely due to high IFN-y levels leading to induction of 
HLA-DM expression, however, studies have shown HLA class II+ tumor cells can 
function as APC (discussed in Section 1. 7 .2). As discussed in Section 1. 7.1, although the 
absence of CD80 and CD86 co-stimulatory molecule expression on tumor cells may 
result in T cell anergy [163], a majority of BCCL express the co-stimulatory molecule 
CD40 [140]. Immunohistochemical assessment of CD40 expression by tumor cells in a 
small sample of invasive breast tumors (N=8) revealed 2/3 HLA-DR+ tumors express 
CD40, as compared to 0/5 HLA-DR- tumors express CD40 (Oldford, unpublished 
observations). Thus, expression ofCD40 or other co-stimulatory molecules expressed on 
breast tumor cells may provide the second signal necessary for T cell activation in the 
context of breast carcinoma. Furthermore, as previously discussed, initial naYve TAA-
specific T cell activation is likely via DC, which present tumor antigen derived peptides 
in the draining lymph node and such antigen-specific T cells have less stringent 
requirements for subsequent re-activation at the tumor site [164]. Future studies aimed at 
elucidating the influence of co-chaperone expression on the antigen presenting capacity 
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of breast tumor cells, utilizing T AA-specific TCL are warranted. As previously 
discussed, HLA-DRI3 allotypes exhibit varying affinities for CLIP, thus assessing the 
relative dependence of individual HLA-DRI3 allotypes on HLA-DM for TAA-derived 
peptide presentation is necessary. 
Furthermore, following the hypothesis that tumor cells that co-express HLA-DM 
and HLA-DR may function as effective antigen presenting cells, facilitating the induction 
of effective THl anti-tumor immunity (Chapter 4), it is possible that deficient antigen 
presentation contributes to the poor survival of breast carcinoma patients with 
DR+Ii+DM- tumors. In vitro studies have shown MHC class II+Ii+ SAl sarcoma cells are 
incapable of presenting endogenously synthesized model tumor antigen targeted to the 
endoplasmic reticulum or plasma membrane as well as exogenously provided antigen. 
Co-expression of DM in these tumor cells facilitated antigen presentation of 
endogenously synthesized antigen targeted to the plasma membrane and exogenous 
antigen [336]. Thus, it is plausible similar phenomenon occur in epithelial cells whereby 
efficient presentation of endogenous tumor antigens by DR+Ii+DM+ breast tumor cells 
may be dependent on the cellular localization of the tumor antigen. Similar studies 
conducted using BCCL expressing varying combinations of HLA class II and co-
chaperone molecules may provide further insight into the control of HLA class II 
mediated presentation of endogenous T AA. 
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7) Effective anti-tumor immunity is dependent on the balance of co-existing effector 
and immunoregulatory mechanisms 
The use of total tumor mRNA determination to assess immune responsiveness is 
an attractive strategy as it is would provide a more economical and time-saving approach 
over immunohistochemical quantification for large scale studies of carcinoma patients. 
However, it is acknowledged this approach is limited by the lack of information on the 
cell subsets producing the relevant transcripts as well as their location within the tumor 
mass. At the time of initiation of these studies, monoclonal antibodies to FOX-P3 were 
not available. Thus, relative FOX-P3 mRNA levels were assessed as an indirect measure 
of infiltrating Treg· Studies on a subset of ovarian carcinoma patients have reported high 
bulk tumor IFN-y independently associates with improved survival [270], while high 
relative mRNA levels of FOX-P3 independently predict poor patient survival [276]. 
Although we have found high IFN-y associates with improved survival in breast 
carcinoma (Chapter 4), FOX-P3 mRNA levels did not predict poor patient survival 
(Chapter 5). FOX-P3 mRNA levels also did not predict patient survival in a group of 98 
colorectal carcinoma patients, although the criterion for cut-point determination was not 
specified [337]. Discrepancies may be methodological as we have used semi-quantitative 
end-point RT-PCR to determine relative mRNA levels, in contrast to the real-time PCR 
methodology of the aforementioned studies [270, 276]. However, the studies in ovarian 
carcinoma employed the optimal/minimal P-value approach to obtain their cut-points for 
elevated IFN-y and FOX-P3, which can introduce bias in the survival estimates by 
inflating the Type I error rate [277]. In an attempt to overcome these limitations, we also 
assessed each mRNA as a continuous variable using univariate Cox regression analysis 
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(Chapter 5). Although FOX-P3 mRNA levels did not associate with patient survival, we 
observed that the ratio of the pro-inflammatory cytokine TNF-a and the 
immunoregulatory cytokine TGF-pl was an independent predictor of survival, although 
the cell subsets producing these cytokines were not identified (Chapter 5). 
A more extensive understanding of the complexities of effector T cell and Treg cell 
interaction within the tumor environment is required to fully understand the balance of 
the two in anti-tumor immunity. Studies in ovarian carcinoma suggest the anti-tumor 
immune response is dependent on the relative proportions of effector CDS+ TIL and 
CD4+CD25+FOX-P3+ Treg cells [195]. Furthermore, recent evidence suggests 
understanding this balance will involve expanded phenotypic characterization of 
infiltrating TIL subsets as the presence of large numbers of effector memory CD45RO+ 
TIL independently predict improved survival in colorectal carcinoma patients [338]. 
However, this study discussed associations in terms of CD8+CD45RO+ effector memory 
TIL, and failed to discuss their results in terms of CD4+ TIL subsets which also express 
CD45RO. Recently, studies have identified IL-17 producing T cells (TH17) with 
important roles in autoimmune tissue destruction [339] yet the roles of these cells in the 
anti-tumor immune response remain to be elucidated. Advances in the field ofHLA class 
II multimer analysis will facilitate their use in the identification of TAA-specific TIL, 
which can be isolated, using techniques such as LCM, and further characterized. Thus, 
extensive phenotyping and quantification of individual TIL subsets will likely determine 
the threshold of the balance of effector and immunoregulatory TIL subsets in determining 
activation or suppression of the in situ anti-tumor immune response. 
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7.4 Concluding Remarks 
Much remains to be studied to expand our understanding of the breakdown in 
anti-tumor immunity that leads to tumor outgrowth. A full understanding of the interplay 
of immune effector cells and tumor cells is necessary before successful 
immunotherapeutic strategies can be designed and employed. The results of this study 
may have important implications for the design of such therapies. It is evident that 
successful immunotherapy will involve evoking multiple immune effectors and the 
maintenance of effective long term memory. As CD4+ T cells are crucial for the 
induction and maintenance of several anti-tumor effector mechanisms (discussed in 
Section 1.8.2) several avenues to exploit anti-tumor immunity currently under 
investigation involve evoking anti-tumor CD4+ T H cell responses. Such methods include 
genetically engineered tumor cells and DC based immunotherapies [340]. However, as 
described in Chapter 3, there are clearly differences in immune responsiveness based on 
the HLA-DRB alleles carried by the patient. Furthermore, the expression of the peptide 
editor HLA-DM in HLA class II+ tumor cells associates with improved patient outcome 
possibly via enhanced presentation of TAA-derived peptides (Chapter 4). Successful 
immunotherapeutic regimes will surely depend on knowledge of the HLA class II alleles 
carried by the individual and a thorough understanding of how HLA-DRf3 allotypes and 
HLA class II co-chaperone molecules influence CD4+ T cell subset activation. It is 
anticipated that future studies aimed at clearly elucidating these relationships will have 
important implications for design and implementation of effective prophylactic and 
therapeutic vaccine strategies. 
274 
REFERENCES 
1. Rosen PP. Rosen's Breast Pathology. Philadelphia, Pennsylvania: Lippincott-
Raven Publishers, 1997. 
2. Jensen HM. On the origin and progression of human breast cancer. Am J Obstet 
Gynecol1986; 154:1280-4. 
3. Ellis 10, Galea M, Broughton N, Locker A, Blarney RW, Elston CW. 
Pathological prognostic factors in breast cancer. II. Histological type. 
Relationship with survival in a large study with long-term follow-up. 
Histopathology 1992;20:479-89. 
4. Ugnat AM, Xie L, Morriss J, Semenciw R, Mao Y. Survival of women with 
breast cancer in Ottawa, Canada: variation with age, stage, histology, grade and 
treatment. Br J Cancer 2004;90: 1138-43. 
5. Bloom HJ, Richardson WW. Histological grading and prognosis in breast cancer; 
a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 
1957; 11:359-77. 
6. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value 
of histological grade in breast cancer: experience from a large study with long-
term follow-up. Histopathology 1991;19:403-10. 
7. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and 
survival in 24,740 breast cancer cases. Cancer 1989;63:181-7. 
8. Greene FL, Page DL, Fleming ID, et al. AJCC Cancer Staging Manual, 6 Edn. 
New York, NY, USA: Springer-Verlag, 2005. 
9. Duraker N, Caynak ZC. Prognostic value of the 2002 TNM classification for 
breast carcinoma with regard to the number of metastatic axillary lymph nodes. 
Cancer 2005;104:700-7. 
10. Marret H, Perrotin F, Bougnoux P, et al. Histologic multifocality is predictive of 
skin recurrences after conserving treatment of stage I and II breast cancers. Breast 
Cancer Res Treat 2001;68:1-8. 
11. Hulka BS, Moorman PG. Breast cancer: hormones and other risk factors. 
Maturitas 2001;38:103-13. 
12. Trichopoulos D, MacMahon B, Cole P. Menopause and breast cancer risk. J Natl 
Cancer Inst 1972;48:605-13. 
275 
13. Hankinson SE, Willett WC, Manson JE, et al. Plasma sex steroid hormone levels 
and risk of breast cancer in postmenopausal women. 1 Natl Cancer Inst 
1998;90: 1292-9. 
14. Huang WY, Newman B, Millikan RC, Schell MJ, Hulka BS, Moorman PG. 
Hormone-related factors and risk of breast cancer in relation to estrogen receptor 
and progesterone receptor status. Am J Epidemiol 2000; 151:703-14. 
15. Rosner B, Colditz GA, Willett WC. Reproductive risk factors in a prospective 
study ofbreast cancer: the Nurses' Health Study. Am J Epidemiol 1994;139:819-
35. 
16. Kordon EC, Molinolo AA, Pasqualini CD, et al. Progesterone induction of 
mammary carcinomas in BALB/c female mice. Correlation between progestin 
dependence and morphology. Breast Cancer Res Treat 1993;28:29-39. 
17. Turan VK, Sanchez RI, Li JJ, et al. The effects of steroidal estrogens in ACI rat 
mammary carcinogenesis: 1 ?beta-estradiol, 2-hydroxyestradiol, 4-
hydroxyestradiol, 16alpha-hydroxyestradiol, and 4-hydroxyestrone. J Endocrinol 
2004;183:91-9. 
18. Hart SM. Modulation of nuclear receptor dependent transcription. Biol Res 
2002;35:295-303. 
19. Bocchinfuso WP, Lindzey JK, Hewitt SC, et al. Induction of mammary gland 
development in estrogen receptor-alpha knockout mice. Endocrinology 
2000; 141 :2982-94. 
20. Lydon JP, DeMayo FJ, Funk CR, et al. Mice lacking progesterone receptor 
exhibit pleiotropic reproductive abnormalities. Genes Dev 1995;9:2266-78. 
21. Lydon JP, Ge G, Kittrell FS, Medina D, O'Malley BW. Murine mammary gland 
carcinogenesis is critically dependent on progesterone receptor function. Cancer 
Res 1999;59:4276-84. 
22. Day JK, Besch-Williford C, McMann TR, Hufford MG, Lubahn DB, MacDonald 
RS. Dietary genistein increased DMBA-induced mammary adenocarcinoma in 
wild-type, but not ER alpha KO, mice. Nutr Cancer 2001;39:226-32. 
23. Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM. Progesterone 
receptor status significantly improves outcome prediction over estrogen receptor 
status alone for adjuvant endocrine therapy in two large breast cancer databases. J 
Clin On col 2003 ;21: 1973-9. 
24. Grann VR, Troxel AB, Zojwalla NJ, Jacobson JS, Hershman D, Neugut AI. 
Hormone receptor status and survival in a population-based cohort of patients 
with breast carcinoma. Cancer 2005;103:2241-51. 
276 
25. Yarden Y. Biology of HER2 and its importance in breast cancer. Oncology 
2001;61 Suppl2:1-13. 
26. Yamamoto T, Ikawa S, Akiyama T, et al. Similarity of protein encoded by the 
human c-erb-B-2 gene to epidermal growth factor receptor. Nature 1986;319:230-
4. 
27. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human 
breast cancer: correlation of relapse and survival with amplification of the HER-
2/neu oncogene. Science 1987;235:177-82. 
28. Ross JS, Fletcher JA, Linette GP, et al. The Her-2/neu gene and protein in breast 
cancer 2003: biomarker and target of therapy. Oncologist 2003;8:307-25. 
29. Venter DJ, Tuzi NL, Kumar S, Gullick WJ. Overexpression of the c-erbB-2 
oncoprotein in human breast carcinomas: immunohistological assessment 
correlates with gene amplification. Lancet 1987;2:69-72. 
30. Varga Z, Zhao J, Ohlschlegel C, Odermatt B, Heitz PU. Preferential HER-2/neu 
overexpression and/or amplification in aggressive histological subtypes of 
invasive breast cancer. Histopathology 2004;44:332-8. 
31. Zheng L, Ren JQ, Li H, Kong ZL, Zhu HG. Downregulation of wild-type p53 
protein by HER-2/neu mediated PI3K pathway activation in human breast cancer 
cells: its effect on cell proliferation and implication for therapy. Cell Res 
2004; 14:497-506. 
32. Vijapurkar U, Kim MS, Koland JG. Roles of mitogen-activated protein kinase and 
phosphoinositide 3'-kinase in ErbB2/ErbB3 coreceptor-mediated heregu1in 
signaling. Exp Cell Res 2003 ;284:291-302. 
33. Tsai MS, Shamon-Taylor LA, Mehmi I, Tang CK, Lupu R. Blockage ofheregulin 
expression inhibits tumorigenicity and metastasis of breast cancer. Oncogene 
2003;22:761-8. 
34. Yen L, Benlimame N, Nie ZR, et al. Differential regulation of tumor angiogenesis 
by distinct ErbB homo- and heterodimers. Mol Bioi Cell 2002; 13:4029-44. 
35. Muller WJ, Sinn E, Pattengale PK, Wallace R, Leder P. Single-step induction of 
mammary adenocarcinoma in transgenic mice bearing the activated c-neu 
oncogene. Cel11988;54: 105-15. 
36. Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, Muller WJ. 
Expression of the neu protooncogene in the mammary epithelium of transgenic 
mice induces metastatic disease. Proc Natl Acad Sci US A 1992;89:10578-82. 
277 
37. Siegel PM, Dankort DL, Hardy WR, Muller WJ. Novel activating mutations in 
the neu proto-oncogene involved in induction of mammary tumors. Mol Cell Biol 
1994; 14:7068-77. 
38. Carlomagno C, Perrone F, Gallo C, et al. c-erb B2 overexpression decreases the 
benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph 
node metastases. J Clin Oneal 1996;14:2702-8. 
39. Elledge RM, Green S, Ciocca D, et al. HER-2 expressi<?n and response to 
tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology 
Group Study. Clin Cancer Res 1998;4:7-12. 
40. Slamon DJ, Leyland-Janes B, Shak S, et al. Use of chemotherapy plus a 
monoclonal antibody against HER2 for metastatic breast cancer that 
overexpresses HER2. N Engl J Med 2001;344:783-92. 
41. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy 
for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-84. 
42. Piccart-Gebhart MJ, Procter M, Leyland-Janes B, et al. Trastuzumab after 
adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 
2005;353: 1659-72. 
43. Colleoni M, Rotmensz N, Robertson C, et al. Very young women (<35 years) 
with operable breast cancer: features of disease at presentation. Ann Oneal 
2002; 13:273-9. 
44. Sidoni A, Cavaliere A, Bellezza G, Scheibel M, Bucciarelli E. Breast cancer in 
young women: clinicopathological features and biological specificity. Breast 
2003;12:247-50. 
45. Anderson BO, Senie RT, Vetto JT, Wong GY, McCormick B, Borgen PI. 
Improved survival in young women with breast cancer. Ann Surg Oncol 
1995;2:407-15. 
46. Rapiti E, Fioretta G, Verkooijen HM, et al. Survival of young and older breast 
cancer patients in Geneva from 1990 to 2001. Bur J Cancer 2005;41: 1446-52. 
47. Chia KS, Du WB, Sankaranarayanan R, et al. Do younger female breast cancer 
patients have a poorer prognosis? Results from a population-based survival 
analysis. Int J Cancer 2004;108:761-5. 
48. Han W, Kim SW, Park lA, et al. Young age: an independent risk factor for 
disease-free survival in women with operable breast cancer. BMC Cancer 
2004;4:82. 
278 
49. Mathew A, Pandey M, Rajan B. Do younger women with non-metastatic and non-
inflammatory breast carcinoma have poor prognosis? World J Surg Oneal 
2004;2:2. 
50. Rosenberg J, Chia YL, Plevritis S. The effect of age, race, tumor size, tumor 
grade, and disease stage on invasive ductal breast cancer survival in the U.S. 
SEER database. Breast Cancer Res Treat 2005;89:47-54. 
51. Loman N, Johannsson 0, Kristoffersson U, Olsson H, Borg A. Family history of 
breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-
based series of early-onset breast cancer. J Natl Cancer Inst 2001;93: 1215-23. 
52. de Sanjose S., Leone M, Berez V, et al. Prevalence of BRCA1 and BRCA2 
germline mutations in young breast cancer patients: a population-based study. Int 
J Cancer 2003;106:588-93. 
53. Moller P, Borg A, Evans DG, et al. Survival in prospectively ascertained familial 
breast cancer: analysis of a series stratified by tumour characteristics, BRCA 
mutations and oophorectomy. Int J Cancer 2002;101:555-9. 
54. Berx G, Cleton-Jansen AM, Nollet F, et al. E-cadherin is a tumour/invasion 
suppressor gene mutated in human lobular breast cancers. EMBO J 
1995;14:6107-15. 
55. Shannon C, Smith IE. Breast cancer in adolescents and young women. Eur J 
Cancer 2003;39:2632-42. 
56. Goldsby RA, Kindt TJ, Osborne BA. Kuby Immunology, 4th Edn. New York: 
W.H. Freeman, 2000. 
57. Horton R, Wilming L, Rand V, et al. Gene map of the extended human MHC. Nat 
Rev Genet 2004;5:889-99. 
58. Complete sequence and gene map of a human major histocompatibility complex. 
The MHC sequencing consortium. Nature 1999;401:921-3. 
59. Marsh SGE, Parham P, Barber LD. The HLA Facts Book. San Diego, CA: 
Academic Press, 2000. 
60. Riteau B, Menier C, Khalil-Daher I, et al. HLA-G 1 co-expression boosts the HLA 
class !-mediated NK lysis inhibition. Int Immunol2001; 13:193-201. 
61. Lepin EJ, Bastin JM, Allan DS, et al. Functional characterization of HLA-F and 
binding of HLA-F tetramers to ILT2 and ILT4 receptors. Eur J Immunol 
2000;30:3552-61. 
279 
62. Jinushi M, Takehara T, Kanto T, et al. Critical role of MHC class !-related chain 
A and B expression on IFN-alpha-stimulated dendritic cells in NK cell activation: 
impairment in chronic hepatitis C virus infection. J Immunol 2003; 170:1249-56. 
63. Basham TY, Nickoloff BJ, Merigan TC, Morhenn VB. Recombinant gamma 
interferon differentially regulates class II antigen expression and biosynthesis on 
cultured normal human keratinocytes. J Interferon Res 1985;5:23-32. 
64. Boyer CM, Dawson DV, Neal SE, et al. Differential induction by interferons of 
major histocompatibility complex-encoded and non-major histocompatibility 
complex-encoded antigens in human breast and ovarian carcinoma cell lines. 
Cancer Res 1989;49:2928-34. 
65. Geppert TD, Lipsky PE. Antigen presentation by interferon-gamma-treated 
endothelial cells and fibroblasts: differential ability to function as antigen-
presenting cells despite comparable Ia expression. J Immunol1985;135:3750-62. 
66. Denzin LK, Cresswell P. HLA-DM induces CLIP dissociation from MHC class II 
alpha beta dimers and facilitates peptide loading. Cel11995;82:155-65. 
67. Kropshofer H, Vogt AB, Thery C, et al. A role for HLA-DO as a co-chaperone of 
HLA-DM in peptide loading ofMHC class II molecules. EMBO J 1998;17:2971-
81. 
68. Pamer E, Cresswell P. Mechanisms ofMHC class !--restricted antigen processing. 
Annu Rev Immunol1998;16:323-58. 
69. Robinson J, Waller MJ, Parham P, et al. IMGT/HLA and IMGT/MHC: sequence 
databases for the study of the major histocompatibility complex. Nucleic Acids 
Research 2003;31:311-4. 
70. Campbell RD, Trowsdale J. Map of the human MHC. Immunol Today 
1993; 14:349-52. 
71. Bonnerot C, Marks MS, Cosson P, et al. Association with BiP and aggregation of 
class II MHC molecules synthesized in the absence of invariant chain. EMBO J 
1994;13:934-44. 
72. Anderson KS, Cresswell P. A role for calnexin (IP90) in the assembly of class II 
MHC molecules. EMBO J 1994;13:675-82. 
73. Roche PA, Marks MS, Cresswell P. Formation of a nine-subunit complex by 
HLA class II glycoproteins and the invariant chain. Nature 1991;354:392-4. 
74. Roche PA, Cresswell P. Invariant chain association with HLA-DR molecules 
inhibits immunogenic peptide binding. Nature 1990;345:615-8. 
280 
75. Cresswell P. Assembly, transport, and function ofMHC class II molecules. Annu 
Rev Immunol1994;12:259-93. 
76. Peters PJ, Neefjes JJ, Oorschot V, Ploegh HL, Geuze HJ. Segregation of MHC 
class II molecules from MHC class I molecules in the Golgi complex for transport 
to lysosomal compartments. Nature 1991;349:669-76. 
77. Ghosh P, Amaya M, Mellins E, Wiley DC. The structure of an intermediate in 
class II MHC maturation: CLIP bound to HLA-DR3. Nature 1995;378:457-62. 
78. Amigorena S, Drake JR, Webster P, Mellman I. Transient accumulation of new 
class II MHC molecules in a novel endocytic compartment in B lymphocytes. 
Nature 1994;369:113-20. 
79. Klitz W, Maiers M, Spellman S, et al. New HLA haplotype frequency reference 
standards: high-resolution and large sample typing of HLA DR-DQ haplotypes in 
a sample of European Americans. Tissue Antigens 2003;62:296-307. 
80. Schreuder GM, Hurley CK, Marsh SG, et al. The HLA Dictionary 2004: a 
summary of HLA-A, -B, -C, -DRB1/3/4/5 and -DQB1 alleles and their 
association with serologically defined HLA-A, -B, -C, -DR and -DQ antigens. 
Tissue Antigens 2005;65:1-55. 
81. Riberdy JM, Newcomb JR, Surman MJ, Barbosa JA, Cresswell P. HLA-DR 
molecules from an antigen-processing mutant cell line are associated with 
invariant chain peptides. Nature 1992;360:474-7. 
82. Sloan VS, Cameron P, Porter G, et al. Mediation by HLA-DM of dissociation of 
peptides from HLA-DR. Nature 1995;375:802-6. 
83. Stebbins CC, Loss GE, Jr., Elias CG, Chervonsky A, Sant AJ. The requirement 
for DM in class II-restricted antigen presentation and SDS-stable dimer formation 
is allele and species dependent. J Exp Med 1995;181:223-34. 
84. Kropshofer H, Hammerling GJ, Vogt AB. How HLA-DM edits the MHC class II 
peptide repertoire: survival ofthe fittest? Immunol Today 1997;18:77-82. 
85. Liljedahl M, Kuwana T, Fung-Leung WP, Jackson MR, Peterson PA, Karlsson L. 
HLA-DO is a lysosomal resident which requires association with HLA-DM for 
efficient intracellular transport. EMBO J 1996; 15:4817-24. 
86. Denzin LK, Sant'Angelo DB, Hammond C, Surman MJ, Cresswell P. Negative 
regulation by HLA-DO of MHC class II-restricted antigen processing. Science 
1997;278:106-9. 
87. Zhou D, Blum JS. Presentation of cytosolic antigens via MHC class II molecules. 
Immunol Res 2004;30:279-90. 
281 
88. Muntasell A, Carrascal M, Alvarez I, et al. Dissection of the HLA-DR4 peptide 
repertoire in endocrine epithelial cells: strong influence of invariant chain and 
HLA-DM expression on the nature ofligands. J Irnrnunol2004;173:1085-93. 
89. Armstrong TD, Clements VK, Ostrand-Rosenberg S. MHC class II-transfected 
tumor cells directly present antigen to tumor-specific CD4+ T lymphocytes. J 
Immunol1998;160:661-6. 
90. Hegde NR, Tornazin RA, Wisner TW, et al. Inhibition of HLA-DR assembly, 
transport, and loading by human cytomegalovirus glycoprotein US3: a novel 
mechanism for evading major histocompatibility complex class II antigen 
presentation. J Virol2002;76:10929-41. 
91. Reith W, Mach B. The bare lymphocyte syndrome and the regulation of MHC 
expression. Annu Rev Immunol2001;19:331-73. 
92. Steimle V, Otten LA, Zufferey M, Mach B. Complementation cloning of an MHC 
class II transactivator mutated in hereditary MHC class II deficiency (or bare 
lymphocyte syndrome). Cel11993;75:135-46. 
93. Masternak K, Barras E, Zufferey M, et al. A gene encoding a novel RFX-
associated transactivator is mutated in the majority of MHC class II deficiency 
patients. Nat Genet 1998;20:273-7. 
94. Steimle V, Durand B, Barras E, et al. A novel DNA-binding regulatory factor is 
mutated in primary MHC class II deficiency (bare lymphocyte syndrome). Genes 
Dev 1995;9:1021-32. 
95. Durand B, Sperisen P, Emery P, et al. RFXAP, a novel subunit of the RFX DNA 
binding complex is mutated in MHC class II deficiency. EMBO J 1997;16:1045-
55. 
96. Muhlethaler-Mottet A, Krawczyk M, Masternak K, et al. The S box of major 
histocompatibility complex class II promoters is a key determinant for recruitment 
of the transcriptional co-activator CIITA. J Bioi Chern 2004;279:40529-35. 
97. Moreno CS, Beresford GW, Louis-Plence P, Morris AC, Boss JM. CREB 
regulates MHC class II expression in a CIITA-dependent manner. Immunity 
1999; 10:143-51. 
98. Reith W, Siegrist CA, Durand B, Barras E, Mach B. Function of major 
histocompatibility complex class II promoters requires cooperative binding 
between factors RFX and NF-Y. Proc Natl Acad Sci US A 1994;91:554-8. 
99. Reith W, LeibundGut-Landrnann S, Waldburger JM. Regulation of MHC class II 
gene expression by the class II transactivator. Nat Rev Irnrnunol2005;5:793-806. 
282 
100. Zhu XS, Linhoff MW, Li G, Chin KC, Maity SN, Ting JP. Transcriptional 
scaffold: CIITA interacts with NF-Y, RFX, and CREB to cause stereospecific 
regulation of the class II major histocompatibility complex promoter. Mol Cell 
Biol 2000;20:6051-61. 
101. Zika E, Ting JP. Epigenetic control of MHC-II: interplay between CIITA and 
histone-modifying enzymes. Curr Opin Immunol2005;17:58-64. 
102. Muhlethaler-Mottet A, Otten LA, Steimle V, Mach B. Expression of MHC class 
II molecules in different cellular and functional compartments is controlled by 
differential usage of multiple promoters of the transactivator CIITA. EMBO J 
1997;16:2851-60. 
103. Waldburger JM, Suter T, Fontana A, cha-Orbea H, Reith W. Selective abrogation 
of major histocompatibility complex class II expression on extrahematopoietic 
cells in mice lacking promoter IV of the class II transactivator gene. J Exp Med 
2001 ;194:393-406. 
104. Dalton DK, Pitts-MeekS, Keshav S, Figari IS, Bradley A, Stewart TA. Multiple 
defects of immune cell function in mice with disrupted interferon-gamma genes. 
Science 1993 ;25 9: 173 9-4 2. 
105. Huang S, Hendriks W, Althage A, et al. Immune response in mice that lack the 
interferon-gamma receptor. Science 1993;259:1742-5. 
106. LeibundGut-Landmann S, Waldburger JM, Reise Sousa, cha-Orbea H, Reith W. 
MHC class II expression is differentially regulated in plasmacytoid and 
conventional dendritic cells. Nat Immunol2004;5:899-908. 
107. Muhlethaler-Mottet A, Di BW, Otten LA, Mach B. Activation of the MHC class 
II transactivator CIITA by interferon-gamma requires cooperative interaction 
between Statl and USF-1. Immunity 1998;8:157-66. 
108. Xi H, Eason DD, Ghosh D, Dovhey S, Wright KL, Blanck G. Co-occupancy of 
the interferon regulatory element of the class II transactivator (CIITA) type IV 
promoter by interferon regulatory factors 1 and 2. Oncogene 1999;18:5889-903. 
109. Hake SB, Tobin HM, Steimle V, Denzin LK. Comparison of the transcriptional 
regulation of classical and non-classical MHC class II genes. Eur J Immunol 
2003;33:2361-71. 
110. Chang CH, Flavell RA. Class II transactivator regulates the expression of multiple 
genes involved in antigen presentation. J Exp Med 1995;181:765-7. 
111. Wu Z, Biro PA, Mirakian R, et al. HLA-DMB expression by thyrocytes: 
indication of the antigen-processing and possible presenting capability of thyroid 
cells. Clin Exp Immunol1999;116:62-9. 
283 
112. Westerheide SD, Louis-Plence P, Ping D, He XF, Boss JM. HLA-DMA and 
HLA-DMB gene expression functions through the conserved S-X-Y region. J 
Immunol1997;158:4812-21. 
113. Tai AK, Zhou G, Chau K, Ono SJ. Cis-element dependence and occupancy of the 
human invariant chain promoter in CIITA-dependent and -independent 
transcription. Mol Immunol 1999;36:447-60. 
114. Mitchison NA, Roes J. Patterned variation in murine MHC promoters. Proc Natl 
Acad Sci US A 2002;99:10561-6. 
115. Emery P, Mach B, Reith W. The different level of expression ofHLA-DRBl and 
-DRB3 genes is controlled by conserved isotypic differences in promoter 
sequence. Hum Immunoll993;38:137-47. 
116. Perfetto C, Zacheis M, McDaid D, Meador JW, III, Schwartz BD. Polymorphism 
in the promoter region ofHLA-DRB genes. Hum Immuno11993;36:27-33. 
117. Louis P, Vincent R, Cavadore P, Clot J, Eliaou JF. Differential transcriptional 
activities ofHLA-DR genes in the various hap1otypes. J Immuno11994;153:5059-
67. 
118. Vincent R, Louis P, Gongora C, Papa I, Clot J, Eliaou JF. Quantitative analysis of 
the expression of the HLA-DRB genes at the transcriptional level by competitive 
polymerase chain reaction. J Immunoll996;156:603-10. 
119. Leen MP, Gorski J. Differential expression of isomorphic HLA-DR beta genes is 
not a sole function oftranscription. Hum Immunol1996;50:111-20. 
120. Leen MP, Gorski J. DRB4 promoter polymorphism in DR7 individuals: 
correlation with DRB4 pre-mRNA and mRNA levels. Immunogenetics 
1997;45:371-8. 
121. Mosmann TR, Sad S. The expanding universe ofT-cell subsets: Thl, Th2 and 
more. Immunol Today 1996;17:138-46. 
122. Baumgart M, Moos V, Schuhbauer D, Muller B. Differential expression of major 
histocompatibility complex class II genes on murine macrophages associated with 
T cell cytokine profile and protective/suppressive effects. Proc Natl Acad Sci U S 
A 1998;95:6936-40. 
123. Ise W, Totsuka M, Sogawa Y, et al. Naive CD4+ T cells exhibit distinct 
expression patterns of cytokines and cell surface molecules on their primary 
responses to varying doses of antigen. J Immunol2002;168:3242-50. 
124. Fleury S, Thibodeau J, Croteau G, et al. HLA-DR polymorphism affects the 
interaction with CD4. J Exp Med 1995;182:733-41. 
284 
125. Chaturvedi P, Hengeveld R, Zechel MA, Lee-Chan E, Singh B. The functional 
role of class II-associated invariant chain peptide (CLIP) in its ability to variably 
modulate immune responses. Int Immunol2000;12:757-65. 
126. Rohn TA, Boes M, Wolters D, et al. Upregulation of the CLIP self peptide on 
mature dendritic cells antagonizes T helper type 1 polarization. Nat Immunol 
2004;5:909-18. 
127. Leitenberg D, Boutin Y, Constant S, Bottomly K. CD4 regulation of TCR 
signaling and T cell differentiation following stimulation with peptides of 
different affinities for the TCR. J Immunol 1998;161: 1194-203. 
128. Iarygin LM, Malyshev VS, Polianskaia IS, et al. [The clinical significance of 
determining the HLA-DR4 antigen in patients with breast cancer]. Vopr Onkol 
1991;37:796-800. 
129. Casoli C, Zanelli P, Adorni A, Starcich BR, Neri T. Serological and molecular 
study on the HLA phenotype of female breast cancer patients. Eur J Cancer 
1994;30A:1207-8. 
130. Song ST. [Association of HLA with breast cancer and its ER status]. Zhonghua 
Zhong Liu Za Zhi 1989;11:19-21. 
131. Chaudhuri S, Cariappa A, Tang M, et al. Genetic susceptibility to breast cancer: 
HLA DQB*03032 and HLA DRBl *11 may represent protective alleles. Proc Natl 
Acad Sci US A 2000;97:11451-4. 
132. Gourley C, Thornton C, Massie C, et al. Is there a relationship between HLA type 
and prognostic factors in breast cancer? Anticancer Res 2003;23:633-8. 
133. Ghaderi A, Talei A, Gharesi-Fard B, Farjadian SH, Amirzargar A, Vasei M. 
HLA-DRBl alleles and the susceptibility of Iranian patients with breast cancer. 
Pathol Oncol Res 2001;7:39-41. 
134. Jabrane-Ferrat N, Faille A, Loiseau P, Poirier 0, Charron D, Calvo F. Effect of 
gamma interferon on HLA class-I and -II transcription and protein expression in 
human breast adenocarcinoma cell lines. Int J Cancer 1990;45:1169-76. 
135. Tabibzadeh SS, Sivarajah A, Carpenter D, Ohlsson-Wilhelm BM, Satyaswaroop 
PG. Modulation of HLA-DR expression in epithelial cells by interleukin 1 and 
estradiol-17 beta. J Clin Endocrinol Metab 1990;71:740-7. 
136. Sedlak J, Speiser P, Zeillinger R, et al. Cytokine (IFN-alpha, IFN-gamma, IL-l-
alpha, TNF-alpha)-induced modulation of HLA cell surface expression in human 
breast cancer cell lines. Neoplasma 1992;39:269-72. 
285 
137. Obiri NI, Siegel JP, Varricchio F, Puri RK. Expression of high-affinity IL-4 
receptors on human melanoma, ovarian and breast carcinoma cells. Clin Exp 
Immunol1994;95:148-55. 
138. Armstrong TD, Clements VK, Ostrand-Rosenberg S. Class II-transfected tumor 
cells directly present endogenous antigen to CD4+ T cells in vitro and are APCs 
for tumor-encoded antigens in vivo. J Immunother 1998;21:218-24. 
139. Nouri AM, Hussain RF, Dos Santos AV, Gillott DJ, Oliver RT. Induction of 
MHC antigens by tumour cell lines in response to interferons. Eur J Cancer 
1992;28A:1110-5. 
140. Edgecombe A. HLA class II expression on breast cancer cells. St. John's, 
Newfoundland, Canada: Memorial University ofNewfoundland, 2002. 
141. Bartek J, Petrek M, Vojtesek B, Bartkova J, Kovarik J, Rejthar A. HLA-DR 
antigens on differentiating human mammary gland epithelium and breast tumours. 
Br J Cancer 1987;56:727-33. 
142. Newman RA, Ormerod MG, Greaves MF. The presence ofHLA-DR antigens on 
lactating human breast epithelium and milk fat globule membranes. Clin Exp 
Immuno11980;41:478-86. 
143. Bernard DJ, Maurizis JC, Chassagne J, Chollet P, Plagne R. Effect of prolactin on 
class II HLA antigen expression by MCF7 cell line. Anticancer Res 1986;6:79-83. 
144. Lee AH, Happerfield LC, Millis RR, Bobrow LG. Inflammatory infiltrate in 
invasive lobular and ductal carcinoma of the breast. Br J Cancer 1996;74:796-
801. 
145. Whitwell HL, Hughes HP, Moore M, Ahmed A. Expression of major 
histocompatibility antigens and leucocyte infiltration in benign and malignant 
human breast disease. Br 1 Cancer 1984;49: 161-72. 
146. Moller P, Mattfeldt T, Gross C, et al. Expression of HLA-A, -B, -C, -DR, -DP, -
DQ, and of HLA-D-associated invariant chain (Ii) in non-neoplastic mammary 
epithelium, fibroadenoma, adenoma, and carcinoma of the breast. Am J Pathol 
1989; 135:73-83. 
147. Concha A, Ruiz-Cabello F, Cabrera T, Nogales F, Collado A, Garrido F. Different 
patterns of HLA-DR antigen expression in normal epithelium, hyperplastic and 
neoplastic malignant lesions of the breast. Eur J Immunogenet 1995;22:299-310. 
148. Zuk JA, Walker RA. HLA class II sublocus expression in benign and malignant 
breast epithelium. J Pathol1988;155:301-9. 
286 
149. Natali PG, Giacomini P, Bigotti A, et al. Heterogeneity in the expression ofHLA 
and tumor-associated antigens by surgically removed and cultured breast 
carcinoma cells. Cancer Res 1983;43 :660-8. 
150. Perez M, Cabrera T, Lopez Nevot MA, et al. Heterogeneity of the expression of 
class I and II HLA antigens in human breast carcinoma. J Immunogenet 
1986; 13:247-53. 
151. Koretz K, Moldenhauer G, Majdic 0, Moller P. Correlation ofHLA-D/Ii antigen 
expression in breast carcinoma with local lymphohistiocytic infiltration reveals 
considerable dysregulation in a subset of tumors. Int J Cancer 1989;44:816-22. 
152. Wintzer HO, Benzing M, von Kleist S. Lacking prognostic significance of beta 2-
microglobulin, MHC class I and class II antigen expression in breast carcinomas. 
Br J Cancer 1990;62:289-95. 
153. Concha A, Esteban F, Cabrera T, Ruiz-Cabello F, Garrido F. Tumor 
aggressiveness and MHC class I and II antigens in laryngeal and breast cancer. 
Semin Cancer Biol1991;2:47-54. 
154. Lucin K, Itemicka Z, Jonjic N. Prognostic significance of T-cell infiltrates, 
expression of beta 2- microglobulin and HLA-DR antigens in breast carcinoma. 
Pathol Res Pract 1994;190:1134-40. 
155. Sheen-Chen SM, Chou FF, Eng HL, Chen WJ. An evaluation of the prognostic 
significance of HLA-DR expression in axillary-node-negative breast cancer. 
Surgery 1994;116:510-5. 
156. Maiorana A, Cesinaro AM, Fano RA, Collina G. Expression ofMHC class I and 
class II antigens in primary breast carcinomas and synchronous nodal metastases. 
Clin Exp Metastasis 1995;13:43-8. 
157. Feinmesser M, Sulkes A, Morgenstern S, Sulkes J, Stem S, Okon E. HLA-DR 
and beta 2 microglobulin expression in medullary and atypical medullary 
carcinoma of the breast: histopathologically similar but biologically distinct 
entities. J Clin Pathol2000;53:286-91. 
158. Lazzaro B, Anderson AE, Kajdacsy-Balla A, Ressner MJ. Antigenic 
characterization of medullary carcinoma of the breast: HLA-DR expression in 
lymph node positive cases. Appl Immunohistochem Mol Morphol2001;9:234-41. 
159. Brunner CA, Gokel JM, Riethmuller, Johnson JP. Expression of HLA-D subloci 
DR and DQ by breast carcinomas is correlated with distinct parameters of 
favourable prognois. Eur J Cancer 1991 ;27 :411-6. 
160. Jiang Z, Xu M, Savas L, LeClair P, Banner BF. Invariant chain expression in 
colon neoplasms. Virchows Arch 1999;435:32-6. 
287 
161. Ishigami S, Natsugoe S, Tok:uda K, et al. Invariant chain expression in gastric 
cancer. Cancer Lett 2001;168:87-91. 
162. Zuk JA, Walker RA. Immunohistochemical analysis of HLA antigens and 
mononuclear infiltrates of benign and malignant breast. J Pathol 1987;152:275-
85. 
163. Becker JC, Brabletz T, Czemy C, Termeer C, Brocker EB. Tumor escape 
mechanisms from immunosurveillance: induction of unresponsiveness in a 
specific MHC-restricted CD4+ human T cell clone by the autologous MHC class 
II+ melanoma. Int Immunol1993;5:1501-8. 
164. Croft M. Activation of naive, memory and effector T cells. Curr Opin Immunol 
1994;6:431-7. 
165. Topalian SL. MHC class II restricted tumor antigens and the role ofCD4+ T cells 
in cancer immunotherapy. Curr Opin Immuno11994;6:741-5. 
166. Pardoll DM, Topalian SL. The role of CD4+ T cell responses in antitumor 
immunity. Curr Opin Immunol1998;10:588-94. 
167. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardon D, Levitsky H. The 
central role of CD4( +) T cells in the antitumor immune response. J Exp Med 
1998; 188:2357-68. 
168. Meazza R, Comes A, Orengo AM, Ferrini S, Accolla RS. Tumor rejection by 
gene transfer of the MHC class II transactivator in murine mammary 
adenocarcinoma cells. Eur J Immunol2003;33:1183-92. 
169. Tuttle TM, Anderson BW, Thompson WE, et al. Proliferative and cytokine 
responses to class II HER-2/neu-associated peptides in breast cancer patients. Clin 
Cancer Res 1998;4:2015-24. 
170. Dadmarz R, Sgagias MK, Rosenberg SA, Schwartzentruber DJ. CD4+ T 
lymphocytes infiltrating human breast cancer recognize autologous tumor in an 
MHC-class-II restricted fashion. Cancer Immunol Immunother 1995 ;40: 1-9. 
171. Sotiriadou R, Perez SA, Gritzapis AD, et al. Peptide HER2(776-788) represents a 
naturally processed broad MHC class II-restricted T cell epitope. Br J Cancer 
2001;85: 1527-34. 
172. Perez SA, Sotiropoulou PA, Sotiriadou NN, et al. HER-2/neu-derived peptide 
884-899 is expressed by human breast, colorectal and pancreatic adenocarcinomas 
and is recognized by in-vitro- induced specific CD4(+) T cell clones. Cancer 
Immunol Immunother 2002;50:615-24. 
173. Li CI, Uribe DJ, Daling JR. Clinical characteristics of different histologic types of 
breast cancer. Br J Cancer 2005;93: 1046-52. 
288 
174. AnT, Sood U, Pietruk T, Cummings G, Hashimoto K, Crissman JD. In situ 
quantitation of inflammatory mononuclear cells in ductal infiltrating breast 
carcinoma. Relation to prognostic parameters. Am J Pathol1987;128:52-60. 
175. Hurlimann J, Saraga P. Mononuclear cells infiltrating human mammary 
carcinomas: immunohistochemical analysis with monoclonal antibodies. Int J 
Cancer 1985;35:753-62. 
176. Balch CM, Riley LB, Bae YJ, et al. Patterns of human tumor-infiltrating 
lymphocytes in 120 human cancers. Arch Surg 1990; 125:200-5. 
177. Gottlinger HG, Rieber P, Gokel JM, Lohe KJ, Riethmuller G. Infiltrating 
mononuclear cells in human breast carcinoma: predominance of T4+ monocytic 
cells in the tumor stroma. Int J Cancer 1985;35:199-205. 
178. Horny HP, Horst HA. Lymphoreticular infiltrates in invasive ductal breast cancer. 
A histological and immunohistological study. Virchows Arch A Pathol Anat 
Histopathol 1986;409:275-86. 
179. Chin Y, Janseens J, Vandepitte J, Vandenbrande J, Opdebeek L, Raus J. 
Phenotypic analysis of tumor-infiltrating lymphocytes from human breast cancer. 
Anticancer Res 1992;12: 1463-6. 
180. Naukkarinen A, Syrjanen KJ. Quantitative immunohistochemical analysis of 
mononuclear infiltrates in breast carcinomas--correlation with tumour 
differentiation. J Pathol 1990; 160:217-22. 
181. Whitford P, Mallon EA, George WD, Campbell AM. Flow cytometric analysis of 
tumour infiltrating lymphocytes in breast cancer. Br J Cancer 1990;62:971-5. 
182. Bell D, Chomarat P, Broyles D, et al. In breast carcinoma tissue, immature 
dendritic cells reside within the tumor, whereas mature dendritic cells are located 
in peritumoral areas. J Exp Med 1999;190:1417-26. 
183. Marrogi AJ, Munshi A, Merogi AJ, et al. Study of tumor infiltrating lymphocytes 
and transforming growth factor-beta as prognostic factors in breast carcinoma. Int 
J Cancer 1997;74:492-501. 
184. Liyanage UK, Moore TT, Joo HG, et al. Prevalence of regulatory T cells is 
increased in peripheral blood and tumor microenvironment of patients with 
pancreas or breast adenocarcinoma. J Immunol 2002; 169:2756-61. 
185. Shimokawara I, Imamura M, Yamanaka N, Ishii Y, Kikuchi K. Identification of 
lymphocyte subpopulations in human breast cancer tissue and its significance: an 
immunoperoxidase study with anti-human T- and B-cell sera. Cancer 
1982;49: 1456-64. 
289 
186. Georgiannos SN, Renaut A, Goode AW, SheaffM. The immunophenotype and 
activation status of the lymphocytic infiltrate in human breast cancers, the role of 
the major histocompatibility complex in cell-mediated immune mechanisms, and 
their association with prognostic indicators. Surgery 2003; 134:827-34. 
187. Treilleux I, Blay JY, driss-Verrnare N, et al. Dendritic cell infiltration and 
prognosis of early stage breast cancer. Clin Cancer Res 2004; 10:7466-74. 
188. Goedegebuure PS, Eberlein TJ. The role of CD4+ tumor-infiltrating lymphocytes 
in human solid tumors. Immunol Res 1995;14:119-31. 
189. Wang RF. The role of MHC class II -restricted tumor antigens and CD4+ T cells 
in antitumor immunity. Trends Immunol2001;22:269-76. 
190. Wang HY, Wang RF. Antigen-specific CD4+ regulatory T cells m cancer: 
implications for immunotherapy. Microbes Infect 2005;7: 1056-62. 
191. Camp BJ, Dyhrrnan ST, Memoli VA, Mott LA, Barth RJ, Jr. In situ cytokine 
production by breast cancer tumor-infiltrating lymphocytes. Ann Surg Oneal 
1996;3: 176-84. 
192. Gaffey MJ, Frierson HF, Jr., Mills SE, et al. Medullary carcinoma of the breast. 
Identification of lymphocyte subpopulations and their significance. Mod Pathol 
1993;6:721-8. 
193. Zhang L, Conejo-Garcia J.R., Katsaros D., et al. Intratumoral T cells, recurrence, 
and survival in epithelial ovarian cancer. N Engl J Med 2003;348:203-13. 
194. Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B. 
Increase of regulatory T cells in the peripheral blood of cancer patients. Clin 
Cancer Res 2003;9:606-12. 
195. Sato E, Olson SH, Ahn J, et al. Intraepithelial CD8+ tumor-infiltrating 
lymphocytes and a high CD8+/regulatory T cell ratio are associated with 
favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 
2005; 102:18538-43. 
196. Schwartzentruber DJ, Solomon D, Rosenberg SA, Topalian SL. Characterization 
of lymphocytes infiltrating human breast cancer: specific immune reactivity 
detected by measuring cytokine secretion. J Immunother 1992;12:1-12. 
197. Wong PY, Staren ED, Tereshkova N, Braun DP. Functional analysis of tumor-
infiltrating leukocytes in breast cancer patients. J Surg Res 1998;76:95-103. 
198. Vitolo D, Zerbe T, Kanbour A, Dahl C, Herberman RB, Whiteside TL. 
Expression of mRNA for cytokines in tumor-infiltrating mononuclear cells in 
ovarian adenocarcinoma and invasive breast cancer. Int J Cancer 1992;51 :573-80. 
290 
199. Green AR, Green VL, White MC, Speirs V. Expression of cytokine messenger 
RNA in normal and neoplastic human breast tissue: identification of interleukin-8 
as a potential regulatory factor in breast tumours. Int J Cancer 1997;72:937-41. 
200. Bidwell J, Keen L, Gallagher G, et al. Cytokine gene polymorphism in human 
disease: on-line databases. Genes Immun 1999;1:3-19. 
201. Dunning AM, Ellis PD, McBride S, et al. A transforming growth factorbetal 
signal peptide variant increases secretion in vitro and is associated with increased 
incidence of invasive breast cancer. Cancer Res 2003;63:2610-5. 
202. Terry CF, Loukaci V, Green FR. Cooperative influence of genetic polymorphisms 
on interleukin 6 transcriptional regulation. J Biol Chern 2000;27 5: 1813 8-44. 
203. Santtila S, Savinainen K, Hurme M. Presence of the IL-lRA allele 2 (IL1RN*2) 
is associated with enhanced IL-l beta production in vitro. Scand J Immunol 
1998;47: 195-8. 
204. Fishman D, Faulds G, Jeffery R, et al. The effect of novel polymorphisms in the 
interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an 
association with systemic-onset juvenile chronic arthritis. J Clin Invest 
1998;102:1369-76. 
205. Pravica V, Asderakis A, Perrey C, Hajeer A, Sinnott PJ, Hutchinson IV. In vitro 
production of IFN-gamma correlates with CA repeat polymorphism in the human 
IFN-gamma gene. Eur J Immunogenet 1999;26:1-3. 
206. Hoffmann SC, Stanley EM, Darrin CE, et al. Association of cytokine 
polymorphic inheritance and in vitro cytokine production in anti-CD3/CD28-
stimulated peripheral blood lymphocytes. Transplantation 2001 ;72: 1444-50. 
207. Hurme M, Santtila S. IL-l receptor antagonist (IL-1Ra) plasma levels are co-
ordinately regulated by both IL-1Ra and IL-l beta genes. Eur J Immunol 
1998;28:2598-602. 
208. Hulkkonen J, Laippala P, Hurme M. A rare allele combination of the interleukin-1 
gene complex is associated with high interleukin-1 beta plasma levels in healthy 
individuals. Eur Cytokine Netw 2000;11:251-5. 
209. Bennermo M, Held C, Stemme S, et al. Genetic predisposition of the interleukin-6 
response to inflammation: implications for a variety of major diseases? Clin 
Chern 2004;50:2136-40. 
210. Smith KC, Bateman AC, Fussell HM, Howell WM. Cytokine gene 
polymorphisms and breast cancer susceptibility and prognosis. Eur J 
Immunogenet 2004;31: 167-73. 
291 
211. Azmy IA, Balasubramanian SP, Wilson AG, et al. Role of tumour necrosis factor 
gene po1ymorphisms ( -308 and -238) in breast cancer susceptibility and severity. 
Breast Cancer Res 2004;6:R395-R400. 
212. Lee KM, Park SK, Hamajima N, et al. Genetic polymorphisms of interleukin-1 
beta (IL-lB) and IL-l receptor antagonist (IL-lRN) and breast cancer risk in 
Korean women. Breast Cancer Res Treat 2005;1-6. 
213. Lee KM, Park SK, Hamajima N, et al. Genetic polymorphisms of TGF-betal & 
TNF-beta and breast cancer risk. Breast Cancer Res Treat 2005;90: 149-55. 
214. Hefler LA, Grimm C, Lantzsch T, et al. Interleukin-1 and interleukin-6 gene 
polymorphisms and the risk of breast cancer in caucasian women. Clin Cancer 
Res 2005;11:5718-21. 
215. Langsenlehner U, Krippl P, Renner W, et al. Interleukin-10 promoter 
polymorphism is associated with decreased breast cancer risk. Breast Cancer Res 
Treat 2005;90: 113-5. 
216. Skerrett DL, Moore EM, Bernstein DS, Vahdat L. Cytokine genotype 
polymorphisms in breast carcinoma: associations of TGF-betal with relapse. 
Cancer Invest 2005;23:208-14. 
217. Ziv E, Cauley J, Morin P A, Saiz R, Browner WS. Association between the T29--
>C polymorphism in the transforming growth factor beta1 gene and breast cancer 
among elderly white women: The Study of Osteoporotic Fractures. JAMA 
2001;285:2859-63. 
218. Iacopetta B, Grieu F, Joseph D. The -174 G/C gene polymorphism in interleukin-
6 is associated with an aggressive breast cancer phenotype. Br J Cancer 
2004;90:419-22. 
219. DeMichele A, Martin AM, Mick R, et al. Interleukin-6 -174G-->C polymorphism 
is associated with improved outcome in high-risk breast cancer. Cancer Res 
2003;63:8051-6. 
220. Nieters A, Brems S, Becker N. Cross-sectional study on cytokine polymorphisms, 
cytokine production after T -cell stimulation and clinical parameters in a random 
sample of a German population. Hum Genet 2001;108:241-8. 
221. Louis E, Franchimont D, Piron A, et al. Tumour necrosis factor (TNF) gene 
polymorphism influences TNF-alpha production in lipopolysaccharide (LPS)-
stimulated whole blood cell culture in healthy humans. Clin Exp Immunol 
1998;113:401-6. 
222. Kroeger KM, Steer JH, Joyce DA, Abraham LJ. Effects of stimulus and cell type 
on the expression of the -308 tumour necrosis factor promoter polymorphism. 
Cytokine 2000;12:110-9. 
292 
223. Warle MC, Farhan A, Metselaar HJ, et al. Are cytokine gene polymorphisms 
related to in vitro cytokine production profiles? Liver Transpl 2003 ;9: 170-81. 
224. Goepel JR, Rees RC, Rogers K, Stoddard CJ, Thomas WE, Shepherd L. Loss of 
monomorphic and polymorphic HLA antigens in metastatic breast and colon 
carcinoma. Br J Cancer 1991;64:880-3. 
225. Cabrera T, Angustias FM, Sierra A, et al. High frequency of altered HLA class I 
phenotypes in invasive breast carcinomas. Hum Immunol1996;50:127-34. 
226. Lehmann F, Marchand M, Hainaut P, et al. Differences in the antigens recognized 
by cytolytic T cells on two successive metastases of a melanoma patient are 
consistent with immune selection. Eur J Immunol1995;25:340-7. 
227. Restifo NP, Marincola FM, Kawakami Y, Taubenberger J, Vannelli JR, 
Rosenberg SA. Loss of functional beta 2-microglobulin in metastatic melanomas 
from five patients receiving immunotherapy. J Natl Cancer Inst 1996;88: 100-8. 
228. Seliger B, Cabrera T, Garrido F, Ferrone S. HLA class I antigen abnormalities 
and immune escape by malignant cells. Semin Cancer Bioi 2002; 12:3-13. 
229. Campoli M, Chang CC, Oldford SA, Edgecombe AD, DroverS, Ferrone S. HLA 
Antigen Changes in Malignant Tumors of Mammary Epithelial Origin: Molecular 
Mechanisms and Clinical Implications. Breast Dis 2004;20:105-25. 
230. Gastl G, Marth C, Leiter E, et al. Effects of human recombinant alpha 2 arg-
interferon and gamma- interferon on human breast cancer cell lines: dissociation 
of antiproliferative activity and induction of HLA-DR antigen expression. Cancer 
Res 1985;45:2957-61. 
231. Ogoshi K, Tajima T, Mitomi T, Tsuji K. HLA antigens are candidate markers for 
prediction of lymph node metastasis in gastric cancer. Clin Exp Metastasis 
1996;14:277-81. 
232. Drover S, Karr RW, Fu XT, Marshall WH. Analysis of monoclonal antibodies 
specific for unique and shared determinants on HLA-DR4 molecules. Hum 
Immunol 1994;40:51-60. 
233. Fu XT, DroverS, Marshall WH, Karr RW. HLA-DR residues accessible under 
the peptide-binding groove contribute to polymorphic antibody epitopes. Hum 
Immunol1995;43:243-50. 
234. Radka SF, Amos DB, Quackenbush LJ, Cresswell P. HLA-DR7-specific 
monoclonal antibodies and a chimpanzee anti-DR7 serum detect different 
epitopes on the same molecule. Immunogenetics 1984;19:63-76. 
235. Bodmer JG, Heyes JM, Lindsay J. Histocompatibility Testing. Berlin: Springer-
Verlag, 1984. 
293 
236. Koning F, Schreuder I, Giphart M, Bruning H. A mouse monoclonal antibody 
detecting a DR-related MT2-like specificity: serology and biochemistry. Hum 
Immunoll984;9:221-30. 
237. Horibe K, Flomenberg N, Pollack MS, Adams TE, Dupont B, Knowles RW. 
Biochemical and functional evidence that an MT3 supertypic determinant defined 
by a monoclonal antibody is carried on the DR molecule on HLA- DR7 cell lines. 
J Immunol1984;133:3195-202. 
238. Jimenez P, Canton J, Collado A, et al. Chromosome loss is the most frequent 
mechanism contributing to HLA haplotype loss in human tumors. Int J Cancer 
1999;83:91-7. 
239. van der Stoep N, Biesta P, Quinten E, van den Elsen PJ. Lack of IFN-gamma-
mediated induction of the class II transactivator (CIITA) through promoter 
methylation is predominantly found in developmental tumor cell lines. Int J 
Cancer 2002;97:501-7. 
240. Naves R, Lennon AM, Barbieri G, et al. MHC class 11-deficient tumor cell lines 
with a defective expression of the class II transactivator. Int Immunol 
2002;14:481-91. 
241. Lee YJ, Han Y, Lu HT, et al. TGF-beta suppresses IFN-gamma induction of class 
II MHC gene expression by inhibiting class II transactivator messenger RNA 
expression. J Immunol1997;158:2065-75. 
242. Maleno I, Lopez-Nevot MA, Cabrera T, Salinero J, Garrido F. Multiple 
mechanisms generate HLA class I altered phenotypes in laryngeal carcinomas: 
high frequency of HLA haplotype loss associated with loss of heterozygosity in 
chromosome region 6p21. Cancer Immunol Immunother 2002;51:389-96. 
243. Ramal LM, Maleno I, Cabrera T, et al. Molecular strategies to define HLA 
haplotype loss in microdissected tumor cells. Hum Immunol2000;61:1001-12. 
244. Qiu X, Singal DP. Allelic polymorphism in the upstream regulatory region of 
HLA-DRB genes: functional role of conserved consensus motifs. Transplant Proc 
1995;27:682-3. 
245. Singal DP, Qiu X. Polymorphism in both X andY box motifs controls level of 
expression ofHLA-DRB1 genes. Immunogenetics 1996;43:50-6. 
246. Agrewala JN, Wilkinson RJ. Influence of HLA-DR on the phenotype of CD4+ T 
lymphocytes specific for an epitope of the 16-kDa alpha-crystallin antigen of 
Mycobacterium tuberculosis. Eur J Immunol 1999;29: 1753-61. 
247. Redondo M, Garcia J, Villar E, et al. Major histocompatibility complex status in 
breast carcinogenesis and relationship to apoptosis. Hum Pathol2003;34:1283-9. 
294 
248. Oldford SA, Robb JD, Watson PH, DroverS. HLA-DRB alleles are differentially 
expressed by tumor cells in breast carcinoma. Int J Cancer 2004; 112:399-406. 
249. Jimenez RE, Wallis T, Tabasczka P, Visscher DW. Determination of Her-2/Neu 
status in breast carcinoma: comparative analysis of immunohistochemistry and 
fluorescent in situ hybridization. Mod Pathol2000;13:37-45. 
250. Sachs JA, Fernandez N, Kurpisz M, et al. Serological biochemical and functional 
characterisation of three different HLA-DR monoclonal antibodies derived from 
C57BL6 mice. Tissue Antigens 1986;28:199-207. 
251. Paterno GD, Mercer FC, Chayter JJ, Yang X, Robb JD, Gillespie LL. Molecular 
cloning of human erl eDNA and its differential expression in breast tumours and 
tumour-derived cell lines. Gene 1998;222:77-82. 
252. Kotake S, Schumacher HR, Jr., Wilder RL. A simple nested RT-PCR method for 
quantitation of the relative amounts of multiple cytokine mRNAs in small tissue 
samples. J Immunol Methods 1996;199:193-203. 
253. Li J, MoranT, Swanson E, et al. Regulation of IL-8 and IL-1beta expression in 
Crohn's disease associated NOD2/CARD 15 mutations. Hum Mol Genet 
2004;13: 1715-25. 
254. Min YG, LeeCH, Rhee CS, Hong SK, Kwon SH. Increased expression of IL-4, 
IL-5, IFN-gamma, IL-6, IL-8, and TGF-beta mRNAs in maxillary mucosa of 
patients with chronic sinusitis. Am J Rhinol1999; 13:339-43. 
255. Takahata Y, Nomura A, Takada H, et al. CD25+CD4+ T cells in human cord 
blood: an immunoregulatory subset with naive phenotype and specific expression 
offorkhead box p3 (Foxp3) gene. Exp Hematol2004;32:622-9. 
256. Oldford SA, Robb JD, Codner D, Gadag V, Watson PH, Drover S. Tumor cell 
expression of HLA-DM associates with a Th1 profile and predicts improved 
survival in breast carcinoma patients. Int Immunol2006;18:1591-602. 
257. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 
2001;357:539-45. 
258. Wang HY, Lee DA, Peng G, et al. Tumor-specific human CD4+ regulatory T 
cells and their ligands: implications for immunotherapy. Immunity 2004;20:107-
18. 
259. Wang HY, Peng G, Guo Z, Shevach EM, Wang RF. Recognition of a new 
ARTC1 peptide ligand uniquely expressed in tumor cells by antigen-specific 
CD4+ regulatory T cells. J Immunol2005;174:2661-70. 
295 
260. Dong Y, Tang L, Letterio JJ, Benveniste EN. The Smad3 protein is involved in 
TGF-beta inhibition of class II transactivator and class II MHC expression. J 
Immunol2001;167:311-9. 
261. Auger I, Roudier J. Interaction between HSP73 and HLA-DRB1 *0401: 
implications for the development of rheumatoid arthritis. Immunol Res 
2005 ;31 :261-6. 
262. Adamski J, Ma Z, Nozell S, Benveniste EN. 17beta-Estradiol inhibits class II 
major histocompatibility complex (MHC) expression: influence on histone 
modifications and cbp recruitment to the class II MHC promoter. Mol Endocrinol 
2004;18:1963-74. 
263. Adamski J, Benveniste EN. 17beta-estradiol activation of the c-Jun N-terminal 
kinase pathway leads to down-regulation of class II major histocompatibility 
complex expression. Mol Endocrinol2005; 19:113-24. 
264. Maret A, Coudert JD, Garidou L, et al. Estradiol enhances primary antigen-
specific CD4 T cell responses and Th1 development in vivo. Essential role of 
estrogen receptor alpha expression in hematopoietic cells. Eur J Immunol 
2003;33:512-21. 
265. Polanczyk MJ, Carson BD, Subramanian S, et al. Cutting edge: estrogen drives 
expansion of the CD4+CD25+ regulatory T cell compartment. J Immunol 
2004; 173:2227-30. 
266. Garcia-Lora A, Algarra I, Gaforio JJ, Ruiz-Cabello F, Garrido F. 
Immunoselection by T lymphocytes generates repeated MHC class !-deficient 
metastatic tumor variants. lnt J Cancer 2001 ;91: 109-19. 
267. Spurrell DR, Oldford SA, Frost T, et al. Discordant expression of HLA class II-
associated co-chaperones and HLA-DRB alleles in cultured fibroblast-like 
synoviocytes. Hum Immunol2004;65:1516-29. 
268. Thompson JA, Dissanayake SK, Ksander BR, Knutson KL, Disis ML, Ostrand-
Rosenberg S. Tumor cells transduced with the MHC class II Transactivator and 
CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for 
invariant chain. Cancer Res 2006;66: 1147-54. 
269. Chamuleau ME, Souwer Y, Van Ham SM, et al. Class II-associated invariant 
chain peptide expression on myeloid leukemic blasts predicts poor clinical 
outcome. Cancer Res 2004;64:5546-50. 
270. Marth C, Fiegl H, Zeimet AG, et al. Interferon-gamma expression is an 
independent prognostic factor in ovarian cancer. Am J Obstet Gynecol 
2004; 191:1598-605. 
296 
271. Madjd Z, Spendlove I, Pinder SE, Ellis IO, Durrant LG. Total loss ofMHC class I 
is an independent indicator of good prognosis in breast cancer. Int J Cancer 
2005; 117:248-55. 
272. Leek RD, Lewis CE, Whitehouse R, Greenan M, Clarke J, Harris AL. Association 
of macrophage infiltration with angiogenesis and prognosis in invasive breast 
carcinoma. Cancer Res 1996;56:4625-9. 
273. Tsutsui S, Yasuda K, Suzuki K, Tahara K, Higashi H, Era S. Macrophage 
infiltration and its prognostic implications in breast cancer: the relationship with 
VEGF expression and microvessel density. Oncol Rep 2005; 14:425-31. 
274. Kondratiev S, Sabo E, Yakirevich E, Lavie 0, Resnick MB. Intratumoral CDS+ T 
lymphocytes as a prognostic factor of survival in endometrial carcinoma. Clin 
Cancer Res 2004;10:4450-6. 
275. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in 
ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat 
Med 2004;10:942-9. 
276. Wolf D, Wolf AM, Rumpold H, et al. The expression of the regulatory T cell-
specific forkhead box transcription factor FoxP3 is associated with poor prognosis 
in ovarian cancer. Clin Cancer Res 2005; 11:8326-31. 
277. Altman DG, Lausen B, Sauerbrei W, Schumacher M. Dangers of using "optimal" 
cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 1994;86:829-
35. 
278. Merogi AJ, Marrogi AJ, Ramesh R, Robinson WR, Fermin CD, Freeman SM. 
Tumor-host interaction: analysis of cytokines, growth factors, and tumor-
infiltrating lymphocytes in ovarian carcinomas. Hum Patholl997;28:321-31. 
279. Zhao H, Langerod A, Ji Y, et al. Different gene expression patterns in invasive 
lobular and ductal carcinomas of the breast. Mol Bioi Cell 2004; 15:2523-36. 
280. Coradini D, Pellizzaro C, Veneroni S, Ventura L, Daidone MG. Infiltrating ductal 
and lobular breast carcinomas are characterised by different interrelationships 
among markers related to angiogenesis and hormone dependence. Br J Cancer 
2002;87:1105-11. 
281. Landis MD, Seachrist DD, Montanez-Wiscovich ME, Danielpour D, Keri RA. 
Gene expression profiling of cancer progression reveals intrinsic regulation of 
transforming growth factor-beta signaling in ErbB2/Neu-induced tumors from 
transgenic mice. Oncogene 2005;24:5173-90. 
282. Rameshwar P, Narayanan R, Qian J, Denny TN, Colon C, Gascon P. NF-kappa B 
as a central mediator in the induction of TGF-beta in monocytes from patients 
297 
with idiopathic myelofibrosis: an inflammatory response beyond the realm of 
homeostasis. 1 Immunol2000;165:2271-7. 
283. Mo R, Chen J, Grolleau-Julius A, Murphy HS, Richardson BC, Yung RL. 
Estrogen regulates CCR gene expression and function in T lymphocytes. 1 
Immunol 2005; 174:6023-9. 
284. Reome 1B, Hylind JC, Dutton RW, Dobrzanski MJ. Type 1 and type 2 tumor 
infiltrating effector cell subpopulations in progressive breast cancer. Clin 
Immunol 2004; Ill :69-81. 
285. Pasare C, Medzhitov R. Toll pathway-dependent blockade of CD4+CD25+ T 
cell-mediated suppression by dendritic cells. Science 2003;299: 1033-6. 
286. Estevam FR, Augusto SF, Rodrigues SA, Pinheiro MR, Monteiro AF. Apoptosis 
and production of TNF-alpha by tumor-associated inflammatory cells in 
histological grade III breast cancer. Cancer Immunol Immunother 2005;54:671-6. 
287. Sabel MS, Skitzki J, Stoolman L, et al. Intratumoral IL-12 and TNF-alpha-loaded 
microspheres lead to regression of breast cancer and systemic antitumor 
immunity. Ann Surg Oncol2004; 11:147-56. 
288. Balkwill F. Tumor necrosis factor or tumor promoting factor? Cytokine Growth 
Factor Rev 2002;13:135-41. 
289. Valencia X, Stephens G, Goldbach-Mansky R, Wilson M, Shevach EM, Lipsky 
PE. TNF down-modulates the function of human CD4+CD25hi T regulatory 
cells. Blood 2006. 
290. Cumis F, Sacchi A, Corti A. Improving chemotherapeutic drug penetration in 
tumors by vascular targeting and barrier alteration. 1 Clin Invest 2002; 110:475-82. 
291. Keen LJ. The extent and analysis of cytokine and cytokine receptor gene 
polymorphism. Transpl Immunol 2002; 10: 143-6. 
292. The Cytokine Handbook, 4 Edn. San Diego, California, USA: Elsevier Science 
Ltd, 2003. 
293. Westendorp RG, Langermans JA, Huizinga TW, et al. Genetic influence on 
cytokine production and fatal meningococcal disease. Lancet 1997;349:170-3. 
294. Pantschenko AG, Pushkar I, Anderson KH, et al. The interleukin-1 family of 
cytokines and receptors in human breast cancer: implications for tumor 
progression. Int J Oncol2003;23:269-84. 
295. Hall SK, Perregaux DG, Gabel CA, et al. Correlation of polymorphic variation in 
the promoter region of the interleukin-1 beta gene with secretion of interleukin-1 
beta protein. Arthritis Rheum 2004;50:1976-83. 
298 
296. Pociot F, Molvig J, Wogensen L, Worsaae H, Nerup J. A Taql polymorphism in 
the human interleukin-1 beta (IL-l beta) gene correlates with IL-l beta secretion 
in vitro. Eur J Clin Invest 1992;22:396-402. 
297. El-Omar EM, Carrington M, Chow WH, et al. Interleukin-1 polymorphisms 
associated with increased risk of gastric cancer. Nature 2000;404:398-402. 
298. Vamvakopoulos J, Green C, Metcalfe S. Genetic control of IL-1beta bioactivity 
through differential regulation of the IL-l receptor antagonist. Eur J Immunol 
2002;32:2988-96. 
299. Chiu JJ, Sgagias MK, Cowan KH. Interleukin 6 acts as a paracrine growth factor 
in human mammary carcinoma cell lines. Clin Cancer Res 1996;2:215-21. 
300. Verhasselt B, Van DJ, van LN, et al. Interleukin-1 is a motility factor for human 
breast carcinoma cells in vitro: additive effect with interleukin-6. Bur J Cell Bioi 
1992;59:449-57 0 
301. Fontanini G, Campani D, Roncella M, et al. Expression of interleukin 6 (IL-6) 
correlates with oestrogen receptor in human breast carcinoma. Br J Cancer 
1999;80:579-84. 
302. Karczewska A, Nawrocki S, Breborowicz D, Filas V, Mackiewicz A. Expression 
of interleukin-6, interleukin-6 receptor, and glycoprotein 130 correlates with good 
prognoses for patients with breast carcinoma. Cancer 2000;88:2061-71. 
303. Zhang GJ, Adachi I. Serum interleukin-6 levels correlate to tumor progression 
and prognosis in metastatic breast carcinoma. Anticancer Res 1999;19:1427-32. 
304. Bachelot T, Ray-Coquard I, Menetrier-Caux C, Rastkha M, Due A, Blay JY. 
Prognostic value of serum levels of interleukin 6 and of serum and plasma levels 
of vascular endothelial growth factor in hormone-refractory metastatic breast 
cancer patients. Br J Cancer 2003;88:1721-6. 
305. Ray P, Ghosh SK, Zhang DH, Ray A. Repression ofinterleukin-6 gene expression 
by 17 beta-estradiol: inhibition of the DNA-binding activity of the transcription 
factors NF-IL6 and NF-kappa B by the estrogen receptor. FEBS Lett 
1997;409:79-85. 
306. Kristiansen OP, Nolsoe RL, Larsen L, et al. Association of a functional 17beta-
estradiol sensitive IL6-174G/C promoter polymorphism with early-onset type 1 
diabetes in females. Hum Mol Genet 2003;12:1101-10. 
307. Venetsanakos E, Beckman I, Bradley J, Skinner JM. High incidence ofinterleukin 
10 mRNA but not interleukin 2 mRNA detected in human breast tumours. Br J 
Cancer 1997;75:1826-30. 
299 
308. Mocellin S, Marincola FM, Young HA. Interleukin-1 0 and the immune response 
against cancer: a counterpoint. J Leukoc Biol2005;78: 1043-51. 
309. Howell WM, Rose-Zerilli MJ. Interleukin-10 polymorphisms, cancer 
susceptibility and prognosis. Fam Cancer 2006;5: 143-9. 
310. Crawley E, Kay R, Silliboume J, Patel P, Hutchinson I, Woo P. Polymorphic 
haplotypes of the interleukin-1 0 5' flanking region determine variable interleukin-
1 0 transcription and are associated with particular phenotypes of juvenile 
rheumatoid arthritis. Arthritis Rheum 1999;42: 1101-8. 
311. Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV. 
An investigation of polymorphism in the interleukin-1 0 gene promoter. Eur J 
Immunogenet 1997;24:1-8. 
312. Marka M, Bessenyei B, Zeher M, Semsei I. IL-10 promoter -1082 polymorphism 
is associated with elevated IL-l 0 levels in control subjects but does not explain 
elevated plasma IL-10 observed in Sjogren's syndrome in a Hungarian cohort. 
Scand J Immunol2005;62:474-80. 
313. Mormann M, Rieth H, Hua TD, et al. Mosaics of gene variations in the 
Interleukin-1 0 gene promoter affect interleukin-1 0 production depending on the 
stimulation used. Genes Immun 2004;5:246-55. 
314. Muraoka-Cook RS, Dumont N, Arteaga CL. Dual role of transforming growth 
factor beta in mammary tumorigenesis and metastatic progression. Clin Cancer 
Res 2005; 11 :937s-43s. 
315. Ivanovic V, Todorovic-Rakovic N, Demajo M, et al. Elevated plasma levels of 
transforming growth factor-beta 1 (TGF-beta 1) in patients with advanced breast 
cancer: association with disease progression. Eur J Cancer 2003;39:454-61. 
316. Desruisseau S, Palmari J, Giusti C, Romain S, Martin PM, Berthois Y. 
Determination of TGFbetal protein level in human primary breast cancers and its 
relationship with survival. Br J Cancer 2006;94:239-46. 
317. Yokota M, Ichihara S, Lin TL, Nakashima N, Yamada Y. Association of a T29--
>C polymorphism of the transforming growth factor-beta! gene with genetic 
susceptibility to myocardial infarction in Japanese. Circulation 2000;101:2783-7. 
318. Shu XO, Gao YT, Cai Q, et al. Genetic polymorphisms in the TGF-beta 1 gene 
and breast cancer survival: a report from the Shanghai Breast Cancer Study. 
Cancer Res 2004;64:836-9. 
319. Krippl P, Langsenlehner U, Renner W, et al. The L10P polymorphism of the 
transforming growth factor-beta 1 gene is not associated with breast cancer risk. 
Cancer Lett 2003;201:181-4. 
300 
320. Mocellin S, Wang E, Marincola FM. Cytokines and Immune Response in the 
Tumor Microenvironment. J Immunother 2001;24:392-407. 
321. Garcia-Tunon I, Ricote M, Ruiz A, Fraile B, Paniagua R, Royuela M. Interleukin-
2 and its receptor complex (alpha, beta and gamma chains) in in situ and 
infiltrative human breast cancer: an immunohistochemical comparative study. 
Breast Cancer Res 2004;6:R1-R7. 
322. Reichert TE, Nagashima S, Kashii Y, et al. Interleukin-2 expression in human 
carcinoma cell lines and its role in cell cycle progression. Oncogene 2000;19:514-
25. 
323. Matesanz F, Fedetz M, Leyva L, Delgado C, Fernandez 0, Alcina A. Effects of 
the multiple sclerosis associated -330 promoter polymorphism in IL2 allelic 
expression. J Neuroimmunol2004;148:212-7. 
324. Pulaski BA, Smyth MJ, Ostrand-Rosenberg S. Interferon-gamma-dependent 
phagocytic cells are a critical component of innate immunity against metastatic 
mammary carcinoma. Cancer Res 2002;62:4406-12. 
325. Pravica V, Perrey C, Stevens A, Lee JH, Hutchinson IV. A single nucleotide 
polymorphism in the first intron of the human IFN-gamma gene: absolute 
correlation with a polymorphic CA microsatellite marker of high IFN-gamma 
production. Hum Immunol2000;61:863-6. 
326. Kamali-Sarvestani E, Merat A, Talei AR. Polymorphism in the genes of alpha and 
beta tumor necrosis factors (TNF-alpha and TNF-beta) and gamma interferon 
(IFN-gamma) among Iranian women with breast cancer. Cancer Lett 
2005;223: 113-9. 
327. Saha A, Dhir A, Ranjan A, Gupta V, Bairwa N, Bamezai R. Functional IFNG 
polymorphism in intron 1 in association with an increased risk to promote 
sporadic breast cancer. Immunogenetics 2005;57:165-71. 
328. Patil NS, Pashine A, Belamares MP, et al. Rheumatoid arthritis (RA)-associated 
HLA-DR alleles form less stable complexes with class II-associated invariant 
chain peptide than non-RA-associated HLA-DR alleles. J Immunol 
2001;167:7157-68. 
329. Knutson KL, Disis ML. IL-12 enhances the generation of tumour antigen-specific 
Th1 CD4 T cells during ex vivo expansion. Clin Exp Immunol2004;135:322-9. 
330. Bengtsson AK, Ryan EJ, Giordano D, Magaletti DM, Clark EA. 17beta-estradiol 
(E2) modulates cytokine and chemokine expression in human monocyte-derived 
dendritic cells. Blood 2004;104:1404-10. 
331. Sasano H, Suzuki T, Nakata T, Moriya T. New development in intracrinology of 
breast carcinoma. Breast Cancer 2006;13:129-36. 
301 
332. Pari FF, Posey YF. Discrepancies of the biochemical and immunohistochemical 
estrogen receptor assays in breast cancer. Hum Pathol 1988; 19:960-6. 
333. HLA 1991 Proceedings of the Eleventh International Histocompatibility 
Workshop and Conference. New York: Oxford University Press, 2004. 
334. Hassan MI, Aschner Y, Manning CH, Xu J, Aschner JL. Racial differences in 
selected cytokine allelic and genotypic frequencies among healthy, pregnant 
women in North Carolina. Cytokine 2003;21:10-6. 
335. Andrews JMJ. Cytokine and Hormone Modulation of HLA-DR Molecules in 
Breast Carcinoma Cell Lines. Memorial University ofNewfoundland, 2006. 
336. Armstrong TD, Clements VK, Martin BK, Ting JP, Ostrand-Rosenberg S. Major 
histocompatibility complex class II-transfected tumor cells present endogenous 
antigen and are potent inducers of tumor-specific immunity. Proc Nat! Acad Sci U 
SA 1997;94:6886-91. 
337. Pages F, Galon J. Author's reply: Immune cells in Colorectal Cancer. N Engl J 
Med 2006;354: 1531-2. 
338. Pages F, Berger A, Camus M, et al. Effector memory T cells, early metastasis, 
and survival in colorectal cancer. N Engl J Med 2005;353:2654-66. 
339. Harrington LE, Mangan PR, Weaver CT. Expanding the effector CD4 T-cell 
repertoire: the Th17 lineage. Curr Opin Immunol2006; 18:349-56. 
340. Ostrand-Rosenberg S. CD4+ T lymphocytes: a critical component of antitumor 
immunity. Cancer Invest 2005;23:413-9. 
302 
Appendix I 
Associations of HLA-DRB alleles carried by breast carcinoma patients with 
prognostic parameters in primary tumors 
A-1 
AI Associations of HLA-DRB alleles carried by breast carcinoma patients with 
prognostic parameters in primary tumors 
To demonstrate that the pnmary tumors selected for immunohistochemistry (IHC) 
evaluation were representative of the entire set of primary tumors, for which outcome 
information was available, associations ofHLA-DRB alleles with prognostic parameters 
were assessed in both tumor sets (Tables AI.l-AI.16). 
A-2 
Table ALl: HLA-DRB allele associations with age of diagno·sis in breast carcinoma 
patients. 
Primarr Tumor IHC Set~ Primarr Tumor Outcome Set'~' 
N Mean DxAge p§ N Mean DxAge p§ 
(± SEM) (± SEM) 
Total 114 59.6 ± 1.4 99 58.8 ± 1.5 
DRBl*Ol- 98 58.6 ± 1.5 85 57.5 ± 1.6 
DRBl *01+ 16 0.066 0.036 65.8 ± 3.1 14 66.2 ± 3.1 
DRB1 *03- 96 58.4 ± 1.5 83 57.6 ± 1.6 
DRB1*03+ 18 0.052 0.075 65.7 ± 3.2 16 64.6 ± 3.5 
DRBl *04- 65 59.9 ± 1.9 59 59.3 ± 2.0 
DRB1*04+ 0.812 
0.639 
49 59.2 ± 1.9 40 57.9 ± 2.1 
DRBl *0401- 89 59.5 ± 1.6 79 58.6 ± 1.7 
0.858 0.838 DRB1 *0401+ 25 60.0 ± 2.8 20 59.4 ± 2.9 
DRB1*07- 83 58.8 ± 1.6 72 58.0 ± 1.7 
DRB1*07+ 0.371 0.388 31 61.6 ± 2.5 27 60.8 ± 2.7 
DRB1 *11- 96 59.6 ± 1.5 82 58.8 ± 1.6 
DRB1*11+ 18 0.978 0.973 59.7 ± 3.3 17 58.7 ± 3.4 
DRB1*13- 93 61.0 ± 1.5 78 60.2 ± 1.7 
DRB1*13+ 0.031 0.056 21 53.4 ± 2.7 21 53.4 ± 2.7 
DRB1 *15- 82 59.4 ± 1.6 73 58.7 ± 1.6 
DRB1*15+ 0.803 0.971 32 60.1 ± 2.7 26 58.9 ± 3.1 
DRB3- 59 59.9 ± 1.9 50 58.8 ± 2.1 
0.829 0.966 DRB3+ 55 59.3 ± 2.0 49 58.7 ± 2.0 
DRB3*01- 89 58.5 ± 1.5 76 57.6 ± 1.7 
DRB3*01+ 0.137 0.159 25 63.4 ± 2.8 23 62.5 ± 2.9 
DRB3*02- 89 60.7 ± 1.5 76 59.3 ± 1.7 
DRB3*02+ 25 0.118 0.466 55.6 ± 2.8 23 56.8 ± 2.9 
DRB4- 39 58.1 ± 2.5 36 57.8 ± 2.6 
DRB4+ 0.444 0.612 75 60.3 ± 1.6 63 59.3 ± 1.7 
DRB5- 77 59.4 ± 1.6 69 59.0 ± 1.7 
60.0 ± 2.5 0.842 30 58.3 ± 2.8 0.825 DRBS+ 37 
t Primary tumors obtained from breast carcinoma patients with outcome information. 
* Primary tumors from outcome set that were analyzed by immunohistochemistry. 
§P-value (two-tailed) calculated using one-way analysis of variance. 
A-3 
Table AI.2: HLA-DRB allele associations with estrogen receptor (ER) expression in 
breast carcinoma .eatients. 
Primar~ Tumor IHC Seti Primar:y Tumor Outcome Set'~' 
N MeanER p§ N MeanER p§ 
(±SEM) (± SEM) 
Total 114 36.0 ± 5.4 99 38.0 ± 6.1 
DRB1 *01- 98 33.7 ± 5.9 85 36.5 ± 6.7 
DRB1 *01+ 16 0.141 0.322 49.8 ± 13.0 14 47.0 ± 14.0 
DRB1*03- 96 38.7 ± 6.2 83 41.2 ± 7.0 
DRB1*03+ 18 0.470 0.320 21.4 ± 9.1 16 21.4 ± 10.3 
DRB1*04- 65 37.8 ± 7.9 59 38.2 ± 8.5 
DRB1*04+ 49 0.559 0.234 33.6 ± 7.1 40 37.7 ± 8.5 
DRB1 *0401- 89 37.9 ± 6.5 79 38.9 ± 7.2 
DRB1*0401+ 25 0.646 0.144 29.1 ± 8.3 20 34.2 ± 10.0 
DRB1*07- 83 34.4 ± 5.8 72 36.3 ± 6.5 
DRB1*07+ 31 0.782 0.432 40.2 ± 12.7 27 42.5 ± 14.5 
DRBI*ll- 96 35.7 ± 5.8 82 37.6 ± 6.6 
DRB1 *11+ 18 0.991 0.908 37.8 ± 15.6 17 39.7 ± 16.4 
DRB1*13- 93 34.2 ± 5.4 78 36.4 ± 6.3 
DRB1*13+ 21 0.907 0.922 44.1 ± 17.3 21 44.1 ± 17.3 
DRB1 *15- 82 39.3 ± 6.7 73 42.1±7.5 
DRB1*15+ 32 0.226 0.180 27.5 ± 8.6 26 26.3 ± 9.9 
DRB3- 59 34.2 ± 6.4 50 34.8 ± 7.3 
DRB3+ 55 0.916 
0.724 
38.0 ± 8.9 49 41.2 ± 9.9 
DRB3*01- 89 34.9 ± 5.7 76 36.9 ± 6.4 
DRB3*01+ 25 0.784 0.960 40.0 ± 14.5 23 41.6 ± 15.7 
DRB3*02- 89 36.3 ± 6.1 76 38.3 ± 7.0 
DRB3*02+ 25 0.913 37.0 ± 12.8 0.859 34.9 ± 11.9 23 
DRB4- 39 29.8 ± 8.2 36 28.5 ± 8.5 
DRB4+ 75 0.403 0.305 39.2 ± 7.0 63 43.4 ± 8.2 
DRB5- 77 39.2 ± 7.0 69 41.8 ± 7.8 
DRB5+ 37 29.4 ± 8.0 0.387 30 29.2 ± 9.3 0.308 
t Primary tumors obtained from breast carcinoma patients with outcome information. 
t Primary tumors from outcome set that were analyzed by immunohistochemistry. 
§P-value (two-tailed) calculated using Mann-Whitney U test. 
A-4 
Table AI.3: HLA-DRB allele associations with progesterone receptor (PR) expression 
in breast carcinoma patients. 
Primar~ Tumor IHC Set~ Primar~ Tumor Outcome Set'~' 
N MeanPR p§ N MeanPR p§ 
(±SEM} (± SEM) 
Total 114 61.1 ± 12.9 99 59.6 ± 14.3 
DRB1 *01- 98 57.8 ± 13.3 85 55.8 ± 14.6 0.213 0.393 DRB1*01+ 16 81.5 ± 43.5 14 82.7 ± 49.8 
DRB1*03- 96 66.6 ± 15.1 83 66.3 ± 16.9 0.807 0.768 DRB1*03+ 18 32.2 ± 10.6 16 24.6 ± 6.9 
DRB1*04- 65 66.0 ± 20.8 59 63.5 ± 22.5 0.489 0.299 DRB1*04+ 49 54.7 ± 11.8 40 53.8 ± 12.8 
DRB1 *0401- 89 63.2 ± 15.8 79 60.7 ± 17.3 0.114 0.089 DRB1*0401+ 25 53.9 ± 16.6 20 55.3 ± 19.5 
DRB1*07- 83 57.2 ± 11.5 72 56.3 ± 12.6 0.428 0.243 DRB1*07+ 31 71.7 ± 36.3 27 68.3 ± 41.0 
DRB1 *11- 96 67.5± 15.1 82 66.0 ± 17.1 0.289 0.543 DRB1*11+ 18 27.1 ± 10.1 17 28.6 ± 10.6 
DRB1 *13- 93 61.7 ± 15.3 78 59.8 ± 17.6 0.846 0.748 DRB1*13+ 21 58.7 ± 17.9 21 58.7 ± 17.9 
DRB1 *15- 82 65.1 ± 17.0 73 64.8 ± 18.7 0.932 0.924 DRB1 *15+ 32 50.9 ± 14.7 26 44.9 ± 14.6 
DRB3- 59 78.7 ± 23.5 50 77.3 ± 26.9 0.698 1.000 DRB3+ 55 42.3 ± 8.4 49 41.5 ± 8.9 
DRB3*01- 89 65.8 ± 16.0 76 65.4 ± 18.2 0.451 0.431 DRB3*01+ 25 44.6 ± 13.8 23 40.4 ± 13.7 
DRB3*02- 89 65.8 ± 16.0 76 64.2 ± 18.1 0.696 0.709 DRB3*02+ 25 44.5 ± 13.4 23 44.5 ± 14.4 
DRB4- 39 61.4 ± 20.5 36 54.5 ± 21.1 0.837 0.870 DRB4+ 75 61.0 ± 16.5 63 62.5 ± 19.1 
DRB5- 77 66.9 ± 18.0 69 66.1 ± 19.7 
DRB5+ 37 49.2 ± 13.1 0.851 30 44.6 ± 13.2 0.799 
t Primary tumors obtained from breast carcinoma patients with outcome information. 
* Primary tumors from outcome set that were analyzed by immunohistochemistry. 
§P-value (two-tailed) calculated using Mann-Whitney U test. 
A-5 
Table AI.4: HLA-DRB allele associations with primary tumor diameter in breast 
carcinoma ,Eatients. 
Primary Tumor Outcome Set'~' Primary Tumor IHC Set~ 
N Mean PR p§ N MeanPR p§ 
(±SEM} (± SEM} 
Total Ill 3.3 ± 0.2 96 3.3 ± 0.2 
DRB1 *01- 97 3.4 ± 0.2 84 3.3 ± 0.3 0.644 0.833 DRB1 *01+ 14 2.9 ± 0.3 12 2.8 ± 0.3 
DRB1*03- 94 3.3 ± 0.2 81 3.3 ± 0.3 0.539 0.492 DRB1*03+ 17 3.3 ± 0.4 15 3.3 ± 0.4 
DRB1*04- 64 3.2± 0.2 58 3.1 ± 0.2 
DRB1*04+ 47 
0.274 38 3.6 ± 0.5 0.394 3.4±0.4 
DRBl *0401- 87 3.4± 0.2 77 3.4 ± 0.2 
DRB1*0401+ 24 0.036 19 2.9± 0.6 0.060 2.9± 0.05 
DRB1*07- 80 3.4 ± 0.3 69 3.4 ± 0.3 0.818 0.610 DRB1*07+ 31 3.1 ± 0.3 27 3.0± 0.3 
DRB1*11- 93 3.2± 0.2 79 3.2± 0.2 
DRB1*11+ 18 0.648 17 3.6± 0.7 0.510 3.6± 0.7 
DRB1*13- 91 3.3 ± 0.2 76 3.3 ± 0.3 
DRB1*13+ 20 0.506 20 3.3 ± 0.4 0.349 3.3 ± 0.4 
DRB1*15- 79 3.2± 0.2 70 3.2± 0.2 
DRBl *15+ 32 
0.722 
26 3.4 ± 0.6 
0.511 
3.4 ± 0.5 
DRB3- 58 3.1 ± 0.3 49 3.1 ± 0.3 0.050 0.076 DRB3+ 53 3.5 ± 0.3 47 3.5 ± 0.3 
DRB3*01- 87 3.2± 0.2 74 3.2 ± 0.3 0.128 0.080 DRB3*01+ 24 3.6 ± 0.4 22 3.6 ± 0.4 
DRB3*02- 86 3.2± 0.2 73 3.2 ± 0.3 0.076 0.113 DRB3*02+ 25 3.7± 0.5 23 3.7 ± 0.5 
DRB4- 38 3.1 ± 0.3 35 3.1 ± 0.3 0.578 0.350 DRB4+ 73 3.4 ± 0.3 61 3.4 ± 0.3 
DRB5- 74 3.3 ± 0.2 66 3.3 ± 0.3 
DRB5+ 37 3.3 ± 0.4 0.564 30 3.3 ± 0.5 0.587 
t Primary tumors obtained from breast carcinoma patients with outcome information. 
t Primary tumors from outcome set that were analyzed by immunohistochemistry. 
§ P-value (two-tailed) calculated using Mann-Whitney U test. 
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Table AI.5: HLA-DRB allele associations with lymph node metastasis in breast 
carcinoma patients. 
Primar~ Tumor Outcome Setr Primar~ Tumor IHC Set~ 
N %LN+ p§ N %LN+ p§ 
Total 113 50.4 98 54.1 
DRB1 *01- 97 52.6 84 57.1 
DRBl *01+ 16 37.5 0.264 14 35.7 0.136 
DRB1 *03- 96 51.0 83 55.4 
DRB1*03+ 17 47.1 
0.762 15 46.7 0.531 
DRB1*04- 64 48.4 58 50.0 
DRB1*04+ 49 53.1 0.626 40 60.0 0.329 
DRB1 *0401- 88 50.0 78 53.8 
DRB1 *0401+ 25 52.0 0.860 20 55.0 0.926 
DRB1*07- 82 50.0 71 53.5 
DRB1*07+ 31 51.6 0.878 27 55.6 0.857 
DRB1 *11- 95 46.3 81 49.4 
DRB1*11+ 18 0.044 17 76.5 0.042 72.2 
DRB1 *13- 93 47.3 78 51.3 
DRB1*13+ 20 65.0 0.151 20 65.0 0.272 
DRB1 *15- 81 56.8 72 59.7 
DRB1*15+ 32 34.4 0.032 26 38.5 0.062 
DRB3- 59 39.0 50 44.0 
DRB3+ 54 63.0 0.011 48 64.6 0.041 
DRB3*01- 89 48.3 76 52.6 
DRB3*01+ 24 58.3 0.384 22 59.1 0.592 
DRB3*02- 88 43.2 75 46.7 
DRB3*02+ 25 76.0 0.004 23 78.3 0.008 
DRB4- 38 50.0 35 51.4 
DRB4+ 75 50.7 0.947 63 55.6 0.694 
DRB5- 76 57.9 68 60.3 
DRB5+ 37 35.1 0.023 30 40.0 0.063 
f Primary tumors obtained from breast carcinoma patients with outcome information. 
t Primary tumors from outcome set that were analyzed by immunohistochemistry. 
§ P-value (two-tailed) calculated using Pearson's Chi square or Fisher's exact test for 2x2 tables 
when at least one expected count was ::;; 5. 
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Table AI.6: HLA-DRB allele associations with histological tumor grade in breast 
carcinoma patients. 
Primarl:': Tumor Outcome Setr Primarl:': Tumor IHC Set~ 
N % Histological p§ N % Histological p§ 
Grade III Grade III 
Total 105 35.2 91 38.5 
DRB1 *01- 92 37.0 80 40.0 
DRBl *01+ 13 0.536 11 27.3 0.521 23.1 
DRB1*03- 87 33.3 75 36.0 
DRB1*03+ 18 0.369 16 50.0 
0.296 
44.4 
DRB1*04- 60 30.0 54 33.3 
DRB1*04+ 45 0.194 37 45.9 0.224 42.2 
DRB1 *0401- 83 34.9 74 39.2 
DRB1*0401+ 22 0.901 17 35.3 0.766 36.4 
DRB1*07- 76 39.5 66 42.4 
DRB1*07+ 29 0.141 25 28.0 0.207 24.1 
DRB1*11- 88 35.2 75 38.7 
DRB1*11+ 17 0.996 16 37.5 0.931 35.3 
DRB1*13- 86 36.0 72 40.3 
DRB1*13+ 19 0.712 19 31.6 0.488 31.6 
DRB1 *15- 77 36.4 68 39.7 
DRB1*15+ 28 0.689 23 34.8 0.675 32.1 
DRB3- 53 37.7 45 42.2 
DRB3+ 52 0.589 46 34.8 0.466 32.7 
DRB3*01- 80 35.0 68 38.2 
DRB3*01+ 25 0.927 23 39.1 0.939 36.0 
DRB3*02- 81 35.8 69 40.6 
DRB3*02+ 24 0.824 22 31.8 0.462 33.3 
DRB4- 35 40.0 33 42.4 
DRB4+ 70 0.470 58 36.2 
0.558 
32.9 
DRB5- 72 34.7 64 37.5 
DRBS+ 33 0.870 27 40.7 0.772 36.4 
t Primary tumors obtained from breast carcinoma patients with outcome information. 
:t Primary tumors from outcome set that were analyzed by immunohistochemistry. 
§ P-value (two-tailed) calculated using Pearson's Chi square or Fisher's exact test for 2x2 tables 
when at least one expected count was:::;; 5. 
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Appendix II 
Associations of clinicopathological parameters with patient survival in primary 
invasive breast carcinomas 
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All Associations of clinicopathological parameters with patient survival in 
primary invasive breast carcinomas 
The prognostic significance of clinicopathological parameters of primary invasive breast 
carcinomas utilized in the studies described in Chapters 3-5 was assessed. Associations 
with recurrence-free survival (Table Ail. I), distant recurrence-free survival (Table AII.2) 
and disease-specific survival (Table AII.3) were determined by Kaplan Meier analysis 
with log rank statistic. 
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Table AII.1: Kaplan Meier Analysis of Clinicopathological parameters with Recurrence-
free survivala. 
Prognostic Parameter N %Survival Log Rank p 
Surgery 25 64.0 0.03 0.866 
Surgery + Adjuvant 87 58.6 
IDC 86 52.9 4.75 0.029 
ILC or Mixed 24 84.0 
Grade I 16 81.3 3.18 0.204 
Grade II 52 57.7 
Grade III 37 54.1 
LN- 56 75.0 6.24 0.013 
LW 57 47.4 
Size ::;2cm 28 78.6 5.45 0.020 
Size >2cm 53 53.0 
cTNM Stage 1 16 81.3 117.95 <0.0001 
cTNM Stage2 73 65.8 
cTNM Stage3 18 27.8 
cTNM Stage4 3 0.0 
DxAge<SO 36 50.0 1.53 0.466 
Dx Age 50-59 18 61.1 
DxAge~60 60 66.7 
ER<lOfmol/mg 48 43.8 8.19 0.004 
ER;;:! Ofmollmg 66 72.7 
PR<lOfmol/mg 39 53.9 2.89 0.089 
PR ;;:i Ofmollmg 75 64.0 
Her-2/neu- (0-2) 70 61.4 2.94 0.087 
Her-2/neu + {3) 19 42.1 
a Recurrence-free survival= Time to Recurrence (Distant or Regional) 
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Table AII.2: Kaplan Meier Analysis of Clinicopathological parameters with Distant 
recurrence-free survival a. 
Prognostic Parameter 
N %Survival Log Rank p 
Surgery 25 72.0 0.00 0.966 
Surgery + Adjuvant 87 65.5 
IDC 86 60.5 5.74 0.017 
ILC or Mixed 24 91.7 
Grade I 16 93.8 5.09 0.078 
Grade II 52 67.3 
Grade III 37 56.8 
LN- 56 80.4 5.54 0.019 
LW 57 56.1 
Size 52cm 28 82.1 4.09 0.043 
Size >2cm 53 61.5 
cTNM Stage 1 16 81.3 114.45 <0.0001 
cTNM Stage2 73 72.6 
cTNM Stage 3 18 44.4 
cTNM Stage4 3 0.0 
DxAge<50 36 52.8 3.91 0.142 
Dx Age 50-59 18 66.7 
DxAge;:::60 60 76.7 
ER <1 Ofmol/mg 48 47.9 12.29 0.0005 
ER ;:I OfmoVmg 66 81.8 
PR<1 OfinoVmg 39 56.4 4.98 0.026 
PR ;:I OfmoVmg 75 73.3 
Her-2/neu- (0-2) 70 68.6 2.20 0.138 
Her-2/neu+ (3) 19 52.6 
a Distant recurrence-free survival= Time to distant metastasis 
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Table AII.3: Kaplan Meier Analysis of Clinicopathological parameters with Disease-
S_Qecific survivala. 
Prognostic Parameter N %Survival Log Rank p 
Surgery 19 63.2 0.44 0.506 
Surgery+ Adjuvant 78 65.4 
IDC 75 62.7 0.82 0.364 
ILC or Mixed 20 75.0 
Grade I 14 78.6 1.14 0.565 
Grade II 43 65.1 
Grade III 34 61.8 
LN- 48 75.0 1.76 0.185 
LW 50 58.0 
Size ~2cm 27 85.2 4.63 0.032 
Size >2cm 70 58.6 
cTNM Stage 1 15 73.3 24.8 <0.0001 
cTNM Stage2 64 71.9 
cTNM Stage3 14 50.0 
cTNM Stage4 3 0.0 
DxAge <50 33 60.6 0.57 0.751 
Dx Age 50-59 18 61.1 
DxAge~60 48 70.8 
ER <1 Ofmol/mg 46 50.0 8.00 0.005 
ER ;;:i O:finol/mg 53 79.3 
PR <1 O:finol/mg 34 44.1 12.60 0.0004 
PR ;;:i O:finol/mg 65 76.9 
Her-2/neu· (0-2) 60 66.7 0.70 0.403 
Her-2/neu+ (3) 17 58.8 
• Breast cancer-free survival= Time to death from breast cancer. Patients who died of other causes or were 
alive with other malignancy were omitted from analysis. 
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Appendix III 
Determination of Hardy-Weinberg equilibrium and associations of cytokine SNPs 
with intratumoral cytokine mRNA levels 
Supplementary Tables for Chapter 6 
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Alii Determination of Hardy-Weinberg equilibrium and associations of cytokine 
SNPs with intratumoral cytokine mRNA levels 
To ensure cytokine SNPs followed Hardy Weinberg equilibrium observed and 
expected frequencies were compared by Chi-Square analysis (Table AIII.l). To 
determine the validity of assessing combined primary and recurrent tumors, associations 
of cytokine SNPs with relative intratumoral cytokine mRNA levels were compared in 
primary tumors and the combined primary and recurrent tumor subsets (Tables AIII.2-
10). 
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Table AIII.1: Comparison of observed and expected SNP genotypes in breast carcinoma patients to 
determine if allele distribution follows Hardy Weinberg eguilibrium. 
SNP Genotype Observed 
Expected• 
xzt P-value 
N % N % 
IL-l f3 -511 CIC 34 57.6 31.3 53.1 3.1 0.209 
IL-lf3 -511 CIT 18 30.5 23.3 39.5 
IL-l~ -511 TIT 7 11.9 4.3 7.4 
Total 59 100.0 59.0 100.0 
IL-lf3 +3962T/T 0 0.0 3.1 5.2 1.8 0.174 
IL-lf3 +3962 TIC 27 45.8 20.8 35.3 
IL-l f3 +3962 C/C 32 54.2 35.1 59.5 
Total 59 100.0 59.0 100.0 
IL-lR pst11970 C/C 25 41.7 26.0 43.3 0.3 0.848 
IL-lR pstl 1970 CIT 29 48.3 27.0 45.0 
IL-lRpstl 1970 TIT 6 10.0 7.0 11.7 
Total 60 100.0 60.0 100.0 
IL-l RN mspa 1 111 OOCIC 6 10.0 6.3 10.6 0.0 0.982 
IL-lRN mspa1 lllOOTIC 27 45.0 26.3 43.9 
IL-l RN mspa 1 111 OOT IT 27 45.0 27.3 45.6 
Total 60 100.0 60.0 100.0 
IL-12 -1188 A/A 35 60.3 34.9 60.2 0.0 0.997 
IL-12 -1188 CIA 20 34.5 20.2 34.8 
IL-12 -1188 C/C 3 5.2 2.9 5.0 
Total 58 100.0 58.0 100.0 
IFNy +874 A/A 16 27.1 16.8 28.5 0.2 0.916 
IFNy +874 A/T 31 52.5 29.4 49.8 
IFNy +874 TIT 12 20.3 12.8 21.7 
Total 59 100.0 59.0 100.0 
TGF-f31 Codon 10 CIC 5 8.9 7.5 13.4 2.1 0.355 
TGF-f31 Codon 10 CIT 31 55.4 26.0 46.4 
TGF-131 Codon 10 TIT 20 35.7 22.5 40.2 
Total 56 100.0 56.0 100.0 
TGF-131 Codon 25 GIG 48 85.7 48.3 86.2 0.0 0.825 
TGF-f31 Codon 25 GIC 8 14.3 7.4 13.3 
TGF-f31 Codon 25 CIC 0 0.0 0.3 0.5 
Total 56 100.0 56.0 100.0 
TNF-a -308 GIG 38 63.3 39.2 65.3 1.0 0.606 
TNF-a-308 GIA 21 35.0 18.6 31.0 
TNF-a -308 A/A 1 1.7 2.2 3.7 
Total 60 100.0 60.0 100.0 
TNF-a -238 GIG 55 91.7 54.2 90.3 3.7 0.155 
TNF-a -238 GIA 4 6.7 5.7 9.5 
TNF-a. -238 A/A 1 1.7 0.2 0.3 
Total 60 100.0 60.0 100.0 
IL-2 -330 TIT 28 46.7 29.4 49.0 0.7 0.690 
IL-2 -330 TIG 28 46.7 25.2 42.0 
IL-2 -330 GIG 4 6.7 5.4 9.0 
Total 60 100.0 60.0 100.0 
IL-2 +166 GIG 28 46.7 28.7 47.8 0.2 0.914 
IL-2 +166 GIT 27 45.0 25.6 42.7 
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SNP Genotype Observed Expected• xzt P-value N o/o N o/o 
IL-2 +166 TIT 5 8.3 5.7 9.5 
Total 60 100.0 60.0 100.0 
IL-4 -1098 TIT 52 86.7 50.4 84.0 7.6 0.023 
IL-4 -1098 TIG 6 10.0 9.2 15.3 
IL-4 -1098 GIG 2 3.3 0.4 0.7 
Total 60 100.0 60.0 100.0 
IL-4 -590 TIT 1.7 1.5 2.5 0.2 0.889 
IL-4 -590 TIC 17 28.3 16.0 26.7 
IL-4 -590 CIC 42 70.0 42.5 70.8 
Total 60 100.0 60.0 100.0 
IL-4 -33 TIT 1 1.7 1.5 2.6 0.2 0.883 
IL-4 -33 TIC 17 28.8 15.9 27.0 
IL-4 -33 CIC 41 69.5 41.5 70.4 
Total 59 100.0 59.0 100.0 
IL-6 -174 GIG 22 36.7 24.7 41.2 2.3 0.317 
IL-6 -174 GIC 33 55.0 27.6 46.0 
IL-6 -174 CIC 5 8.3 7.7 12.8 
Total 60 100.0 60.0 100.0 
IL-6 nt565 GIG 22 36.7 25.4 42.3 3.7 0.160 
IL-6 nt565 GIA 34 56.7 27.3 45.5 
IL-6 nt565 NA 4 6.7 7.4 12.3 
Total 60 100.0 60.0 100.0 
IL-10 -1082 GIG 10 16.9 12.4 20.9 1.6 0.460 
IL-10 -1082 G/A 34 57.6 29.3 49.6 
IL-10 -1082 NA 15 25.4 17.4 29.4 
Total 59 100.0 59.0 100.0 
IL-10 -819 CIC 31 52.5 31.3 53.1 0.0 0.978 
IL-10 -819 CIT 24 40.7 23.3 39.5 
IL-10 -819 TIT 4 6.8 4.3 7.4 
Total 59 100.0 59.0 100.0 
IL-10 -592 CIC 33 55.9 32.1 54.4 0.4 0.827 
IL-10 -592 CIA 21 35.6 22.9 38.7 
IL-10 -592 NA 5 8.5 4.1 6.9 
Total 59 100.0 59.0 100.0 
"Expected frequencies determined using Hardy-Weinberg equation (l=p2+2pq+q2, where p=proportion of 
common allele and q=proportion of rare allele and p2 represents common allele homozygotes, pq represents 
heterozygotes and q2 represents rare allele homozygotes). 
tThe Chi-square statistic was computed by squaring the residual for each genotype, dividing by its expected 
value, and summing for all genotypes. 
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Table AIII.2: Associations ofiL-2 SNPs with intratumoral IL-2 mRNA• in breast carcinoma tumors 
Primary Tumors Primary and Secondary Tumors 
N IL-2 SEM p N IL-2 SEM p 
IL-2 -330 T- 4 3.8 1.5 0.149 4 3.8 1.5 0.156 
IL-2 -330 T+ 48 13.4 1.8 56 12.8 1.6 
IL-2 -330 G- 24 12.7 2.0 0.451 28 12.8 2.0 0.299 
IL-2 -330 G+ 28 12.5 2.7 32 11.7 2.4 
IL-2 -330 T!T 24 12.7 2.0 0.313 28 12.8 2.0 0.278 
IL-2 -330 TIG 24 14.0 3.0 28 12.8 2.6 
IL-2 -330 GIG 4 3.8 1.5 4 3.8 1.5 
IL-2 +166 G- 5 6.2 3.0 0.210 5 6.2 3.0 0.259 
IL-2 +166 G+ 47 13.3 1.8 55 12.7 1.7 
IL-2 +166 T- 23 14.1 2.4 0.265 28 14.0 2.2 0.106 
IL-2 +166 T+ 29 11.4 2.3 32 10.5 2.2 
IL-2 + 166 GIG 23 14.1 2.4 0.323 28 14.0 2.2 0.206 
IL-2 +166 GIT 24 12.5 2.7 27 11.4 2.5 
IL-2 +166 T!T 5 6.2 3.0 5 6.2 3.0 
IL-2 -330+ 166 TG- 23 9.3 2.6 0.017 25 8.6 2.5 0.006 
IL-2 -330+166 TG+ 29 15.3 2.1 35 14.7 1.9 
IL-2 -330+166 GG- 24 12.7 2.0 0.451 28 12.8 2.0 0.299 
IL-2 -330+166 GG+ 28 12.5 2.7 32 11.7 2.4 
IL-2 -330+166 TT- 23 14.1 2.4 0.265 28 14.0 2.2 0.106 
IL-2 -330+166 TT+ 29 11.4 2.3 32 10.5 2.2 
IL-2 -330+166 GG/GG 4 3.8 1.5 0.313 4 3.8 1.5 0.278 
IL-2 -330+166 GG/x 24 14.0 3.0 28 12.8 2.6 
IL-2 -330+166 x/x 24 12.7 2.0 28 12.8 2.0 
IL-2 -330+166 TG!TG 9 15.7 3.0 0.052 12 15.8 3.1 0.020 
IL-2 -330+ 166 TGix 20 15.1 2.8 23 14.2 2.4 
IL-2 -330+166 x/x 23 9.3 2.6 25 8.6 2.5 
IL-2 -330+166 TTITT 5 6.2 3.0 0.323 5 6.2 3.0 0.206 
IL-2 -330+166 TT/x 24 12.5 2.7 27 11.4 2.5 
IL-2 -330+166 x/x 23 14.1 2.4 28 14.0 2.2 
• Relative mRNA levels determined using RT-PCR to amplify total RNA (1 1-1g) prepared from fresh-frozen breast 
carcinoma tissue. Relative amounts of cytokine mRNA were determined by normalizing spot densities of amplified 
products to ~-actin spot density for each sample. 
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Table AIII.3: Associations ofiFN-y SNPs with intratumoral IFN-y mRNA• in breast carcinoma tumors 
Primary Tumors Primary and Secondary Tumors 
N IFN-y SEM P N IFN-y SEM P 
IFN-y +874 A/A 15 4.8 1.6 0.028 16 4.6 1.5 0.010 
IFN-y+874A/T 25 17.2 3.7 31 16.9 3.1 
IFN-y +874 TIT 11 6.6 1.4 12 6.4 1.3 
IFN-y +874 A- 11 6.6 1.4 0.792 12 6.4 1.3 0.658 
IFN-y +874 A+ 40 12.5 2.5 47 12.7 2.3 
IFN-y +874 T- 15 4.8 1.6 0.016 16 4.6 1.5 0.007 
IFN-y +874 T+ 36 13.9 2.7 43 13.9 2.4 
• Relative mRNA levels determined using RT-PCR to amplify total RNA (1 J,tg) prepared from fresh-frozen breast 
carcinoma tissue. Relative amounts of cytokine mRNA were determined by normalizing spot densities of amplified 
products to 13-actin spot density for each sample. 
Table AIII.4: Associations ofiL-12 SNPs with intratumoral IL-12 mRNA* in breast carcinoma tumors 
Primary Tumors Primary and Secondary Tumors 
N IL-12 SEM p N IL-12 SEM p 
IL-12 -1188 A/A 29 8.3 1.6 0.771 34 7.4 1.4 0.959 
IL-12 -1188 CIA 15 6.1 1.4 18 5.6 1.2 
IL-12 -1188 CIC 2 5.8 3.7 2 5.8 3.7 
IL-12 -1188 C- 29 8.3 1.6 0.473 34 7.4 1.4 0.774 
IL-12 -1188 C+ 17 6.0 1.3 20 5.6 1.1 
IL-12 -1188 A- 2 5.8 3.7 0.812 2 5.8 3.7 0.981 
IL-12 -1188 A+ 44 7.5 1.1 52 6.8 1.0 
• Relative mRNA levels determined using RT-PCR to amplify total RNA (1 J,tg) prepared from fresh-frozen breast 
carcinoma tissue. Relative amounts of cytokine mRNA were determined by normalizing spot densities of amplified 
products to P-actin spot density for each sample. 
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Table AIII.5: Associations ofl1-4 and I1-4Ra SNPs with 11-4 mRNA" in breast carcinoma tumors 
Primary Tumors Primary and Secondary Tumors 
N IL-4 SEM p N IL-4 SEM p 
11-4 -1098 T- 3.1 nc 2 1.6 1.6 nc 
11-4 -1098 T+ 47 1.1 0.4 54 1.0 0.3 
11-4 -1098 G- 43 1.0 0.4 nc 49 0.9 0.4 nc 
11-4 -1098 G+ 5 2.6 1.1 7 1.8 0.9 
11-4 -1098 TIT 43 1.0 0.4 nc 49 0.9 0.4 nc 
11-4-1098 TIG 4 2.4 1.4 5 1.9 1.2 
11-4 -1098 GIG 1 3.1 2 1.6 1.6 
!1-4 -590 T- 32 1.4 0.6 0.830 38 1.1 0.5 0.808 
11-4-590 T+ 16 0.7 0.2 18 0.8 0.2 
IL-4 -590 C- 1 2.0 0.333 1 2.0 0.321 
IL-4 -590 C+ 47 1.1 0.4 55 1.0 0.3 
IL-4 -590 TIT 1 2.0 0.381 1 2.0 0.490 
IL-4 -590 TIC 15 0.6 0.2 17 0.7 0.2 
IL-4 -590 CIC 32 1.4 0.6 38 1.1 0.5 
IL-4 -33 T- 31 1.3 0.6 0.635 37 1.1 0.5 0.368 
11-4-33 T+ 16 0.9 0.3 18 0.9 0.3 
IL-4 -33 C- 1 2.0 0.333 1 2.0 0.321 
IL-4 -33 C+ 47 1.1 0.4 55 1.0 0.3 
IL-4 -33 TIT 1 2.0 0.431 1 2.0 0.337 
IL-4 -33 TIC 15 0.8 0.3 17 0.9 0.3 
11-4-33 CIC 31 1.3 0.6 37 1.1 0.5 
11-4 -1098-590-33 TIT- 32 1.4 0.6 nc 38 1.1 0.5 nc 
11-4-1098-590-33 TTT+ 15 0.8 0.2 17 0.8 0.2 
IL-4 -1098-590-33 TCC- 2 2.6 0.6 nc 3 1.7 0.9 nc 
IL-4 -1098-590-33 TCC+ 46 1.1 0.4 53 1.0 0.4 
IL-4 -1098-590-33 GCT- 47 1.1 0.4 nc 55 1.0 0.3 nc 
IL-4 -1098-590-33 GCT + 1 3.1 1 3.1 
11-4 -1098-590-33 GCC- 43 1.0 0.4 nc 49 0.9 0.4 nc 
IL-4 -1098-590-33 GCC+ 5 2.6 1.1 7 1.8 0.9 
IL-4 -1098-590-33 GCCIGCC 0 nc 1 0.0 nc 
IL-4 -1098-590-33 GCC/x 5 2.6 1.1 6 2.1 1.0 
IL-4 -1098-590-33 xlx 42 1.0 0.4 48 0.9 0.4 
IL-4 -1098-590-33 TCCITCC 27 1.1 0.6 nc 31 1.0 0.6 nc 
IL-4 -1098-590-33 TCCix 18 1.1 0.4 21 1.0 0.3 
11-4 -1098-590-33 x/x 2 2.6 0.6 3 1.7 0.9 
IL-4 -1098-590-33 TTT/TTT 2.0 nc 1 2.0 nc 
11-4 -1098-590-33 TTT/x 14 0.7 0.2 16 0.7 0.2 
IL-4 -1098-590-33 x/x 32 1.4 0.6 38 1.1 0.5 
*Relative mRNA levels determined using RT-PCR to amplify total RNA (1 1-1g) prepared from fresh-frozen breast 
carcinoma tissue. Relative amounts of cytokine mRNA were determined by normalizing spot densities of amplified 
products to 13-actin spot density for each sample. 
nc=Not Calculated; IL-4 -1098 genotype did not follow Hardy-Weinberg equilibrium (Table A3.l ). 
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Table AIII.6: Associations of IL-l 0 SNPs with intratumoral IL-l 0 mRNA • in breast carcinoma tumors 
Primary Tumors Primary and Secondary Tumors 
N IL-10 SEM p N IL-10 SEM p 
IL-10 -1082 G- 15 20.7 3.6 0.479 15 20.7 3.6 0.609 
IL-10 -1082 G+ 32 23.4 2.1 39 22.4 1.9 
IL-10 -1082 A- 7 25.3 4.8 0.510 8 23.9 4.4 0.648 
IL-10 -1082 A+ 41 21.7 1.9 47 21.3 1.8 
IL-10 -1082 GIG 7 25.3 4.8 0.706 8 23.9 4.4 0.841 
IL-10 -1082 G/A 25 22.8 2.3 31 22.0 2.1 
IL-10 -1082 A/A 15 20.7 3.6 15 20.7 3.6 
IL-10 -819 C- 4 22.6 6.6 0.985 4 22.6 6.6 0.861 
IL-10 -819 C+ 43 22.5 1.9 50 21.8 1.7 
IL-10 -819 T- 23 23.6 2.4 0.599 27 22.1 2.2 0.946 
IL-10 -819 T+ 25 21.0 2.6 28 21.3 2.5 
IL-10 -819 CIC 23 23.6 2.4 0.926 27 22.1 2.2 0.980 
IL-10 -819 CIT 20 21.4 3.0 23 21.6 2.8 
IL-10 -819 TIT 4 22.6 6.6 4 22.6 6.6 
IL-10 -592 C- 5 20.1 5.7 0.700 5 20.1 5.7 0.817 
IL-10 -592 C+ 42 22.8 1.9 49 22.1 1.8 
IL-10 -592 A- 25 22.0 2.4 0.579 29 20.8 2.2 0.353 
IL-10 -592 A+ 22 23.2 2.7 25 23.2 2.6 
IL-10 -592 CIC 25 22.0 2.4 0.688 29 20.8 2.2 0.540 
IL-10 -592 CIA 17 24.1 3.2 20 24.0 3.0 
IL-10 -592 AlA 5 20.1 5.7 5 20.1 5.7 
IL-10 -1082-819-592 ACA- 46 22.8 1.8 0.468 53 22.1 1.7 0.481 
IL-10 -1082-819-592 ACA+ 1 10.1 1 10.1 
IL-10 -1082-819-592 ACC- 22 21.9 2.6 0.865 26 21.7 2.4 0.945 
IL-10 -1082-819-592 ACC+ 25 23.1 2.5 28 22.0 2.4 
IL-10 -1082-819-592 ATA- 26 22.3 2.3 0.748 30 21.1 2.1 0.486 
IL-10 -1082-819-592 ATA+ 21 22.8 2.9 24 22.9 2.7 
IL-10 -1082-819-592 ATC- 45 23.3 1.8 0.046 52 22.5 1.7 0.050 
IL-l 0 -1082-819-592 ATC+ 2 5.9 2.2 2 5.9 2.2 
IL-10 -1082-819-592 GCA- 46 22.4 1.8 0.553 53 21.7 1.7 0.519 
IL-10 -1082-819-592 GCA+ 30.4 30.4 
IL-l 0 -1082-819-592 GCC- 17 21.6 3.2 0.740 17 21.6 3.2 0.918 
IL-10 -1082-819-592 GCC+ 30 23.1 2.2 37 22.0 2.0 
IL-10 -1082-819-592 GTC- 46 22.5 1.8 0.809 53 21.8 1.7 0.741 
IL-10 -1082-819-592 GTC+ 1 26,2 1 26.2 
IL-l 0 -1082-819-592 GCC/GCC 7 25.3 4.8 0.813 8 23.9 4.4 0.918 
IL-10 -1082-819-592 GCCix 23 22.4 2.5 29 21.5 2.2 
IL-l 0 -1082-819-592 x/x 17 21.6 3.2 17 21.6 3.2 
IL-10 -1082-819-592 ACCIACC 2 11.8 3.9 0.353 2 11.8 3.9 0.407 
IL-10 -1082-819-592 ACC/x 23 24.1 2.6 26 22.8 2.5 
IL-l 0 -1082-819-592 x/x 22 21.9 2.6 26 21.7 2.4 
IL-10 -1082-819-592 ATA/ATA 4 22.6 6.6 0.947 4 22.6 6.6 0.785 
IL-10 -1082-819-592 ATA/x 17 22.9 3.3 20 23.0 3.0 
IL-10 -1082-819-592 x/x 26 22.3 2.3 30 21.1 2.1 
• Relative mRNA levels determined using RT-PCR to amplify total RNA (1 )lg) prepared from fresh-frozen breast 
carcinoma tissue. Relative amounts of cytokine mRNA were determined by normalizing spot densities of amplified 
products to P-actin spot density for each sample. 
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Table AIII.7: Associations ofTGF-~ SNPs with intratumoral TGF-~ 1 mRNA* in breast carcinoma tumors 
Primnry Tumors Primary and Secondary Tumors 
N TGF-~ SEM p N TGF-~ SEM p 
TGF-P 1 Codon 10 C- 16 52.4 8.0 0.586 19 54.4 7.3 0.697 
TGF-p 1 Codon 10 C+ 29 55.9 3.9 33 54.5 3.6 
TGF-131 Codon 10 T- 5 76.1 16.0 0.067 5 76.1 16.0 0.052 
TGF-~1 Codon 10 T+ 40 52.0 3.6 47 52.2 3.4 
TGF-~1 Codon 10 CIC 5 76.1 16.0 0.183 5 76.1 16.0 0.152 
TGF-~1 Codon 10 CIT 24 51.7 3.0 28 50.7 2.8 
TGF-P1 Codon 10 TIT 16 52.4 8.0 19 54.4 7.3 
TGF-p 1 Codon 25 G- 0 NC 52 54.5 3.5 NC 
TGF-131 Codon 25 G+ 45 54.7 3.8 
TGF-~ 1 Codon 25 C- 38 53.0 3.8 0.702 44 53.5 3.5 0.931 
TGF-~1 Codon 25 C+ 7 63.8 13.5 8 60.0 12.2 
TGF-131 Codon 25 GIG 38 53.0 3.8 0.684t 44 53.5 3.5 0.919t 
TGF-131 Codon 25 GIC 7 63.8 13.5 0.702t 8 60.0 12.2 0.931t 
TGF-131 Codon10Codon25 CG- 21 51.4 6.2 0.317 25 52.3 5.7 0.301 
TGF-131 Codon10Codon25 CG+ 24 57.5 4.6 27 56.4 4.2 
TGF-131 Codon10Codon25 CC- 38 53.0 3.8 0.702 44 53.5 3.5 0.931 
TGF-131 Codon10Codon25 CC+ 7 63.8 13.5 8 60.0 12.2 
TGF-JH Codon10Codon25 TG- 5 76.1 16.0 0.067 5 76.1 16.0 0.052 
TGF-131 Codon10Codon25 TG+ 40 52.0 3.6 47 52.2 3.4 
TGF-131 Codon10Codon25 TGITG 16 52.4 8.0 0.183 19 54.4 7.3 0.152 
TGF-p1 Codon10Codon25 TGix 24 51.7 3.0 28 50.7 2.8 
TGF-pl Codon10Codon25 x/x 5 76.1 16.0 5 76.1 16.0 
TGF-p1 Codon10Codon25 CGICG 3 58.5 3.9 0.524 3 58.5 3.9 0.472 
TGF-131 Codon10Codon25 CGix 21 57.4 5.2 24 56.2 4.7 
TGF-131 Codon10Codon25 x/x 21 51.4 6.2 25 52.3 5.7 
TGF-131 Codon10Codon25 CCix 7 63.8 13.5 0.684t 8 60.0 12.2 0.919t 
TGF-~1 Codon10Codon25 x/x 38 53.0 3.8 0.702t 44 53.5 3.5 0.931 t 
• Relative mRNA levels determined using RT-PCR to amplify total RNA (1 1-1g) prepared from fresh-frozen breast 
carcinoma tissue. Relative amounts of cytokine mRNA were determined by normalizing spot densities of amplified 
froducts to P-actin spot density for each sample. 
P-value calculated using Kruskal-Wallis H test. 
tP-value calculated using Mann-Whitney U test for 2 independent samples. 
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Table AIII.8: Associations ofTNF-a SNPs with intratumoral TNF-a mRNA• in breast carcinoma tumors 
Primary Tumors Primary and Secondary Tumors 
N TNF-a SEM p N TNF-a SEM p 
TNF-a -308 G- 1 3.1 0.417 3.1 0.357 
TNF-a -308 G+ 47 1.8 0.3 55 1.6 0.3 
TNF-a -308 A- 33 1.4 0.3 0.143 35 1.4 0.2 0.618 
TNF-a -308 A+ 15 2.7 0.7 21 2.1 0.6 
TNF-a -308 GIG 33 1.4 0.3 0.263 35 1.4 0.2 0.502 
TNF-a -308 GIA 14 2.7 0.8 20 2.1 0.6 
TNF-a -308 AlA 1 3.1 1 3.1 
TNF-a -238 G- 1 0.9 0.833 1 0.9 0.893 
TNF-a -238 G+ 47 1.8 0.3 55 1.7 0.3 
TNF-a -238 A- 44 1.8 0.3 0.957 51 1.7 0.3 0.738 
TNF-a -238 A+ 4 1.7 0.9 5 1.3 0.8 
TNF-a -238 GIG 44 1.8 0.3 0.934 51 1.7 0.3 0.935 
TNF-a -238 G/A 3 1.9 1.2 4 1.5 1.0 
TNF-a -238 A/A 1 0.9 1 0.9 
TNF-a -308-238 GG- 2 2.0 1.1 0.64 3 1.3 0.9 0.891 
TNF-a -308-238 GG+ 46 1.8 0.3 53 1.7 0.3 
TNF-a -308-238 AG- 33 1.4 0.3 0.143 35 1.4 0.2 0.618 
TNF-a -308-238 AG+ 15 2.7 0.7 21 2.1 0.6 
TNF-a -308-238 GA- 44 1.8 0.3 0.957 51 1.7 0.3 0.738 
TNF-a -308-238 GA+ 4 1.7 0.9 5 1.3 0.8 
TNF-a -308-238 AG/AG 1 3.1 0.263 1 3.1 0.502 
TNF-a -308-238 AGix 14 2.7 0.8 20 2.1 0.6 
TNF-a -308-238 x/x 33 1.4 0.3 35 1.4 0.2 
TNF-a -308-238 GGIGG 29 1.4 0.3 0.36 31 1.4 0.3 0.797 
TNF-a -308-238 GGix 17 2.6 0.7 22 2.2 0.5 
TNF-a -308-238 x/x 2 2.0 1.1 3 1.3 0.9 
TNF-a -308-238 GA/GA 1 0.9 0.934 1 0.9 0.935 
TNF-a -308-238 GA/x 3 1.9 1.2 4 1.5 1.0 
TNF-a -308-238 x/x 44 1.8 0.3 51 1.7 0.3 
• Relative mRNA levels determined using RT-PCR to amplify total RNA (1 J.tg) prepared from fresh-frozen breast 
carcinoma tissue. Relative amounts of cytokine mRNA were determined by normalizing spot densities of amplified 
products to 13-actin spot density for each sample. 
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Table AIII.9: Associations ofiL-1~,IL-lR and IL-lRN SNPs with IL-l~ mRNA• in breast carcinomas 
Primary Tumors Primary and Secondary Tumors 
N IL-1(3 SEM p N IL-lp SEM p 
IL-1(3 -511 C- 7 17.9 3.1 0.529 7 17.9 3.1 0.61 
IL-l~ -511 C+ 41 21.5 2.0 49 20.6 1.8 
IL-l~ -511 T- 27 22.6 2.7 0.432 32 21.3 2.4 0.765 
IL-ll3 -511 T+ 20 18.4 2.1 23 18.6 1.8 
IL-ll3 -511 C/C 27 22.6 2.7 0.712 32 21.3 2.4 0.887 
IL-113 -511 CIT 13 18.7 2.9 16 18.9 2.3 
IL-l~ -511 TIT 7 17.9 3.1 7 17.9 3.1 
IL-1l3 +3962 T- 22 22.8 3.4 0.609 26 21.6 3.0 0.661 
IL-1~ +3962 T+ 25 19.0 1.7 29 18.9 1.5 
IL-1l3 +3962 C- 1 38.3 0.213 2 26.1 12.3 0.743 
IL-ll3 +3962 C+ 46 20.4 1.8 53 19.9 1.6 
IL-l~ +3962 TIC 24 18.2 1.5 0.360t 27 18.4 1.4 0.567t 
IL-113 +3962 CIC 23 23.5 3.3 0.360t 28 21.9 2.9 0.567* 
IL-113 -511+3962 CT- 23 22.6 3.2 0.685 27 21.5 2.9 0.755 
IL-113 -511+3962 CT+ 17 19.7 2.3 20 19.6 2.0 
IL-113 -511+3962 CC- 8 20.5 3.7 0.908 9 19.7 3.4 0.74 
IL-1l3 -511+3962 CC+ 32 21.6 2.5 38 20.9 2.2 
IL-113 -511+3962 TT- 39 21.5 2.1 1 46 20.7 1.9 0.979 
IL-1l3 -511+3962 TT+ 18.2 18.2 
IL-113 -511+3962 TC- 27 22.6 2.7 0.549 32 21.3 2.4 0.991 
IL-1l3 -511+3962 TC+ 13 18.9 3.0 15 19.3 2.6 
IL-1l3 -511+3962 CC/CC 10 27.5 6.2 0.521 12 24.2 5.7 0.905 
IL-113 -511+3962 CCix 22 19.0 2.1 26 19.3 1.8 
IL-113 -511+3962 x/x 8 20.5 3.7 9 19.7 3.4 
IL-113 -511+3962 TCITC 6 17.9 3.7 0.746 6 17.9 3.7 0.759 
IL-l~ -511 + 3962 TC/x 7 19.8 4.9 9 20.2 3.8 
IL-1[3 -511+3962 xlx 27 22.6 2.7 32 21.3 2.4 
IL-113 -511+3962 CT/CT 1 38.3 0.324 2 26.1 12.3 0.877 
IL-113 -511+3962 CTix 16 18.6 2.1 18 18.8 1.9 
IL-113 -511+3962 x/x 23 22.6 3.2 27 21.5 2.9 
IL-lR pstl 1970 CIC 21 20.1 1.8 0.328 24 20.2 1.6 0.177 
IL-1R pstl 1970 CIT 21 20.2 3.4 26 19.0 2.8 
IL-lR pstl 1970 TIT 6 26.6 5.4 6 26.6 5.4 
IL-1R pstl1970 C- 6 26.6 5.4 0.213 6 26.6 5.4 0.177 
IL-lR pstl 1970 C+ 42 20.2 1.9 50 19.5 1.6 
IL-lR pstl1970 T- 21 20.1 1.8 0.763 24 20.2 1.6 0.436 
IL-lR pstl 1970 T+ 27 21.6 2.9 32 20.4 2.5 
IL-IRN rnspal 11100CIC 5 24.4 6.3 0.304 6 22.6 5.5 0.397 
IL-IRN rnspal lllOOTIC 21 18.3 2.2 24 17.7 2.1 
IL-1RN rnspal lllOOTIT 22 22.8 3.0 26 22.2 2.5 
IL-1RN mspa1 lllOOT- 5 24.4 6.3 0.338 6 22.6 5.5 0.56 
IL-1RN mspa1 lllOOT+ 43 20.6 1.9 50 20.0 1.7 
IL-lRN mspa1 11100C- 22 22.8 3.0 0.42 26 22.2 2.5 0.341 
IL-lRN msEal 111 OOC+ 26 19.4 2.1 30 18.7 2.0 
'Relative mRNA levels determined using RT-PCR to amplify total RNA (I j..lg) prepared from fresh-frozen breast carcinoma tissue. 
Relative amounts of cytokine mRNA were determined by normalizing spot densities of amplified products to f3-actin spot density for 
each sample. tP-value calculated using Kruskal-Wallis H test. tP-value calculated using Mann-Whitney U test for 2 independent 
samples. 
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Table AIII.1 0: Associations of IL-6 SNPs with intra tumoral IL-6 mRNA • in breast carcinoma tumors 
Primary Tumors Primary and Secondary Tumors 
N IL-6 SEM p N IL-6 SEM p 
IL-6 -174 G- 4 37.6 6.8 0.375 5 36.5 5.4 0.259 
IL-6 -174 G+ 44 29.1 3.1 51 28.0 2.8 
IL-6 -174 C- 17 32.1 5.9 0.73 19 32.3 5.3 0.467 
IL-6 -174 C+ 31 28.6 3.2 37 26.9 2.9 
IL-6 -174 GIG 17 32.1 5.9 0.551 19 32.3 5.3 0.304 
IL-6 -174 GIC 27 27.3 3.5 32 25.4 3.2 
IL-6 -174 CIC 4 37.6 6.8 5 36.5 5.4 
IL-6 nt565 G- 3 42.7 6.3 0.229 4 40.1 5.2 0.163 
IL-6 nt565 G+ 45 29.0 3.0 52 27.9 2.7 
IL-6 nt565 A- 17 32.1 5.9 0.730 19 32.3 5.3 0.467 
IL-6 nt565 A+ 31 28.6 3.2 37 26.9 2.9 
IL-6 nt565 GIG 17 32.1 5.9 0.380 19 32.3 5.3 0.211 
IL-6 nt565 GIA 28 27.1 3.4 33 25.3 3.1 
IL-6 nt565 NA 3 42.7 6.3 4 40.1 5.2 
IL-6 -174nt565 GG- 4 37.6 6.8 0.375 5 36.5 5.4 0.259 
IL-6 -174nt565 GG+ 44 29.1 3.1 51 28.0 2.8 
IL-6 -174nt565 CG- 47 30.0 3.0 0.833 55 28.9 2.6 0.857 
IL-6 -174nt565 CG+ 22.0 1 22.0 
IL-6 -174nt565 CA- 17 32.1 5.9 0.730 19 32.3 5.3 0.467 
IL-6 -174nt565 CA+ 31 28.6 3.2 37 26.9 2.9 
IL-6 -174nt565 CNCA 3 42.7 6.3 0.380 4 40.1 5.2 0.211 
IL-6 -174nt565 CNx 28 27.1 3.4 33 25.3 3.1 
IL-6 -174nt565 x/x 17 32.1 5.9 19 32.3 5.3 
IL-6 -174nt565 GGIGG 17 32.1 5.9 0.551 19 32.3 5.3 0.304 
IL-6 -174nt565 GGix 27 27.3 3.5 32 25.4 3.2 
IL-6 -174nt565 x/x 4 37.6 6.8 5 36.5 5.4 
• Relative mRNA levels determined using RT-PCR to amplify total RNA (1 J.lg) prepared from fresh-frozen breast 
carcinoma tissue. Relative amounts of cytokine mRNA were determined by normalizing spot densities of amplified 
products to P-actin spot density for each sample. 
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